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Acute decompensated heart failure (ADHF) is associated with a high incidence of 
acute kidney injury (AKI), an abrupt loss of kidney function associated with a near 
doubling of mortality at one year. In addition to the direct threat ADHF itself poses to 
kidney function, several drugs commonly used to treat HF can exacerbate kidney 
dysfunction and the beneficial effects of these treatments must be weighed against their 
adverse effects on glomerular perfusion. Serum creatinine (SCr), the gold-standard 
marker for glomerular filtration, is a delayed and insensitive marker of kidney function 
that can delay the diagnosis of AKI by 24-72 hours. During this time, irreversible kidney 
damage can occur. Consequently, there is an urgent need to identify early markers for 
AKI and long-term renal impairment in ADHF to facilitate timely implementation of 
supportive measures to minimise kidney damage and improve patient outcomes.  
This project performed a search for novel markers of AKI in ADHF across two 
classes of potential biomarkers, circulating microRNAs (miRNAs) in patients with 
ADHF and kidney proteins in an ovine model of renal impairment in ADHF. First, a 
large-scale screen of 375 miRNAs was performed in a well-phenotyped discovery cohort 
consisting of ADHF patients who incurred AKI (n=19), and age- and gender-matched 
ADHF patients who did not incur AKI (n=20), to identify a panel of candidate miRNA 
markers for AKI in ADHF. Subsequently, circulating concentrations of the 10 most 
promising candidate miRNAs were measured in 200 consecutively-recruited ADHF 
patients (with a spectrum of kidney dysfunction) to determine whether any of the 
candidate miRNAs had potential to provide independent prognostic information beyond 
established markers such as SCr and markers of ADHF severity including amino-
terminal pro b-type natriuretic peptide (NT-proBNP).  
Second, kidney tissue samples from an ovine model of ADHF were used to 
characterise the changes in renal protein expression that occur in response to the 
development of, and recovery from, renal impairment as a result of ADHF, and identify 
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candidate protein markers of AKI in ADHF. Relative protein quantification was 
performed in kidney tissue from healthy control sheep (n=5), sheep with established 
ADHF (n=8) and sheep recovered from ADHF (n=7) using Sequential Window 
Acquisition of all Theoretical Mass Spectra (SWATH-MS). By investigating 
associations between candidate miRNA concentrations and AKI, and characterising 
alterations in renal protein expression in response to development of renal impairment 
following ADHF, this work aimed to identify clinically useful biomarkers which could 
be used to identify ADHF patients at risk of AKI. 
Key findings from this research included identification of 26 candidate miRNAs 
which were differentially expressed between patients with ADHF who incurred AKI, and 
patients with ADHF who did not. Of these candidates, only miR-454-3p validated in a 
larger, independent cohort. Higher concentrations of miR-454-3p prior to discharge from 
hospital were associated with lower risk of AKI or intermediate kidney dysfunction in 
ADHF patients and may add value beyond established risk factors including age in 
predicting AKI (Odds Ratio 0.58, 95% CI 0.34-1.01, adjusted for ethnicity, age, gender 
and NT-proBNP). The association between miR-454-3p and AKI was consistent across 
all major ethnic groups in the validation study (European, Māori and Pasifika), but the 
study was only sufficiently powered to detect this effect in patients of European ancestry. 
Through protein expression profiling, this work identified 189 proteins that were 
altered > 1.2-fold during the development of and recovery from ADHF in an ovine 
model. Of these, 11 proteins were detectable in serum, plasma or urine and had a fold-
change > 1.2 with an adjusted p-value < 0.05. These included seven candidate protein 
markers of kidney injury (Filamin A, T-complex protein 1 subunit gamma, Talin 1, 
Chaperonin containing TCP1 subunit 8, T-complex 1, Crystallin zeta, Peroxiredoxin), 
one potential protein marker of kidney recovery (Apolipoprotein A4) and three potential 
protein markers of long-term renal impairment (Apolipoprotein E, Tripeptidyl peptidase 
1, Chaperonin containing TCP1 subunit 6A). Of these candidates, eight had never 
previously been associated with AKI. Differentially expressed proteins were enriched in 
two pro-inflammatory signalling pathways: the Glycoprotein VI signalling pathway was 
activated during ADHF development (Z-score 2.65, p< 0.01), and the acute phase 
response signalling pathway was repressed during recovery from ADHF (Z-score -2.25, 
p< 0.01). 
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In conclusion, these findings suggest that miR-454-3p and candidate protein 
biomarkers, potentially together and in combination with existing clinical risk factors, 
have the potential to improve detection of AKI, kidney recovery and long-term renal 
impairment in ADHF. New biomarkers for AKI in ADHF may facilitate targeted 
treatment and monitoring of patients with ADHF.  
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Heart failure (HF) is a leading cause of hospitalisation in New Zealand [1, 2] and 
worldwide [3] [4], and results in high rates of mortality [1, 5-7]. Acute decompensated 
heart failure (ADHF) is the sudden or gradual onset of the signs or symptoms of HF, such 
that cardiac output fails to meet the body’s metabolic demands and there is a resulting 
need for urgent therapy [8, 9]. Acute kidney injury (AKI) is a complex disorder caused 
by an abrupt loss of kidney function [10, 11], occurring in approximately 25% of patients 
with ADHF [12, 13] and resulting in a near doubling of mortality at one year [14, 15]. 
Aside from prophylactic measures, there is currently no treatment for AKI [16], and 
efforts to treat AKI in ADHF with pharmacotherapies have been ineffective [15]. 
Therefore, early recognition of AKI is critical for provision of effective preventive 
management. The current diagnostic tools for AKI are plasma or serum creatinine 
concentrations (SCr) and measurement of urinary output – both markers of renal function 
but not kidney damage [17]. As such, SCr is a delayed and insensitive biomarker of 
changes in kidney function [18] and reliance on serial measurements SCr to monitor renal 
function potentially delays diagnosis of AKI by 24-72 hours [19]. During this time, 
irreversible kidney damage may occur [20]. Thus, there is an important and unmet need 
for early markers of AKI in ADHF to facilitate timely implementation of supportive 
measures and improve outcomes [17]. The primary hypothesis of this work is that 
circulating miRNAs or proteins may be differentially expressed between patients with 
ADHF who incur AKI and those who do not, and that members of both of these classes 




• That in ADHF, AKI is triggered by haemodynamic derangement and is 
subsequently mediated by adverse and compensatory changes in kidney gene, 
miRNA and protein expression. 
• That circulating concentrations of specific microRNAs (miRNAs) may increase 
(or decrease) prior to the rise in plasma creatinine in patients with ADHF who 
incur AKI. These miRNAs may add independent diagnostic and prognostic 
information beyond established markers such as SCr. 
• That changes in protein expression occur in the kidney in response to the 
development of, and recovery from, renal impairment as a result of ADHF. 
Characterising these alterations in protein expression will identify candidate 
protein biomarkers of kidney injury, recovery and long-term renal impairment in 
ADHF. 
1.3 Aims	
1. To determine whether circulating miRNAs have potential as diagnostic markers 
for AKI in the setting of ADHF, by conducting a large-scale screening study in 
patients admitted to hospital with ADHF. 
2. To validate candidate miRNAs identified in Aim 1 in a larger, independent cohort 
of consecutively-recruited patients and determine whether these miRNAs add 
independent prognostic information beyond pre-established markers such as SCr 
and markers of ADHF severity, including NT-proBNP. 
3. To determine whether candidate miRNA markers perform effectively in Māori, 
Pasifika and European ethnic groups, and explore associations between candidate 
markers and potential confounding factors such as age and gender.  
4. To identify the optimal sample preparation method for SWATH-MS from ovine 
kidney tissue and plasma samples, comparing the performance of three separate 
sample preparation methods. 
5. To quantify changes in protein expression in the kidney that occur in response to 
ADHF development and recovery in an ovine model of ADHF, and identify novel 
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candidate protein biomarkers of kidney injury, recovery and long-term renal 
impairment in ADHF. 
6. To investigate the molecular pathways altered in the kidney in response to ADHF 
development and recovery by performing comparative pathway analysis in the 
protein expression data collected in Aim 5. 
7. To determine whether changes in kidney gene expression are reflected at the 
protein level by comparing protein data collected in Aim 5 with transcriptomic 





Chapter Two of the thesis reviews previous literature on miRNA and protein 
biomarkers for the prediction and diagnosis of ADHF, AKI, and AKI in the context of 
ADHF. As this thesis is comprised of two strands of complementary biomarker research, 
miRNA and protein, methods and results chapters are presented sequentially for ease of 
reading. 
 
Figure 1: Research workflow for the thesis. This thesis addressed the central aim (identification 
of markers of AKI in ADHF) through utilisation of two separate, complementary strands of 
biomarker research. 
 
Experimental methods for miRNA work are outlined in Chapter Three (aims 1-3). 
Results of miRNA quality control analysis are presented in Chapter Four (aims 1-3) and 
results from the miRNA screening study in which associations between circulating 
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miRNAs and AKI were investigated are detailed in Chapter Five (aim 1). Chapter Six 
outlines results from the miRNA validation study (aims 2 and 3). The experimental 
methods for proteomic work are outlined in Chapter Seven (aims 4-7), and optimisation 
of a method for the preparation of kidney tissue for subsequent SWATH-MS is presented 
in Chapter Eight (aim 4). Results from relative quantitative protein profiling in an ovine 
model of ADHF to identify candidate biomarkers for AKI in ADHF are detailed in 
Chapter Nine (aims 5-7). Results from miRNA and protein work are discussed, 
conclusions are presented and future directions arising from this work are outlined in 
Chapter Ten. 
1.5 Publications	 and	 conference	 proceedings	 arising	 from	 this	
thesis	
Table 1: Thesis chapters, paper titles, authorship, journals and publication status for the journal 
article and conference proceeding produced for this thesis. 
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Additional pieces of work beyond the specific scope of the thesis were undertaken 
during the duration of the PhD. Two peer-reviewed articles were published during the 
PhD programme, as well as conference proceedings for research the candidate 
contributed to. The most recent publication addresses the impact of COVID-19 on health 
research in New Zealand (NZ), in which the candidate performed qualitative research 
into the effects of COVID-19 lockdown on postgraduate research students. The 
remaining publications incorporate RT-qPCR experimental work (miRNA 
quantification, gene expression quantification and genotyping) performed by the 
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Literature Review: Biomarkers of 
Acute Kidney Injury in Acute 
Decompensated Heart Failure 
2.1 Acute	decompensated	heart	failure	
Heart failure (HF) is a leading cause of hospitalisation in New Zealand [1, 2] and 
worldwide [3] [4], imposing a significant health care and economic burden [5]. HF 
affects more than 23 million people globally [21] and morbidity and mortality remain 
high despite major advances in drug and device therapy and other improvements in 
clinical management [5]. Moreover, the prevalence of HF is increasing due to rising rates 
of obesity and diabetes, greater life expectancy, and improved long term survival in 
individuals with coronary heart disease and hypertension [22]. Mortality after HF 
hospitalisation is approximately 10% at 1 month, 20%-35% at 12 months and 45-60% at 
5 years [1, 5-7]. In NZ, there are over 12,000 HF hospital admissions each year [1, 6], 
and the combined costs for HF (including in-patient care) account for two percent of the 
NZ healthcare budget [6]. HF disproportionately affects Māori, who experience HF onset 
15 years younger than non-Māori and have hospitalisation rates 8-9 times that of non-
Māori [23]. Furthermore, Māori experience worse HF outcomes independent of 
socioeconomic deprivation [24], with the overall HF mortality rate 3.5 times higher for 
Māori than non-Māori [23]. 
Acute decompensated heart failure (ADHF) is the sudden or gradual onset of the 
signs or symptoms of HF, such that cardiac output fails to meet the body’s metabolic 
demands and there is a resulting need for urgent therapy [8, 9]. ADHF is the acute stage 
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of HF, and most ADHF hospitalisations comprise patients with a worsening of chronic 
HF [8]. Unlike ADHF, chronic HF is managed without hospitalisation [25, 26].  Only 
15-20% of ADHF hospitalisations represent new HF diagnoses [8]. Irrespective of the 
underlying cause of the exacerbation, systemic and pulmonary congestion due to 
increased right- and left-heart filling pressures is an almost universal characteristic of 
ADHF [8]. Newly diagnosed patients are more likely to present with cardiogenic shock 
or pulmonary oedema, whilst patients with decompensated chronic HF commonly 
present with other signs of fluid retention and congestion, such as dyspnoea on exertion, 
weight gain or orthopnoea (shortness of breath when lying flat) [8, 27].  
2.2 Acute	kidney	injury	
Acute kidney injury (AKI) is a complex disorder caused by an abrupt loss of 
kidney function which can lead to numerous complications including metabolic acidosis, 
elevated nitrogenous wastes, high potassium concentrations, and death [10, 11]. The 
pathogenesis of AKI is complicated and multifactorial, involving vascular dysfunction, 
tubular injury and inflammation [28], and is generally classified as prerenal, intrinsic or 
postrenal [29]. Prerenal pathologies result from decreased blood flow through the kidney 
and causes include heart failure, low blood pressure, ischaemia/reperfusion injury and 
liver cirrhosis [29, 30]. In contrast, postrenal pathologies result from acute obstruction to 
urinary flow and causes include gynaecologic cancers in women, prostate cancer and 
benign prostatic hyperplasia in men, ureteral stones, neurogenic bladder, intratubular 
obstruction and retroperitoneal fibrosis [8]. Intrinsic pathologies can be difficult to 
evaluate due to the wide variety of injuries which can occur to the kidney, but in general 
result from damage to the glomeruli, the tubules, the interstitium or the intrarenal blood 
vessels [8].  
The current diagnostic tools for AKI are the measurement of plasma or serum 
creatinine concentrations (SCr) and assessment of urinary output – these are markers of 
renal function but not kidney damage [17]. Creatinine is a breakdown product from 
muscle metabolism and its concentration in the serum is routinely measured to assess 
kidney function as it represents the balance between generation and excretion [31]. Since 
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creatinine is a muscle breakdown product rather than released by the kidney, SCr is a 
delayed and insensitive biomarker of alterations in kidney function [18]. Measurement 
of SCr does not allow detection of subtle injuries nor does it relate to type or cause of 
renal insult [8]. Furthermore, SCr concentrations can be confounded by many factors, for 
example, individuals with reduced muscle mass may not experience a significant increase 
in SCr despite substantial kidney injury [16, 32]. This is particularly salient in the context 
of ADHF, as the majority of patients are over 65 years old [6] and muscle mass declines 
with age [33]. 
Traditionally, AKI has been ill defined, leading to the creation of a consensus 
definition by the international non-profit foundation, Kidney Disease: Improving Global 
Outcomes (KDIGO). KDIGO aims to improve the care and outcomes for patients with 
kidney disease through development of evidence based clinical practice guidelines [34]. 
In 2011 the evidence based KDIGO Clinical Practice Guideline for Acute Kidney Injury 
were released [35]. The definition of AKI was based on the Acute Kidney Injury Network 
(AKIN) [36] and Risk, Injury, Failure; Loss, End-Stage Renal Disease (RIFLE) criteria 
[35, 37]. KDIGO defines AKI as an increase in SCr by ≥ 26.5 μmol/L within any 48-
hour period from admission until discharge; or an increase in SCr to ≥ 1.5 times baseline, 
which is known or presumed to have occurred within the previous 7 days [35, 38]. 
2.3 Acute	kidney	injury	in	acute	decompensated	heart	failure	
Patients with ADHF incur a high incidence of AKI, approximately 25% [12, 13]. 
AKI occurs within the first few days after ADHF diagnosis and is associated with a near 
doubling of HF mortality at one year [14, 15]. ADHF itself may severely challenge renal 
function via reducing kidney perfusion pressure [39]. In addition, drugs commonly 
administered in ADHF treatment, including loop diuretics and vasodilators, directly or 
indirectly reduce renal perfusion and/or intra-glomerular filtration pressures hence 
promoting AKI in ADHF [40]. A challenge in ADHF management is weighing the 
beneficial effects of these medications on the cardiac system (relief of pulmonary oedema 
and improved survival [8, 41, 42]) against their potentially detrimental effects on the 
kidneys [14]. Being aware of early kidney injury in this context can trigger supportive 
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actions (avoidance of nephrotoxic drugs and hypotension, and careful titration of any 
treatments affecting volume and pressure homeostasis) and can lead to improved 
outcomes in ADHF [43]. Aside from prophylactic measures, there is currently no specific 
effective treatment for AKI [16], and efforts to treat AKI in ADHF with 
pharmacotherapies have been ineffective to date [15]. Therefore, early recognition of 
AKI is critical for provision of effective preventive management.  
Reliance on serial measurements of plasma or serum creatinine to monitor renal 
function potentially delays diagnosis of AKI by 24-72 hours [19]. During this time, 
irreversible kidney damage may occur [20]. Additionally, many patients with ADHF 
have near normal SCr upon admission, but have AKI that is not apparent due to a lack of 
information on baseline concentrations prior to admission. Thus, there is an important 
and unmet need for both early markers of AKI in ADHF and markers of long-term renal 
impairment, to facilitate timely implementation of supportive measures and improve 
outcomes [15, 17].  
2.4 Established	and	emerging	peptide	markers	in	heart	failure	
Several peptide biomarkers, including the natriuretic peptides and cardiac troponins, are 
routinely used in the clinic as diagnostic and prognostic markers in heart failure [44]. 
Circulating concentrations of the B-type natriuretic peptides (BNP and its amino-
terminal pro-hormone fragment, NT-proBNP) are markedly elevated in heart failure: 
NT-proBNP is the international gold standard marker for the diagnosis of ADHF [45, 46] 
and both peptides are strong predictors of subsequent adverse events [47-50]. Natriuretic 
peptides (NPs) are secreted by the heart and act as homeostatic signals to maintain stable 
plasma volume and blood pressure, and to prevent excess water and salt retention [51, 
52]. BNP is secreted by the ventricles in response to wall tension or left ventricular 
stretching; therefore BNP concentrations increase when cardiac myocytes are strained 
due to volume overload in heart disease conditions, including congestive heart failure 
[52]. BNP induces vasodilation, increases smooth muscle relaxation, and promotes 
diuresis and natriuresis through haemodynamic mechanisms of the kidney and 
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antagonism of the renin-angiotensin-aldosterone system [51]. Additionally, BNP acts 
locally in the heart where it displays antihypertrophic and antifibrotic actions [51]. 
The OPTIMISE study of over 7,000 patients with ADHF demonstrated that 
absolute concentrations of BNP at discharge provided the most potent prediction of post-
discharge mortality or rehospitalisation [53] compared with clinical variables alone, BNP 
at admission or the ratio of discharge/admission. Furthermore, the change in BNP 
concentrations over time may provide additional prognostic information – for example, 
in a study of 1,038 ADHF patients, a fall in BNP concentrations of 30% or more during 
the first 5 days in-hospital was associated with improved survival at 31 and 180 days 
[54]. In contrast, patients with an increase in BNP concentration between hospital 
admission and day 5 had a mortality rate three times greater than those patients with a 
30% or more decrease in BNP [54]. 
This discovery, combined with the finding that therapy for HF was associated 
with a reduction in the circulating natriuretic peptide concentrations, led to investigation 
of NT-proBNP and BNP as targets against which to titrate HF therapy (i.e. ‘guiding’ 
treatment according to natriuretic peptide concentrations). A recent individual patient 
data meta-analysis in 2,000 patients demonstrated that BNP-guided treatment reduced 
all-cause mortality in patients < 75 years of age and reduced HF and cardiovascular 
hospitalisation in all patients [55]. This is an example of how biomarkers may be used to 
improve clinical outcomes through the development of new treatment strategies that use 
a more personalised approach to HF care. 
Cardiac Troponin I, a marker of cardiomyocyte cell death, is another clinically 
used peptide biomarker in the diagnosis/prognosis of heart failure [56]. Troponin I is a 
protein which helps to modulate interactions between myosin and actin within the 
contractile apparatus of striated muscle [57]. Cardiac troponin I (cTnI) is specifically 
found in the heart, both as a part of the structural mechanism of cardiomyocytes and in a 
smaller pool possibly in the cytoplasm [58]. cTnI is released into circulation following 
irreversible cardiomyocyte injury [57], although some evidence suggests that cTnI may 
also be released after reversible ischaemia [57, 59] and sepsis [60]. Measurement of cTnI 
using high-sensitive Troponin I assays is thought to be highly specific for cardiomyocyte 
injury [57], therefore cTnI is the primary biomarker for the diagnosis of MI [56]. In 
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ADHF, high-sensitivity cTnI (hsTnI) can be used as a prognostic marker as elevated cTnI 
concentrations have consistently been shown to correlate with increased mortality [61] 
and readmission rates [56, 62]. In addition to this, cTnI has frequently been shown to be 
an independent predictive variable in prognostic multimarker models in ADHF [56, 63-
65]. 
Beyond hsTnI and NT-proBNP, emerging peptide biomarkers for heart failure 
include soluble suppression of tumorigenicity 2 (ST2), copeptin and midregional pro-
adrenomedullin [66]. These emerging markers provide prognostic information in HF 
independent of hsTnI and NT-proBNP [66]. Despite biomarkers leading to 
improvements in HF diagnosis and prognosis, no single biomarker, imaging modality or 
existing composite score algorithm can yet predict HF readmissions or mortality reliably 
in all individuals. Consequently, investigations into these and other novel biomarkers 
remain ongoing [66].  
2.5 Established	and	emerging	peptide	markers	in	acute	kidney	
injury	
Analagous to the cardiac biomarkers described above, injury to the kidney results 
in the release of molecules which have potential to act as valuable diagnostic or 
prognostic biomarkers [67, 68]. Thus far, several peptide biomarkers of renal cellular 
damage have been identified which may facilitate earlier detection of AKI compared with 
creatinine [20, 69, 70]. These markers have been reviewed extensively [71, 72] and are 
summarised in Table 3. Notable examples include neutrophil gelatinase-associated 
lipocalin (NGAL), cystatin C, proenkephalin, interleukin-18 (IL-18), liver-type fatty 
acid-binding protein (L-FABP), tissue inhibitor of metalloproteinases type 2 (TIMP-2), 
insulin-like growth factor binding protein 7 (IGFBP7), and kidney injury molecule-1 
(KIM-1).  
The measurement of the proteins TIMP-2 and IGFBP7 in urine has been approved 
by the US Food and Drug Administration (FDA) for the diagnosis of AKI [73]. IGFBP7 
is expressed in renal epithelial cells and regulates cell repair, cell adhesion and insulin-
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like growth factors [74]. Following ischaemia, IGFBP7 is induced in the 
microvasculature of the kidney [75] and is involved in cell senescence [74]. TIMP-2 is a 
protein expressed in renal tubular cells which irreversibly inactivates metalloproteinases 
[76], and induces G1 cell cycle arrest through binding to cells via integrins [77]. TIMP-
2 is involved in AKI through its role in innate immunity [74], including sloughing of 
epithelial tubular cells, loss of cell-cell adhesion, modulation of apoptosis, changes in 
endothelial permeability, and structural changes which influence leukocyte migration 
from capillaries to areas of injury inside the renal tubule [74]. 
NephroCheck (Astute Medical, Inc., USA) is the first point-of-care device to 
utilise these kidney damage biomarkers to evaluate the risk of developing moderate-to-
severe AKI within 12 hours of testing [73]. This technology was approved by the FDA 
based on evidence from two prospective multicentre studies in critically ill patients – 
Topaz [78] (n=420) and Opal [79] (n=154). However, the first study to describe the 
diagnostic performance of TIMP-2 and IGFBP7 in AKI was the Sapphire study [70] 
(n=744), which demonstrated that TIMP-2 and IGFBP7 outperformed seven other 
markers of AKI damage. The clinical utility of the remaining markers is still under 
investigation and none have yet entered routine clinical practice, with the exception of 
L-FABP, which is only used in Japan in the specific setting of AKI in hepatic failure [69] 
and NGAL, which is available for use in some European jurisdictions as dictated by local 
policies [80]. 
The potential of NGAL as marker of AKI has been investigated in depth [16]. 
NGAL is normally expressed in a range of adult human tissues including kidney, liver 
and bone marrow [81], and its expression is markedly induced in injured epithelial cells 
(such as renal epithelial cells) [82]. The biological role of NGAL in the context of an 
injured mature organ, for instance, the kidney, is the preservation of organ function 
through an enhanced proliferation response and attenuation of apoptosis [83]. The 
performance of NGAL as a biomarker has been analysed in a variety of settings, 
including the prediction of AKI in critically ill patients [84], adult cardiac surgery 
patients [85], patients who had received a kidney transplant [86], and in patients in the 
emergency department [87]. However, appropriate cut-off concentrations for NGAL for 
the diagnosis of AKI in these settings have not been established [16]. Due to the multiple 
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causes of AKI and its varying and uncertain timing after the start of a renal insult, it has 
been proposed that multiple biomarkers may be needed to identify AKI before 
irreversible damage has occurred [88]. Employing a panel of AKI biomarkers could lead 
to identifying different stages of injury and repair and therefore guide better targeted 
therapies [89].  
A recent systematic review by Pedroso et al. [90] evaluated the performance of 
biomarkers for early AKI diagnosis in the Intensive Care Unit (ICU). Eleven studies with 
a total of 2,289 patients were included and the performance of several candidate markers 
including cystatin c, NGAL, IL-18, chitinase-3-like protein and KIM-1 were assessed. 
The authors concluded that although some biomarkers showed good performance as 
assessed by sensitivity, specificity and area under the receiver operating characteristic 
curve (AUC-ROC), no biomarker had been externally validated and further large, 
prospective studies are required. This finding is concordant with the recent consensus 
statement on AKI biomarkers released by the Acute Disease Quality Initiative Consensus 
Conference (ADQI) [91], who surmised that there remains an ongoing unmet need for 
earlier identification of patients with AKI and improved diagnostic tools. 
 
 16 
Table 3: Common peptide biomarkers of AKI. Adapted from Ostermann et al. (2020) [91].  










Enzymes present on brush border villi of proximal 
tubular cells; detectable in urine after tubular 
damage 
Urine Diagnosis of AKI Coca et al. (2008) 
[68] 
Calprotectin (heterodimer of 
S100A8 and S100A9) 
Cytosolic calcium-binding complex; present in 
urine in intrinsic AKI 
Urine Diagnosis of AKI Charlton et al. (2014) 
[92]; Heller et al. 
(2011) [93] 
C-C motif chemokine ligand 
14 (CCL14) 
Pro-inflammatory chemokine; present in urine 
following damage or stress of tubular cells 
Urine Assessment of 
kidney recovery 
Hoste et al. (2020) 
[67] 
Chitinase 3-like protein 1 
(CHI3L1) 
Intracellular protein; expressed by neutrophils, 
endothelial cells and macrophages 
Urine and 
plasma 
Diagnosis of AKI De Loor et al. (2016) 
[94] 
Cystatin C (CysC) Cysteine protease inhibitor; filtered freely Plasma Diagnosis of AKI; 
assessment of AKI 
severity 
Coca et al. (2008) 
[68]; Ho et al. (2015) 









Dickkopf-3 (DKK3) Kidney tubular epithelia-derived glycoprotein; 
released into urine under conditions of tubular 
stress 
Urine Prediction of AKI Schunk et al. (2019) 
[97] 
α glutathione S-transferase 
(α-GST) 
Cytoplasmic enzyme located in the proximal tubule Urine Diagnosis of AKI Koyner et al. (2010) 
[98] 
п glutathione S-transferase 
(п-GST) 
Cytoplasmic enzyme located in the distal tubule Urine Diagnosis of AKI Coca et al. (2008) 
[68]; Charlton et al. 
(2014) [92] 
Hepatocyte growth factor 
(GHF) 
Antifibrotic cytokine; involved in regeneration of 
tubular cells following AKI 




Heller et al. (2011) 
[93]; Vaidya et al. 
(2008[99]) 
Hepcidin (HAMP) Peptide hormone; filtered freely Urine and 
plasma 
Diagnosis of AKI; 
assessment of AKI 
severity 
Ho et al. (2015) [95] 
Tissue metalloproteinase-2 
(TIMP-2); insulin-like 
Metalloproteinases released in cell cycle arrest Urine Prediction of AKI; 
diagnosis of AKI; 
Kashani et al. 
(2013[70]); 
Ostermann et al. 
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growth factor binding 
protein -7 (IGFBP7) 
assessment of AKI 
severity 
(2018) [100]; 
Joannidis et al. 
(2019) [101] 
Interleukin-18 (IL-18) Pro-inflammatory cytokine; present in urine after 
tubular damage 
Urine Prediction of AKI; 
diagnosis of AKI 
Coca et al. (2008) 
[68]; Ho et al. (2015) 
[95] 
Kidney injury molecule 1 
(KIM-1) 
Transmembrane glycoprotein expressed by 
proximal tubular cells; detectable in urine 
following tubular damage 
Urine Prediction of AKI; 
diagnosis of AKI 
Coca et al. (2008) 
[68]; Ho et al. (2015) 
[95]; Koyner et al. 
(2010) [98] 
Liver-type fatty acid-binding 
protein (L-FABP) 
Intracellular lipid chaperone; excreted in urine 
following tubular cell damage 
Urine and 
plasma 
Diagnosis of AKI Ho et al. (2015) [95] 
Monocyte chemoattractant 
peptide-1 (MCP-1) 
Peptide expressed in kidney podocytes, kidney 
mesangial cells, and tubular epithelial cells 
Urine Assessment of AKI 
severity 




Lysosomal enzyme, present in urine following 
tubular damage 
Urine Diagnosis of AKI Charlton et al. (2014) 
[92] 
Neutrophil gelatinase-
associated lipocalin (NGAL) 
Protein occurring in at least 3 different forms: i) 
monomeric glycoprotein expressed by epithelial 
Urine and 
plasma 
Diagnosis of AKI Coca et al. (2008) 
[68]; Ho et al. (2015) 
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cells and neutrophils; ii) homodimeric protein 
expressed by neutrophils; iii) heterodimeric protein 
expressed by tubular cells 
[95]; Charlton et al. 
(2014) [92] 
Netrin-1 (NTN1) Laminin-related molecule expressed at low levels 
in proximal tubular cells of healthy kidneys; 
present in urine following tubular cell damage 
Urine Diagnosis of AKI Ramesh et al. (2010) 
[103] 
Osteopontin (OPN) Glycoprotein present in tubular and interstitial 
infiltrating cells in regions of tubulointerstitial 
damage 
Urine Diagnosis of AKI Lorenzen et al. 
(2011) [104] 
Proenkephalin A (PENK) Polypeptide hormone in renal tissue, nervous 
system, adrenal medulla and immune system; 
filtered freely 
Plasma Diagnosis of AKI; 




Legrand et al. (2019) 
[105] 
Tumour necrosis factor 
(TNF) 
Pro-inflammatory cytokine; released following 
tubular damage 
Plasma Diagnosis of AKI Ho et al. (2015) [95] 
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2.6 Emerging	peptide	markers	 of	 acute	 kidney	 injury	 in	 acute	
decompensated	heart	failure	
Despite the diagnostic and prognostic success of several candidate AKI 
biomarkers in cohorts of critically ill patients in the ICU, none of these biomarkers have 
proven definitively successful in the specific context of AKI subsequent to ADHF. 
Recently, Manguba et al. [106] comprehensively reviewed the prognostic and diagnostic 
utility of biomarkers of kidney injury in ADHF, as summarised in the first two tables of 
the publication by Manguba et al. (2019). The authors highlighted that investigations to 
date have yielded mixed and inconclusive results, and concluded that the current body of 
evidence for the prognostic and diagnostic utility of various protein biomarkers for 
kidney injury in ADHF does not support routine use of any of these biomarkers [106]. 
Following FDA approval of TIMP-2 and IGFBP7, Schanz et al. tested the 
predictive ability of this combination of markers in a cohort of 40 ADHF patients [107]. 
They measured the urinary concentrations of TIMP-2 and IGFBP7 and found that these 
markers discriminated AKI stage 2-3 from no AKI/stage 1 AKI over the first 24 hours 
from admission with an AUC of 0.84 (95% CI 0.72-0.93) and over 7 days with an AUC 
of 0.77 (95% CI 0.65-0.88). To date, this has been the only study investigating the utility 
of TIMP-2 and IGFBP7 as markers of AKI in patients with ADHF, and whilst this 
research produced a promising result, the study was significantly limited by the small 
sample size. Validation in larger, more diverse cohorts of patients with ADHF is 
necessary to confirm this preliminary evidence that the combination of TIMP-2 and 
IGFBP7 may be clinically useful markers of AKI in this setting. 
L-FABP has also been investigated as a marker of AKI in the context of ADHF. 
Hishikari et al. measured urinary L-FABP concentrations in 281 patients with ADHF and 
found that baseline L-FABP was an independent predictor of AKI (OR 1.08, 95% CI 
1.05-1.12) [108]. Further to this, a study of 293 ADHF patients revealed that higher 
concentrations of urinary L-FABP on admission were independently associated with AKI 
during the first 7 days (OR 3.85, 95% CI 1.13-13.14) [109]. However, other studies have 
had varying results [110, 111], with some finding no association between L-FABP 
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concentrations and outcomes. One such study by Shirakabe et al. [110] studied 281 
patients with acute HF and found no association between urinary L-FABP and 
development of worsening renal function (defined as an increase in SCr of ≥ 0.3 mg/dL 
from baseline during the first 7 days of hospitalisation or patients receiving renal 
replacement therapy during the first 7 days). Considered together, these studies indicate 
inconsistency in the efficacy of urinary L-FABP as a biomarker for predicting AKI in 
HF patients, and warrant further investigation into the utility of L-FABP, in larger 
cohorts.  
Whilst early studies indicated that plasma or serum NGAL predicted 
development of kidney dysfunction in patients hospitalised for ADHF [112-114], newer 
studies have produced opposing findings. The Controlled Rosuvastatin in Multinational 
Trial in HF (CORONA) study of 1,415 chronic HF patients demonstrated that plasma 
NGAL was not an independent predictor of clinical events after adjusting for C-reactive 
protein, NT-proBNP and estimated glomerular filtration rate (eGFR) [115]. Concordant 
with this, the Acute Kidney Injury NGAL Evaluation of Symptomatic heart failure Study 
(AKINESIS) found that neither peak nor baseline concentrations of NGAL were better 
than baseline SCr at predicting worsening renal function (here defined as a sustained 
increase in creatinine of ≥ 0.5 mg/dl or ≥ 50% of the first creatinine value obtained, or 
initiation of renal replacement therapy within 5 days of hospitalisation) [116]. 
Further to this, plasma and urinary concentrations of NGAL appear to be poorly 
correlated in HF [117]: serum concentrations of NGAL are generally elevated in ADHF 
patients who develop AKI, whereas urinary NGAL concentrations are not [112, 118]. 
Similarly, in over 2,000 patients with chronic HF (Gruppo Italiano per lo Studio della 
Sopravvivenza nell'Insufficienza Cardiaca-HF, GISSI-HF cohort), urinary NGAL was 
not an independent predictor of AKI (in contrast to urinary KIM-1 and eGFR), and whilst 
urinary NGAL predicted all-cause mortality, it did not predict HF hospitalisation [119]. 
Additionally, a study of 90 chronic HF patients found no association between urinary 
NGAL concentrations and clinical outcome [120]. Therefore, the utility of urinary and 
plasma NGAL as a diagnostic or prognostic biomarker in AKI remains uncertain, 
particularly in the context of AKI in HF. 
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Variations in methodologies, study populations, settings and definitions of kidney 
impairment may be responsible for the varied and inconclusive results obtained in 
research assessing efficacy of protein markers of AKI in patients with ADHF [106]. In 
addition to this, the majority of studies used SCr as the standard with which to compare 
the novel biomarkers. Use of an imperfect gold-standard, which is neither specific nor 
sensitive (such as creatinine), carries inherent limitations [106]. As demonstrated by 
Waikar et al., even if a novel renal injury biomarker is 100% specific and 100% sensitive, 
it may appear inaccurate when using SCr for comparison as the gold-standard [121]. 
Conversely, novel biomarkers which have perfect correlation with creatinine may 
possess the same limitations as creatinine [121]. Therefore, it is important to link novel 
biomarkers to patient outcomes rather than solely comparing with imperfect SCr.  
Perhaps the most important factor when considering the inconsistency in results 
in the current body of evidence on markers of AKI in ADHF, is that all studies thus far 
have been observational in nature and may be limited by several confounders [106]. The 
most significant confounding factor is the modification of decongestive therapy (which 
aims to remove large volumes of fluid safely and quickly [122])  in response to declining 
renal function, a factor which may directly influence patient outcomes [106]. 
Decongestive therapy may be withheld from ADHF patients with elevations in 
creatinine, influencing health outcomes [106] – however, these creatinine elevations do 
not always represent true kidney injury [123, 124]. Therefore, creatinine concentrations 
should not necessarily dictate the withdrawal of decongestive therapies (including 
diuretic agents and neurohormonal antagonists) in this setting. Strengthening this 
hypothesis, decongestion is of utmost importance and surpasses the prognostic value of 
renal impairment during the treatment of ADHF [125-129]. For instance, 
haemoconcentration (a marker of decongestion) has been shown to be associated with 
improved survival despite concurrent worsening renal function [130-133]. To date, none 
of the emerging peptide markers discussed in this Section (2.6) have been investigated 
in a randomised control trial to assess the effects of a biomarker-guided strategy on 




In-depth interrogation of the proteome provides a new approach for the discovery 
of novel peptide biomarkers. Current technological approaches for identification and 
quantification of proteins include mass spectrometry-based methods, and techniques 
which rely on the use of antibodies and aptamers [134]. Mass spectrometry (MS) 
represents a key strategy for protein analysis due to its specificity, comprehensive protein 
identification and quantification in a single sample run, and its capability for discovering 
post-translational protein modifications [134]. Whilst MS based approaches require more 
specialised equipment and are generally limited by lower throughput than antibody-based 
approaches, a higher specificity for analytes, rapid technological development and novel 
chromatography technologies make this technology an attractive option for both 
discovery of biomarkers as well as use in clinical diagnostics laboratories [135].  
Two MS-based proteomics approaches exist for the identification and 
quantification of proteins, each with their own advantages and disadvantages: top-down 
and bottom-up proteomics [134, 136]. In bottom-up proteomics, complex protein 
mixtures or purified proteins are enzymatically proteolysed, and the resulting peptide 
products analysed using MS. The information gathered from this peptide analysis is used 
to infer the identity and quantity of proteins present in the sample [136]. In top-down 
proteomics, intact proteins or large protein fragments are analysed, as opposed to 
peptides [137]. This decreases the sample complexity (in comparison to bottom-up 
proteomics in which proteolytic digestion substantially increases sample complexity) and 
preserves information about the intact protein including truncations, alternative splicing 
events, sequence variation arising from mutations, and post-translational modifications 
[136, 137]. However, large-scale separation of intact proteins is challenging due to the 
much greater physiochemical diversity of intact proteins in comparison to peptides – 
therefore, traditional top-down research has predominantly focused on analysis of a 
single or small number of proteins [136]. For this reason, bottom-up proteomics is better 
suited for biomarker discovery investigations in which the aim is to analyse as many 




In addition to the two MS-based proteomics approaches described, multiple MS 
data acquisition modes exist, each possessing distinct strengths and weaknesses [138]. 
For the last two decades, Data Dependent Acquisition mass spectrometry (DDA MS) has 
been the standard in proteomics research when discovery and sampling breadth were the 
primary objectives [138-140]. In contrast, Multiple Reaction Monitoring mass 
spectrometry (MRM MS, also known as Selective Reaction Monitoring mass 
spectrometry or SRM MS) has been the standard in targeted proteomics when accurate 
quantification, validation and reproducibility were the main goals [138, 141]. Recent 
improvements in the design of mass spectrometers and bioinformatic algorithms have 
resulted in the development of a relatively new sampling method, Data Independent 
Acquisition MS (DIA MS). This method currently approaches the identification breadth 
of DDA MS whilst also achieving reproducible quantification of proteins, a characteristic 
of MRM MS [138, 140]. In comparative de novo quantification and identification studies 
in human cell lysates, DIA MS identified up to 89% of proteins detected in a similar 
DDA MS experiment, and provided reproducible quantification of 85% of proteins [138]. 
Data Dependent Acquisition mass spectrometry (DDA MS), also known as 
the shotgun or discovery approach, yields qualitative information about what proteins are 
present in a sample (Figure 2) [139, 140]. Samples containing a mixture of proteins 
proteolysed enzymatically into peptides are injected into the MS, and a peptide precursor 
(MS1) scan of all peptides is performed. Peptide signals with the highest intensities (e.g. 
top 20 intensities) are selected for fragmentation in the gas phase, producing tandem 
(MS2) spectra in a second MS scan. These tandem spectra can then be matched to a 
database containing theoretical masses of proteolysed proteins. While manual peptide 
sequencing of mass spectra is theoretically possible, specialised search engine software 
is usually employed to align these empirically measured tandem mass spectra to the 
peptide sequence information contained in the protein database. The database contains a 
suitably large number of proteins covering those which would be expected in the given 
sample [140]. Since DDA is inherently biased to pick precursors with the strongest signal 
it is challenging to detect low-abundance peptides [139, 140]. DDA traditionally has 
limited quantification capabilities on large sample sets due to under-sampling [142] and 
irreproducible precursor ion selection [143]. DDA represents an ideal technique for 
mapping out the proteome content of a sample (i.e. identifying as many peptides, proteins 
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and post-translational modifications as possible) as it does not require any prior 
knowledge or hypotheses about the biologically relevant proteins [144].  
 
Figure 2: Schematic of Data Dependent Acquisition Mass Spectrometry (DDA MS). DDA MS 
measurements are performed on mass spectrometers which typically use a quadrupole as the 
first mass analyser (Q1) and a Time of Flight (TOF) or OrbiTrap analyser as a second mass 
analyser. A full MS1 survey scan without fragmentation is performed and the top N most 
abundant precursor ions are selected and sequentially isolated and fragmented in MS2 to yield 
peptide sequence information. In this example, the N=3 top peptides (represented by blue, purple 
and green) identified in the MS1 scan are isolated and fragmented in MS2. Quantification using 
an extracted ion chromatogram (XIC) is possible on the MS1 level, but not at the MS2 level. 




MRM MS is a highly sensitive and specific technique which can selectively 
quantify compounds within complex mixtures (Figure 3) [138, 145]. Samples containing 
proteolytic peptides are injected onto the liquid chromatography column and into the MS. 
As the peptide elutes MS1 scans of all peptides are performed. Unlike DDA MS, which 
selects the peptides with the highest intensities for further fragmentation in a subsequent 
MS2 scan, MRM MS selects only precursors and fragments with a mass to charge (m/z) 
ratio and elution time which matches a pre-specified peptide of interest for subsequent 
fragmentation [138, 145]. Each pre-specified peptide is fragmented and a subset of pre-
specified fragmented ions is then measured in the following MS2 scan [146]. Only 
compounds which fulfil both the criteria (i.e. the specific peptide ion and specific 
fragment ions m/z ratio) are isolated - all other ions are excluded through filtering at the 
first and third quadrupoles, granting MRM MS experiments a high level of specificity 
[145]. The same precursors are selected multiple times per instrument cycle in MS1 and 
fragmented many times to gain accurate quantification information as the peptides elutes, 
which is in contrast to DDA MS which is characterised by stochastic sampling [138, 
140]. MRM MS requires a priori knowledge of a peptides MS1 and MS2 m/z value and 
its robustly detectable fragments prior to running the MRM MS experiment, therefore 
although MRM MS is the gold-standard for protein and peptide quantification, it is not a 
suitable method for novel biomarker discovery [138].  
 
Figure 3: Schematic of Multiple Reaction Monitoring mass spectrometry (MRM MS). In MRM 
MS a triple-quadrupole mass spectrometer is commonly used in which two mass filters (Q1 and 
Q3) are used for precursor and fragment ion selection, whilst Q2 (also known as the collision 
cell) generates fragment ions. In this example, one of the five precursor ions is selected in Q1 
(represented in blue), fragmented in Q2 and is subsequently quantified using one of the fragment 
ions in Q3 (using the relative intensity of the fragment ions peak area). XIC = Extracted ion 
chromatogram. Created using biorender.com. 
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In contrast to DDA and MRM MS, Data Independent Acquisition mass 
spectrometry (DIA MS) (Figure 4) does not strictly require an MS1 survey scan 
(although an MS1 scan is routinely carried out to create a peptide library from DIA MS 
runs without running a separate DDA library). Instead, in DIA MS all precursors within 
a defined m/z ratio (known as a window) are fragmented and fragment ion spectra (MS2) 
are continuously acquired in an unbiased fashion [140]. This allows accurate peptide 
quantification of all peptides and all fragments without being limited to predefined 
peptides of interest – the key difference between DIA MS and MRM MS [139]. DIA MS 
is untargeted and in this regard similar to DDA (although DDA is non-quantitative) as it 
covers all peptides through the use of all-inclusive, wide MS1 windows (up to 25 m/z 
units wide), whilst MRM MS is targeted and quantifies peptides using strictly defined 
(very narrow, i.e. 1 m/z wide) MS1 and MS2 windows. 
Sequential Windowed Acquisition of All Theoretical Fragment Ion Mass Spectra 
(SWATH-MS) is a specific form of DIA, which is performed on hybrid full-scan 
instruments such as the AB Sciex 5600+ TripleTOF mass spectrometer used in this 
thesis. In SWATH-MS, sequential pre-defined ranges (known as windows) of precursor 
m/z ratios are isolated and co-fragmented [144]. The analysis of DIA and SWATH-MS 
data sets is complicated as the direct link between the fragment ions and the precursor 
peptides they are derived from is lost [144]. In addition, the use of large selection 
windows which contain fragment ions from a number of concurrently fragmented 
precursor peptides results in complex composite fragment ion spectra, necessitating the 
use of comprehensive spectral libraries [144]. A significant advantage of SWATH-MS 
over MRM is that it allows relative quantitative analysis of peptides covering potentially 
hundreds to thousands of proteins (depending on sample type and instrument 
performance), with high accuracy and consistency. As such, SWATH-MS is ideally 
suited for biomarker studies with large numbers of samples requiring accurate and 
reproducible quantification of the expressed proteome [140]. SWATH-MS also allows 
retrospective analysis for markers which may not have been under investigation during 
the time MS experiments were performed – a valuable feature when working with 
valuable biological samples of limited quantity. However, a limitation of SWATH MS 
(and other forms of DIA MS) is lower sensitivity and precision compared with MRM 
MS [138]. Therefore, MRM MS remains the superior option if quantification of specific, 
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low abundance peptides is required. As concluded in a review by Hu et al. [138], DIA 
MS remains the best choice for large-scale quantification and bottom-up discovery 
proteomics, as it provides the breadth of protein identification delivered by DDA MS, 
and precision and sensitivity approaching that delivered by MRM MS. 
 
Figure 4: Schematic of Sequential Windowed Acquisition of All Theoretical Fragment Ion Mass 
Spectra (SWATH-MS). In SWATH-MS, measurements are performed on fast scanning hybrid 
mass spectrometers which typically use a quadrupole as a first mass analyser (Q1) and a Time 
of Flight (TOF) or OrbiTrap analyser as a second mass analyser. In SWATH-MS an optional 
MS1 scan can (and should) be performed in which all precursor ion spectra are recorded. 
Following this, a series of fragment ion (MS2) spectra are recorded, with wide precursor 
isolation windows (e.g. 25 m/z). Repeated cycling of consecutive precursor isolation windows is 
performed, covering a defined mass range (e.g. 400-1200 m/z). This results in a comprehensive 
data set containing continuous information on all detectable precursor and fragment ions. 
Extracted ion chromatograms (XIC) can be produced at the MS2 level as well as the MS1 level, 
if an optional MS1 scan was performed. Adapted from Ludwig et al. (2018) [140] and created 




A further class of novel biomarkers are microRNAs (miRNAs) – a class of small 
(19-25 nucleotides long), non-coding, single-stranded ribonucleic acids (RNAs) that 
negatively regulate gene expression [147]. Originally discovered in Caenorhabditis 
elegans in 1993 [148], miRNA sequences make up 1-5% of the human genome [149] 
and are commonly conserved across species [150]. Thousands of miRNAs have been 
identified [151], each with the potential to down-regulate the expression of multiple 
genes by binding to specific sites on the 3’ untranslated region of the transcribed 
messenger RNA (mRNA) [147]. Almost all protein-coding genes contain multiple 
miRNA binding sequences and may be regulated by multiple miRNAs [147]. 
Consequently, miRNAs orchestrate biological processes and have garnered attention as 
potential biomarkers for complex diseases including ADHF and AKI [28, 152]. MiRNA 
function and regulation, and their role in kidney pathophysiology, have been 
comprehensively reviewed elsewhere [28, 147, 152]. 
2.8.1 MicroRNA	biogenesis	and	function	
MiRNAs are synthesised in the nucleus and then further processed in the 
cytoplasm [153] where they function as guides through complementary base-pairing with 
target mRNA to regulate gene expression [154]. MiRNA genes are transcribed under the 
control of their own promoters by RNA polymerase II or III [154] into primary miRNA 
precursors (pri-miRNA), which have a 5’ cap and poly-A tail [155]. The pri-miRNAs 
fold into a stem-loop structure with two single-stranded flanking regions upstream (5’) 
and downstream (3’) of the stem-loop [153]. These 5’ and 3’ arms are cleaved in the 
nucleus by the microprocessor complex formed by the double-stranded-RNA-binding 
protein DGCR8 [153] and the RNAse III enzyme Drosha [156]. Processing generates a 
pre-miRNA stem-loop structure approximately 70-nucleotides in length [153]. The pre-
miRNA is then transported to the cytoplasm [157] and processed by the RNAse III 
enzyme, Dicer [158], which generates the miRNA duplex [159] – a double-stranded 
RNA 19-25 nucleotides in length. A single strand of the miRNA duplex destined to 
become the mature sequence is loaded onto Argonaute (Ago) proteins [148] to form the 
RNA-induced silencing complex (RISC) [160], a ribonucleoprotein complex which can 
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be programmed to target almost any nucleic acid sequence for silencing [161]. The 
activated RISC can then bind target mRNA through Watson-Crick base-pairing, typically 
between the 3’untranslated region of the mRNA target sequence and the guide strand of 
miRNA [149]. This target recognition and binding relies greatly on base-pairing between 
the mRNA and the seed region of the miRNA guide [149] – a conserved sequence 
situated at residues 2-8 of the 5’ end. Even though base pairing between the miRNA 
guide and target mRNA does not require perfect complementarity [148], the seed 
sequence is generally 100% complementary in animals (that is, the seed sequence of the 
miRNA has perfect base pairing to the mRNA target) [149]. The extent of 
complementarity between the mRNA target and the miRNA guide determines which 
mechanism of silencing will be employed – translational repression, or destabilisation or 
cleavage of the target mRNA transcript, which leads to degradation [149, 154].  
 
2.8.2 MicroRNAs	as	circulating	biomarkers	
MiRNAs can be detected in all body fluids including serum, plasma, urine and 
saliva, with altered concentrations reported in many disease states (reviewed in [162, 
163]. In blood, miRNAs are protected from degradation through association with RNA-
binding proteins, high-density lipoprotein, or microparticles, or are enclosed in exosomes 
or vesicles which shield the RNA. As a result of associations with carrier proteins or 
vesicles in the circulation, miRNAs have been found to be relatively unaffected by 
freeze-thawing [147, 152, 164] (Figure 5). This stability means miRNAs can be 
reproducibly detected in plasma and serum, and that changes in concentrations associated 




Figure 5: MicroRNA biogenesis, function and cellular release mechanisms. 
In response to a physiological stimulus (e.g. a decrease in renal perfusion pressure), 
transcription of miRNAs from DNA in the nucleus can be altered. MiRNAs can associate with 
high-density lipoproteins or bind to RNA-binding proteins and be released into circulation. They 
may be released actively, passively, as by-products of dead cells, or through interactions with 
specific membrane proteins or channels. MiRNAs in the cytoplasm (pre-miRNA or mature) can 
be released by micro-vesicles which exit through blebbing of the cell membrane. Pre-miRNAs 
can also be assimilated into exosomes, which are released from the cell when multi-vesicular 
bodies (MVB) fuse with the cell membrane. The export of miRNAs into circulation provides the 
opportunity for quantitation in blood. Created using biorender.com. 
 
2.8.3 MicroRNAs	in	heart	failure	
Since the early 2000s, miRNAs have been investigated as diagnostic and 
prognostic markers in HF [165-168]. A comprehensive review by Wong et al. of 21 
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research articles published between 2008 and 2015 [5] showed that of 71 miRNAs 
reportedly associated with HF, only 13 were replicated in at least one other study (miR-
1, -21, -30a, -92a, 124-3p, -126, -150, -195, -210, -342-3p, -423-5p, -499-5p and -622). 
In a subsequent meta-analysis and systematic review, Yan et al.[169] analysed 31 
miRNAs from ten research articles published before August 2016 and found only miR-
423-5p was consistently identified as a potential biomarker for the presence of HF. 
Notably, the combination of miR-423-5p with B-type natriuretic peptide (BNP) 
improved the discrimination of patients with HF from those without when compared with 
BNP alone, highlighting the potential for miRNAs to improve risk prediction and add 
value beyond established markers.  
 At the time of writing, a total of 23 studies have been published since these 
reviews reporting miRNAs as biomarkers in HF patients (Table 4). Together, these 
studies increase the total number of emerging diagnostic or prognostic miRNA markers 
for HF replicated in independent studies from 13 [5] to 26 (Figure 6). Although these 
miRNAs have been validated in independent cohorts they do not necessarily out-perform 
or add value to established clinical markers, as evidenced by miR-423-5p [169] and miR-
1306-5p [170].  
A notable exception is an 8-miRNA panel, recently developed in several large 
cohorts by Wong et. al. [171] which is diagnostic for compensated HF and discriminates 
between HF with reduced ejection fraction (HFrEF) and HF with preserved ejection 
fraction (HFpEF). Ejection fraction is the percentage of blood which is pumped out of 
the left ventricle with each contraction of the heart, and is a defining feature of these sub-
types of HF. In patients with HFrEF, the left ventricle is dilated and relatively 
hypocontractile, resulting in a low ejection fraction. In contrast, the contractile function 
of the heart is largely preserved in HFpEF, but the left ventricle fails to relax normally 
and thereby prevents normal filling.  HFpEF and HFrEF share a clinical phenotype, but 
each have different causes, representing two equally prevalent but distinct sub-types of 
HF [172, 173]. Wong et. al. utilised large and well-phenotyped discovery (n=546) and 
validation cohorts (n=448 and n=716), and employed a rigorous methodological 
approach that allowed absolute quantification of miRNA copy number and maximised 
sensitivity and reproducibility when compared to high-throughput array platforms. 
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Importantly, the 8-miRNA panel in combination with NT-proBNP had a higher 
specificity and improved diagnostic performance for chronic HF, and for HFpEF, than 
either marker alone. When considered with previous literature, this work suggests that 
the small individual effects of miRNA combine synergistically to improve diagnostic 
performance compared with any individual miRNA or NT-proBNP alone. 
 Together, all these studies suggest that miRNAs may have utility as biomarkers 
for HF across the spectrum of mild to severe, and from acute to chronic disease. 
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Table 4. miRNAs associated with HF, reported since 2016. Comprehensive review articles by Wong et al. [5] and Yan et al. [169] detailed miRNAs associated 
with HF prior to 2016, thus for brevity only miRNA studies published since 2016 (and therefore not yet reviewed) are reported here.  
Diagnostic or 
prognostic 
miRNAs Altered Number of 
miRNAs 
Tested 
Sample Type Test Cohort 
Diagnostic 
 





­ miR-4491  
12 Plasma and 
heart tissue 













15 Plasma Discovery and extended study: 118 AHF patients, 10 CHF 
patients, 24 healthy controls tested for mortality 
 
Validation: 9 AHF patients, 10 CHF patients, 8 patients with acute 




He et al. 
(2017)[176] 
­ miR-195-3p 26 Plasma Screen: 8 ischaemic HF patients, 8 non-ischaemic HF patients, 8 
healthy volunteers 
 
Validation: 60 ischaemic HF patients, 48 non-ischaemic HF 




­ miR-21 1 Serum 80 HF patients, 40 healthy controls tested for diagnosis, severity, 





miRNAs Altered Number of 
miRNAs 
Tested 
Sample Type Test Cohort 









3 Plasma Screen: 13 HF patients, 3 healthy controls 
 
Validation: 33 HF patients, 20 healthy controls 
Diagnostic 
 
Lin et al. 
(2019)[179] 
¯ miR-150 8 Serum 54 patients with post-AMI HF, 59 patients with post-AMI non-
HF, 59 healthy controls 
Diagnostic 
 
Wu et al. 
(2018)[180] 
­ exo-miR-92b-5p 3 Serum 
exosomes 
28 HFrEF patients hospitalised for AHF, 30 healthy controls 
Diagnostic 
 




2 Plasma 94 elderly HF patients, 31 healthy controls 
Diagnostic 
 












miRNAs Altered Number of 
miRNAs 
Tested 
Sample Type Test Cohort 
Diagnostic 
 














PBMCs Screen: 6 CHD patients with HF, 6 CHD patients without HF 
 




Liu et al. 
(2018)[183] 
¯ miR-132 1 Peripheral 
blood 
67 HF patients, 65 patients without HF 
Diagnostic 
 




­ exo-miR-146a 3 Plasma 
exosomes 
40 HF patients, 20 healthy controls 
Diagnostic 
 









Plasma 338 HF patients, 208 non-HF controls 
 






miRNAs Altered Number of 
miRNAs 
Tested 
































 96 AHF patients, 96 AHF free patients with other cardiovascular 





miRNAs Altered Number of 
miRNAs 
Tested 






Diagnostic of HF 
aetiology 
 














9 Plasma taken 
simultaneously 
from the aorta 
and coronary 
venous sinus 
23 patients with non-ischemic HF, 23 patients with ischemic HF, 
11 control patients 
Prognostic 
 







12 Plasma 100 AHF patients, 24 healthy controls tested for biomarkers 





miRNAs Altered Number of 
miRNAs 
Tested 




Scrutinio et al. 
(2017)[188] 






Serum Screen: 5 healthy volunteers, 5 mild to moderate HF patients, 5 
advanced HF patients  
 
Validation: 15 healthy volunteers, 25 mild to moderate HF 
patients, 29 advanced HF patients tested for mortality, VAD 
implantation, HT and hospitalisation for HF 
Prognostic 
 
van Boven et al. 
(2017)[189] 
¯ miR-22-3p 7 Plasma 263 CHF patients tested for HF hospitalisation, cardiovascular 
mortality, cardiac and LVAD transplantation 
Prognostic 
 
Xiao et al. 
(2017)[190] 
¯ miR-30d 1 Serum 95 AHF patients tested for mortality 
Prognostic 
 
van Boven et al. 
(2018)[191] 
­ miR-1306-5p 12 Plasma 496 AHF patients tested for mortality and HF re-hospitalisation 
Prognostic 
 




12 Plasma 834 CHF patients tested for mortality and HF hospitalisation 
 





miRNAs Altered Number of 
miRNAs 
Tested 
Sample Type Test Cohort 
Prognostic 
 
Masson et al. 
(2017)[192] 
¯ miR-132 1 Plasma 953 patients with CHF tested for HF hospitalisation 
Prognostic 
 





3 Plasma 48 HF patients tested for mortality and HF re-hospitalisation 
ACC = American College of Cardiology, AHA = American Heart Association, AHF = acute heart failure, AMI = acute myocardial infarction, 
BNP = B-type natriuretic peptide, CHF = chronic heart failure, COPD = chronic obstructive pulmonary disease, ESC = European Society of 
Cardiology, HF = heart failure, HT = heart transplantation, IV = intravenous, LVAD = left ventricular assist device, LVEF = left ventricular 
ejection fraction, NT-BNP = N-terminal B-type natriuretic peptide, NT-proBNP = amino-terminal pro brain natriuretic peptide, NYHA = New 




MicroRNAs regulate a variety of physiological and cellular activities in the 
kidney and may influence the development of kidney disease and progression [28, 152]. 
Circulating and urinary miRNAs investigated as diagnostic and prognostic biomarkers 
in AKI, either in specific clinical contexts or as generalised markers of AKI irrespective 
of aetiology [28] are reviewed in Table 5. Those studies have identified 28 miRNAs as 
diagnostic or prognostic markers of AKI [194-207], of which 17 have been validated in 
independent cohorts by the same group (miR-10a-5p, miR-16, miR-26b-5p, miR-27a-3p, 
miR-29a-3p, miR-93-3p, miR-101-3p, miR-126-3p, miR-127-3p, miR-146a-5p, miR-
200c, miR-210, miR-210-3p, miR-423, miR-4270, miR-4321, miR-4640) [195, 197-
200], while miR-21 [197, 201, 204, 205], miR-30a and miR-30e [206, 208] have been 
validated by multiple groups (Figure 6).
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Aetiology of AKI Sample 
type 
Test cohort Time point/s Human replication 
cohort 




























Screen: AKI subsequent to 
acute tubular necrosis 
 
Validation 1: patients 
diagnosed with AKI in 
context of multiorgan 
failure 
 
Validation 2: CSA-AKI 
 
Diagnosed by AKIN and 
RIFLE criteria 
Serum 10 healthy 
controls, 4 
AKI patients 
Screen: not stated 
 
Validation 1: time of 
diagnosis 
 
Validation 2: baseline, 
immediately post-
surgery, and at 1, 2,3 
and 7 days after 
surgery. 
Validation 1: 35 ICU 
patients with AKI, 
20 healthy controls. 
 















Aetiology of AKI Sample 
type 







ran et al. 
(2013)[197] 
 
­ miR-21  
­ miR-200c 







Diagnosed by SCr increase 









Not stated 98 patients with AKI  
 
97 patients without 
AKI (74 healthy 










1 Diagnosed by RIFLE-
AKIN criteria 
Urine 16 ICU 
patients with 


















Aetiology of AKI Sample 
type 




Chen et al. 
(2016)[198] 











All, diagnosed by RIFLE-
AKIN criteria 
Urine For screen: 4 
ICU patients 
with AKI, 2 
healthy 
controls 
Immediately on hospital 
admission 
7 ICU patients with 
AKI, 7 ICU patients 
without AKI, 4 
healthy volunteers 
 















Non post-renal AKI, 
diagnosed by RIFLE 
criteria 
Plasma 5 patients with 





before start of RRT 
77 patients with 
AKI, 30 healthy 
controls, 18 critically 
ill patients with AMI 
tested for mortality. 












Aetiology of AKI Sample 
type 




Ge et al. 
(2017)[200] 












diagnosed by KDIGO 
criteria 
Serum 6 patients with 
sepsis-induced 
AKI, 6 sepsis 
patients 
without AKI, 3 
healthy 
controls 
First day of diagnosis 35 patients with 
sepsis-induced AKI, 
30 sepsis patients 
without AKI, 20 
healthy controls 
(including 



















Ischaemic or septic AKI, 
diagnosed by a rise in SCr 
of at least 100% over 
baseline OR histological 
confirmation of acute 
tubular injury 
Urine 22 patients 
with AKI, 25 
healthy 
controls 
Not stated NA 
Diagnostic, cardiac surgery-associated AKI 
Diagnostic 
 







in 9 rats 
CSA-AKI, diagnosed by 
KDIGO criteria 
Plasma 35 CS patients 
with AKI, 35 
CS patients 
without AKI 
Preoperation, 0, 2, 24 
and 72 h after 














Aetiology of AKI Sample 
type 























21 rats with 
I/R surgery, 







CSA-AKI, diagnosed by 
KDIGO criteria 
Urine 71 CS patients Prior to surgery at 0 h 
and at 2, 6, 12, 24, 48, 















Aetiology of AKI Sample 
type 




Arvin et al. 
(2017)[209] 
¯ miR-21 1 CSA-AKI, diagnosed by 
an absolute increase in 








Prior to and 6, 12 and 
24 hours after surgery 
NA 
Prognostic, cardiac surgery-associated AKI 
Prognostic 
 










40 CS patients 
without AKI, 
39 CS patients 
with 
progressive 









postoperative (by the 





¯ miR-21 1 CSA-AKI, diagnosed by 
KDIGO criteria 
Serum 115 patients 
undergoing 
major CS 















Aetiology of AKI Sample 
type 
Test cohort Time point/s Human replication 
cohort 






Diagnostic, contrast-induced AKI 
Diagnostic 
 
















CI-AKI, diagnosed by an 
absolute SCr increase 
≥0.3 mg/dL OR relative 
SCr increase ≥25% OR 
CyC ≥10% over baseline. 
Plasma 71 patients 
who 
underwent 






Baseline and 4 to 























by > 25% SCr increase OR 
absolute SCr increase to 
≥0.5mg/dL at 24-48h after 
administration of CM 
when no other major 
Plasma 92 patients 
with CIN, 92 
patients 
without CIN 
Prior to and at 3, 6, 12, 















Aetiology of AKI Sample 
type 








kidney insult could be 
identified  










423 to predict 
AKI 
3 Drug-induced AKI, 
diagnosed by SCr 
concentrations  > 1 mg/dL 
Urine 43 patients 
with APAP-







Not stated for APAP 
cohort 
 
Validation cohort: Prior 
to therapy and 4, 8, 12, 
24, 48, 72, 96, 120, and 
144 hours. 








ADHF=acute decompensated heart failure, AKI=acute kidney injury, AKIN=Acute Kidney Injury Network, AMI=acute myocardial 
infarction, APAP-OD=acetaminophen overdose, CAG= coronary angiography, CI-AKI=contrast-induced AKI, CIN = contrast-induced 
nephropathy, CM=contrast medium, CS=cardiac surgery, CSA-AKI=cardiac surgery-associated AKI, ICU=intensive care unit, KDIGO=Kidney 
Disease: Improving Global Outcomes, PCI=percutaneous coronary intervention, RIFLE=Risk, Injury, Failure, Loss of kidney function, and End-














Figure 6: Summary of microRNAs associated with heart failure and acute kidney injury. For a microRNA to be considered replicated, it must have been tested 
in separate discovery and validation cohorts within the same study AND/OR the microRNA must have been tested by two or more completely independent 
studies. microRNAs which have been replicated in two or more independent studies have been highlighted in bold.
Heart Failure miRNAs – Not Replicated AKI miRNAs - Not Replicated
Heart Failure miRNAs – Replicated AKI miRNAs - Replicated






































































































































































To date there has been minimal investigation into the clinical utility of miRNA 
biomarkers of AKI in the context of ADHF. Bruno et al. measured circulating 
concentrations of 12 miRNAs previously associated with HF in samples obtained from 
98 patients on the first day of hospitalisation for ADHF, finding lower concentrations of 
miR-423-3p, miR-199a-3p, and miR-let-7i-5p in 17 patients with worsening renal 
function (defined as an increase in serum creatinine by 0.3mg per decilitre or more from 
admission to day 3, Table 6) [196]. The strongest predictor of worsening renal function 
was miR-199a-3p, with each unit decrease in relative miRNA expression associated with 
a 1.5-fold increase in risk of worsening renal function (95% confidence interval for odds 
ratio 1.1-2.1). In addition, lower concentrations of miR-423-5p, miR-199a-3p, miR-652-
3p, miR-let-7i-5p and miR-27a-3p were associated with an absolute increase in creatinine 
over three days. However, the findings have yet to be confirmed in an independent cohort 
and no adjustment was made for clinical factors and SCr [196]. Notably, these 
investigators did not identify any circulating microRNAs which rose in association with 
AKI. However, this study provided proof-of-principle that miRNAs may identify patients 
at risk of renal injury in ADHF and highlights the need for comprehensive miRNA 
screening and validation studies. Such research should be performed in large, well-
phenotyped cohorts with samples collected before, during and after AKI, for comparison 
of candidate miRNA biomarkers with SCr and other emerging peptide markers for early 
detection of AKI and prediction of clinical outcomes in HF [210].
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Aetiology of AKI Sample 
type 
Test cohort Time point/s Human 
replication 
cohort 
Prognostic, WRF in HF 
Prognostic 
 





12 All, WRF defined as an 
increase in the SCr level of 
0.3 mg/dL or more on day 3 
 
Plasma 98 patients hospitalised 
with ADHF tested for 
WRF 
 
Day of hospital 
admission 
NA 




 MiRNAs can exert protective or pathogenic effects in AKI via a multitude of 
mechanisms (reviewed in [211], summarised in Table 7). Notable examples include miR-
155 and miR-199a. MiR-155 is pathogenic for AKI and acts by suppressing cell 
proliferation and promoting apoptosis via down-regulation of the gene encoding 
transcription factor 4 (TCF4), a key component of the TCF4/Wnt/β-catenin signalling 
pathway [212]. In contrast, miR-199a is protective in AKI and exerts anti-inflammatory 
and anti-apoptotic effects by down-regulating genes encoding inhibitor of NF-kB kinases 
b (IKKb), hypoxia inducible factor 1-α (HIF1-α) and extracellular signal-regulated 
kinase 2 (ERK-2) [211]. While the mechanisms underlying the association between these 
miRNAs and AKI are well-described, for many miRNAs the biological actions remain 
unknown, highlighting the need for further functional studies in relevant cell lines and 
animal models (Table 7,  refer to section 10.7 for full discussion). 
Table 7: Mechanisms of action of miRNAs associated with AKI 
miRNA Role Mechanism Reference 
miR-101 Pathogenic for AKI NFKB pathway [213] 
miR-10a Protective for AKI Anti-inflammation 
Anti-apoptosis 
[211] 






















miR-127 Protective for AKI Protects proximal tubule 
cells against 
ischemia/reperfusion 
Protects the cytoskeleton 
[194] 
 
miR-146 Protective for AKI Anti-inflammation [211] 
miR-155 Pathogenic for AKI Pro-apoptosis 






miRNA Role Mechanism Reference 
miR-16 Pathogenic for AKI NFKB pathway [214] 
miR-188 Undefined for AKI Unknown mechanism, 
associated with a 1.3-fold 
increase in patients with 
CI-AKI compared with 
those without CI-AKI 
[206] 
 
miR-192 Pathogenic for AKI Pro-apoptosis 
Pro-fibrosis 
[211] 
miR-199a Protective for AKI Anti-inflammation 
Anti-apoptosis 
[211] 
miR-200c Protective for AKI Anti-fibrosis [211] 
miR-21 Protective AND 




















miR-210 Protective for AKI 
 













Undefined for HF 
Unknown mechanism, 
associated with a 7.5-fold 
decrease in AKI patients 
















Undefined for HF 
Unknown mechanism, 
associated with a 5.09-
fold decrease in AKI 











miR-29a Protective for AKI Anti-fibrosis [211] 






associated with a 7.6-fold 
increase between CIN 









miRNA Role Mechanism Reference 
 
Undefined for HF 
 
Anti-hypertrophy 
miR-30c Undefined for AKI Unknown mechanism, 
associated with a 3.5-fold 
increase in CIN patients 





miR-30e Undefined for AKI Unknown mechanism, 
associated with a 2.6-fold 
increase in CIN patients 
compared with non-CIN 
patients 
[208] 
miR-423 Undefined for AKI Unknown mechanism, 
associated with an 8.81-
fold increase in AKI 
patients compared with 
patients without AKI 
[197] 
miR-4270 Undefined for AKI Unknown mechanism, 
associated with a 2.33-
fold increase in sepsis-
induced AKI compared 
with sepsis non-AKI 
[200] 
miR-4321 Undefined for AKI Unknown mechanism, 
associated with a 1.72-
fold increase in sepsis-
induced AKI compared 
with sepsis non-AKI 
[200] 
miR-4640 Undefined for AKI Unknown mechanism, 
associated with a 10.17-
fold decrease in AKI 
patients compared with 
patients without AKI 
[197] 
miR-494 Protective AND 








miR-93-3p Undefined for AKI Unknown mechanism, 
associated with a 22.03-
fold decrease in AKI 





AKI = acute kidney injury, CI-AKI = contrast induced acute kidney injury, CIN = 
contrast induced nephropathy, HF = heart failure, NFKB = nuclear factor kappa-light-
chain-enhancer of activated B cells 
2.8.7 Comparing	 microRNAs	 biomarkers	 for	 heart	 failure	 and	 acute	
kidney	injury	
Of the 94 candidate miRNA biomarkers replicated in HF and the 20 candidate 
miRNA biomarkers replicated in AKI, five microRNAs were common to both disorders: 
miR-21 (the most consistently replicated miRNA for AKI [177, 197, 201, 204, 205, 220, 
221]), miR-126 [195, 222-224], miR-210 [195, 199, 225, 226], miR-30a [206, 208, 227] 
and miR-423 [167, 196, 197, 220] (Figure 2). Of these, miR-21, miR-126 and miR-210, 
have established functional roles in heart and kidney, suggesting a biological basis for 
the shared association (reviewed in [211]). For example, miR-126 is expressed in 
vascular endothelial cells and has a wide range of cardio- and reno-protective effects, 
including cardiac neovascularisation and renal tubular cell proliferation [5, 211]. Lower 
circulating concentrations of miR-126 are consistently associated with greater disease 
severity and worse clinical outcomes in HF [222-224], and with risk of AKI in cardiac 
surgery and intensive care settings [195]. However, this, and other miRNAs altered in 
both HF and AKI, will require careful assessment as biomarkers for AKI in ADHF, as 
circulating concentrations may be confounded by HF severity. 
Five of the remaining miRNAs associated with AKI, miR-29a, miR-127, miR-
146a, and the kidney-enriched miRNAs, miR-10a and miR-200c, have established 
functional roles in kidney pathophysiology that may explain their association with AKI 
risk. Specifically, miR-29a, miR-10a and miR-200c have anti-fibrotic effects; miR-10a 
and miR-146a have anti-inflammatory effects; miR-127 protects the cytoskeleton; and 
miR-10a and miR-200c are released from the kidney in response to injury [211]. These 
miRNAs have not been associated with HF in any study, and warrant further 




2.8.8 Challenges	 and	 future	 directions	 for	 discovery	 of	 microRNA	
biomarkers	 for	 acute	 kidney	 injury	 in	 acute	 decompensated	
heart	failure	
 Despite promising initial findings, some studies described above have significant 
limitations, including small cohort size and lack of consideration of potential 
confounding by age, co-morbidities and drug treatments [214, 228]. Moreover, 
comparisons between studies remain challenging owing to the lack of standardised 
methods for isolation and quantification of miRNAs from urine, plasma or serum, and 
differences in study participants with regards to age, sex, ethnicity, and other inclusion 
criteria [5, 162, 214, 228, 229]. A further challenge is that miRNAs can have pleiotropic 
effects in different tissues and their concentrations change over time relative to a clinical 
event, emphasising the need to take the clinical context and timing of sample selection 
into account. For example, in heart and kidney miR-21 promotes adverse cardiac 
remodelling and renal fibrosis. [5, 211], Higher circulating and urinary concentrations of 
miR-21 have been associated with the development and progression of HF [177, 220, 
221], and risk and severity of AKI in the intensive care unit [197] and in the settings of 
sepsis [201] and cardiac surgery [204]. However, miR-21 can also have reno-protective 
effects by inhibiting apoptosis and inflammation [211], and these diverse actions of miR-
21 in the kidney may explain why Gaede et al., showed that patients with lower 
concentrations of miR-21 in venous blood prior to major cardiac surgery (a procedure 
that puts renal function at risk) were more likely to incur AKI (n=115) [205]. This 
example highlights the potential for miRNAs to have opposing effects at different times 
or in different patient groups. Detailed phenotyping of patients with AKI will be 
important to avoid masking the discovery of distinct miRNA profiles associated with 
each aetiology.  
 Consequently, several aspects of study design warrant special consideration in 
miRNA biomarker studies of AKI in ADHF: (i) the timing of sample collection relative 
to the time of hospitalisation with ADHF needs to be carefully considered and reported; 
(ii) assessment of AKI should be clearly defined, whether documented prospectively or 
assessed retrospectively based on clinical adjudication of baseline SCr concentrations 
and serial SCr measurements; (iii) potential confounding by medications, particularly for 
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miRNAs measured in urine (where changes in urine volume with diuretic treatment can 
effect miRNA concentrations, referred to as the diuretic dilution effect [230]); and lastly, 
(iv) clinical implications of all potential miRNA biomarkers for AKI in ADHF should be 
assessed by comparison of temporal profiles with SCr. This should include consideration 
of whether the candidate miRNA marker is able to resolve the presence of residual renal 
parenchymal damage from functional SCr elevation, or whether renal fibrosis will 
succeed an episode of AKI despite a return of SCr to baseline - that is, whether the 
candidate miRNA is a marker of renal function or renal damage. Consequently, large, 
well-phenotyped cohorts with serially-collected plasma, serum or urine samples are 
needed to identify and validate miRNA biomarkers that may add value to SCr and 
improve early diagnosis of AKI in patients with ADHF. As illustrated for HF, panels of 
miRNA markers may have greater utility than a single miRNA marker alone [171], and 
a rigorous methodological approach, such as that outlined by Wong et al. [171], should 
be used for accurate measurement of miRNAs in biofluids. 
2.9 Rationale	for	research	
AKI remains a serious problem in the setting of ADHF, having a high incidence 
(~25%) and being associated with an approximate doubling of mortality at one year 
follow up. Clinically useful markers have been identified for HF diagnosis and prognosis, 
but not for AKI in combination with ADHF. The ability to recognise patients with ADHF 
with early AKI is a crucial step to minimise kidney damage in these patients. Such early 
markers could facilitate timely implementation of measures such as adjustment of 
diuretic medications, to ultimately improve patient outcomes. While miRNAs and 
peptide markers have shown promise as novel biomarkers for AKI and ADHF separately, 
there is limited evidence reporting effective biomarkers for AKI in ADHF [106, 196]. 
This mandates further research to gain a better understanding of the role of circulating 
miRNAs and peptide markers in AKI in the setting of ADHF, and to develop new 





Patient Cohorts and MicroRNA 
Methods 
This chapter describes the patient cohorts from which plasma samples were analysed 
for miRNA markers of AKI, as well as the methods of miRNA screening and validation. 
This includes outlining study design, patient selection, methods of RNA extraction, 
complementary DNA (cDNA) synthesis, reverse transcription quantitative polymerase 
chain reaction (RT-qPCR) for quantifying miRNAs, as well as the subsequent data 
processing. Finally, the statistical methods used to identify candidate miRNA markers of 
AKI in ADHF are described. 
3.1 The	Patient	Cohort	
3.1.1 IMPERATIVE-HF	
Patient plasma samples for miRNA analysis were generously provided by 
Professor. Richard Troughton and Professor Rob Doughty. The Intensified Management 
using PERi-dischArge biomarker Testing and InterVEntion in acute HF 
(IMPERATIVE-HF) study is a multicentre, parallel group, randomised, open label, 
blinded endpoint (PROBE) design study comparing peri-discharge management of 
patients with ADHF with usual care (Australian New Zealand Clinical Trials Registry – 
IMPERATIVE-HF Trial, ACTRN12614001030662 [231]). Patients admitted to the 
medical and cardiology wards at Auckland and Christchurch hospitals from November 
2014 to September 2019 with ADHF as a primary diagnosis were screened for eligibility 
and randomised to NT-proBNP-guided care (natriuretic peptide ‘NP’ arm, n=225) or 
clinically-guided care (‘usual care’ arm, n=225). Inclusion criteria for the 
IMPERATIVE-HF study included age >18 years, admission with ADHF as evidenced 
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by typical clinical features plus either radiological evidence of HF or an NT-proBNP 
level > 120 pmol/L (1000pg/ mL), and ability to provide informed consent. Patients were 
excluded if there was a primary diagnosis of acute coronary syndrome (ACS), HF due to 
mitral stenosis, pericardial constriction, myocarditis/pericarditis, a life expectancy of < 6 
months due to non-cardiac disease, severe renal impairment (plasma creatinine > 250 
µmol/L), concurrent severe hepatic or pulmonary disease (volume exhaled at the end of 
the first second of forced expiration (FEV1) < 1L), severe valvular disease requiring 
surgery, severe aortic stenosis (valve area < 1 cm²), or were under consideration for 
cardiac transplantation. Patient ethnicity was self-declared and the investigation was 
conducted in accordance with the Ethical Guidelines for Interventional Studies (2012). 
All patients gave written, informed consent. IMPERATIVE-HF was approved by the 
Central Health and Disability Ethic Committee (Ethics reference: 14/CEN/147/AM04).  
Diabetes diagnosis was categorised at enrolment and was based on prior history 
(primary or secondary care), identified from patient self-report and from medical notes. 
Likewise, hypertension diagnosis at baseline was based on a prior history (self-reported 
and from medical notes) of hypertension (made by primary or secondary care physician), 
usually requiring antihypertensive therapy.  
To identify cohort differences for the subsequent biomarker analysis, 
IMPERATIVE-HF patient characteristics were compared by recruitment location. The 
miRNA screen (Section 3.4) was carried out on IMPERATIVE-HF patients recruited in 
Christchurch, whilst the miRNA validation (Section 3.5) was carried out on patients 
recruited in both Auckland and Christchurch. At the time of carrying out experimental 
work for this thesis, recruitment for IMPERATIVE-HF was n=325 out of a total 
recruitment goal of n=450. Therefore, only the portion of the cohort which was recruited 
as of that time (n=325) are included in this study and are reported throughout the thesis 
(Table 8).  
On average, patients were 64 years old at admission (range 20-89 years) and were 
predominantly male (69.5%). Approximately half the patients were European (54.5%), 
with 46 patients identifying as Māori (14.2%). Body mass index (BMI) averaged 31.8 
kg/m2 (range 15.5-67.0 kg/m2), and the median NT-proBNP at pre-discharge for the 
cohort was 204 pmol/L (IQR 104-387 pmol/L). Almost 65% of patients had documented 
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hypertension, 28% had diabetes, 23.7% had a previous history of myocardial infarction 
(MI) and 37.2% patients had a previous HF admission. 
Patients recruited in Christchurch were on average older (Christchurch 68 years; 
Auckland 60 years), and more people self-identified as NZ European compared with 
those recruited in Auckland (Christchurch 74.7% NZ European, 12.7% Māori, 0.7% 
Pasifika; Auckland 37.1% NZ European, 15.4% Māori, 28.6% Pasifika). In addition, 
patients recruited in Christchurch had lower mean BMI (Christchurch 29.6 kg/m2; 
Auckland 33 kg/m2) and were less likely to have a history of diabetes than those in 
Auckland (Christchurch 20.7%; Auckland 34.3%).  
Systolic blood pressure (Christchurch 118 mmHg; Auckland 113 mmHg) and 
E/e’ (a marker of the function of the left ventricle of the heart [232]; Christchurch 21.5; 
Auckland 17.9) were highest in patients recruited in Christchurch, indicating elevated 
filling pressures. Further to this, the median concentrations of NT-proBNP (Christchurch 
241 pmol/L; Auckland 170 pmol/L) and high sensitivity troponin T (hsTnT) at pre-
discharge (Christchurch 28.3 pg/mL; Auckland 25 pg/mL) were higher in patients 
recruited in Christchurch. Patients from Christchurch were more likely to be taking anti-
hypertensive medications (Christchurch 100%; Auckland 95.4%) or beta-blockers 
(Christchurch 99.3%; Auckland 93.1%) than their counterparts from Auckland.  
The New York Heart Association (NYHA) functional classification system was 
used to classify patients’ HF according to the severity of symptoms (class one being the 
least severe; class four being the most severe). Patients from Auckland were more likely 
to have a higher NYHA class at 6 weeks than those from Christchurch, and were less 
likely to have hypertensive or ischaemic aetiology of HF. A potential explanation for 
these observed differences could be the age profile of the two groups, as the portion of 
the cohort recruited in Christchurch tended to be older. Age has reported associations 
with NT-proBNP [233], hsTnT [234], E/e’ [235] and systolic blood pressure [236]. 
No differences were detected between patients recruited in Auckland and 
Christchurch in gender, eGFR, plasma creatinine concentration (PCr), left ventricular 
ejection fraction (LVEF), smoking status, previous HF, MI, percutaneous coronary 
intervention (PCI), coronary artery bypass graft (CABG), or device therapy. 
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Selected samples from the IMPERATIVE-HF cohort were used to screen and 
validate a panel of miRNAs to identify ADHF patients at risk of AKI (described in 
Sections 2-4 below).  








P-value Entire cohort 
(n=325) 
Age (years) § 68 (±12) 60 (±15.7) <0.001 63.8 (±14.7) 
Gender (M) 98 (65.3%) 128 (73.1%) 0.127 226 (69.5%) 
Ethnicity   <0.001  
NZ European 112 (74.7%) 65 (37.1%)  177 (54.5%) 
Māori 19 (12.7%) 27 (15.4%)  46 (14.2%) 
Pasifika 1 (0.7%) 50 (28.6%)  51 (15.7%) 
BMI (kg/m²) § 29.6 (±6.4) 33.1 (±9.2) 0.001 31.8 (±8.4) 
eGFR PD 
(mL/min/1.73 m2) § 
55.1 (±16.2) 56.9 (±18.9) 0.391 56 (±17.6) 
Systolic BP, 
supine/lying (mmHg) § 
118 (±21.6) 113 (±18.7) 0.030 116 (±20.2) 
HF Aetiology †     
Ischaemic 57 (38%) 48 (27.4%) 0.028 105 (32.3%) 
Hypertensive 41 (27.3%) 31 (17.7%) 0.024 72 (22.2%) 
NYHA Class at 6 
weeks 
  0.002  
Class 1 30 (20.7%) 14 (8.4%)  44 (13.5%) 
Class 2 88 (60.7%) 105 (62.9%)  193 (59.4%) 
Class 3 27 (18.6%) 43 (25.7%)  70 (21.5%) 
Class 4 0 (0%) 5 (3%)  5 (1.5%) 
LVM (g) § 278 (±103) 264 (±136) 0.295 270 (±122) 
E/e’ § 21.5 (±9.1) 17.9 (±8.2) 0.002 19.7 (±8.8) 
LVEF § 30.4 (±15.7) 30.1 (±10) 0.876 30.3 (±13.5) 













241 (127-470) 170 (98.8-
329) 
0.005 204 (104-387) 
PCr PD (µmol/L)† 110 (95-125) 107 (88-134) 0.659 109 (90-129) 






Previous History     
Previous HF 48 (32%) 73 (41.7%) 0.071 121 (37.2%) 
Diabetes 31 (20.7%) 60 (34.3%) 0.014 91 (28%) 
Previous MI 36 (24%) 41 (23.4%) 0.648 77 (23.7%) 
Hypertension 93 (62%) 117 (66.9%) 0.361 210 (64.6%) 
PCI 22 (14.7%) 25 (14.3%) 0.922 47 (14.5%) 
Prior CABG 23 (15.3%) 21 (12%) 0.381 44 (13.5%) 
Medications     
Anti-hypertensives 150 (100%) 167 (95.4%) 0.008 317 (97.5%) 
Hypolipidaemic agents 90 (60%) 112 (64%) 0.459 202 (62.2%) 
Diuretics 150 (100%) 175 (100%)  325 (100%) 




12 (8%) 38 (21.7%) <0.001 50 (15.4%) 
Smoking Status   0.109  
Current Smoker 16 (10.7%) 33 (18.9%)  49 (15.1%) 
Ex-smoker 71 (47.3%) 79 (45.1%)  150 (46.2%) 
Device therapy 
(existing pacemaker) 
17 (11.3%) 23 (13.1%) 0.621 40 (12.3%) 
P values generated using ANOVA or Chi squared tests, as appropriate. §Arithmetic mean 
(SD); †Median (IQR); ACEI=angiotensin converting enzyme inhibitors; 
ARB=angiotensin II receptor blocker; BMI=body mass index; BP=blood pressure; 
CABG=coronary artery bypass graft; ED=emergency department; eGFR=estimated 
glomerular filtration rate using the Chronic Kidney Disease Epidemiology Collaboration 
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equation [237]; HF=heart failure; hsTnT=high sensitivity troponin T; LVEF=left 
ventricular ejection fraction; LVM=left ventricular mass; MI=myocardial infarction; 
NT-proBNP=N-terminal pro b-type natriuretic peptide; PCI=percutaneous coronary 
intervention; PD=pre-discharge; PCr=plasma creatinine 
3.2 Study	Protocol	
Whole blood samples were collected at enrollment (within a median of four days 
of hospital admission, referred to as ‘baseline’) and also at 2 weeks, 6 weeks and 12 
weeks post discharge, as part of the IMPERATIVE-HF protocol. For patients in the 
usual-care arm of the trial, inpatient care was carried out per usual local practice, 
followed by an early post-discharge contact/review within 48 hours. The usual care 
follow-up pathway included in-hospital education about HF, low salt diet, weigh self-
monitoring, an exercise program, optimisation of medications according to HF guidelines 
and coordinated input from district nursing and allied health at the discretion of the 
attending physician to ensure adequate support and housing (allied health professionals 
are qualified practitioners who provide specialised support across a range of health 
settings in NZ). An optional primary care visit was recommended within 7-14 days of 
discharge, and continued monitoring and usual care within primary and secondary care 
settings was given. Trial mandated HF clinic visits occurred at 2-, 6- and 12-weeks post 
discharge for the majority of patients. For patients in the NP-guided arm of the trial, 
inpatient care and early post-discharge contact was guided by plasma NT-proBNP 
concentrations. Patients with pre-discharge NT-proBNP < target (NT-proBNP < 120 
pmol/L) were contacted by telephone at 48 hours as per usual care, whilst patients with 
pre-discharge NT-proBNP > target were visited at home by a HF specialist nurse within 
48 hours. An optional primary care visit was recommended within 7-14 days of 
discharge, and additional monitoring in primary care given as required. As with the usual 
care group, patients attended HF clinics at 2, 6- and 12-weeks post discharge, with 
additional 2-week visits (i.e. potential extra visits at 4, 8 and 10 weeks) to achieve NT-
proBNP targets. Additional unscheduled hospital visits that were clinically indicated 
based on HF decompensation and hospital readmissions within 180 days were recorded 






Figure 7: IMPERATIVE-HF study timeline. Study protocols for each arm of the study are described at each study time point. Usual care arm is represented by 
blue boxes, whilst the NP guided arm is represented by red boxes. CRISS = Cardio Respiratory Integrated Specialist Services; hsTnT = high sensitivity cardiac 




Blood was collected at the same time as clinical laboratory blood samples for biomarker 
and genetic analysis (2 x 9 mL Ethylenediaminetetraacetic acid (EDTA) tubes, 1 x 4 mL 
EDTA tube). Whole blood was chilled and centrifuged at 4oC at 4000 rpm for 10 minutes 
within 1 hour, then separated and plasma stored in 1 mL aliquots at -80oC for assessment 
of established and emerging biomarkers including hsTnT, creatinine, BNP, C reactive 
protein and miRNAs. Samples collected from Auckland patients were stored on site and 
shipped to the Christchurch Heart Institute (University of Otago, Christchurch) at regular 
intervals for measurement of established and emerging biomarkers. 
3.4 MicroRNA	Screening	Study	
Samples from the IMPERATIVE-HF cohort were selected to screen a panel of miRNAs 
for association with AKI in patients with ADHF. An overview of the miRNA screening 
study is shown in Figure 2. The methods described for the miRNA screening study 
include the development of criteria to identify which IMPERATIVE-HF patients 
incurred AKI within 90 days of admission to hospital with ADHF, selecting which 
sample timepoints to assay, processing plasma samples for miRNA analysis (RNA 
extraction, cDNA synthesis), performing RT-qPCR, and performing data quality control 









Figure 8: Methodology flow chart for miRNA screening and validation studies. ADHF = acute 
decompensated heart failure; AKI = acute kidney injury; cDNA = complementary DNA;  
KDIGO = Kidney Disease: Improving Global Outcomes; miRNA = microRNA; RNA = 
ribonucleic acid; RT-qPCR = reverse transcription quantitative polymerase chain reaction.  
Selection of patients for miRNA screen - KDIGO criteria and clinical adjudication
Sample Selection
18 ADHF patients with AKI, 20 ADHF patients without AKI (Christchurch only)
Randomisation - blocking design
RNA extraction
cDNA synthesis
RT-qPCR - 375 microRNA panel
Data processing pipeline - Interplate calibration, application of zero-detection limit cut 
offs, haemolysis testing, normalisation to global mean, assessment of spike in controls
Statistical analysis
Assessment of miRNA functional groupings - Ingenuity Pathway Analysis
Selection of miRNAs for validation and selection of miRNAs for normalisation in 
validation study 





AKI was defined as per the KDIGO criteria with slight modifications (an increase 
in PCr by 50% within 7 days, or an increase in PCr by 26.5 µmol/l within 2 days) [35] 
or by clinical adjudication (i.e. patients considered to have AKI by a clinician based on 
serial PCr readings over time). These approaches require knowledge of a patient’s normal 
circulating creatinine concentrations prior to admission with ADHF. These creatinine 
concentrations were not available for the Auckland arm of the cohort at the time of 
selection of cases. Consequently, only Christchurch IMPERATIVE-HF patients for 
whom historical creatinine data were available were included in the sample selection 
process for the miRNA study (n=125). 
3.4.1.2 Selecting	ADHF	patients	with	AKI	(“Cases”)	
A total of ten Christchurch IMPERATIVE-HF patients met the KDIGO criteria 
for AKI. For patients that did not meet KDIGO criteria, Dr. Daniel Herzberg (MD, PhD 
in Peri-operative Acute Kidney Injury, Karolinska Institute) clinically adjudicated their 
creatinine traces and selected a pool of patients (n=24) who would be considered to have 
AKI in the clinic. From this pool, 18 patients were selected who met or closely met 
KDIGO criteria and for whom appropriate plasma sample capturing/encompassing the 
AKI episode were available.  
The median PCr change was 30 µmol/L within 2 days (minimum 14 µmol /L; 
maximum 45 µmol/L) for cases included in the screening study through an absolute 
increase in PCr. The median percentage of PCr increase was 50% within 7 days 
(minimum 42.4%; maximum 55%) for those cases included in the screening study 
through a percentage increase in PCr. 
3.4.1.3 Selecting	ADHF	patients	without	AKI	(“Controls”)	
A pool of controls (n=61) was selected by excluding any patients meeting 
KDIGO criteria, any clinically adjudicated cases and any patients with poor kidney 
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filtration (eGFR < 40 mL/min). Dr. Daniel Herzberg then adjudicated the pool of controls 
to exclude those with potential chronic kidney disease or acute kidney disease, leaving 
41 potential controls for comparison with the AKI cases. Twenty controls were matched 
to the 18 cases on age and gender using the MatchIt package in R [238] (exact matching 
for gender, nearest matching for age at study eligibility screening).  
3.4.2 Sample	Timepoints	
3.4.2.1 Rules	for	selecting	samples	to	assay	
Following patient selection, a series of guidelines were developed to determine 
the number of samples and time points to be assayed for each case and control, to ensure 
that changes in miRNA and PCr concentrations over time were compared using 
consistent criteria.  
The guidelines used to select which study samples to assay are shown in Table 9. 
For controls, a single timepoint, at pre-discharge, was selected for comparison with cases 
in the miRNA screening study. This timepoint was selected because it was reliably 
available for all patients and is representative of kidney function of control patients 
during their hospitalisation for ADHF ( Table 9). 
For cases, multiple timepoints were selected based on PCr (illustrated in Figure 
9, using an example creatinine trace). For all AKI cases a sample directly preceding the 
rise in PCr (representing the timepoint closest to kidney insult (e.g. through ADHF)) was 
selected (sample A.1, Figure 9) to identify potential miRNA markers that change earlier 
than the current gold-standard marker, PCr. In instances where the qualifying AKI PCr 
peak overlapped with an earlier rise in creatinine, an additional plasma sample preceding 
the first creatinine rise was also selected for miRNA analysis. Where available, an 
additional sample on the peak of the qualifying AKI rise was selected (sample B.1, Figure 
9), along with a 90-day sample or sample as close to 90 days as possible (sample C.1, 
Figure 9). These two additional timepoints were included to assess the general trend of 
the miRNA over time – that is, does the miRNA stay elevated or return to baseline, and 
is the profile mirroring that of PCr. 
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A total of 70 plasma samples were selected: 20 pre-discharge samples from 20 
patients were selected as controls (one per patient). For the 20 cases with multiple 
timepoints a total of 50 plasma samples were selected (median of 3 samples per case; 18 
samples before the PCr peak (sample A.1, Figure 9), 4 samples before the PCr peak but 
superimposed on another rise (sample A.2, Figure 9), 14 samples on the PCr peak 
(sample B.1, Figure 9), and 14 samples after the PCr peak (sample C.1, Figure 9)). After 
selecting timepoints and collecting samples from the biobank, it was discovered that two 
of the selected cases had no available sample at the timepoint before the PCr peak 
(sample A.1., Figure 9). One of these patients had no other available timepoints for 
assaying and was excluded from the screening study, whilst the other had all three other 
timepoints (A.2., B.1. and C.1.) available for assaying and was kept in the screen for time 
course analysis. This resulted in a total of 20 control patients and 19 cases. 
Table 9: Guidelines for selection of samples for AKI cases and controls 
Case samples timing Control sample timing 
Prior to the PCr peak 
A.1. Prior to the KDIGO or 
adjudicated PCr rise. 
A.2. If PCr rise in A.1 overlaps 
with a prior rise, take the closest 
sample prior to the A.1 rise. 
Pre-discharge  
On the PCr peak 
B.1.  Sample must be on the peak 
of the KDIGO or adjudicated PCr 
rise. 
After the PCr peak 
C.1. 90-day sample, or if 
unavailable, the closest sample to 






Figure 9: Representative plasma creatinine trace for an IMPERATIVE-HF patient, 
demonstrating sampling timepoint selection. Creatinine concentration against time to 
Emergency Department (ED) admission. Filled black circles represent a plasma creatinine assay 
result, and filled red circles represent a plasma creatinine assay result for which a blood sample 
was also available for miRNA measurement. Dotted blue lines represent scheduled (6 weeks, 90 
day) or unscheduled (Uns) study visits. Orange arrows represent possible sampling timepoints. 
Code for the creation of plasma creatinine traces was provided by Moritz Lassé. 
 
3.4.3 Sample	Randomisation	during	Processing	
During the RNA extraction and cDNA synthesis steps, the number of samples 
being processed required batching of samples for concurrent processing. To minimise 
potential batch effects, a randomised block design was used to assign samples into 
batches for these steps. All timepoint samples from a single patient were kept in the same 
batch at each step, and cases and controls were spread equally across batches. RNA 
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extraction required 7 batches of 10-11 samples. Following RNA extraction, each batch 
was split into two groups for cDNA synthesis (2 batches).  
3.4.4 RNA	Extraction	
Total RNA (containing miRNA) must be extracted from samples in order to 
transcribe complementary DNA (cDNA), for subsequent amplification and 
quantification in RT-qPCR. RNA extraction was performed using the Qiagen miRNeasy 
Serum/Plasma Advanced kit (Cat. No. 217204, Qiagen, Aarhus, Denmark) according to 
the manufacturer’s instructions. Briefly, frozen plasma was thawed on ice, aliquoted (250 
μL) and centrifuged at 3,000 x g for 15 min at 4°C to pellet and remove cell debris. The 
RNA-containing cell- and debris-free plasma (200 μL) was transferred to a new 2 mL 
microcentrifuge tube for subsequent RNA purification. UniSp2, UniSp4 and UniSp5 
synthetic spike-in mix (synthetic RNAs of non-endogenous sequences; 1 μL; Qiagen 
RNA Spike-in Kit, Cat. No. 339390) was added to each sample as technical quality 
controls for the RNA extraction (each spike-in was added at a concentration 100-fold 
less than the other: UniSp2 > UniSp4 > UniSp5). The use of synthetic spike-ins of 
different abundance gives the ability to track the extraction efficiency of high, moderate 
and low abundance miRNAs. Furthermore, the addition of these spike-ins at known 
concentrations allows monitoring of the consistency of RNA extraction and can help 
identify where quality issues may have originated. In an additional optional step, 1.25 μL 
of MS2 carrier RNA (RNA derived from bacteriophage MS2; Roche, Cat. No. 
10165948001) was added to each sample to improve the miRNA yield during RNA 
extraction. The miRNeasy Serum/Plasma RNA extraction kit employs a column 
purification system, in which resin in the column binds RNA in a manner dependent on 
ionic concentrations. This means that only RNA binds to the column, whilst residual 
proteins are retained on top of the resin or removed in the flow-through. The bound RNA 
was then washed to remove impurities and eluted in 20 μL of RNAse-free water.  Purified 




RNA cannot be amplified directly by RT-qPCR, therefore the total RNA 
(containing miRNA) extracted from samples must first be transcribed into cDNA. Plasma 
RNA samples were reverse-transcribed to generate cDNA using the Qiagen miRCURY 
LNA RT Kit (Cat. No. 339340, Qiagen, Aarhus, Denmark). The efficiency of cDNA 
synthesis was optimised by testing three different volumes of RNA template – 2 μL, 4 
μL and 8 μL. RT-qPCR revealed that 8μL of template RNA was the most efficient for 
conversion of RNA to cDNA as this condition produced the most RT-qPCR product 
across the majority of assays tested (four of seven) (Appendix Section 1.1 Figure 62).  
All reverse transcription reactions were performed at 42°C for 60 min in a final 
volume of 40 μL containing 8 μL of template RNA, 5x miRCURY RT Reaction Buffer, 
10x miRCURY RT Enzyme Mix, RNAse-free water and 2 μL of UniSp6 and cel-miR-
39-3p spike-in mix (synthetic RNAs of non-endogenous sequences; Qiagen RNA Spike-
in Kit, Cat. No. 339390). These are different spike-ins from those used in the RNA 
extraction and were added at known concentrations to track efficiency of cDNA synthesis 
of miRNAs of differing abundance, monitor consistency and effectiveness of cDNA 
synthesis, and to allow identification of the origin of any quality issues at this step. 
Reactions were terminated by incubating at 95°C for 5 min and then cooled to 4°C. 
cDNA was stored at -30°C.  
3.4.6 RT-qPCR	
RT-qPCR is a highly sensitive and specific method for the quantification of 
miRNAs. cDNA (transcribed from total RNA containing miRNA) is amplified using 
miRNA-specific forward and reverse primers and a fluorescent dye used for detection 
[239]. The current experiment utilises the fluorescent dye SYBR Green, which 
intercalates into double-stranded DNA molecules and emits a fluorescent signal [239]. 
In an RT-qPCR assay, positive reactions are detected by the accumulation of fluorescent 
signals. Ct (cycle threshold) refers to the number of amplification cycles needed for a 
fluorescent signal to exceed background levels, and thus cross a threshold [240]. 
Therefore, a Ct value is inversely correlated to the number of copies of the target nucleic 
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acid in the sample (i.e. a lower Ct value indicates a greater concentration of the miRNA 
in the sample). 
Expression levels for 375 miRNAs were determined by RT-qPCR using the 
Exiqon microRNA Ready-to-Use PCR Human Panel I V4.R (Cat. No. 203618, Exiqon, 
Aarhus, Denmark) or its Qiagen equivalent, the miRCURY LNA miRNome PCR Panel 
Human Panel I V5m (Cat. No. 339322, Qiagen, Aarhus, Denmark). A final reaction 
volume of 10 μL was used, consisting of 5 μL of ExiLENT SYBR Green Master Mix 
(Cat. No. 203421, Exiqon, Aarhus, Denmark) or its Qiagen equivalent, 2x miRCURY 
SYBR Green Master Mix (Cat. No. 339347, Qiagen, Aarhus, Denmark), and 5 μL cDNA 
diluted 1:51.5 (equivalent to 0.095 μL of the cDNA synthesis reaction). The 
manufacturer recommends using 5 μL cDNA diluted in 245 μL RNAse-free water (ratio 
1:49), but my preliminary experiments showed that a dilution factor of 1:51.5 was needed 
to ensure sufficient volume to cover the entire plate. Panels were run on a LightCycler 
480 (Roche, Penzberg, Germany) using the PCR cycling conditions outlined in Table 10. 
For the screen, reagents were purchased from Exiqon owing to their high 
sensitivity [241]. The Exiqon company was acquired by Qiagen part-way through the 
screen and subsequently only Qiagen products were available, resulting in samples being 
assayed with a combination of Exiqon and Qiagen products. As a result, 36 of the samples 
were assayed with the Exiqon microRNA Ready-to-Use PCR Human Panel I V4.R and 
35 samples with the Qiagen miRCURY LNA miRNome PCR Panel Human Panel I V5m, 
while all assays used the Qiagen 2x miRCURY SYBR Green Master Mix chemistry. 
Due to block randomisation during sample preparation, case and control samples 
were split almost equally across the chemistries. Nine control samples and 10 case 
samples were assayed using the first combination (Exiqon/Qiagen), whilst 11 controls 
and 8 cases were assayed using the second combination (Qiagen/Qiagen). 
3.4.6.1 PCR	conditions	
The following conditions were used for PCR cycling (Table 10): 
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Table 10: PCR cycling conditions. Fluorescence was acquired with each cycle following the 
combined annealing/extension step. 
Step Time Temperature Ramp rate 
PCR initial heat 
activation 
2 min 95°C Maximal/fast mode 
2 step cycling:    
Denaturation 10 s 95°C Maximal/fast mode 
Combined 
annealing/extension 
60 s 56°C Maximal/fast mode 
Number of cycles 50   
Melting curve 
analysis 
 60-95°C  
Cooling 30 s 37°C  
 
On completion of amplification, PCR products were exposed to a temperature 
gradient from 60-95°C, holding at 60°C for 60 seconds then increasing by 0.11 degree 
every second to 95°C to determine the melting temperatures of all PCR products. A single 
melt peak at the same temperature across all samples at the end of the RT-qPCR run 
indicated successful amplification of the miRNA of interest. 
3.4.7 Quality	Control	and	Data	Processing	
3.4.7.1 Interplate	Calibrators	
Each of the 384 well plates used to screen 375 miRNAs (Exiqon microRNA 
Ready-to-Use PCR Human Panel I V4.R or the Qiagen equivalent, the miRCURY LNA 
miRNome PCR Panel Human Panel I V5m) contained three UniSp3 Interplate Calibrator 
(IPC) wells. These wells contained a standardised amount of the probe UniSp3, such that 
technical variation between RT-qPCR runs could be identified by comparing the amount 
of amplified UniSp3 PCR product in these wells. As described in Section 3.4.6, different 
combinations of chemistries were used in the current study and likely introduced 
variation. Therefore, IPCs were assessed separately for each chemistry combination and 
 
 76 
inspection of median and interquartile ranges (IQRs) was undertaken to assess 
consistency across runs. 
Analysis of the IPCs indicated a batch effect based on the chemistries used 
(Figure 10). The mean Ct for IPC wells on Exiqon plates run with Qiagen SYBR (n=36) 
was 28.0 (range 26.5-29.3). Amongst Qiagen plates run with Qiagen SYBR (n=35), Ct 
values clustered into two groups. The majority of runs (28 runs) yielded IPC Cts between 
19.5-20.1 cycles (mean Ct = 19.8), whilst a smaller subset (7 runs) yielded Cts of 25.2-
28.6 (mean Ct = 26.5). Plates from the smaller subset came from two packages of plates 
(4 plates per package) which were run consecutively, suggesting a batch effect. To adjust 
and account for this variation, all raw miRNA data were normalised, as described in 
Section 3.4.7.6. 
 
Figure 10: The effect of reagent chemistry on interplate calibrators. Each 384-well plate had 
wells containing UniSp3 (the interplate calibrator) at a standardised concentration. The mean 
Ct for IPC wells on Exiqon plates run with Qiagen SYBR (n=36) was 28.0 (range 26.5-29.3). 
Two apparent groupings were formed for Qiagen plates run with Qiagen SYBR (n=35): the 
majority of runs (28) yielded a mean Ct of 19.8 (range 19.5-20.1), and a smaller subset (n=7) 





























Haemolysis gives rise to cellular derived miRNA contamination in serum/plasma 
samples, and can occur in various steps of sampling and handling procedures until the 
serum/plasma has been separated from other circulatory components [242]. A key PCR 
inhibitor which has been identified in human blood is haeme, a part of haemoglobin 
[243]. Haeme is thought to impact PCR by releasing ferrous or ferric ions, impacting the 
ion balance and disturbing probe and primer annealing as well as polymerase activity 
[243]. It is therefore important to assess whether haemolysis occurred and could be 
influencing miRNA expression profiles or PCR efficiency.  To test for haemolysis in 
purified RNA, the difference in Ct values between hsa-miR-23a-3p and hsa-miR-451a 
was calculated (Cthsa-miR-23a-3p – Cthsa-miR-451a) [242]. These specific miRNAs were 
used as miR-451 is known to be enriched in erythrocytes, and miR-23a is relatively stable 
in plasma/serum and is unaffected by haemolysis [242]. A simple threshold value of an 
erythrocyte enriched miRNA (miR-451) cannot be used alone as concentrations of this 
miRNA can also be influenced by factors such as disease state, pre-clinical variables, 
tissue damage and natural variation, necessitating comparison of the erythrocyte specific 
miRNA to a miRNA unaffected by haemolysis (miR-23a). This method allows the 
identification and, if needed, elimination of outliers. Values < 7 indicated the absence of 
haemolysis, whilst those ≥ 7 indicated haemolysis has occurred and the sample should 
be considered for exclusion [242]. No samples in the study exceeded the threshold of ≥ 
7, with an average value of 0.09 (range -6.76 – 5.47).  
3.4.7.3 Setting	zero-detection	limit	and	coding	missing	values	
Every experimental test which quantifies analytes, such as RT-qPCR, has a limit 
of detection - defined as the lowest amount of analyte which can be detected, although 
perhaps not quantified as an exact value  [244]. It is important to identify data points 
below the limit of detection to assess whether miRNAs are reliably quantified, and so 
that these data are not incorrectly used to quantify miRNAs [245]. This process is 
recommended by Exiqon [245]. 
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A lower limit of detection of 36.5 cycles was set, based on the median Ct for 
detection of UniSp5 (median 36.54 Ct, SD 2.54). UniSp5 is a synthetic RNA spike-in 
control which is added at the lowest concentration of all the added synthetic RNA spike-
ins, and our lab has consistently observed that UniSp5 as supplied in the kit is just above 
the detection limit on our instrument (LightCycler 480, Roche, Penzberg, Germany). As 
UniSp5 is a synthetic addition to samples, using it as a lower limit of detection is 
advantageous as it removes the reliance on a detection limit based on an endogenous 
marker which may naturally vary between samples. MiRNAs with Ct values > 36.5 
(noting that lower substrate concentrations require more PCR cycles to cross the 
detection threshold and hence have higher Ct values), were recoded to the lower limit of 
detection +1 (37.5 Ct), and miRNAs with undetectable (missing) Ct values were recoded 
as the lower limit of detection + 2 (38.5 Ct) [245].  
3.4.7.4 Applying	Ct	Cut-offs	and	Excluding	Poorly	Detected	miRNAs	
Low abundance miRNAs that were not reliably detected in the majority of 
samples were excluded from further analysis by applying Ct cut-offs to the data, as 
recommended by Exiqon [245]. This involved calculating the percentage of samples for 
which the miRNA was detected below the lower-detection limit or not detected at all (i.e. 
Ct values of 37.5 and 38.5). Any miRNA for which > 20% of samples had Ct values  
≥ 37.5 were excluded to ensure robust detection of miRNA biomarkers in most human 
plasma samples. Of 375 miRNAs measured in total, 240 (64%) were excluded from 
further analysis based on these criteria. This left 135 (36%) robustly detected miRNAs 
for further analysis, consistent with studies in human plasma [162, 242, 246, 247]. 
3.4.7.5 Spike-in	Controls	
The quality of the experimental RT-qPCR data was assessed across all plates by 
comparing the Ct values of the spike-in controls (UniSp2, UniSp4, UniSp5, UniSp6, cel-
miR-39) with each other and two validated endogenous reference miRNAs for patients 
with cardiac and cardiometabolic phenotypes (miR-93 and miR-222) [248, 249] and the 
global mean (calculated as the geometric mean of all measured miRNAs in a given 
sample [250]), as recommended by the manufacturer.  
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UniSp2, UniSp4 and UniSp5 were added during sample preparation at the RNA 
extraction step, each at a different concentration with 100-fold increments. Similarly, 
UniSp6 and cel-miR-39-3p were added at the cDNA synthesis step with a 100-fold 
difference in concentration between them. Due to the logarithmic relationship between 
concentration and signal read-out in RT-qPCR, it would be expected that an 
approximately 3.3 Ct difference would be seen between spike-ins which are 10-fold 
different in concentration, and a 6.6 Ct difference would be seen between spike-ins which 
are 100-fold different in concentration. For each plate, the change in Ct was calculated 
for given pairs of spike-ins (UniSp2 and UniSp4, UniSp2 and UniSp5, UniSp4 and 
UniSp5, UniSp6 and cel-miR-39-3p). By comparing the expected difference in Ct versus 
the observed difference in Ct within the RNA spike-ins and the cDNA spike-ins, the 
efficiency of RNA isolation and cDNA synthesis was assessed, allowing identification 
of experimental and technical outliers. 
Further quality assessment of the miRNA included removal of outliers using the 
median and interquartile range (IQR) of the Ct-values. Samples with Ct values more than 
two IQRs from the upper quartile (Q3) were considered as outliers for exclusion from 
further data analysis. This process yielded the equation:  
!"	$%&'(!"#$%&' > *( + 2	-*. 
Additionally, the global mean for each plate was assessed for falling within 2 IQR 
of the upper quartile of the global mean across all of the plates. It would be expected that 
all plates would have similar global means (reflecting similar total miRNA content), and 
any plates identified as outliers should subsequently be checked at the normalisation step 
(3.4.7.6) to ensure normalisation has successfully compensated for the outlying global 
mean. Checking for outliers also allows identification of potential batch effects. 
Causes for outliers within samples include the presence of inhibitors in the 
sample, and poor-quality RNA extraction or cDNA synthesis. None of the samples in the 
screen had outlying Ct values for the more abundant spike-ins, UniSp2, UniSp4, UniSp6 
and cel-miR-39-3p. Four samples were identified as having outlying Ct Values for the 
lowest abundance spike-in, UniSp5, but these were only just outside the 2 IQR threshold 
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and were likely due to random variation resulting from measuring a low abundance 
transcript. In these samples, none of the other spike ins nor the global mean showed 
evidence of being outliers, suggesting they should not be excluded from further analysis. 
All of these processes were completed across all RNA extraction and cDNA 
synthesis batches. Comparing the median Ct and IQR for each spike-in between batches 
allowed detection of batch effects, and visual inspection was used to compare the 
distribution of these data from each batch. RNA extraction was completed in 7 batches 
(6 batches of 10 samples, 1 batch of 11 samples) and cDNA synthesis was completed in 
2 batches (1 batch of 35 samples and 1 batch of 36 samples). 
3.4.7.6 Normalisation	
Normalisation was performed to account for and reduce the technical variation 
introduced during experiments. Although recommended guidelines exist [251], there is 
currently no standardised method which is globally adhered to for normalisation in RT-
qPCR. Various normalisation methods each possess certain limitations which must be 
considered. The normalisation approach I employed combined integration of synthetic 
spike-ins, removal of low abundance miRNAs, assessment of haemolysis and the use of 
global mean normalisation to accurately assess miRNA concentrations in the plasma 
samples. For a full discussion on the advantages and disadvantages of various 
normalisation strategies, refer to Section 4.4. 
The global mean is calculated as the geometric mean of all measured miRNAs in 
a given sample [250]. Using the global mean normalisation approach is based on the 
assumption that on average, the expression of most miRNAs in a sample is constant (i.e. 
intra-individually constant), and provided enough miRNAs are analysed (>~100), their 
average expression gives a good estimate of the amount of RNA in a sample [162]. When 
a large number (>~100) of miRNAs are investigated - as in the current study - using the 
global mean to normalise avoids the need to select a specific reference control and hence 
provides a straightforward method for normalisation [162]. However, this strategy is not 
appropriate in situations where a large proportion of miRNAs demonstrate a high 
variability in expression, or when only small numbers of miRNAs are assayed.  
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The raw Ct values generated by RT-qPCR are on a binary logarithmic scale (log2) 
in which each unit increase in Ct represents a doubling in the concentration of the 
measured product. Therefore, these raw Ct values were back transformed into a linear 
scale for normalisation, using the equation: 2-Ct. Back-transformed Ct values were 
converted to relative expression by setting the sample with the highest miRNA 
concentration to 1, before normalising to the global mean [250]. 
Because relative expression of miRNAs typically displays a skewed distribution, 
these values were natural log-transformed, a mean of these natural log-transformed 
relative expressions taken per sample, and this mean back-transformed to give the 
geometric mean or global mean for each sample. This resulted in a unique global mean 
per sample, to be used as a normalisation factor [250]. The relative expression data was 
then divided by the corresponding global mean data. 
3.4.8 Data	Analysis	
3.4.8.1 Statistical	Analysis	
All statistical analyses were performed using SPSS version 24, with advice and 
guidance from Professor Chris Frampton, Biostatistician.  
Normalised miRNA expression levels displayed skewed distributions and were 
natural log-transformed prior to statistical analysis. Normalised and natural log-
transformed expression levels of each miRNA were compared between ADHF patients 
who developed AKI at the ‘before’ timepoint and ADHF patients who did not develop 
AKI using analysis of variance (ANOVA), adjusted for assay chemistry. The resulting F 
statistics were converted into effect sizes using the equation: 
/00(1"	234( = 	√7 ∗	√[:1 + :2:1 ∗ 	:2] 
Where n1 and n2 represent the sample sizes of the two groups (ADHF patients 
who developed AKI, ADHF patients without AKI). Effect size is the magnitude of the 
difference between groups [252], and in this case represents the magnitude of difference 
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between mean miRNA expression in cases and controls. The larger an effect size, the 
stronger the relationship between the two variables (e.g. miRNA expression and group). 
Effect sizes were used for subsequent ranking of candidate miRNAs as described in 
Section 3.4.8.3. 
Fold changes for each miRNA were calculated by first taking the geometric 
means of the miRNA concentration in each group. The geometric mean for patients who 
developed AKI was divided by the geometric mean for patients who did not, to give a 
magnitude and direction of the relative change. Reporting both fold-changes and effect 
sizes gives a more complete picture than either metric alone as it gives the strength of the 
relationship between miRNA expression and group (effect size) and an easily-
interpretable magnitude of the difference in miRNA expression between the groups (fold-
change).  
All box and whisker plots in this thesis were created using the ggplot2 package 
[253] in RStudio [254], in which whiskers represent the range of data, excluding outliers. 
3.4.8.2 Assessment	of	miRNA	functional	groups	
Seed sequences are conserved sequences situated at residues 2-8 of the 5’ end of 
a miRNA which guide target recognition between the miRNA and their target mRNAs, 
therefore defining miRNA function [149]. To determine the seed sequence of the 
candidate miRNAs and group them by this sequence (and therefore group them by their 
function), the ANOVA outputs (effect sizes and p-values from ANOVA described in 
Section 3.4.8.1) for all miRNAs detectable in > 80% of samples were uploaded to 
Ingenuity Pathway Analysis software (IPA; Qiagen Inc., 
https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis) and the 
‘microRNA Target Filter Analysis’ workflow run. This analysis provides insights into 
the biological functions of miRNAs by using experimentally validated and predicted 
miRNA-mRNA interactions from the Ingenuity Knowledge Base (Qiagen Inc., 
https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis) to filter 
and prioritise miRNAs based on function. A filter was applied to only include results that 
had been ‘experimentally observed OR were based on high confidence in silico 
predictions’. Results from this analysis were used to help select miRNA candidates for 
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validation (to ensure selection of miRNAs to a range of gene targets), as described below 
in Section 3.4.8.3. 
3.4.8.3 Selection	of	miRNAs	for	Validation	
Results from the ANOVA comparing concentrations of each miRNA between 
ADHF patients who developed AKI and ADHF patients who did not develop AKI in the 
screening study were ranked on effect size. A two-step selection process was applied to 
identifying miRNA candidates for validation based on miRNA effect size and predicted 
miRNA function (from IPA). First, all miRNAs with an effect size greater than 0.5 that 
had previously been implicated in AKI were selected for validation. 
Second, miRNAs with an effect size of 0.75 or greater were prioritised based on 
their seed sequence functional groups, as reported using IPA software. The miRNA with 
the greatest effect size from each functional group was selected, such that each miRNA 
measured in the validation would give independent information to avoid redundant 
interrogation of correlated miRNAs in further validation studies. Correlations between 
miRNAs were also considered. Any miRNAs which had been used as reference miRNAs 
in AKI or HF studies were not selected (miR-93-5p, U6 snRNA). The effect size 
threshold of 0.75 for miRNAs not previously implicated in AKI was selected based on 
the size of the validation cohort and the anticipated number of patients expected to incur 
AKI. The validation cohort contained approximately 200 patients and it was expected 
that 25% of these patients would develop AKI [15] (approximately 50 patients). 
However, as only a single pre-discharge timepoint was to be measured it is likely that 
some incidences of AKI would develop too late for the measured markers to detect them. 
A sample size of 32 per group is needed to detect an effect size of 0.75 and a sample size 
of 64 is required to detect an effect size of 0.5 [255]. Therefore, in a cohort of 200 patients 
in which at least 32 patients incurred AKI, we would expect to have sufficient power to 
replicate differences in miRNA concentrations between groups for miRNAs with effect 




For the ten miRNAs selected for validation, exploratory time course analysis for 
miRNA expression was undertaken in patients with samples assayed at all three possible 
timepoints (before PCr peak, on PCr peak, after PCr peak). Temporal profiles were 
assessed qualitatively by plotting miRNA expression of all 10 candidate miRNAs 
alongside PCr over the study period for each patient (one graph per patient, all miRNAs 
shown). Additionally, expression of individual miRNA for all patients across 
standardised time points (before PCr spike, on PCr spike, after PCr spike) was plotted. 
This allowed comparison for expression of each miRNA over the three time points 
between patients, but did not accurately depict the true time difference between sampling 
points. As AKI episodes do not correspond to a standardised time of the study protocol 
the onset of AKI from hospitalisation with ADHF is variable – for example, the before 
PCr peak time point in patient A may have been at 10 days after hospital admission, 
whilst in patient B it may have been at 13 days.  
3.4.8.5 Selection	of	reference	miRNAs	for	normalisation	in	validation	study	
Data from the miRNA screen were used to identify potential reference miRNAs 
for the miRNA validation study. From the ANOVA data, the 80 miRNAs with the 
smallest effect sizes (i.e. those miRNAs which differed the least between patients with 
ADHF who did or did not develop AKI) were selected (see Appendix Table 58, Section 
4.1). miRNAs with any previous associations in the literature with HF or AKI were 
removed, and the remaining 59 candidates entered into geNorm software (qbase+ 3.1, 
Biogazelle, Zwijnaarde, Belgium). A conservative initial selection size of 80 was chosen 
in order to guarantee a minimum of 50 of the most stably expressed miRNAs for entry 
into geNorm as potential housekeepers. GeNorm is a specialised analysis software which 
calculates a gene stability measure (M), relying on the principle that the ratio of two ideal 
reference genes will be identical across all samples. An M value is calculated as the 
average pairwise variation between a specific gene and all other genes in the data set – 
when one or more of the genes being compared is not constantly expressed, the 
expression stability decreases. GeNorm operates in a step-wise manner in which the least 
stable gene (highest M value) is excluded at each analysis step and a new M value is 
calculated, repeating until only the two most stable genes remain. Following this, 
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geNorm determines the optimum number of genes for normalisation using the two most 
stable genes as a starting point. Proceeding from most stable (lowest M) to least stable 
(highest M), genes are added one after the other until the pairwise variation between two 
sequential normalisation factors falls below a certain threshold. This indicates that the 
gene set immediately prior is adequate for accurate normalisation [256]. Based on 
findings from their research, Vandesompele et. al. recommend a pairwise variation 




This experiment aimed to validate the ten candidate miRNA markers of AKI in 
ADHF identified and selected in the screening study (Section 3.4). To do this, 
concentrations of the ten candidate miRNAs were measured in the plasma of 200 patients 
with ADHF using RT-qPCR. Assessment of kidney function was undertaken after all 
experimental work and miRNA data processing was completed, so that I was blinded to 
patient group prior to statistical analysis.  
3.5.1 Cohort	
The miRNA validation study included all patients from the IMPERATIVE-HF 
cohort (Auckland and Christchurch) who had been recruited at the time of analysis but 
not included in the miRNA screening study (n=200 consecutively-recruited patients with 
ADHF, Figure 11). 
3.5.2 Assessment	of	kidney	function	
Patients were divided into three groups to represent the spectrum of kidney function 
in patients with ADHF, as illustrated in Figure 11: 
§ AKI group: ADHF patients who met KDIGO AKI diagnostic criteria (n=71), 
§ Intermediate group: ADHF patients with renal impairment not meeting KDIGO 
AKI diagnostic criteria (n=98), 
§ Control group: ADHF patients with no apparent change in eGFR or PCr spikes 
of 20 µmol/L or more for 100 days from admission (n=31). 
While inclusion of three patient groups differed from the miRNA screening study 
design, many patients in the full IMPERATIVE-HF cohort experienced an increase of 
PCr of > 40% within 7 days that would not be classified as AKI by KDIGO diagnostic 
criteria but was suggestive of a very different kidney functional profile (based on PCr 
clearance and eGFR) compared to patients deemed ‘kidney healthy’. Inclusion of an 
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intermediate group allowed us to test whether candidate miRNAs were expressed 
differentially across these three phenotypic groups. 
 
Figure 11: Criteria for the assessment of kidney function in IMPERATIVE-HF patients. AKI 
group n=71 (red), Intermediate Group n=98 (purple), ADHF Control Group n=31 (blue). 
Created using BioRender.com. 
 
3.5.3 Sampling	timepoint	
MiRNAs were measured at pre-discharge for all 200 patients. Of the sample 
collection timepoints in IMPERATIVE-HF, the pre-discharge sample represented the 
most clinically relevant time point at which to detect AKI for the following reasons. In 
the screen, pre-discharge was the timepoint most commonly preceding a significant rise 
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in PCr and thus a decline in renal function (apparent in 11 out of 19 patients with AKI). 
AKI usually becomes apparent within the first few days after ADHF diagnosis [15], and 
the mean length of hospital stay for IMPERATIVE-HF patients in the validation study 
was 7 days. Furthermore, between admission and pre-discharge would be a suitable time 
point to assess kidney function, providing an opportunity for early intervention before 
the patient is discharged for follow up in primary care. 
3.5.4 Sample	Randomisation	
To minimise batch effects, a crossover design was used to randomise samples 
into batches for RNA extraction and cDNA synthesis. The RNA extraction step required 
20 batches of 10 samples. Following RNA extraction, each batch was split into four 
groups for cDNA synthesis step, which was performed in four batches of 50 samples. 
3.5.5 RNA	Extraction	
RNA extraction was performed using the Qiagen miRNeasy Serum/Plasma 
Advanced kit (Cat. No. 217204, Qiagen, Aarhus, Denmark) according to the 
manufacturer’s instructions, as described in Section 3.4.4. 
3.5.6 cDNA	Synthesis	
Plasma RNA samples were reverse-transcribed to generate cDNA using the 
Qiagen miRCURY LNA RT Kit (Cat. No. 339340, Qiagen, Aarhus, Denmark), as 
described in Section 3.4.5. 
3.5.7 RT-qPCR	
Expression levels for the ten candidate miRNAs were determined by RT-qPCR 
using Qiagen miRCURY LNA miRNA PCR Assays (hsa-let-7g-5p, hsa-miR-18a-5p, 
hsa-miR-26b-5p, hsa-miR-106a-5p, hsa-miR-140-5p, hsa-miR-146a-5p, hsa-miR-374b-
5p, hsa-miR-382-5p, hsa-miR-454-3p, hsa-miR-484. See Appendix Table 48, Section 1.3 
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for catalogue numbers. Each PCR primer comes separately in a vial, allowing 
customisation of PCR 384-well plates). A final reaction volume of 10 μL was used, 
consisting of 5 μL of 2x miRCURY SYBR Green Master Mix, 1 μL of the appropriate 
PCR primer and 3 μL of diluted cDNA template diluted 1:30. Panels were run on a 
LightCycler 480 (Roche, Penzberg, Germany) using the PCR cycling conditions 
described above (Table 10) in Section 3.4.6.1 of the miRNA Screen methods.  
3.5.8 Quality	Control	and	Data	Processing	
The quality control metrics run on data in the validation study differed slightly 
from those performed in the original screening study. In the validation, for each miRNA, 
all samples were run on the same 384 well plate in a single RT-qPCR run, removing the 
need for interplate calibration and IPC wells. The same lower detection limits identified 
in the miRNA screen were employed (refer to Sections 3.4.7.3-3.4.7.4). All ten assayed 
miRNAs were consistently detected, and none were excluded in this quality control 
process. 
3.5.8.1 Spike-in	Controls	
Refer to Section 3.4.7.5 Spike-in Controls for an introduction and description of 
the use of spike-in controls. To maximise time and cost efficiency, only one RNA spike 
(UniSp2) and one cDNA spike (cel-miR-39-3p) were run in validation samples. This 
provided enough information to identify potential batch effects occurring during sample 
preparation. The analysis process for these spike-ins followed that described earlier in 
Section 3.4.7.5. 
Medians and IQRs were calculated for each synthetic spike-in (UniSp2: 
median=19.5, IQR = 18.6-20.4; cel-miR-39-3p: median = 28.0, IQR = 26.8-29.8) and 
reference miRNA (Appendix Section 1.4). Samples with a Ct value > 2 IQR from the 
upper quartile were considered as potential outliers. This approach identified three 
samples which had outlying Ct values for either one or both spike-ins, or a reference 





In contrast to the miRNA screen (Section 3.4), the small number of miRNAs 
assayed in the validation meant that data could not be normalised to the global mean, and 
instead were normalised to a set of reference genes (selected in Section 3.4.8.5). The 
reference miRNA-derived normalisation factor is calculated as the geometric mean of all 
measured reference miRNAs in a given sample. Reference miRNAs need to be validated 
to ensure they are stable across experimental groups, and are ideally expressed at the 
same abundance as the transcripts of interest because RNA extraction and cDNA 
synthesis efficiency can vary depending on transcript abundance [162]. Using two or 
more stably expressed endogenous miRNA controls accounts for differences in the 
amount of RNA between samples. Suitable endogenous reference miRNAs can be 
identified by testing a set of stably expressed miRNAs (ideally identified in a profiling 
study) using a software such as Normfinder [257] or geNorm [256], as described above 
in Section 3.4.8.3. Refer to Section 4.4 for a full discussion on the advantages and 
disadvantages of various normalisation strategies. 
Raw Ct values were back-transformed into a linear scale and converted to relative 
expression by setting the sample with the highest miRNA level to 1, before normalising 
to a set of reference miRNAs [256]. 
Relative expression data for reference miRNAs were ln-transformed, an average 
of these ln-transformed relative expressions taken per sample, and this average back 
transformed to give the reference miRNA-derived normalisation factor. The relative 
expression data for miRNAs of interest were then divided by the reference miRNA-
derived normalisation factor to normalise the data. 
3.5.9 Assessment	of	miRNA	performance	in	validation	study	
Normalised miRNA expression levels displayed skewed distributions and were ln-
transformed prior to statistical analysis. Associations between miRNAs, creatinine, age, 
gender, ethnicity, NT-proBNP and subsequent AKI were tested using ANOVA and 




Results of MicroRNA Quality 
Control Analysis 
4.1 Introduction	
RT-qPCR is a highly sensitive and specific method capable of quantifying the low 
concentrations of miRNAs in serum and plasma [162], but presents several challenges in 
regards to generating accurate and reproducible data [162, 258]. Performing an RT-qPCR 
experiment requires several experimental steps which can all introduce technical 
variation, including sample collection method, sample starting amount, sample storage 
conditions, miRNA extraction efficiency, cDNA synthesis efficiency, and equipment-
related variation between RT-qPCR runs. All of these experimental steps can introduce 
variation which can profoundly affect the final concentration of miRNAs – potentially to 
such an extent that true biological responses may be masked [258]. Technical 
considerations are therefore an important feature of miRNA studies [162, 258]. In this 
chapter, I will outline the quality control and normalisation strategies applied to the 
miRNA screen and validation data (Figure 12). Through the application of these quality 
control and normalisation strategies, and the subsequent assessment of their efficacy, I 
aimed to reduce technical variation in the data and ensure an accurate and reproducible 




Figure 12: Overview of RT-qPCR data generation, quality control and normalisation strategy. 
Technical variation can be introduced during RNA extraction, cDNA synthesis and RT-qPCR. A 
known source of variation in the miRNA screen was the use of different combinations of kits from 
different vendors for RT-qPCR. As part of the overall normalisation strategy, synthetic spike-ins 
were added during RNA extraction and cDNA synthesis. Data were normalised to the global 
mean (screen) or to selected reference miRNAs (validation) to account for technical variation. 
Created using BioRender.com. 
 
A major element of the quality control and normalisation strategy employed in 
both the screen and validation study is the use of synthetic spike-ins and endogenous 
reference miRNAs (i.e. miRNAs stably expressed across disease groups or treatment 
groups [259]). Synthetic spike-ins allow assessment of the efficiency of RNA extraction 
and cDNA synthesis across miRNAs of low, medium and high abundance, whereas 
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endogenous reference miRNAs can indicate how a sample has been collected and stored. 
For example, a poorly stored plasma sample may have degraded endogenous miRNAs 
but synthetic spike-ins added after storage still perform well in RNA extraction and 
cDNA synthesis. Thus, the measurement of synthetic spike-ins and endogenous reference 
miRNAs across RNA extraction and cDNA synthesis batches allows identification of 
batch effects and samples which should be considered for exclusion. 
In addition to quality control, normalisation is an attempt to correct for technical 
variation in RNA extraction, cDNA synthesis and RT-qPCR steps between samples. Two 
distinct methods of normalisation were utilised in the screen and validation studies, 
owing to differences in study design (refer to Section 4.4 for full discussion). In the 
screening study, data was normalised to the global mean - the geometric mean of all 
measured miRNAs in a given sample was set to 1 [258]. As all endogenous miRNAs 
within a sample undergo the same preparation and experimental conditions, normalised 
miRNA values should give a true representation of the abundance of the miRNA in the 
sample, relative to other miRNAs. Thereby, normalisation allows comparison of miRNA 
abundances across separate samples, whilst preserving the relative miRNA intensities 
within each sample. Normalisation is particularly important in plasma miRNA 
experiments where it is challenging to accurately quantify the amount of starting RNA 
owing to its low concentration in the circulation. Therefore, the same volume of plasma 
is used in experiments, but the amount of RNA in each sample could differ [162]. In the 
validation study, data were normalised to a set of pre-selected reference miRNAs 
identified in the screening study using geNorm software (as described in Section 3.4.8.5. 
These reference miRNAs were stably expressed across samples in the screen and 
validation studies (regardless of renal status) and had no previous association with HF or 
AKI.  
4.2 miRNA	Screening	Study	
This study aimed to investigate whether circulating miRNAs can improve 
prediction of AKI in patients with ADHF by performing a screen of 375 miRNAs in 39 
patients with ADHF, 19 of whom incurred AKI. An unexpected challenge which 
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emerged during the screening process was the acquisition of the company Exiqon by 
Qiagen, resulting in combinations of different vendors reagents being employed during 
RT-qPCR. This factor needed to be accounted for in order to minimise potential 
confounding effects. 
4.2.1 Synthetic	Spike-ins	
Synthetic spike-ins were added at the RNA extraction step (UniSp2, UniSp4, 
UniSp5) and the cDNA synthesis step (UniSp6, cel-miR-39-3p) to assess the efficiency 
of these processes for miRNAs of different abundances. Analysis of the RNA spike-ins 
(comparing the mean difference between pairs of spike-ins across sample and RNA 
batches) indicated better extraction efficiency of high abundance miRNAs than lower 
abundance miRNAs, and no major RNA extraction batch effects (see Appendix Section 
3.1). In contrast, analysis of the cDNA spike-ins identified two distinct clusters of 
samples that were directly aligned with the two cDNA synthesis batches, indicating a 
potential cDNA synthesis batch effect (Figure 13). cDNA synthesis was performed in 





Figure 13: Number of RT-qPCR cycles between cDNA spike-ins UniSp6 and cel-miR-39-3p by 
cDNA synthesis batch. At the cDNA synthesis step, cel-miR-39-3p was added at a concentration 
100-fold less than UniSp6, giving rise to a predicted 6.6 Ct difference between the spike-ins.  The 
median Ct difference between the spike-ins in cDNA synthesis batch one was 11.2 Cts (IQR 10.9-
11.6), whilst it was 6.91 Cts for batch two (IQR 6.88-7.11). 
 
Comparing raw Ct values for each spike-in between batches revealed that the 
median Cts for UniSp6 were similar across the batches (batch 1: 19 Ct; batch 2: 20.8 Ct) 
whilst the median Cts for cel-miR-39-3p were noticeably different (batch 1: 31.8 Cts; 
batch 2: 26.0 Cts, see Appendix Section 3.2 for further detail). This suggested that the 
miRNAs of lower abundance converted to cDNA less efficiently in batch one for 
unknown technical reasons. This finding was consistent with previous studies by our 
group, which also found marked differences in the efficiency of cDNA synthesis between 
batches [248]. Comparison of the synthetic spike-ins controls with the global mean and 
two endogenous reference miRNAs (miR-93-3p and miR-222-3p, previously validated 
for cardiometabolic phenotypes [248, 249]) confirmed that although the synthetic spike-
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ins varied between cDNA synthesis batches, the relationship between UniSp6 and cel-
miR-39-3p was consistent within each sample. This suggested that normalisation may be 
used to address the batch effects (refer below to Section 4.2.2.1 for detailed explanation). 
4.2.2 Normalisation	of	RT-qPCR	Data	in	microRNA	Screen	
The goal of normalisation is to reduce technical variation between RNA extraction 
batches, cDNA synthesis batches and RT-qPCR runs to ensure the data can be compared 
between disease or treatment groups. In the screening experiment I observed two separate 
batch effects – a batch effect generated during cDNA synthesis (described above), and a 
batch effect based on the combination of reagents used for RTqPCR (referred to as 
chemistry groups, described in Section 3.4.6.  
4.2.2.1 Assessing	the	effects	of	normalisation	
To assess the effect of normalisation, I explored metrics of variability and data 
spread both before and after normalising. Normalisation reduced the clear separation in 
the relative expression of the spike-ins between cDNA synthesis batches (Figure 14A 
and Figure 14B). Before normalising, independent t-tests demonstrated a difference in 
the mean relative expression of UniSp6 between batches (cDNA batch 1: -2.72, cDNA 
batch 2: -1.15, p< 0.001), whereas normalisation mitigated this difference (cDNA batch 
1: 2.28, cDNA batch 2: 1.87, p=0.25, Figure 4A). This normalisation strategy also 
reduced the difference between batches for the lower abundance cDNA spike-in, cel-
miR-39-3p, but did not entirely remove the difference (pre-normalisation cDNA batch 1: 
-6.13, cDNA batch 2: -0.52, p< 0.001; post-normalisation cDNA batch 1: -1.13, cDNA 
batch 2: 2.50, p< 0.001). Therefore, normalising did not remove the batch effect entirely, 
but rather accounted for it in part. 
Interplate calibrators (IPCs, wells on each 384 well miRNA panel containing a 
standardised amount of the probe UniSp3) were used to assess technical variation 
between RT-qPCR runs by comparing the amount of amplified UniSp3 PCR product. 
Plotting IPC data revealed that normalisation reduced the separation in the mean relative 
expression of the IPC between chemistry groups (Figure 14 C), but did not eliminate the 
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difference entirely (before normalisation group 1: -8.26, group 2: -0.34, p< 0.001; after 
normalisation group 1: -4.38, group 2: 3.91, p< 0.001). Based on the visual clustering of 
the data observed in Figure 14C, chemistry groups 1 and 3 were combined into group 1 





                C 
 
Figure 14: (A) The effect of normalisation on the relative expression of cDNA synthetic spike-in 
UniSp6; (B) The effect of normalisation on the relative expression of the low abundance cDNA 
synthetic spike-in cel-miR-39-3p; (C) The effect of normalisation on the relative expression of 
IPCs. For (A), (B) and (C) the Log 2 of the miRNAs relative expression is plotted both before 
and after normalisation, illustrating the effect of normalisation on the distribution of data. cDNA 
synthesis batch is indicated by the colour of data points. 
 
Plotting the coefficient of variation (CV) across all 135 consistently detected 
miRNAs before and after normalisation demonstrated a reduction in median CV after 
normalisation (paired sample t-test of data before and after normalisation: p< 0.001, 
Figure 15A). This indicated that normalising reduced the variation generated through 
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processing multiple RNA extraction batches, cDNA synthesis batches and chemistry 
groups. 
To examine the impact of normalisation on endogenous miRNAs, relative 
expression data for stably expressed miRNAs of high, medium and low abundance were 
plotted before and after normalisation, with cDNA conversion batch indicated (Figure 15 
B, C and D). For miR-222-3p (low abundance, validated endogenous reference miRNA), 
miR-93-5p (medium abundance, validated endogenous reference miRNA) and miR-223-
3p (high abundance, amongst the 50 most stably expressed miRNAs in our data set), 
independent t-tests identified differences in the mean relative expression of each miRNA 
based on cDNA synthesis batch prior to normalisation. After normalisation, these 
differences were still detectable by independent t-tests, but the difference in mean relative 
expression by cDNA batch was reduced for the medium (pre-normalisation cDNA batch 
1: -7.42, cDNA batch 2: -3.12, p< 0.001; post-normalisation cDNA batch 1: -1.97, cDNA 
batch 2: -056, p< 0.001) and low abundance miRNAs (pre-normalisation cDNA batch 1: 
-7.45, cDNA batch 2: -1.40, p<0.001; post-normalisation cDNA batch 1: -2.00, cDNA 
batch 2: 1.16, p< 0.001). In contrast, the difference in mean relative expression by cDNA 
batch was increased after normalisation for the high abundance miRNA, miR-223-3p 
(pre-normalisation cDNA batch 1: -2.70, cDNA batch 2:-1.85, p< 0.05; post-
normalisation cDNA batch 1: 2.74, cDNA batch 2: 0.71, p< 0.001). In the raw expression 
data, low abundance miRNAs were affected by cDNA synthesis batch to a greater extent 
than high abundance miRNAs, suggesting that normalisation overcompensates for high 
abundance miRNAs. 
In our dataset, only 9 miRNAs had a mean Ct value < 25 and would be considered 
of high abundance, whilst 40 miRNAs had mean Ct values between 25-30, and the 
remaining 86 miRNAs were of low abundance (mean Ct > 30). Given that low abundance 
miRNAs make up the majority of the detected miRNAs in this dataset, the positive effect 
of normalisation on the low abundance miRNA species outweighs the slight over-










Figure 15: (A)The effect of normalisation on the coefficient of variation across all 135 consistently detected miRNAs. The coefficient of variance is plotted for 
each miRNA both before and after normalisation, demonstrating a reduction in the median CV after normalisation. miR-374a-5p was an outlier for CV both 
before and after normalisation, and the CV was not improved by normalisation. miR-374a-5p is a low abundance miRNA (mean Ct = 30.7) which may have 
been affected by the cDNA batch effect to a greater extent than more abundant miRNAs, meaning normalisation would not account for this technical error 
completely (i.e. undercompensation for the batch effect). Normalising increased the CV for one miRNA, miR-93-5p. The sample with the highest concentration 
of miR-93-5p (lowest Ct value, 23.1) was not an outlier by the 2IQR rule, but this samples Ct value fell in the ‘high abundance’ miRNA category, so normalisation 
likely overcompensated and produced the larger CV. 
(B) The effect of normalisation on the relative expression of the low abundance endogenous miRNA miR-222-3p (mean Ct = 32.0); (C) the effect of normalisation 
on the relative expression of the medium abundance endogenous miRNA miR-93-3p (mean Ct = 28.4). (D) the effect of normalisation on the relative expression 
of the high abundance miRNA miR-223-3p (mean Ct = 23.1).  For (B), (C) and (D) the Log 2 of the miRNAs relative expression is plotted both before and after 
normalisation, illustrating the effect of normalisation on the distribution of data. cDNA synthesis batch is indicated by the colour of data points.
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Finally, I investigated the impact of batch effects in our data by performing a 
Principal Component Analysis (PCA) before and after normalisation. PCA analysis 
revealed two broad clusters that persisted after normalisation (Figure 16).  Drawing these 
PCA plots with cDNA synthesis batch, RNA extraction batch and chemistry group as 
plotting factors revealed that none of these factors were the leading cause of variation in 
miRNA concentrations before or after normalisation.
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Figure 16: Principal component analysis before and after normalisation, indicating two broad clusters. The colour of data points indicates cDNA synthesis 
batch, RNA synthesis batch or chemistry group. The equal distribution of samples across the two clusters indicates that neither cDNA synthesis batch, RNA 
batch or chemistry group accounts for the variability explained by the first two principal components
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In summary, normalisation to the global mean markedly reduced the influence of 
cDNA synthesis and reagent chemistry batch effects on miRNAs of low and medium 
abundance, but overcompensated for miRNAs of high abundance, a relatively small 
portion of the miRNAs assayed. It must be acknowledged that although the comparability 
of data across batches has been improved, there is potential for some residual 
confounding in the miRNA screening study. 
4.3 miRNA	Validation	Study	
This study aimed to validate 10 miRNAs identified in the miRNA screen which 
were differentially expressed between patients with ADHF who experienced AKI and 
those who did not. The panel of miRNAs were measured in the plasma of a larger 
(n=200), independent cohort of consecutively-recruited patients (‘all-comers’) with 
ADHF to determine whether these miRNAs added independent information beyond 
established markers such as PCr and markers of ADHF severity including NT-proBNP. 
The small number of miRNAs analysed meant that there was not the large, unbiased 
dataset to permit normalisation to the global mean, and endogenous reference miRNAs 
identified in the miRNA screen were used for normalisation (refer to Methods Sections 
3.4.8.5 and 3.5.8.2 for detail). 
4.3.1 Spike-ins	
To maximise cost-efficiency, only the most abundant RNA spike-in (UniSp2) and 
cDNA spike-in (cel-miR-39-3p) were included in the validation study. This provided 
sufficient information to identify potential batch effects, but did not enable assessment 
of the efficiency of RNA extraction or cDNA synthesis for miRNAs of high, medium 
and low abundance. 
Comparing the median Ct and IQR for each spike-in between batches demonstrated no 
evidence for batch effects during either the RNA extraction or cDNA synthesis steps (see 




Relative expression data was normalised to a reference miRNA-derived 
normalisation factor to minimise technical variability across the experiment. Although 
no large RNA extraction or cDNA synthesis batch effects were observed in the validation 
study, normalising significantly reduced the CV across all 10 miRNAs assayed (Figure 
17 A, paired sample t-test of data before and after normalisation: p=0.001, mean of the 
differences = 0.354, 95% CI = 0.184-0.524).  
 
 
Figure 17: The effect of normalisation on the coefficient of variation across all 10 assayed 
miRNAs. The coefficient of variation is plotted for each miRNA before and after normalisation, 
demonstrating a reduction in the median CV after normalisation.  
 
In summary, normalisation to four endogenous reference miRNAs (miR-24-3p, 





The preceding analyses assessed the efficiency and consistency of RNA extraction, 
cDNA synthesis and RT-qPCR using a combination of synthetic spike-in controls, 
validated reference genes and endogenous miRNAs of varying abundance. These results 
indicated that RNA extraction efficiency was consistent in both the screen and validation 
study, but that a batch effect occurred at the cDNA synthesis step in the screening study 
resulting in poor conversion of low abundance miRNAs to cDNA. However, this batch 
effect was able to be partially mitigated by normalising to the global mean. Normalising 
also partially accounted for the effects of the varied combinations of Qiagen and Exiqon 
products observed in the screen (identified by interplate calibrators).  
Whilst all large miRNA studies face the challenge of minimising and accounting 
for technical variation introduced at various experimental steps, this study faced an 
additional unexpected challenge in the miRNA screen. During the course of the study, 
the company initially supplying reagents, Exiqon was acquired by Qiagen, resulting in a 
change in RT-qPCR chemistry. Despite reassurances from Qiagen that the re-branded 
reagents would perform the same as their Exiqon predecessors, distinct batch effects 
based on the combinations of vendors kits being used were observed. This needed to be 
accounted for to minimise potential confounding of results, further complicating the 
challenge of normalisation. 
The use of synthetic RNA spike-ins at both the RNA extraction and cDNA 
synthesis steps is an important aspect of quality control in miRNA studies [162]. At both 
of these experimental steps, RNA extraction batches may vary in purity, yield and 
integrity, and some sample types (including plasma) may retain compounds which inhibit 
cDNA synthesis and RT-qPCR despite using high quality purification procedures [260]. 
In addition, cDNA synthesis relies on the performance of an enzyme (Reverse 
Transcriptase). This may result in different enzymatic turnover number of reverse 
transcription between batches, either affecting all miRNAs in a sample or affecting a 
subset of miRNAs of a specific abundance [260]. Differences in enzymatic turnover can 
result due to sensitivity of the enzyme to temperature, salt concentration and pH [261, 
262] - although use of a consistent mastermix across batches should prevent differences 
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in salt concentration and pH. The addition of RNA spike-ins at the cDNA synthesis step 
in these experiments identified a striking cDNA synthesis batch effect in the screening 
study – miRNAs of low abundance were synthesised with lower efficiency in cDNA 
synthesis batch one than in batch two. This effect was subsequently mitigated during the 
normalisation step. 
Study design plays a key role in generating accurate and reproducible RT-qPCR 
data [162]. In the current experiments, care was taken to randomise samples across the 
various RNA extraction and cDNA synthesis batches such that if a batch effect was to 
occur, it would not bias the comparison between the patient groups (i.e. ADHF patients 
with AKI and ADHF patients without AKI). Ideally, all samples would be processed in 
a single RNA extraction and cDNA synthesis batch and be run on the same RT-qPCR 
machine on the same day, minimising any technical variation. However, due to the 
intensive hands-on nature of these steps, only a certain number of samples can be 
processed at a time. To an extent, thoughtful study design, including randomisation of 
disease or treatment groups across these steps, can minimise the impact of technical 
variability.  
A critical step in RT-qPCR analysis is the use of an appropriate normalisation 
strategy. Although recommended guidelines exist [251], there is currently no 
standardised, consensus approach for normalisation which is globally adhered to [162, 
258]. Commonly used normalisation strategies include normalising to the global mean, 
exogenous synthetic spike-in controls, and endogenous reference miRNAs [263]. 
However, none of these methods are without drawbacks and each provide different 
advantages. Synthetic spike-in controls are only able to correct RT-qPCR data for 
variability related to specific processes such as RNA extraction and cDNA synthesis, but 
cannot correct for sample related intrinsic factors to which they are not exposed (i.e. 
sample collection method, sample starting amount, sample storage conditions) [258, 
263]. In contrast, endogenous reference miRNAs (aka housekeepers) are able to correct 
RT-qPCR data for all intrinsic factors, as their expression is affected by the same 
variables as the target miRNAs [258]. However, identification and optimisation of 
reliable endogenous reference (housekeeper) miRNAs can be expensive and laborious, 
and a given reference miRNA/set of reference miRNAs must be validated for each 
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phenotype being investigated [162]. Compounding this issue, there is no universally 
accepted strategy for testing the selected miRNAs and checking they correctly adjust for 
technical and environmental variation without introducing bias into the analysis [264]. 
Therefore, when normalising miRNA data to endogenous reference miRNAs, it is also 
useful to include synthetic spike-in controls to assess the extent of technical variation in 
the experiment and to identify samples which have performed poorly [162]. 
An alternative, and commonly used normalisation strategy is normalising to the 
global mean – the geometric mean of all measured miRNAs in a given sample [258]. 
This method is commonly used in experiments assaying a large number of miRNAs and 
is particularly useful in cases where stable endogenous reference miRNAs are unknown 
[250]. This strategy relies on the assumption that on average, the expression of most 
miRNAs in a sample is constant, and provided enough miRNAs are analysed (>~100), 
their average gives a good estimate of the amount of RNA in a sample [162]. However, 
this strategy is not appropriate in situations where a large proportion of miRNAs 
demonstrate a high variability in expression, or when only small numbers of miRNAs 
are assayed [250]. Normalising to the global mean is an appropriate strategy in the plasma 
of patients with ADHF in which a proportion have AKI, as only a few miRNAs should 
be widely different in concentration between patients who do and do not have AKI [195]. 
None of the above normalisation strategies provides a complete solution in itself – 
as such, I have applied aspects of each method across the screening and validation studies 
to take advantage of the various strengths of each strategy [265, 266]. This approach has 
previously been used in miRNA biomarker studies with discovery and validation phases 
[267-270]. Due to the large number of miRNAs being assayed in the screen, 
normalisation using the global mean was feasible, and the miRNA expression data 
generated was used to identify stably expressed endogenous reference miRNAs in the 
validation study. As the field of miRNA research continues to evolve, the development 
of a standard normalisation protocol would ensure reproducibility across studies, 






Results of MicroRNA Screening 
Study 
5.1 Introduction	
In this chapter, I aimed to identify miRNAs which have potential as diagnostic 
markers for AKI in the setting of ADHF by conducting a large-scale screening study in 
39 patients admitted to hospital with ADHF. 
Over the last two decades, a large number of studies have explored the utility of 
miRNAs as novel biomarkers for AKI or ADHF separately, but there is limited literature 
investigating the value of miRNAs as markers of AKI in the context of HF [196]. In the 
sole paper investigating a similar research question to the current screen, Bruno et al. 
measured circulating concentrations of 12 miRNAs previously associated with HF in 98 
patients hospitalised for ADHF [196]. They demonstrated lower concentrations of miR-
423-3p, miR-199a-3p and miR-let-7i-5p in 17 patients with worsening renal function 
(defined as an increase in serum creatinine by 0.3 mg/dL or more from admission to day 
3).  However, the authors did not confirm their findings in an independent cohort, nor 
did they report whether their candidate miRNAs were predictive of worsening renal 
function after adjustment for clinical factors and SCr. This study provides important 
proof-of-principle that miRNAs have potential to identify patients at risk of renal injury 
after hospital admission with ADHF and highlights the need for comprehensive miRNA 
screening and validation studies in large, well-phenotyped cohorts. These cohorts need 
to have samples collected at several timepoints for comparison of candidate miRNA 
biomarkers with the time-course of PCr and other emerging peptide markers for AKI, 
along with markers of clinical outcomes in HF such as NT-proBNP [210]. 
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In this study, I have taken a well-phenotyped cohort of patients with ADHF and 
used AKI diagnostic criteria and clinical adjudication to select patients who experienced 
AKI (n=19), along with a matched group of controls with no AKI (n=20). I then screened 
a panel of 375 miRNAs in the plasma of these patients using RTqPCR immediately prior 
to the AKI-qualifying increase in PCr, to identify miRNAs that differed between patients 
who experienced AKI and those who did not. I also investigated the biological function 
and associations of candidate miRNAs in order to select an optimal panel of candidate 
miRNAs for validation in a larger, independent cohort (validation study results are 
reported in Chapter Six). 
5.2 Results	
As described in Chapter Four, the following data have been through quality control 
processing, and have been normalised using the global mean to adjust for technical 
variation introduced at the cDNA synthesis step. 
5.2.1 The	screening	cohort	
Patient characteristics for the screening cohort are shown in Table 11, presenting 
data separately for patients with ADHF with and without AKI. In the screening cohort 
overall, the mean age of ADHF patients (n = 39) at admission was 73 years (range 54-83 
years) and 69% of patients were male. The majority of patients were European (95%), 
with 2 patients identifying as Māori. BMI data, available for 26 individuals, averaged 
28.1 kg/m² (range 18-55 kg/m²). Nearly 67% of patients had documented hypertension, 
20.5% had diabetes, 25.6% had a previous history of MI and 41% of patients had a 
previous HF admission. The median NT-proBNP at pre-discharge for the screening 
cohort was 304 pmol/L (123-729 pmol/L).  
At pre-discharge (PD), patients with ADHF who later developed AKI had worse renal 
function (ADHF without AKI, median eGFR 105 µmol/L; ADHF and AKI, median 
eGFR 124 µmol/L; p=0.002) than patients with ADHF alone. In addition, median hsTnT 
(a marker of cardiomyocyte necrosis) at PD was, on average, 11 pg/mL higher in patients 
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with ADHF and AKI (33 pg/mL) than in ADHF patients without AKI (22 pg/mL, 
p=0.031). A larger proportion of patients with ADHF and AKI had a hypertensive 
aetiology (42.1%) than ADHF patients without AKI (15%, p=0.005).  
For ADHF aetiology, two patients were classified as having both an ischaemic and 
hypertensive aetiology, whilst one individual was classified with an ischaemic, 
hypertensive and ‘other’ aetiology. Four patients were classified in hypertensive and 
‘other’ aetiology groups. The aetiologies included in the ‘other’ category include alcohol 
abuse, toxin drug related, hypertrophic cardiomyopathy, myocarditis, idiopathic 
cardiomyopathy, valvular, familial cardiomyopathy, congenital heart disease, other 
aetiology and unknown aetiology.  
We did not detect differences between cases and controls in smoking status, 
LVEF, E/e’, previous PCI, CABG or device therapy. 
Table 11 Demographics of screening cohort. Basic demographics of the cohort are presented 
based on the two kidney function groups patients were separated into for analysis – ADHF and 








Age (years) § 72 (±8) 74 (±8) 0 (0%) 0.502 
Gender (M) 14 (70%) 13 (68.4%) 0 (0%) 0.915 
Ethnicity   0 (0%) 0.136 
NZ European 20 (100%) 17 (89.5%)   
Māori 0 (0%) 2 (10.5%)   
BMI (kg/m²) § 28.5 (±9) 27.8 (±5) 13 (33.3%) 0.814 
eGFR PD (mL/min) 
§ 




114 (±19) 130 (±27) 1 (2.6%) 0.047 
ADHF Aetiology†     












































LVM (g) § 302 (±78) 293 (±101) 1 (2.6%) 0.740 
E/e’§ 20.7 (±7) 18.7 (±8) 7 (17.9%) 0.427 
LVEF § 41.2 (±13) 38 (±15) 3 (7.7%) 0.607 
PCr PD (µmol/L)† 105 (90-110) 124 (110-139) 0 (0%) 0.002 





258 (120-783) 3 (7.7%) 0.767 
hsTnT PD (pg/mL)† 22 (15-39) 33 (23-68) 4 (10.3%) 0.031 
Previous History     
Previous HF 6 (30%) 10 (52.6%) 0 (0%) 0.151 
Diabetes 2 (10%) 6 (31.6%) 0 (0%) 0.095 
Previous MI 4 (20%) 6 (31.6%) 0 (0%) 0.408 
Hypertension 13 (65%) 13 (68.4%) 0 (0%) 0.821 
PCI 4 (20%) 4 (21.1%) 0 (0%) 0.935 
Prior CABG 5 (25%) 4 (21.1%) 0 (0%) 0.770 
Medications     
Anti-hypertensives 20 (100%) 19 (100%) 0 (0%) 1 
Hypolipidaemic 
agents 
14 (70%) 12 (63%) 0 (0%) 0.651 
Diuretics 20 (100%) 19 (100%) 0 (0%) 1 














Smoking Status   0 (0%) 0.980 
Current Smoker 1 (5%) 1 (5.3%)   




3 (15%) 3 (15.8%) 0 (0%) 0.946 
Days from ED to 
PD 
3 (±1) 4 (±3) 1 (2.6%) 0.183 
ED to discharge 3 (±2) 4 (±3) 0 (0%) 0.253 
PD to discharge 0 (±1) 0 (±1) 0 (0%) 0.776 
P values generated using ANOVA or Chi squared tests, as appropriate. §Arithmetic mean 
(SD); †Median (IQR); ACEI=angiotensin converting enzyme inhibitors; ADHF=acute 
decompensated heart failure; ARB=angiotensin II receptor blocker; BMI=body mass 
index; BP=blood pressure; CABG=coronary artery bypass graft; ED=emergency 
department; GFR=glomerular filtration rate; HF=heart failure; hsTnT=high sensitivity 
troponin T; LVEF=left ventricular ejection fraction; LVM=left ventricular mass; 
MI=myocardial infarction; NTproBNP=N-terminal pro b-type natriuretic peptide; 
PCI=percutaneous coronary intervention; PD=pre-discharge; PCr=plasma creatinine. 
5.2.2 Comparing	expression	 levels	of	miRNAs	between	ADHF	patients	
with	and	without	AKI	
In ADHF patients who did not develop AKI (referred to as controls), plasma from 
pre-discharge was assayed (this timepoint was considered to be representative of kidney 
function of control patients during their hospitalisation for ADHF). For ADHF patients 
who developed AKI (referred to as cases), a sample was selected directly preceding a 
rise in PCr (indicating worsening kidney function, as described in Methods Section 
3.4.2). Comparison of miRNA expression levels in the plasma immediately preceding 
AKI in cases, or at the pre-discharge timepoint in controls, forms the core analysis of 
Sections 5.2.2 - 5.2.6. 
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Of 375 miRNAs screened, 135 miRNAs were consistently detected in the plasma 
samples. ANOVA was used to compare miRNA expression between AKI cases and 
controls using F statistics and generate effect sizes for each miRNA (described in 
Methods Section 3.4.8.1). F statistics for all 135 miRNAs are shown in Table 58 
Appendix Section 4.1. For exploratory purposes, miRNAs were considered differentially 
expressed and included in subsequent analysis if there was an effect size of ≥ 0.5. This 
analysis identified 26 miRNAs that were differentially expressed between groups (Table 
12). Of these, 12 miRNAs displayed an effect size greater than the pre-stipulated 0.75 
threshold for optimal power in the validation study (see Methods Section 3.4.8.3).  
A seed sequence is a conserved sequence situated at residues 2-8 of the 5’ end of 
a miRNA which guides target recognition between the miRNA and mRNAs, and 
therefore determines miRNA function [149]. Clustering of the 26 miRNAs into 
functional groupings based on their seed sequences revealed 18 functional groups and 
this will be described further in Section 5.2.3 and Table 14.  
Table 12: MiRNAs differing in expression between ADHF patients with and without AKI, with 
an effect size of 0.5 or greater. Each miRNA is presented with the F statistic generated using 
ANOVA, the effect size and the fold change observed in patients with ADHF and AKI. In addition, 
seed sequences are recorded and functional groups assigned based on these sequences. 
miRNA F 
statistic 












miR-26b-5p 17.16 <0.001 1.35 ¯ 1.9 1 UCAAGUA 
miR-106a-5p 11.54 0.002 1.10 ¯ 2.1 2 AAAGUGC 
miR-17-5p 9.41 0.004 1.00 ¯ 2.9 2 AAAGUGC 
miR-454-3p 8.83 0.005 0.97 ¯ 1.8 3 AGUGCAA 
let-7g-5p 8.66 0.006 0.96 ¯ 1.6 4 GAGGUAG 

















miR-18b-5p 7.15 0.011 0.87 ¯ 2 5 AAGGUGC 
miR-20a-5p 7.09 0.012 0.86 ¯ 1.6 2 AAAGUGC 
miR-374b-5p 6.43 0.016 0.82 ¯ 2 6 UAUAAUA 
miR-140-5p 5.73 0.022 0.78 ¯ 1.6 7 AGUGGUU 
miR-484 5.56 0.024 0.77 ¯ 1.8 8 CAGGCUC 
miR-382-5p 5.35 0.027 0.75 ­ 1.7 9 AAGUUGU 
let-7b-5p 4.90 0.034 0.72 ¯ 1.5 4 GAGGUAG 
miR-10b-5p 4.17 0.049 0.66 ­ 1.7 10 ACCCUGU 
miR-93-5p 4.13 0.05 0.66 ¯ 1.9 2 AAAGUGC 
miR-584-5p 3.92 0.056 0.64 ­ 1.6 11 UAUGGUU 
miR-146a-5p 3.79 0.06 0.63 ­ 1.4 12 GAGAACU 
miR-152-3p 3.46 0.071 0.60 ­ 1.2 13 CAGUGCA 
miR-130b-3p 3.03 0.091 0.57 ­ 1.3 3 AGUGCAA 
miR-214-3p 2.93 0.096 0.56 ­ 1.7 14 CAGCAGG 
miR-320a 2.90 0.098 0.55 ­ 1.6 15 AAAGCUG 
miR-125a-5p 2.89 0.098 0.55 ­ 1.3 16 CCCUGAG 
miR-99b-5p 2.75 0.106 0.54 ­ 1.5 17 ACCCGUA 
miR-665 2.66 0.112 0.53 ­ 2.2 18 CCAGGAG 
miR-106b-5p 2.65 0.112 0.53 ¯ 1.3 2 AAAGUGC 





Figure 18: All reliably detected miRNAs plotted by ANOVA F-statistic size. The dashed line 
represents the cut-off threshold applied for miRNAs to be considered for validation (0.50). The 
26 miRNAs for which the bar extends above the dotted line were considered for further analysis. 
 
5.2.3 Assessment	of	miRNA	Functional	Groups	
Functional groupings for miRNAs with an effect size of 0.5 or greater are 
presented above in Table 12, alongside the miRNA seed sequence. The multitude of 
functional groups represented indicates that a variety of genes and cellular pathways may 
be targeted by these 26 miRNAs. To filter and prioritise miRNAs based on function, 
‘microRNA Target Filter Analysis’ was run using Ingenuity Pathway Analysis (IPA, 
Table 13). This analysis provides insights into the biological functions of miRNAs by 
using experimentally validated and predicted miRNA-mRNA interactions. The 





















































































































































































































































































































































































































































































































































































































































































































































































































F−statistics of Candidate miRNAs
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renal inflammation/renal nephritis (p< 0.001), suggesting that miRNAs altered in the 
plasma of ADHF patients with AKI may be directly associated with the AKI itself. The 
miRNAs were also enriched for liver (p=0.001 – 0.036) and cardiac (p=0.037) pathways, 
potentially suggesting involvement of these organs in the pathophysiology of AKI in 
ADHF or overlap between the miRNAs that regulate these pathways in liver and cardiac 
tissue with the miRNAs that regulate the same pathways in kidney tissue.  
Table 13: Top miRNA pathways generated using IPA. miRNAs and seed sequences involved in 
each pathway are listed. This list includes only pathways with experimentally observed or high 
predicted confidence. P-values are adjusted for multiple comparisons (Benjamini-Hochberg 
procedure). 
Category P-Value Seed sequences miRNAs 






































































Congenital heart anomaly 0.037 AGUGCAA miR-454-3p, miR-
130b-3p 












Correlations between all miRNAs with an effect size greater than 0.5 were 
assessed to determine the extent to which each miRNA may contribute independent 
prognostic information. As seen in Figure 19, eight broad clusters of miRNAs with 
similar correlation profiles were identified using hierarchical clustering. Associations 
between miRNAs ranged from lack of correlation through to strong correlations (e.g. 
Spearman correlation 0.848, p< 0.001, for miR-106a-5p and miR-18a-5p).  
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Inspection of the functional groupings and seed sequences represented in each 
cluster (Table 14), revealed that miRNAs from the same functional group tended to have 
similar correlation profiles (e.g. both miRNAs from functional group 1 clustered 
together). The exception to this statement were miR-17-5p and miR-106b-5p, which each 
clustered with a miRNA from another functional group rather than the three other 
members of functional group two. Similarly, miR-130b-3p and miR-454-3p, both 
members of functional group 3, were not placed in the same correlation cluster. 
This observation that miRNAs with the same seed sequence tended to show a 
similar pattern of expression implies that miRNAs from within the same functional group 
provide correlated information. Therefore, assaying representative miRNAs from each 




Figure 19: Correlation matrix of miRNAs with an effect size >0.5. Colour signifies the 
directionality of correlations, with red showing a negative correlation and blue showing a 
positive correlation. Colour intensity and size of squares are proportional to the correlation 
coefficients. In the right side of the correlogram, the legend shows the correlation coefficients 
and the corresponding colours. Boxes indicate eight broad groups with similar correlation 
profiles (Spearman correlation, hierarchical clustering method “Ward”). Age, NTpro-BNP, 




































































































































































































































Table 14: Clusters of miRNAs with similar correlation profiles formed using Spearman 
correlation and the hierarchical clustering method “Ward”. Functional group and seed 
sequence are noted for each miRNA. 
Cluster miRNA Functional Group Seed Sequence 
1 miR-10b-5p 10 ACCCUGU 
 miR-130b-3p 3 AGUGCAA 
 miR-214-3p 14 CAGCAGG 
2 miR-125a-5p 16 CCCUGAG 
 miR-665 18 CCAGGAG 
 miR-99b-5p 17 ACCCGUA 
 miR-584-5p 11 UAUGGUU 
 miR-320a 15 AAAGCUG 
3 miR-382-5p 9 AAGUUGU 
 miR-146a-5p 12 GAGAACU 
4 miR-152-3p 13 CAGUGCA 
5 miR-106b-5p 2 AAAGUGC 
 miR-93-5p 2 AAAGUGC 
 miR-140-5p 7 AGUGGUU 
 miR-106a-5p 2 AAAGUGC 
 miR-18a-5p 5 AAGGUGC 
 miR-18b-5p 5 AAGGUGC 
 miR-20a-5p 2 AAAGUGC 
6 miR-17-5p 2 AAAGUGC 
 miR-484 8 CAGGCUC 
7 let-7g-5p 4 GAGGUAG 
 let-7b-5p 4 GAGGUAG 
8 miR-26b-5p 1 UCAAGUA 
 miR-454-3p 3 AGUGCAA 
 miR-374b-5p 6 UAUAAUA 





As described above, miRNAs with an effect size greater than 0.5 which had 
previously been implicated in AKI were selected for inclusion in the validation study. 
This included miR-26b-5p and miR-146a-5p, both of which had been validated as 
diagnostic markers in AKI [195]. Of these two miRNAs, only miR-146a-5p had an effect 
size less than 0.75. 
MiRNAs with an effect size greater than 0.75 were also considered for inclusion 
in the validation study and were prioritised on seed sequences/functional groups as 
shown in Figure 20. MiRNAs which had been used as housekeepers in AKI or HF studies 
were excluded (miR-93-5p, u6 snRNA). The miRNAs selected as candidates for 




Table 15: MiRNAs selected for validation. Effect sizes, p-values and changes observed in the screening study are reported. The reason for selection of the 
miRNA for validation is listed, as well as biological pathways implicated by Ingenuity Pathway Analysis and any previous associations with AKI or HF. MiRNAs 











Reason for selection Associated pathways 
indicated by Ingenuity 
Pathway Analysis 
Previous associations with 
AKI or HF 
let-7g-5p 0.96 0.006 ¯ 1.6 Greatest effect size of 
miRNAs in functional 
group 4 


















Reason for selection Associated pathways 
indicated by Ingenuity 
Pathway Analysis 
Previous associations with 
AKI or HF 
miR-18a-
5p 
0.92 0.008 ¯ 2.1 Greatest effect size of 




Diagnostic and prognostic for 




1.35 <0.001 ¯ 1.9 Greatest effect size of 
miRNAs in functional 
group 1; effect size >0.5 




Diagnostic for AKI [195]; 




1.10 0.002 ¯ 2.1 Greatest effect size of 
miRNAs in functional 
group 2 
Hepatocellular carcinoma, liver 
hyperplasia/hyperproliferation; 
cardiac dilation 
Diagnostic/prognostic for AHF 













Reason for selection Associated pathways 
indicated by Ingenuity 
Pathway Analysis 
Previous associations with 
AKI or HF 
subtype stratification [171]; 
prognostic for AHF [187] 
miR-
140-5p 
0.78 0.022 ¯ 1.6 Greatest effect size of 





0.63 0.06 ­ 1.4 Effect size >0.5 and 
previously implicated in 
AKI 
Hepatocellular carcinoma, liver 
hyperplasia/hyperproliferation; 
cardiac infarction 
Diagnostic for AKI [195] 
miR-
374b-5p 
0.82 0.016 ¯ 2 Greatest effect size of 















Reason for selection Associated pathways 
indicated by Ingenuity 
Pathway Analysis 
Previous associations with 
AKI or HF 
miR-
382-5p 
0.75 0.027 ­ 1.7 Greatest effect size of 





0.97 0.005 ¯ 1.8 Greatest effect size of 
miRNAs in functional 
group 3 




liver damage, liver 
inflammation/hepatitis, liver 















Reason for selection Associated pathways 
indicated by Ingenuity 
Pathway Analysis 
Previous associations with 
AKI or HF 
miR-484 0.77 0.024 ¯ 1.8 Greatest effect size of 
miRNAs in functional 
group 8 
Renal inflammation, renal 
nephritis 
None 









Concentrations of 8 of the 10 selected miRNA candidates (let-7g-5p, miR-18a-
5p, miR-26b-5p, miR-106a-5p, miR-140-5p, miR-374b-5p, miR-454-3p and miR-484) 
were lower in patients with ADHF and AKI when compared to ADHF patients without 
AKI (Figure 20). In contrast, concentrations of miR-148a-5p and miR-382-5p were 
higher in patients with ADHF and AKI compared to ADHF patients without AKI. 
However, despite the separation of the median miRNA expression between the two 
groups, there was considerable overlap of individual data points between the groups. This 
implies that individual miRNAs alone could not distinguish between patients with AKI 
from those without, but that they may add information to established risk factors such as 
















































































































































Figure 21: Relative expression of the 10 miRNA candidates selected for validation. Logged, 
normalised relative expression data is presented by patient group. All data is presented relative 
to the median of the ADHF with no AKI group, which is set to a value of 1. Median and 
interquartile range are shown as boxes. Whiskers represent the range of data, excluding outliers. 
 
As a final quality control check, I explored whether the association between miRNA and 
patient group was influenced by residual batch effects from cDNA synthesis. All but two 
of the miRNAs (miR-484 and miR-382-5p) remained significantly associated with 
patient group (Table 59 in Appendix Section 4.2). These two miRNAs narrowly dropped 
below the 0.5 effect size threshold and the difference in mean miRNA expression 
between patient groups was only slightly reduced after batch correction. Therefore, it 






























































































Where available, additional timepoints were assayed in ADHF patients with AKI 
to assess the general trend of candidate miRNA expression over time. This aimed to 
determine whether the expression of miRNAs was temporarily altered during AKI, or 
whether their expression remained permanently changed following AKI. Refer to 
Methods Section 3.4.2.1 for detail on selection of these additional timepoints. 
For patients with samples assayed at all three possible timepoints (before PCr 
spike, on PCr spike, after PCr spike), the relative expression of the 10 candidate miRNAs 
was graphed alongside PCr (Figure 22). These time-course graphs showed considerable 
variability between individuals and there did not appear to be any clear trends in 
expression for any of the candidate miRNAs over time. That is, the candidate miRNAs 
in this small subset of patients did not behave in a uniform fashion like established 
markers such as PCr. For example, in some patients, relative expression of a specific 
miRNA continued to rise after PCr had returned to near baseline (e.g. miR-140-5p in 
patient CH2-212), whilst in other patients, the relative expression of the same miRNA 
decreased once PCr had returned to near baseline (e.g. miR-140-5p in patient CH1-019). 
This exploratory analysis was undertaken on a sub-group of our modestly-sized cohort 
and hence numbers are very limited. Standardised time-course graphs showing the 
median and IQR per miRNA across the entire cohort could not be drawn, as timepoints 
were non-standard between the groups. For example, although multiple patients had a 
sample assayed when their PCr was at its highest, this occurred at a different number of 
days from AKI onset for each patient. It would not be an accurate representation to 
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Figure 22: Time-course of candidate miRNAs in patients with three sampling timepoints available. For each patient, relative miRNA expression and creatinine 
concentration are graphed on the Y axis, with time (days) on the X axis, with admission to Emergency Department (ED) at time zero. Filled black circles 
represent a plasma creatinine assay result, and filled red circles represent a plasma creatinine assay result for which a blood sample was also available for 
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5.2.8 Selection	 of	 reference	 miRNAs	 for	 normalisation	 in	 validation	
study	
In addition to identifying candidate miRNAs for validation, data from the 
screening study was used to identify stable reference miRNAs for normalisation in the 
validation study. Candidate miRNAs that did not differ between the groups and had no 
previous associations with HF or AKI (n=59, selection criteria described in Methods 
Section 3.4.8.5) were entered into geNorm software (qbase+ 3.1, Biogazelle, Zwijnaarde, 
Belgium) as potential housekeepers. geNorm determines the stability of each miRNA 
across samples (termed target stability and presented as an M value) and identifies the 
optimal number of reference miRNAs required for reliable normalisation (refer to 
Methods Section 3.1.5). GeNorm observed medium reference target stability for our data 
set (the average M value was > 0.5 and ≤ 1.0), which is consistent with other studies 
evaluating reference targets on a heterogeneous set of samples [271], and determined that 
the four most stably expressed reference miRNAs would be needed for a reliable 
normalisation in the validation study: miR-30b-5p, miR-92b-3p, miR-24-3p and miR-
361-5p. 
 
Figure 23: GeNorm analysis and ranking of candidate reference miRNAs. Candidate reference 
miRNAs (X axis) are plotted against the geNorm M value (Y axis), a measure of expression 
stability. miRNAs with the lowest M value are the most stably expressed and are therefore the 
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Data from the screening study identified 26 miRNAs that were differentially 
expressed prior to a maximum in PCr between patients with ADHF who experienced 
AKI, and patients with ADHF who did not. Based on effect sizes, miRNA functional 
groupings and previously reported findings in the literature, 10 candidate miRNAs were 
selected for validation – let-7g-5p, miR-18a-5p, miR-26b-5p, miR-106a-5p, miR-140-
5p, miR-146a-5p, miR-374b-5p, miR-382-5p, miR-454-3p and miR-484. These data 
represent a novel contribution through identification of candidate miRNAs for validation 
as prognostic markers of AKI in patients with ADHF, a group frequently affected by 
AKI.  
As evidenced in the literature on miRNAs as biomarkers of HF, the utilisation of a 
panel of miRNAs may be superior to the use of single miRNAs alone. For example, 
although miR-423-5p [169] and miR-1306-5p [170] have been validated in independent 
cohorts as diagnostic markers of HF, they do not out-perform or add value to established 
clinical markers. In contrast, an 8-miRNA panel recently developed in several large 
cohorts by Wong et. al. [171] proved to have higher specificity and improved diagnostic 
performance for chronic HF, and for HFpEF when combined with NT-proBNP than 
either the panel or NT-proBNP alone. When considered with previous literature, this 
work suggests that the small individual effects of miRNA combine synergistically to 
improve diagnostic performance compared with any individual miRNA or NT-proBNP 
alone. On the basis of this concept, I explored a similar model to Wong et. al. by selecting 
a panel of miRNAs from different functional groups to take forward for validation. 
Ingenuity pathway analysis software was used to explore the biological functions 
and characteristics of the candidate miRNAs. This analysis revealed several 
commonalities between candidates, suggesting there may be some redundancy between 
miRNAs. Clustering of seed sequences (a conserved sequence situated at residues 2-8 of 
the 5’ end of a miRNA which guides target recognition between the miRNA and mRNAs, 
and therefore determines miRNA function [149]) into functional groupings revealed that 
the 26 differentially expressed miRNAs represented 18 functional groups, indicating that 
some of the 26 miRNAs may be regulating the same cell pathways.  
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Correlation analysis of the 26 differentially expressed candidate miRNAs revealed 
eight broad clusters of miRNAs with similar expression profiles. The majority of 
miRNAs with the same seed sequence (and therefore in the same functional group) were 
within the same cluster, suggesting that miRNAs which carry out the same function have 
a similar expression pattern. If miRNAs in the same functional group are well correlated, 
then assaying more from each group will not provide more diagnostic information than 
assaying one. Therefore, to maximise the collection of independent information from a 
set number of assays, only one member from each miRNA functional group was selected 
for validation. Briefly, the 26 differentially expressed candidate miRNAs were ranked 
by effect size and those with the largest effect sizes prioritised for validation. Once a 
member of a miRNA group was selected for validation, other miRNAs from this group 
with smaller effect sizes were excluded for selection. This process resulted in 9 miRNAs 
from different functional groups being selected. An additional miRNA, miR-146a-5p, 
was included for validation as it had previously been reported as a diagnostic marker for 
AKI [195]. 
The most common functional grouping were miRNAs with the seed sequence 
AAAGUGC – a group containing the differentially expressed miRNAs miR-106a-5p, 
miR-17-5p, miR-20a-5p, miR-93-5p and miR-106b-5p. The direction of the change in 
expression observed between patients with ADHF who experienced AKI and those who 
did not was consistent across all miRNAs of this functional grouping, with lower 
concentrations of the miRNAs detected in the plasma of patients with AKI compared to 
controls, suggesting reduced inhibition of their target mRNA transcripts. This group of 
miRNAs is implicated in cardiac dilation, a process that can promote the development of 
HF, but have not previously been associated with AKI. From this functional group, miR-
106a-5p was selected for validation as it had the largest effect size. miR-106a-5p has 
previously been reported as being diagnostic for acute heart failure (AHF) [175], 
diagnostic for HF subtype stratification [171] and prognostic for AHF [187]. 
The next three most common functional groups each contained two miRNAs and 
were also expressed at lower concentrations in the plasma of ADHF patients who 
experienced AKI when compared to those who did not. Let-7g-5p and let-7b-5p, sharing 
the seed sequence GAGGUAG, play a role in renal inflammation, renal nephritis and 
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cardiac dilation. Neither have any prior reported associations with AKI or HF in humans. 
MiR-26b-5p and miR-26a-5p share the seed sequence UCAAGUA and are associated 
with a protective, anti-hypertrophic effect in HF [217]. MiR-18a-5p, miR-18b-5p, with 
seed sequence AAGGUGC, have no previously documented association with AKI. Let-
7g-5p, miR-26b-5p and miR-18a-5p had the largest effect sizes from their respective 
functional groups and were selected for validation. 
Interestingly, one functional group was not consistent in directionality (group 3, 
seed sequence AGUGCAA) – miR-454-3p was lower in patients with AKI compared to 
those without, whilst miR-130b-3p was higher in those with AKI. IPA revealed that 
miRNAs of this functional group are involved in a range of pathways including renal 
inflammation, renal nephritis, congenital heart anomaly, liver cirrhosis, liver damage, 
liver inflammation/hepatitis, hepatocellular carcinoma and liver 
hyperplasia/hyperproliferation. The opposing direction of change between miR-454-3p 
and miR-130b-3p could be a chance finding owing to the small sample size, or could 
represent a real difference due to pleiotropic effects of miRNAs with this seed sequence. 
It is known that miRNAs can have pleiotropic effects in different tissues and that their 
concentrations change over time relative to a clinical event. For example, miR-21 
promotes renal fibrosis in the kidney[211] and adverse cardiac remodeling in the heart[5], 
and higher circulating and urinary concentrations have been associated with HF 
development and progression, and risk and severity of AKI [177, 220, 221]. However, 
miR-21 can also have reno-protective effects by inhibiting inflammation and 
apoptosis[211]. The involvement of miR-454-3p and miR-130b-3p in multiple pathways 
across kidney, heart and liver could potentially explain why the miRNAs have opposite 
expression. MiR-454-3p was selected for validation due to its greater effect size, 
although it has not previously been associated with AKI or HF. 
The remaining 13 of the 26 differentially-expressed miRNAs were sole members 
in their respective functional groupings. Of these miRNAs, implicated pathways 
included: cardiac enlargement (miR-214-3p), cardiac infarction (146a-5p, miR-320a), 
cardiac necrosis (miR-320a), renal inflammation or renal nephritis (miR-320a, miR484), 
cardiac fibrosis (miR-125a-5p), liver hyperplasia (miR-125a-5p, miR-99b-5p) 
hepatocellular carcinoma (146a-5p, miR-99b-5p), liver hyperplasia/hyerproliferation 
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(146a-5p, miR-99b-5p), liver damage (miR-99b-5p), liver inflammation/hepatitis (miR-
99b-5p) and liver cirrhosis (miR-99b-5p). Furthermore, miR-146a-5p (seed sequence 
GAGAACU) is known to be protective for AKI, exerting its anti-inflammatory effect by 
down-regulating interleukin-1 receptor-associated kinase 1 (IRAK-1) and TNF receptor-
associated factor 6 (TRAF-6). From these 13 remaining differentially-expressed 
miRNAs, those with the largest effect sizes were selected for validation (miR-374b-5p, 
miR-140-5p, miR-484 and miR-382-5p). 
Prior to our current study, only one published paper investigated the utility of circulating 
miRNAs as diagnostic markers of kidney function in ADHF patients. Bruno et al. 
measured circulating concentrations of 12 miRNAs previously associated with HF in 
samples obtained from 98 patients on the first day of hospitalisation for ADHF, finding 
lower concentrations of miR-423-3p, miR-199a-3p, and miR-let-7i-5p in 17 patients with 
worsening renal function (WRF, defined as an increase in serum creatinine by 0.3mg/dL 
or more from admission to day 3) [196]. In our screen, we found no evidence that any of 
these miRNAs were differentially expressed between ADHF patients who incurred AKI 
versus those who did not. This lack of overlap may be attributable to the slightly different 
renal phenotypes being investigated (WRF versus AKI), or the different time-point at 
which miRNAs were assayed (first day of hospitalisation versus immediately prior to a 
spike in PCr). Interestingly however, miR-let-7i-5p and one of my top candidates, let-
7g-5p, are both members of the let-7 miRNA family, indicating a shared seed sequence 
and thus a similar biological function [272]. This could suggest concordance between the 
identification of miR-let-7i-5p by Bruno et al. and my identification of let-7g-5p as 
potential markers of the kidney function of patients with ADHF. Furthermore, Bruno et 
al. did not identify any circulating miRNAs which were higher in ADHF patients with 
worsening renal function, which my findings are largely consistent with. Of the top 10 
candidates selected for validation, eight were lower in the circulation of patients with 
ADHF who incurred AKI, whilst two were higher in the circulation of those who incurred 
AKI. Finally, it is crucial to note that Bruno et al. did not validate or compare the miRNA 
markers they identified with established markers in an independent cohort of ADHF 
patients, a step we performed (see Chapter Six). Validation is a critical step towards the 
delivery of high-quality research data required for the assessment of biomarkers [273]. 
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In addition to the primary analysis comparing the circulating concentrations of 
miRNAs between ADHF patients who incurred AKI and those who did not, I also 
conducted an exploratory analysis into the time-course of candidate miRNA expression. 
Although this was an opportunity to look for patterns in candidate miRNA expression 
and assess the size, if any, of the “window of opportunity” in which a marker may be 
used, it did not reveal any consistent results. This exploratory analysis was done in a 
subset of our already modestly-sized cohort, meaning the numbers were very small. 
Furthermore, the miRNAs being investigated in this exploratory analysis did not have 
established, validated relationships with the clinical condition (AKI) with which I was 
looking to associate their expression with. Perhaps this time-course analysis, although 
exploratory, should only be performed on validated novel miRNAs for which there is 
more likely to be an observable pattern of expression over time. 
As reflected by the scarcity of literature in this area, discovering new miRNA 
biomarkers for AKI in ADHF remains challenging. Significant challenges were 
encountered when retrospectively assessing the kidney function of each patient to 
identify cases and controls. The KDIGO consensus definition was applied to identify 
patients with AKI, but these criteria employ strict time and PCr concentration cut-offs 
which exclude patients with severely impaired kidney function who very narrowly fail 
to meet the criteria. This group of patients represent those who would likely be diagnosed 
with AKI by a clinician upon manual inspection of a trace of PCr over time. For example, 
as shown in Figure 24, patient CH1-070 experienced a PCr increase of 85% but did not 
satisfy the KDIGO diagnostic criteria as this change in PCr occurred over 8 days rather 
than the required 7. To reflect clinical practice as closely as possible, clinical adjudication 
of the PCr traces was used to classify patients, like CH1-070, whose PCr increase was 
not of sufficient magnitude or speed to qualify as KDIGO defined AKI, but was clearly 





Figure 24: Plasma creatinine traces of two patients from our case group (ADHF with AKI). For 
each patient, creatinine concentration is graphed on the Y axis, with time on the X axis 
(admission to Emergency Department (ED) = time 0). Filled black circles represent a plasma 
creatinine assay result, and filled red circles represent a plasma creatinine assay result for which 
a blood sample was also available for miRNA measurement. Dotted blue lines represent 
scheduled or unscheduled study visits. Patient CH1-070 did not meet KDIGO diagnostic criteria 
but was clinically adjudicated as AKI, whilst patient CH2-208 satisfied the KDIGO diagnostic 
criteria. When comparing these two traces there is not an obvious difference in PCr profile, 





















































































































































Classifying patients with ‘healthy’ kidneys in a cohort of ADHF patients also 
proved challenging. In patients with ADHF, the renal system is adversely affected due to 
volume overload caused by congestion. Furthermore, several medications given in 
ADHF including loop diuretics and vasodilators are known to reduce renal perfusion 
and/or intra-glomerular filtration pressures, hence promoting AKI in ADHF [40]. To 
select appropriate controls, a pool was created by excluding patients meeting KDIGO 
criteria or were clinically adjudicated as having AKI, and any patients with an eGFR of 
< 40 mL/min. Clinical adjudication was then undertaken to exclude any patients with 
potential chronic kidney disease or acute kidney disease. This strategy appeared 
successful at removing any patients with PCr traces which appeared abnormal. 
A further challenge in assessing and diagnosing AKI in the IMPERATIVE-HF 
cohort was missing baseline or a lack of historic creatinine data. KDIGO diagnostic 
criteria require pre-existing PCr measurements or a known historic baseline to diagnose 
a patient on admission. A patient with no previously recorded PCr measurements could 
present in hospital with higher than normal PCr, indicating loss of kidney function. 
However, despite a clear impairment of kidney function reflected by the high 
concentration of PCr, if there was no reference or baseline PCr value for this patient, they 
may not be diagnosed using KDIGO criteria. It has been reported that up to 50% of 
patients admitted to hospital do not have prior creatinine data [274-276]. In the screening 
study, 14% of the cohort did not have any prior creatinine data, meaning that I likely did 
not capture all patients with AKI, resulting in a smaller sample size. This challenge 
reaffirms why relying on changes in PCr from known baseline values to diagnose AKI 
is problematic.  
A major limitation of the current study was the small sample size. This issue was 
compounded not only by missing historic creatinine data as described above, but by the 
frequency of sample collection. The IMPERATIVE-HF study is a clinical trial which we 
have utilised for research beyond its original design. As this study was not specifically 
designed for monitoring PCr, sample collection was more infrequent than would be 
desired (baseline, pre-discharge, seven days, two weeks, six weeks, twelve weeks). 
Ideally, sampling would be done daily to monitor PCr to maximise the ability to identify 
rapid changes in PCr concentrations occurring between IMPERATIVE-HF study time 
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points, and to allow miRNA assaying immediately preceding these spikes. For some 
patients, PCr maxima meeting AKI diagnostic criteria did not have study samples 
available immediately prior to this rise (the main time point of interest to identify an early 
maker for AKI), meaning several patients with AKI had to be excluded. This contributed 
to low numbers in the screening study. 
In summary, these results show that of 375 screened miRNAs, 26 were differentially 
expressed between patients with ADHF who experienced AKI and patients with ADHF 
who did not. From these miRNAs, a panel of 10 candidates were selected for future 
validation based on miRNA functional groupings, seed sequences and previously 
reported findings in the literature - let-7g-5p, miR-18a-5p, miR-26b-5p, miR-106a-5p, 
miR-140-5p, miR-146a-5p, miR-374b-5p, miR-382-5p, miR-454-3p and miR-484. Of 
these miRNAs, two had previously been associated with AKI (miR-26b-5p and miR-
146a-5p), three had previously been associated with HF (miR-18a-5p, miR-26b-5p and 
miR-106a-5p) and six were truly novel candidates (let-7g-5p, miR-140-5p, miR-374b-
5p, miR-382-5p, miR-454-3p and miR-484). 
This screen was conducted in patients with extreme renal phenotypes; those in the 
cohort with the most severe acute renal impairment and matched controls with the most 
stable PCr profiles. Whilst a pragmatic approach for identifying potential new markers, 
this selected cohort does not represent the true spectrum of kidney dysfunction present 
in a real-life cohort of all-comers presenting to the emergency department with ADHF. 
In a real-world scenario, patients do not fall into a dichotomy of AKI or kidney-healthy, 
but present with a wide range and variety of PCr profiles representing different levels of 
renal impairment. Therefore, these candidate markers need to be studied in a larger, 
independent cohort of consecutively recruited patients and assessed for their ability to 





Results of MicroRNA Validation 
Study 
6.1 Introduction	
In the screening study, 10 miRNAs were identified as being differentially 
expressed between patients with ADHF who incurred AKI and those who did not. In this 
chapter, I aimed to validate this panel of miRNAs in a larger, independent cohort of 
consecutively-recruited patients (n=200) and determine whether these miRNAs add 
independent information beyond established markers such as PCr and markers of ADHF 
severity including NT-proBNP. Here, I have quantified plasma concentrations of 10 
candidate miRNAs at the pre-discharge timepoint (PD). All measurements and data 
quality control processing were undertaken blind as to the renal status of the patients.  
As discussed in Section 5.3, the experimental approach utilised in the screen, in 
which only extreme phenotypes were considered, does not reflect a real-world population 
in which candidate markers would need to perform. To address this, a cohort of ‘all-
comers’ (i.e. consecutively-recruited patients that were not pre-selected based on 
phenotype) were included in the validation study. Following blinded quantification of 
the 10 candidate miRNAs using RT-qPCR, patients were divided into groups based on 
their kidney function (referred to throughout as ‘kidney status groups’). In this cohort of 
all-comers it was deemed inappropriate to dichotomise patients into only two groups - 
those with AKI by KDIGO criteria and those without AKI - as patients in the non-AKI 
group would have a vast range of PCr and eGFR profiles reflecting a wide spectrum of 
renal function from near-normal to potential AKI. To account for this, patients were 
classified into three renal status groups based on PCr and eGFR throughout the study 
period (0-100 days after hospital admission, illustrated in Figure 25, specific criteria 
described in Methods Section 3.2). The first group consisted of patients who met KDIGO 
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diagnostic criterion for AKI; the second consisted of patients who did not fulfil KDIGO 
criteria but would not be considered kidney healthy – therefore, these patients presented 
an intermediate level of kidney dysfunction; and the final group consisted of patients who 
maintained a relatively healthy level of kidney function. Inclusion of the intermediate 
group enabled investigation of whether the candidate miRNA concentrations 
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Figure 25: Plasma creatinine traces of three patients representative of each of the three kidney 
status groups – AKI (patient AK1-499), intermediate kidney dysfunction (AK1-411), and kidney 
healthy (AK1-511). For each patient, creatinine concentration is graphed on the Y axis, with time 
(days) on the X axis, with admission to Emergency Department (ED) at time zero. Filled black 
circles represent a plasma creatinine assay result, and filled red circles represent a plasma 
creatinine assay result for which a blood sample was also available for miRNA measurement. 
Dotted blue lines represent scheduled or unscheduled study visits. Red dotted lines indicate the 
plasma creatinine value used as a baseline for each patient. ED = emergency department 
admission; PD = pre-discharge; Uns = unscheduled study visit; 2wk = 2 week scheduled study 
visit. 
In the screening study, patients with and without AKI were matched on age and 
gender, and there was no statistical evidence for a difference in ethnicity between the two 
groups. However, in this cohort of all-comers we could not control for these factors. 
Consequently, in this chapter, I have first investigated associations between the candidate 
miRNAs and age, gender and ethnicity, to identify possible relationships which could 
confound the results. Second, I have explored clinically relevant associations between 
the concentrations of the 10 candidate miRNAs – that is, I have determined whether 
miRNA expression is associated with presence or absence of AKI, and whether the 
direction of change is consistent with the data from the screening study. Third, I have 
assessed associations between the candidate miRNAs and established markers for AKI 
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confounding variables was applied to the whole cohort to determine the relationship 
between candidate miRNA expression and renal status.  
This study is the first to attempt to validate a panel of candidate circulating 
miRNAs as markers of AKI in the context of ADHF and assess the novel contribution of 
information provided by miRNAs compared to well-established markers such as PCr and 
markers of ADHF severity including NT-proBNP. If successful, this research has the 
potential to improve the early detection of AKI, facilitating more targeted treatment and 
monitoring of ADHF patients. Fulfilling the important and currently unmet need for early 
markers of AKI in ADHF could ultimately improve patient outcomes by reducing 
mortality and morbidity.  
6.2 The	cohort	
Patient characteristics for the validation cohort are shown in Table 16. The mean 
age of ADHF patients (n = 200) at admission was 61.1 years (range 20-89 years) and 
72.5% of patients were male. Approximately half the patients were European (52%), with 
30 patients identifying as Māori (15%) and 50 identifying as one of the Pasifika ethnic 
groups (25%). BMI data, available for 81.5% of the cohort, averaged 32.6kg/m² (range 
17.8-69.3). Nearly 65% of patients had documented hypertension, 32.5% had diabetes, 
24% had a previous history of MI and 40% of patients had a previous HF admission. The 
median NT-proBNP at before discharge from hospital (“pre-discharge” time point, PD) 
for the validation cohort was 170.7 pmol/L (range 30-1855).  
Several differences were observed between ADHF patients when separated 
according to their kidney status (Table 16). Patients with ADHF who developed AKI or 
had intermediate kidney dysfunction after hospital admission were older than patients 
who remained kidney healthy. Ethnicity also differed across the groups with Māori and 
Pasifika patients making up a disproportionate number of the ADHF with AKI group in 
spite of Māori and Pasifika patients being younger on average than European patients 
(see Section 6.3): Māori made up 15% of the total cohort, and made up 23% of the AKI 
group; Pasifika made up 25% of the total cohort and made up 30% of the AKI group. 
Although patients were categorised into kidney status groups based on PCr and eGFR 
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throughout the entire study period (100 days after hospital admission), patients with 
ADHF who developed AKI or had intermediate kidney dysfunction had significantly 
lower mean eGFR and higher median PCr at pre-discharge than patients with ADHF 
alone, indicating worse renal function at this time-point. Furthermore, at pre-discharge, 
NT-proBNP and hsTnT were highest in the group of patients with AKI. E/e’, a marker 
of ventricular filling pressure available in only 62% of patients, was highest in ADHF 
patients with AKI. A larger proportion of patients with ADHF and AKI had previously 
been hospitalised with ADHF than the ADHF groups with intermediate or no kidney 
dysfunction. Patients with ADHF and AKI typically had longer hospital stays as 
measured by time from ED to discharge. 
I did not detect any differences between kidney status groups in systolic BP, LVEF, 
NYHA class, LVM, smoking status, previous PCI, CABG or device therapy. 
Table 16: Demographics of the validation cohort, according to the three kidney status groups 
used for analysis – ADHF and kidney healthy, ADHF and intermediate kidney dysfunction and 

















Age (years) § 53 (±14) 63 (±16) 62 (±15) 0 (0%) 0.005 
Gender (M) 18 
(58.1%) 
74 (75.5%) 53 (74.6%) 0 (0%) 0.146 
Ethnicity    0 (0%) 0.044 
NZ European 19 
(61.3%) 
58 (59.2%) 27 (38%)   
Maori 5 
(16.1%) 
9 (9.2%) 16 (22.5%)   
Pacific Islander 7 
(22.6%) 
22 (22.4%) 21 (29.6%)   



















BMI (kg/m²) § 34 (±16) 31 (±10) 33 (±12) 37 
(18.5%) 
0.405 













115 (±19.4) 111 
(±17.8) 
0 (0%) 0.336 
ADHF Aetiology†      
Ischaemic 8 
(25.8%) 
27 (27.6%) 23 (32.4%) 0 (0%) 0.722 
Hypertensive 7 
(22.6%) 
19 (19.4%) 9 (12.7%) 0 (0%) 0.729 
NYHA Class at 6 
weeks 
   8 (4%) 0.059 
Class 1 3 (10%) 12 (12.6%) 4 (6%)   
Class 2 24 (80%) 54 (56.8%) 39 (58.2%)   
Class 3 3 (10%) 28 (29.5%) 20 (29.9%)   
Class 4 0 (0%) 1 (1.1%) 4 (6%)   
LVM (g) § 236 
(±113) 
254 (±130) 283 (±141) 0 (0%) 0.717 
E/e’§ 12.7 
(±5.4) 
18.0 (±7.5) 20.0 (±9.4) 76 
(38%) 
0.009 
LVEF § 28.7 
(±12.3) 

















PCr (µmol/L)† 82 (77-
95) 
105 (92-125) 130 (99-
162) 



















hsTnT (pg/mL)† 16 (11-
26) 
25 (18-37) 31 (23-55) 30 
(15%) 
<0.001 
Previous History      
Previous HF 5 
(16.1%) 
38 (38.8%) 37 (52.1%) 0 (0%) 0.003 
Diabetes 5 
(16.1%) 
30 (30.6%) 30 (42.3%) 0 (0%) 0.09 
Previous MI 6 
(19.4%) 
25 (25.5%) 17 (23.9%) 0 (0%) 0.678 
Hypertension 15 
(48.4%) 
62 (63.3%) 52 (73.2%) 0 (0%) 0.051 
PCI 3 (9.7%) 16 (16.3%) 10 (14.1%) 0 (0%) 0.652 




     
Anti-hypertensives 31 
(100%) 





61 (62.2%) 52 (73.2%) 0 (0%) 0.049 
Diuretics 31 
(100%) 
98 (100%) 71 (100%) 0 (0%) 1 
Beta blockers 30 
(96.8%) 




3 (9.7%) 21 (21.4%) 15 (21.1%) 0 (0%) 0.323 



















Current Smoker 10 
(32.3%) 
15 (15.3%) 10 (14.1%)   
Ex-Smoker 8 
(25.8%) 




1 (3.2%) 14 (14.3%) 11 (15.5%) 0 (0%) 0.207 




6.1 (±5.8) 8.3 (±10) 3 (1.5%) 0.002 
ED to discharge 6.4 
(±4.5) 
6.6 (±4.9) 8.8 (±6.0) 0 (0%) <0.001 
PD to discharge 0.07 
(±1.8) 
-0.29 (±0.78) 0.81 (±1.8) 0 (0%) 0.389 
P values generated using ANOVA or Chi squared tests, as appropriate. §Arithmetic mean 
(SD); †Median (IQR); ACEI=angiotensin converting enzyme inhibitors; ADHF=acute 
decompensated heart failure; ARB=angiotensin II receptor blocker; BMI=body mass 
index; BP=blood pressure; CABG=coronary artery bypass graft; ED=emergency 
department; GFR=glomerular filtration rate; HF=heart failure; hsTnT=high sensitivity 
troponin T; LVEF=left ventricular ejection fraction; LVM=left ventricular mass; 
MI=myocardial infarction; NTproBNP=N-terminal pro b-type natriuretic peptide; 
PCI=percutaneous coronary intervention; PD=pre-discharge; PCr=plasma creatinine 
6.3 Ethnicity,	age	and	miRNA	expression	
The following section explores the potential confounding effect of age and 
ethnicity on miRNA expression and kidney status group using univariable and 
multivariable analyses.  For the ethnicity analyses, the three most prevalent ethnic groups 
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have been included, European, Māori and Pasifika. Patients of ‘other’ ethnicity (n=16) 
were excluded owing to the small sample size. Normalised miRNA expression levels 
displayed skewed distributions and were natural log-transformed prior to statistical 
analysis.  
In this cohort, ethnicity and age were strongly associated (ANOVA p< 0.001). 
Pairwise comparisons revealed that the mean age of each ethnic group differed from the 
other two groups (p≤ 0.001 for all comparisons), with Pasifika patients the youngest, 
European patients the oldest and Māori patients intermediate between the two (Table 17).  
Table 17: Mean age of patients in the validation cohort grouped by ethnicity. 
 Mean age (±SD) 
European (n=102) 69.3 ± 11.6 
Māori (n=30) 56.6 ± 11.8 
Pasifika (n=50) 47.2 ± 14.3 
 
6.3.1 Age	and	miRNA	expression	
  The relationship between concentrations of the 10 candidate miRNAs and age 
were investigated with Pearson correlation coefficients (r). This revealed weak, negative 
correlations between age and let-7g-5p, miR-26b-5p, miR-146a-5p, miR-374b-5p and 
miR-454-3p (Table 18).  
Table 18: Pearson correlations between age and the concentrations of the 10 candidate miRNAs 
in the validation cohort.  
miRNA r p-value 
let-7g-5p -0.242 0.001 
miR-18a-5p 0.109 0.126 
miR-26b-5p -0.298 <0.001 
miR-106a-5p -0.043 0.547 
miR-140-5p 0.012 0.868 
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miRNA r p-value 
miR-146a-5p -0.172 0.015 
miR-374b-5p -0.203 0.004 
miR-382-5p 0.091 0.203 
miR-454-3p -0.224 0.002 
miR-484 -0.091 0.203 
 
6.3.2 Ethnicity	and	miRNA	expression	
ANOVA was used to investigate associations between the candidate miRNAs and 
ethnicity (Table 19). This revealed associations between ethnicity and the concentration 






































































































Figure 26: Boxplots of relative expression for the four miRNAs associated with ethnicity – miR-26b-5p, miR-
374-5p, miR-382-5p and miR-454-3p. Data has been log transformed (hence each unit increase on the y-axis 
represents a doubling in miRNA concentration). 
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Table 19: Associations between candidate miRNA expression and ethnicity 
(European/Māori/Pasifika). Medians and IQRs are presented by ethnicity. miRNA relative 










let-7g-5p 1.51 (1.07-2.09) 1.75 (1.22-2.38) 1.81 (1.35-2.30) 0.377 




















































The expression levels of three miRNAs, miR-26b-5p, miR-374b-5p and miR-454-3p, 
were lowest in Europeans and highest in Māori, with Pasifika patients having 
intermediate expression (Table 20). Conversely, expression of miR-382-5p was highest 




Table 20: ANOVA post hoc pairwise comparisons for candidate miRNAs associated with 
ethnicity. P values for the mean difference between groups are reported. Comparisons are listed 
between all groups –European and Māori, European and Pasifika, and Māori and Pasifika. 
miRNA European vs 
Māori p value 
European vs 
Pasifika p value 
Māori vs Pasifika 
p value 
miR-26b-5p 0.011 0.026 0.528 
miR-374b-5p 0.413 0.001 0.080 
miR-382-5p 0.474 0.002 0.086 
miR-454-3p 0.026 0.058 0.550 
 
6.3.3 Ethnicity,	age	and	gender	
Because of the strong relationship between age and ethnicity, associations 
between miRNA expression, age, ethnicity and gender were tested in a multivariable 
linear regression. The majority of candidate miRNAs showed no evidence for association 
with age, ethnicity or gender, with the exception of let-7g-5p, miR-26b-5p, miR-382-5p 
and miR-454-3p (Table 21). See Appendix Section Appendix Five for full details of the 
model. 
Let-7g-5p expression was negatively associated with age (p=0.001), whilst miR-
382-5p was associated with ethnicity (p=0.025, highest in Europeans, lowest in Pasifika, 
and intermediate in Māori). MiR-26b-5p expression was negatively associated with age 
(p=0.001) and was associated with ethnicity (p=0.010, highest in Māori, lowest in 
Europeans, and intermediate in Pasifika). Similarly, miR-454-3p showed evidence for a 
negative association with age (p=0.024) and an association with ethnicity (p=0.028, 





Table 21: Associations between candidate miRNA expression and age, ethnicity 
(European/Māori/Pasifika) and gender.  
miRNA Age p-value Ethnicity p-value Gender p-value 
let-7g-5p 0.001 0.064 0.928 
miR-18a-5p 0.212 0.787 0.734 
miR-26b-5p 0.001 0.010 0.773 
miR-106a-5p 0.603 0.070 0.301 
miR-140-5p 0.992 0.765 0.436 
miR-146a-5p 0.109 0.903 0.676 
miR-374b-5p 0.250 0.180 0.516 
miR-382-5p 0.474 0.025 0.525 
miR-454-3p 0.024 0.028 0.689 
miR-484 0.589 0.384 0.897 
 
Taken together, the results in Section 6.3 suggest that in our cohort, various 
associations exist between ethnicity, age and miRNA expression. Separate univariable 
analyses revealed that all three of these key variables were associated with one another. 
Multivariable linear regression analysis suggested that for let-7g-5p, miR-26b-5p, miR-
382-5p and miR-454-3p, age and ethnicity could confound the association between 
miRNA and kidney status group. Therefore, it is essential these variables be adjusted for 




The relative expression of candidate miRNAs in the three kidney status groups is 


































































































































































Figure 27: Relative expression of the 10 candidate miRNAs measured in patients with ADHF 
and AKI, patients with ADHF and intermediate kidney dysfunction, and patients with ADHF and 
no AKI. Data has been Log2 transformed (hence each unit increase on the y-axis represents a 
doubling in miRNA concentration) and the median of the control group (ADHF with no AKI) set 
to 1. 
 
Associations between candidate miRNAs and kidney status group were 
assessesed after adjustment for age, gender and ethnicity in a multivariable linear 
regression model (Table 22). Fold changes in miRNA expression between kidney status 
groups were calculated and are presented alongside fold change data from the screening 




































































































Table 22: Associations between candidate miRNA relative expression and kidney status group 
adjusted for age, gender and ethnicity. miRNA data was natural log transformed prior to 
statistical analysis. Fold changes relative to the control group (ADHF with no AKI) are 
presented, along with p-values from multivariable linear regression analysis. The fold change 
for each miRNA observed in patients with AKI compared to those without in the screening study 
is also reported, to display whether the direction and magnitudes observed in the validation study 
were consistent with these values.  
miRNA P-value Fold change in 
intermediate 
group 








let-7g-5p 0.889 ¯ 1.01 ¯ 1.05 ¯ 1.6 
miR-18a-5p 0.305 ¯ 1.03 ¯ 1.15 ¯ 2.1 
miR-26b-5p 0.740 ­ 1.07 ¯ 1.00 ¯ 1.9 
miR-106a-5p 0.613 ¯ 1.09 ¯ 1.07 ¯ 2.1 
miR-140-5p 0.964 ­ 1.07 ­ 1.05 ¯ 1.6 
miR-146a-5p 0.523 ­ 1.02 ¯ 1.18 ­ 1.4 
miR-374b-5p 0.015 ­ 1.3 ¯ 1.1 ¯ 2 
miR-382-5p 0.663 ­ 1.18 ­ 1.15 ­ 1.7 
miR-454-3p 0.047 ¯ 1.3 ¯ 1.5 ¯ 1.8 
miR-484 0.812 ­ 1.03 ¯ 1.04 ¯ 1.8 
 
Of the 10 candidate miRNAs, after adjustment for age, ethnicity and gender, only 
miR-454-3p (p=0.047) and miR-374b-5p (p=0.015) were associated with kidney status 
group (median miRNA expression and pairwise p-values shown in Table 23 and Table 
24 respectively). miR-454-3p was highest in ADHF patients who did not incur AKI 
(control group, median=0.96, IQR=0.49-1.69) and lowest in those with AKI 
(median=0.66, IQR=0.46-1.16; pairwise comparisons: control vs AKI p=0.014; control 
vs intermediate p=0.070; intermediate vs AKI p=0.246). MiR-374b-5p was highest in 
ADHF patients with intermediate kidney dysfunction (median=0.77, IQR=0.51-1.19) 
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and lowest in those with AKI (median=0.53, IQR=0.34-0.98; pairwise comparisons: 
intermediate vs AKI p=0.005; control vs AKI p=0.628; control vs intermediate p=0.122). 
This suggests the two extreme opposing phenotypes – AKI and kidney healthy – have 
similar concentrations of miR-374b-5p, whilst the intermediate kidney function group 
have higher concentrations. This is an unexpected result which would complicate its use 
as a biomarker for AKI, therefore miR-374b-5p was excluded from the final list of 
candidate biomarkers. 
Table 23: Geometric means and 95% CIs by group for the two miRNAs associated with kidney 
function (miR-374b-5p and miR-454-3p). Adjusted for age, gender and ethnicity. 
Group miR-374b-5p relative 
expression (Geometric mean 
(95% CI)) 
miR-454-3p relative 
expression (Geometric mean 
(95% CI)) 
ADHF controls 0.62 (0.46 – 0.84) 1.14 (0.87 – 1.51) 
Intermediate 0.79 (0.66 – 0.95) 0.87 (0.74 – 1.04) 
AKI 0.57 (0.48 – 0.69) 0.77 (0.65 – 0.92) 
 
Table 24: Pairwise comparisons for the two miRNAs associated with kidney function (miR-374b-
5p and miR-454-3p). mean difference (95% CI) between pairs is reported along with the pairwise 
comparison p-value. Comparisons were adjusted for age, gender and ethnicity. Comparisons are 
listed between all groups – controls (ADHF with no AKI), intermediate (ADHF with intermediate 
kidney dysfunction) and AKI (ADHF with AKI). 
Pair miR-374b-5p  
(Mean difference (95% 
CI, p-value)) 
miR-454-3p 
(Mean difference (95% 
CI, p-value)) 
Control vs AKI 1.09 (0.78 – 1.51, 0.628) 1.48 (1.09 – 2.03, 0.014) 
Control vs Intermediate 0.78 (0.58 – 1.07, 0.122) 1.31 (0.98 – 1.75, 0.070) 
Intermediate vs AKI 1.38 (1.10 – 1.74, 0.005) 1.13 (0.92 – 1.41, 0.246) 
 
Pearson correlations were performed to determine whether the candidate 
miRNAs were associated with the current gold-standard marker, PCr (Table 25). miR-
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454-3p was weakly and inversely correlated with plasma creatinine (Pearson correlation 
-0.18, p=0.013) and age (-0.224, p=0.002), and weakly positively correlated with eGFR 
at pre-discharge (0.21, p=0.006).  
miR-374b-5p was weakly and inversely correlated with age (Pearson correlation 
-0.203, p=0.004) but there was no evidence for any associations with eGFR, PCr or NT-
proBNP at pre-discharge.  
Table 25: Pearson correlations between miR-374b-5p, miR-454-3p and age, plasma creatinine, 
NT-proBNP and glomerular filtration rate at pre-discharge. 
 miR-374b-5p† miR-454-3p† 
Plasma creatinine at pre-
discharge† 
-0.69 (p=0.332) -0.18 (p=0.013) 
NT-proBNP at pre-
discharge† 
-0.51 (p=0.526) -0.07 (p=0.410) 
eGFR at pre-discharge 0.067 (p=0.393) 0.21 (p=0.006) 
Age -0.203 (p=0.004) -0.224 (p=0.002) 




Figure 28: Correlation matrix of the 10 candidate miRNAs measured in the validation study and 
age, PCr, eGFR and NT-proBNP at pre-discharge. Colour signifies the directionality of 
correlations, with red showing a negative correlation and blue showing a positive correlation. 
Colour intensity and size of squares are proportional to the correlation coefficients. Boxes 
indicate broad groups with similar correlation profiles (hierarchical clustering method 
“Ward”). 
6.5 Analysing	Each	Ethnicity	Separately	
As identified in Section 6.3, there was a strong association in the cohort between 
ethnicity and age. Further to this, the most promising candidate miRNA (miR-454-3p) 
was associated with ethnicity and was weakly and inversely associated with age. These 
associations present an analytical challenge as it is difficult to determine to what extent 
any associations between miRNA expression and kidney status group are being 







































































































effects of ethnicity on the relationship between miR-454-3p expression and kidney status 
group, each of the three major ethnic groups was analysed separately in an exploratory 
analysis.  
6.5.1 Europeans	
In European patients (n=104, 52% of total cohort; controls n=19, intermediate 
group n=58, AKI group=27) miR-454-3p was associated with kidney status group 
(p=0.043). miR-454-3p was 1.67-fold lower in the intermediate group and 1.48-fold 
lower in the AKI group when compared to kidney healthy controls. These differences 
were consistent in both direction and magnitude to the difference observed between cases 
and controls in the miRNA screening study. 
Table 26: Associations between candidate miRNA relative expression and kidney function group 
in Europeans only, adjusted for age and gender. miRNA data was natural log transformed prior 
to statistical analysis. Fold changes relative to the control group (ADHF with no AKI) are 
presented, along with p-values from multivariable linear regression analysis and comment as to 
whether the direction of the change in the miRNA was consistent with the direction change 
observed in the screening study. 
miRNA P-value Fold change in 
intermediate 
group 





miR-454-3p 0.043 ¯ 1.67 ¯ 1.48 Yes 
 
Table 27: Median and interquartile ranges by group for the miRNA associated with kidney 
function in Europeans (miR-454-3p). 
Group Median (IQR) miR-454-3p relative expression 
ADHF controls 1.06 (0.491-1.97) 
Intermediate 0.652 (0.489-0.852) 




Table 28: Pairwise comparisons for the miRNA associated with kidney function in Europeans 
(miR-454-3p). Comparisons are listed between all groups – controls (ADHF with no AKI), 
intermediate (ADHF with intermediate kidney dysfunction) and AKI (ADHF with AKI). 
Pair p-value for miR-454-3p 
Control vs AKI 0.016 
Control vs Intermediate 0.030 
Intermediate vs AKI 0.415 
 
6.5.2 Māori	and	Pasifika	
In Māori patients (n=30, 15% of total cohort; controls n=5, intermediate group 
n=9, AKI group=16), there was no evidence that any of the candidate miRNAs were 
associated with kidney status group.  
Similarly, in Pasifika patients (n=50, 25% of total cohort; controls n=7, 
intermediate group n=22, AKI group=21), there was no evidence that any of the 
candidate miRNAs were associated with kidney status group.  
Table 29: Associations between miR-454-3p relative expression and kidney function group in 
Māori and Pasifika only, adjusted for age and gender. miRNA data was natural log transformed 
prior to statistical analysis. Fold changes relative to the control group (ADHF with no AKI) are 
presented, along with p-values from multivariable linear regression analysis and comment as to 
whether the direction of the change in the miRNA was consistent with the direction change 
observed in the Europeans only. 
Ethnicity P-value Fold change in 
intermediate 
group 






Māori 0.942 ¯ 1.03 ¯1.09 Yes 





As revealed in Sections 6.5.1-6.5.2, miR-454-3p was differentially expressed 
between European ADHF patients who remained kidney healthy and those who did not, 
whilst there was no evidence for differential expression of miR-454-3p in Māori or 
Pasifika patients. It should be noted, however, that the number of Māori and Pasifika 
patients (n=30 and n=50, respectively) was much lower than the number of European 
patients (n=104), meaning this exploratory analysis could have lacked sufficient 
statistical power to detect any effect in these small sub-groups. Therefore, binary logistic 
regression was performed in each ethnic group separately to determine whether miR-
454-3p showed a consistent pattern of association with AKI and intermediate kidney 
dysfunction across all ethnicities. 
To perform a binary logistic regression, patient groups were dichotomised based 
on the results of pairwise comparisons for miR-454-3p (Table 24 in Section 6.4). miR-
454-3p expression differed between the control group and both the AKI and intermediate 
group, but no difference was detected between the AKI group and the intermediate group. 
Therefore, for the purposes of running binary logistic regression, the AKI and 
intermediate groups were combined. 
This binary logistic regression for AKI or intermediate kidney dysfunction with 
miR-454-3p at pre-discharge was run for each of the major ethnic groups, with and 
without adjustment for established clinical risk factors, age, gender and NT-proBNP at 
pre-discharge. All unadjusted and adjusted Odds Ratios were < 1, indicating that an 
increased concentration of miR-454-3p is associated with a lower risk of AKI or 
intermediate kidney dysfunction across all ethnic groups. However, the magnitude of the 
point estimate odds ratios varied from 0.238-0.607 after adjustment, and the confidence 
intervals (CI) were all very wide. Therefore, it appears that miR-454-3p is expressed in 
a consistent pattern across Europeans, Māori and Pasifika, but this study was not powered 




Table 30: Unadjusted and adjusted Odds Ratios for binary logistic regression with miR-454-3p 
at pre-discharge in European, Māori and Pasifika patients. Adjustment was made for age, gender 
and NT-proBNP at pre-discharge. 95% confidence intervals presented.  P-values for all Odds 
Ratios > 0.05. 
 Unadjusted Odds Ratio 
(95% CI) 
Adjusted Odds Ratio 
(95% CI) 
European 0.445 (0.254-0.779) 0.607 (0.287-1.286) 
Māori 0.985 (0.290-3.34) 0.409 (0.054-3.12) 
Pasifika 0.712 (0.342-1.483) 0.238 (0.034-1.673) 
 
6.6 Multivariable	model	for	the	whole	cohort	
Finally, a multivariable binary logistic regression adjusting for confounding 
variables was applied to the combined cohort to determine the relationship between 
candidate miRNA expression and renal status when all three major ethnic groups 
(European, Māori and Pasifika) were considered together. The same dichotomised 
grouping of control group vs combined AKI or intermediate kidney dysfunction group 
was used, as described above in Section 6.5.3.  
miR-454-3p was predictive of patient group (control group (n=26) vs AKI or 
intermediate kidney dysfunction group (n=129)) after adjustment for NT-proBNP at pre-
discharge, age, ethnicity and gender (binary logistic regression p=0.053, OR=0.582, 95% 
CI 0.337-1.007). An OR confidence interval of 0.337-1.007 means that there is a 95% 
chance that a one unit increase in the relative miR-454-3p concentration will be 
associated with an altered odds of AKI between a 3-fold decrease and a < 1% increase. 
As described by Greenland et al. [277], using a strict p value threshold of p< 0.05 to 
conclude there is “no association” or “no evidence of an effect” may be an error in 
interpretation in this instance as the observed association does not equal the null value 
exactly. A null p value < 1 indicates that a level of association is present in the data, 
therefore the point estimate must be examined to determine the most compatible effect 
size for the data under the assumed model [277]. In this instance, the confidence interval 
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for the OR indicates that there is likely an association occurring between miR-454-3p 
and patient group in the data.  
Table 31: Adjusted Odds Ratios for binary logistic regression with miR-454-3p at pre-discharge 
in European, Māori and Pasifika patients. Adjustment was made for ethnicity, age, gender and 
NTproBNP at pre-discharge. 95% confidence intervals and p values presented.   
 Odds 
Ratio 





Upper Bound  
Age (years) 1.086 1.033 1.141 0.001 
NT-proBNP at pre-
discharge (pmol/L) † 
2.631 1.512 4.578 0.001 
miR-454-3p at pre-
discharge† 
0.582 0.337 1.007 0.053 
Ethnicity (reference 
“European”) 
   0.002 
Māori 4.086 0.787 21.202  
Pasifika 33.533 4.701 239.195 <0.001 
Gender (reference “male”)     
Female 0.281 0.092 0.860 0.026 
†Data represented skewed distributions and were log2-transformed prior to analysis 
6.7 Discussion	
This study represents the first to attempt to validate a panel of candidate miRNA 
markers for AKI in ADHF in an independent cohort. Previous work by Bruno et al. [196] 
provided important proof of principle that miRNAs may predict worsening renal function 
in a cohort of patients with ADHF, but did not validate candidate markers in a separate 
cohort or assess their performance in conjunction with established clinical markers. 
Using a similar approach to Bruno et al., I identified miRNAs that were differentially 
expressed in AKI in ADHF in a large-scale screen (Chapter Five). Here, I have 
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progressed my investigation by considering the performance of 10 candidate miRNAs in 
a validation cohort alongside well-established markers of ADHF severity such as NT-
proBNP. In a univariable analysis miR-454-3p was associated with AKI, but in a 
multivariable model miR-454-3p narrowly missed reaching a significance threshold of 
p< 0.05 for association with AKI independent of established risk factors (p=0.053). 
However, the confidence interval for the odds ratio indicates that there is likely to be an 
association between miR-454-3p and patient group independent of established risk 
factors (OR=0.582, 95% CI=0.337-1.007). It is possible that in a larger patient sample, 
the independent association of miR-454-3p with AKI may have reached significance. 
miR-454-3p has not previously been reported as a marker of AKI and represents a 
potential novel marker for AKI in ADHF. However, miR-454-3p has been reported as a 
diagnostic marker of HF in conjunction with seven additional miRNAs. Wong et al. [171] 
recently developed an 8-miRNA panel diagnostic for HF in a series of large, independent 
discovery and validation cohorts, which in combination with NT-proBNP, improved the 
identification of chronic HF. Wong et al. reported lower plasma concentrations of miR-
454-3p in patients with HF compared to non-HF controls. Similarly, I found lower 
plasma concentrations in HF patients with AKI compared to HF patients without AKI. 
This suggests that miR-454-3p may be a marker of both HF severity (independent of NT-
proBNP) and for renal impairment. For example, patients who experience more severe 
HF are more likely to have greater cardiorenal stress and impaired kidney function [278], 
potentially resulting in lower levels of miR-454-3p. Similarly, patients with HF often 
have impaired renal function compared to healthy controls [279] and therefore may be 
more likely to have lower circulating concentrations of miR-454-3p. The enrichment 
analysis generated by IPA suggests that miR-454-3p may be involved in HF, liver and 
renal disease networks including renal inflammation, renal nephritis, hepatocellular 
carcinoma, liver hyperplasia/hyperproliferation or hypoproliferation, liver damage, liver 
inflammation/hepatitis, liver cirrhosis and congenital heart anomalies (networks 
generated through the use of Ingenuity Target Explorer, QIAGEN, Inc., https:// 
targetexplorer.ingenuity.com/). It is widely acknowledged that in clinical practice, 
combined liver and heart dysfunctions coexist in the setting of the main liver and heart 
diseases due to complex cardiohepatic interactions [280]. Acute HF can lead to 
cardiogenic ischaemic hepatitis – a condition in which reduced cardiac output fails to 
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fulfil the metabolic demands of hepatic cells in patients with HF [280, 281]. This well-
described relationship and interconnected pathology between the heart and the liver in 
HF may explain the IPA enrichment analysis results suggesting involvement of miR-
454-3p in liver disease networks, in addition to those of the heart and kidney. 
In contrast to miR-454-3p, much less is known about miR-374b-5p in the setting 
of AKI or ADHF. My data showed that miR-374b-5p concentrations were highest in HF 
patients with intermediate kidney dysfunction and lower in those with AKI or ‘healthy’ 
kidneys. This is an unexpected pattern of expression, in which the two extreme opposing 
phenotypes possessed similar concentrations of the marker whilst an intermediate 
phenotype had higher levels. Practically, use of this miRNA as a biomarker would be 
problematical, and for this reason, the utility of miR-374b-5p as a predictor for AKI in 
ADHF was not compared with established markers in a multivariable model. miR-374b-
5p has not previously been reported as a marker of AKI or HF, and was not found to be 
implicated in established cardiac or renal functional pathways by IPA. However, miR-
374b-5p has previously been reported as marker of subtype in acute coronary syndromes 
(ACS) patients [282]. In 2013, Ward et al. found that miR-374b-5p was lower in the 
peripheral blood mononuclear cells (PBMCs) of patients with ST-elevation myocardial 
infarction (STEMI) than non-ST-elevation myocardial infarction (NSTEMI), and 
conversely, that miR-374b-5p was higher in the plasma of patients with STEMI 
compared to NSTEMI [282].  
In an all-comers cohort including patients of a range of ages and ethnicities, care 
must be taken to unravel the complex interactions between candidate markers and these 
potential confounders [162, 283]. To address this, I investigated the relationships 
between age, ethnicity and our candidate markers. In this cohort, patients with ADHF 
who later developed AKI or intermediate kidney dysfunction were older than patients 
who remained kidney healthy, and Māori and Pasifika patients were over represented in 
the ADHF with AKI group. In addition, there was a strong association between ethnicity 
and age, with Pasifika and Māori patients being, on average, 22.1 years and 12.7 years 
younger than their European counterparts, respectively. miR-374b-5p and miR-454-3p 
were both weakly and inversely associated with age, and were both associated with 
ethnicity. This presented an analytical challenge; if concentrations of candidate miRNAs 
are lower in patients with AKI, but these patients are older and more likely to be of Maori 
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or Pacific ancestry, are the lower concentrations of candidate miRNAs due to a true 
association with clinical outcome, or could it be due to the confounding effects of age 
and/or ethnicity? To account for this, a multivariable model was used in which I adjusted 
for not only age and ethnicity, but also gender and NT-proBNP concentration at pre-
discharge.  
Subsequently, to minimise confounding by ethnicity, an exploratory analysis was 
undertaken in each of the three major ethnic groups separately. In Europeans miR-454-
3p was differentially expressed between patients who remained kidney healthy and those 
who did not, whereas there was no evidence for differential expression of miR-454-3p in 
Māori or Pasifika patients. This could be because i) the miRNA is not associated with 
AKI in ADHF in these ethnic groups, or ii) there is a consistent effect across ethnicities 
but this study lacked sufficient statistical power to detect the effect in small sub-groups. 
To investigate this, binary logistic regression was conducted in each ethnic group 
separately to determine whether miR-454-3p showed a consistent pattern of association 
with AKI and intermediate kidney dysfunction across all ethnicities. This revealed 
unadjusted and adjusted Odds Ratios of < 1 in all ethnic groups, suggesting that an 
increased concentration of miR-454-3p may be associated with lower risk of AKI or 
intermediate kidney dysfunction regardless of ethnicity. It must be noted that the 
magnitude of these ORs ranged from 0.238-0.607 after adjustment, and the confidence 
intervals were all very wide. Thus, it appears that miR-454-3p expression in association 
with AKI demonstrates a consistent pattern across all three major ethnic groups, but this 
study was not powered to detect such small effects. For a marker to be clinically useful, 
it should perform equally across all ethnic groups to avoid perpetuation of healthcare 
disparities. In NZ, Māori and Pasifika have higher rates of cardiovascular mortality and 
morbidity than non-Māori and non-Pasifika [284], therefore it is of utmost importance to 
consider and assess the performance of new candidate biomarkers across different ethnic 
groups [285, 286]. 
In summary, in this study I aimed to validate a panel of miRNAs to predict AKI in 
an independent cohort of all-comers with ADHF to determine whether these miRNAs 
add independent information beyond established markers. Plasma concentrations of 10 
candidate miRNAs were quantified at pre-discharge in 200 patients and although plasma 
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concentrations of miR-454-3p and miR-374b-5p differed among ADHF patients with 
AKI, those without AKI and those with intermediate kidney function, only miRNA miR-
454-3p was found to potentially add value beyond age and NT-proBNP, a marker of 
ADHF severity, in predicting imminent AKI. This is the first screening and validation 
study of its kind to investigate the diagnostic power of miRNAs for AKI in a cohort of 
patients with ADHF. Despite the overall marginal finding, miRNAs could still hold 
promise as markers of AKI in ADHF – however, much larger cohorts which include 
adequate representation of patients from indigenous and minority populations would be 
required. Further validation is required to determine whether pre-discharge is in fact the 
most appropriate and clinically useful time point to assay miRNA concentrations, 






This chapter describes the SWATH-MS experiments in sheep kidney tissue that 
aimed to identify candidate protein markers of AKI in ADHF (Section 7.1). In addition, 
it outlines the method development for sample preparation of sheep kidney tissue and 
plasma for proteomic analysis using SWATH-MS (Section 7.2). The preclinical ovine 
models utilised in the study, optimisation of experimental methods for extracting 
proteins, and methods for performing SWATH-MS, data quality control and analysis are 
outlined. 
7.1 Identifying	candidate	protein	markers	of	AKI	in	ADHF	
This experiment aimed to identify biomarkers of kidney repair and long-term renal 
impairment in ADHF using an established sheep model. Using SWATH-MS, 
quantitative protein profiling was carried out on kidney tissue samples from sheep with 
established ADHF (n=8), sheep recovered from ADHF (n=7) and healthy control sheep 
(n=5). Differentially expressed proteins were identified and compared with genes 
previously identified as differentially expressed between Baseline, HF and Recovery 
time points to test whether transcriptomic candidate markers could be detected in the 






Figure 29: Experimental workflow for identifying candidate protein markers of AKI in ADHF 




Kidney cortex and plasma samples from control sheep were collected for this 
experiment by Associate Professor Miriam Rademaker and Dr Nicola Scott (n=5, Animal 
Ethics Committee of the University of Otago, Christchurch approval AUP-19-77). 
Archived kidney cortex and plasma samples (n=15) collected from sheep with pacing-
induced ADHF in two earlier studies (led by Associate Professor Rademaker) were 
utilised for the current experiment (n=15, ethics approval AEC C23/10). The sheep 
model utilised faithfully reproduces the haemodynamic, neurohormonal and renal 
consequences of severe HF, in which clinically-relevant kidney dysfunction occurs 
[287]. The first study aimed to assess urocortin 2 as a short-term therapy in ADHF, with 
a focus on its renal effects (referred to throughout this chapter as the ‘Ucn2 study’) [288]. 
Samples from the Ucn2 study (n=8) were used in the current experiment as the study 
group of sheep with ADHF. The second study aimed to investigate the renal response to 
the development of, and recovery from ADHF using serial haemodynamic, hormone and 
renal function measurements along with transcriptome analysis of kidney tissue (referred 
to throughout as the ‘RNA-seq study’, unpublished [289]). Samples from the RNA-seq 
study were used in the current experiment as the study group of sheep recovered from 
ADHF (n=7). The candidate did not contribute to the preparation of sheep or the 
collection of samples, but conducted the proteomics experimental work described in 
section 7.1.3 onwards. 
7.1.1.1 Preparation	of	paced	sheep	
Adult Coopworth ewes (Ucn2 study n=18; RNA-seq study n=9; aged 4-6 years; 
41-69 kg; sourced from Lincoln University Farm, Canterbury, New Zealand) were 
instrumented with a 7-French His-bundle electrode stitched sub-epicardially to the left 
ventricle (LV), to allow subsequent cardiac pacing. Instrumentation was performed via a 
left lateral thoracotomy as previously described [288] to allow blood and hemodynamic 
sampling. Following instrumentation, animals recovered for at least 14 days before 
beginning the respective study protocols. Throughout the investigations, sheep were held 
in metabolic cages with free access to water and received a diet of food pellets and 




Rapid left ventricular (LV) pacing at 180 beats per minute (bpm) was carried out 
for 7 days to produce a state of mild compensated HF (Days 0-7), followed by pacing at 
225 bpm for 4 days to induce ADHF (days 7-11, Figure 30A). Samples from sheep in the 
vehicle control arm were utilised in the current experiment (n=8). 
Haemodynamic measurements (including cardiac output, mean arterial pressure, 
central venous pressure and left atrial pressure) were measured using an on-line data 
acquisition system (PowerLab Systems; ADInstruments, New Zealand) at 15-minute 
intervals in the hour before initiation of pacing (baseline), and then once a day for the 
remainder of the study, with an extra three recordings made every 2 hours following the 
initiation of treatment. Measurements of water intake and urine collection were made 
daily for measurement of volume and sodium, potassium, urea, cyclic adenosine 
monophosphate and creatinine excretion. Creatinine clearance (mL/min) was calculated 
as urine creatinine concentration x volume/plasma creatinine (measured 2-hourly and 
daily). 
1.1.1.1.1 Specimen	preparation,	handling	and	storage	in	the	Ucn2	Study	
Blood samples were collected following each hemodynamic measurement. Blood 
was drawn into EDTA tubes on ice, centrifuged at 4°C and stored at -20°C or -80°C 
before assay for a number of neurohormones and plasma analytes including creatinine 
[288, 289]. Neurohormone assays were performed by staff in the Translational Biology 
Laboratory at the Christchurch Heart Institute and plasma protein and electrolyte assays 
were performed by Canterbury Health Laboratories. Blood was stored for subsequent 
protein analysis. 
Sheep were euthanised at the study end (100mg/kg IV Pentobarb 300). Small 
pieces of kidney cortex were fixed in formalin (10% at 4°C overnight) or snap frozen in 
liquid nitrogen and stored at -80°C for subsequent gene expression and proteomics 
studies. A total of 8 kidney cortex samples from the study end were utilised from the 




Sampling was conducted over a 5-day baseline period (Days -4 to day 0, 
‘Baseline’, Figure 30B), followed by 14-days of rapid LV pacing at 220 bpm to induce 
ADHF (Days 1-14, ‘Paced’, Figure 30B). Pacing was then terminated followed by 25-
days recovery (Days 15-44, ‘Recovery’). 
Haemodynamic measurements were recorded as described above. These 
measurements were made prior to the initiation of pacing (Baseline; Days -4, -2, 0), 
during pacing (Days 1, 2, 3, 4, 7, 8, 9, 10, 11, 14) and following termination of pacing 
(daily for the first 4 days and then every 2-3 days until study completion). 
In order to measure volume and excretion of sodium, potassium, urea and 
creatinine, water intake and urine collections were measured daily prior to initiation of 
pacing (Baseline) and daily during the 14-day pacing period. Following cessation of 
pacing, these measurements continued daily for the first week of Recovery, and then 





Table 32: Physiological characteristics of sheep throughout the RNA-seq study. Mean and 
standard deviations are reported at Baseline (Day 0), during pacing induced HF (Day 14) and 
during recovery (Day 39). 
 Baseline (Day 0) Pacing (Day 14) Recovery (Day 39) 
Cardiac output 
(L/min) 
7.52 (± 1.26) 3.75 (± 0.57) 7.2 (± 0.96) 
B-type natriuretic 
peptide (pmol/L) 
1.5 (± 1.5) 47.9 (± 19.5) 2.4 (± 1.8) 
Renal perfusion 
pressure (mmHg) 




0.091 (± 0.009) 0.065 (± 0.009) 0.074 (± 0.012) 
Central venous 
pressure (mmHg) 
3.3 (± 1.5) 23.6 (± 2.7) 3.4 (± 1.2) 
Mean arterial 
pressure (mmHg) 
88.6 (± 6.39) 67.4 (± 5.52) 87 (± 11.73) 
Atrial natriuretic 
peptide (pmol/L) 
20 (± 6.9) 348.2 (± 113.1) 23.9 (± 6) 
Left atrial 
pressure (mmHg) 
4.7 (± 1.41) 28.7 (± 3.9) 5.9 (± 1.44) 
Urine volume 
(L/24hrs) 
1.216 (± 0.432) 0.674 (± 0.231) 1.772 (± 0.657) 
Urine creatinine 
(mmol/hr) 
0.414 (± 0.06) 0.34 (± 0.04) 0.358 (± 0.022) 
Urine sodium 
(mmol/hr) 






Blood samples were collected and assayed as described above in Section 1.1.1.1.1. 
Kidney cortex biopsies were taken in duplicate prior to pacing (Baseline), on day 
14 of pacing, and at the end of the 25-day recovery period. Sheep were anesthetised for 
the first two biopsies and two adjacent percutaneous kidney biopsies performed under 
ultrasonic guidance (Philips iE33; Philips Ultrasound, WA, UA) using a 14 g spring-
loaded automated biopsy gun (BARD Peripheral Vascular, Inc., Tempe, USA). The final 
kidney cortex samples were collected at the end of the study protocol, immediately 
following euthanasia (100 mg/kg IV Pentobarb300). At each biopsy collection, one of 
the biopsies was fixed in 10% formalin (4°C overnight) for histological analysis, and the 
other snap frozen in liquid nitrogen and stored at -80°C for subsequent RNA extraction 
for RNA-seq and protein preparation for mass spectrometry. A total of 7 kidney cortex 
samples from the final time point (‘Recovery’) were utilised in the current experiment. 
7.1.2 Preparation	of	control	sheep	
Adult Coopworth ewes (n=5; 2-5 years; Lincoln University Farm, Canterbury, 
New Zealand) underwent a transthoracic echocardiography exam while conscious, and 
were then housed in a metabolic crate for 24 hours to allow for urine collection. During 
this time, sheep had free access to food and water. After 24 hours, conscious sheep 
underwent a venepuncture of the jugular vein (after the area was numbed using topical 
lidocaine spray) to obtain a 50 mL blood sample. Sheep were subsequently euthanised 
via intravenous anaesthetic overdose (150mg/kg Pentobarbital). Cardiac tissues and 
















Figure 30: Study timelines for preparation of paced sheep (Figure 12A, n=8 samples utilised), 
sheep recovered from heart failure (Figure 12B, n=7 samples utilised), and control sheep 
(Figure 12C, n=5 samples utilised). Created using BioRender.com. 
7.1.3 Peptide	preparation	
A method for preparing proteins from sheep kidney tissue for SWATH-MS was 
optimised by assessing three protein preparation methods (Section 7.2). As a result, the 
Sample Preparation by Easy Extraction and Digestion method [290] (SPEED) was 
identified as the optimal method for preparation of sheep kidney tissue for subsequent 
SWATH-MS, and was used to prepare all kidney cortex samples in this experiment. All 
samples were processed in a single batch to eliminate batch effects.  
7.1.3.1 Tissue	preparation	for	SPEED	
Ground, frozen kidney cortex (100mg) was added to an Eppendorf tube 
containing 400 µL trifluoroacetic acid (TFA; ~1:4 v/v ratio) and incubated at room 
temperature for 20 minutes with occasional mixing by inversion, until all tissue was 
dissolved. To neutralise the pH of the mixture, 2M TrisBase was added at 10x the volume 
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of TFA. Samples were then reduced using Tris(2-carboxyethyl)phosphine (TCEP) at a 
final concentration of 10 mM and simultaneously alkylated using 2-Chloroacetamide 
(CAA) at a final concentration of 40 mM, and incubated at 95°C for 5 minutes [290]. 
Next, the concentration of protein in the mixture was determined by turbidity by 
measuring Absorbance (360 nm) and MacFarland turbidity standards [290]. 
Corresponding protein concentrations for each MacFarland standard were previously 
determined by Doellinger et al. [290] using tryptophan fluorescence measurements as a 
reference (Table 33). This allows the calibration of any UV-spectrophotometer using 
commercial MacFarland standards, such that a measured A360 value can be used to 
calculate the corresponding protein concentration in SPEED-derived samples using 
Equation 1. For example, Doellinger et al. determined that MacFarland standard 3 
contained the protein concentration equivalent of 0.36 μg/μL – therefore, multiplying the 
turbidity (A360) of the sample in question by the ratio of 0.36 / the turbidity (A360) of 
MacFarland standard 3 would calculate the protein concentration of the sample in 
question. 
Absorbances at 360 nm (A360) were measured for each MacFarland standard 
(bioMérieux, OT-70900, France) on a MultiSkan Go plate reader (ThermoFisher 
Scientific) using SkanIt Re 5.0 software (ThermoFisher Scientific). Measurements at  
360 nm were taken in triplicate. The protein concentration of samples based on their 
A360 turbidity measurement were calculated using the following equation:  










Table 33: Corresponding protein concentrations for MacFarland standards as determined by 
Doellinger et al., using tryptophan fluorescence as a reference. The absorbance at 360nm for 
each MacFarland standard as measured in the current experiment on a Multiskan Go is also 
presented. All A360 readings were taken in triplicate and the average A360 presented. 
MacFarland Standard Protein Concentration 
equivalent according to 
Doellinger et al. [µg/µL] 
A360 measured on 
Multiskan Go 
0.5 0.06 0.14 
1 0.14 0.16 
2 0.22 0.23 
3 0.36 0.36 
4 0.51 0.54 
5 0.60 0.54 
 
Using the above equation, the protein concentration of each sample was 
calculated. An aliquot containing 150 μg was taken, and the concentration of protein in 
this aliquot adjusted to 0.75 μg/μL using Dilution Buffer (a 10:1 (v/v) mix of 2M 
TrisBase and TFA). Samples were further diluted 1:5 using high-performance liquid 
chromatography (HPLC) grade water before trypsinisation. Digestion was carried out for 
20 hours at 37°C at 600 rpm on a Thermomixer, using a protein:enzyme ratio of 25:1 
(Sequencing Grade Modified Trypsin, PRV5111, Promega, Fitchburg, WI). To cease 
digestion, TFA was added to a final concentration of 2%. 
7.1.4 Purifying	and	drying	down	peptides	
Following trypsinisation and peptide concentration via Speed-Vac, peptide 
purification was performed using reverse phase Vydac C18 Silica 96-well MACROSpin 
plates (SNS SS18V-L, The Nest Group Inc.). Peptides prepared using SPEED were 
purified in the final solution from trypsinisation containing 2% TFA. Peptides were 
loaded onto the C18 resin and salts and buffers washed thrice using 0.2% TFA and 
centrifugation (50 g, 110 g, 200 g and 400 g for 1 minute each, followed by 750 g for 2 
minutes) [291]. Peptides were eluted using a high-organic mobile phase (0.1% formic 
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acid in 60% acetonitrile (ACN)) [291] and centrifugation (50 g, 110 g, 200 g and 400 g 
for 1 minute each, followed by 750 g for 2 minutes). Peptides were stored at 4 ºC for 72 
hours to achieve equilibrium of peptide degradation, before being concentrated in a 
Speed-Vac (Concentrator 5301, Eppendorf) at 37 ºC to near-dryness (~5 µL remaining). 
7.1.5 Mass	Spectrometry	
As described in literature review Section 2.7, a key part of a traditional SWATH-
MS experiment is acquiring a DDA-MS scan to generate a spectral library. DDA, also 
known as the shotgun or discovery approach, maps out the proteome content of a sample 
by identifying as many peptides and proteins as possible, thereby creating a spectral 
library [144]. The complex spectral data gathered in SWATH-MS can then be searched 
against this spectral library, enabling identification and accurate quantification of 
specific proteins [140]. 
7.1.5.1 Mass	Spectrometry	conditions	
To mitigate batch effects, the injection sequence was alternated between the three 
sheep groups (paced, recovered and controls). To correct for differences in peptide 
relative retention times between runs, retention time calibration peptides (iRT-Kit, 
Biognosys) were spiked into each sample at 75x dilution of the iRT stock solution (final 
sample volume was 30 µL) [292]. SWATH-MS was performed on a 5600+ TripleTOF 
mass spectrometer coupled to an ekspert nanoLC 415 system (eksigent, AB Sciex, 
Dublin, CA, USA) by Dr Torsten Kleffmann at the Centre for Protein Research at the 
University of Otago (Dunedin, New Zealand). Spectral libraries were generated over a 
2-hour gradient by running the mass spectrometer in Data Dependent Acquisition (DDA, 
or shotgun) mode. For each sample, an MS1 survey scan was run (400 ms) followed by 
22 MS2 scans in which the most abundant peptides were fragmented, covering a 
precursor mass range of 400-1300 m/z. All high-sensitivity fragment ion scans used an 




SWATH-MS spectra were acquired over a 2-hour gradient using variable window 
width for precursor ion selection. Typically, fixed windows of 25 m/z are used for 
SWATH-MS [293]. Using variable windows, which are narrower than the standard 25 
m/z at mass regions of high precursor intensity or density, results in improved selectivity 
of targeted analytes in each window [293]. Consequently, the use of variable windows 
results in more reliable quantification results and more confident identifications than the 
use of fixed windows. Previous work in our laboratory has optimised window sizes using 
the AB Sciex SWATH Variable Window Calculator (V1.0) and MS1 signal spread from 
DDA runs [294]. A survey scan was run (100 ms), followed by a total of 34 SWATH-
MS2 scans with overlapping mass/charge (m/z) windows (1 m/z for the window overlap), 
covering a precursor mass range of 400-1250 m/z. SWATH-MS2 spectra were collected 
from 100-1600 m/z. Collision energy spread (CE) was automatically optimised for each 
window using a CE spread of 15 eV. All high-sensitivity fragment ion scans used an 
accumulation time of 96 ms, resulting in a total cycle time of ~3.4 seconds for all 35 
scans. Each sample was injected three times and the median of ion level data calculated 
across the three SWATH-MS runs. 
7.1.6 Data	Processing	
7.1.6.1 Creating	Spectral	Libraries	for	SWATH	Using	DDA	Data	
To generate a spectral library for SWATH from DDA data, AB Sciex *.wiff DDA 
files were loaded into ProteinPilot (v4.5). Protein identification searches were performed 
with the Paragon™ algorithm (v4.5.0.0) using a reverse-decoy database search strategy 
with the following search parameters: sample type: identification; cys alkylation: 
iodoacetamide; digestion: trypsin; instrument: TripleTOF 5600; special factors: none; ID 
focus: biological modifications, amino acid substitutions; search effort: thorough ID; 
detected protein threshold: > 0.05 (10.0%). The UniProtKB [295] TrEMBL Sheep 
Proteome was used as the reference proteome (accessed 22 July 2020). 
This process was run once including all kidney tissue DDA files. At a False 
Discovery Rate (FDR) of 1.0%, this yielded 1,777 proteins in the tissue library. This 
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spectral library was exported as a *.group file and was used for subsequent SWATH-MS 
analyses. 
7.1.6.2 SWATH-MS	searches	
Protein quantification of SWATH MS was carried out with AB Sciex software 
(SWATH Acquisition™MicroApp in PeakView Software, v2.2). The spectral library 
was loaded excluding shared peptides (also known as non-proteotypic peptides) [296] to 
avoid peptides mapping to more than one protein. Retention times for all 60 SWATH-
MS files (20 biological samples with three technical injection replicates each) were 
aligned using retention time standard peptides from Biognosys (see Appendix Section 
2.2.2, Table 53 for identities). Retention time alignment is performed so that the same 
components (i.e. peptides) in different runs are grouped together for appropriate 
comparison [297]. 
Processing settings in the SWATH Acquisition™MicroApp were set to the 
following conditions: 6 peptides per protein, 6 transitions per peptide, FDR threshold of 
1.0%, fixed library rank of peptides, a 20 minute window for the extracted ion 
Chromatogram (XIC) and a mass accuracy of 75 ppm [298]. Extracted transition ion peak 
areas, peptide peak areas and protein peak areas were exported in Excel format (.xlsx) 
for further processing using R. 
7.1.6.3 SWATH	data	processing	
Ion level data generated using PeakView (Section 7.1.6.2) was processed using 
R [299] and RStudio [254] using established protocols in our lab [294]. To normalise 
data across runs, a normalisation factor was calculated and applied for each sample using 
the ratio of the mean ion intensity (area under the curve, AUC) across all samples to the 
AUC of the individual sample. Following this, a lower detection limit was set for each 
ion (across all samples) in which any low-end outliers were excluded if the ion intensity 
was less than Q1 – (1.5 x IQR). The coefficient of variation (CV) for technical injection 
replicates was calculated for each ion and a cut-off value of < 25 in at least 80% of 
samples applied to ensure robust detection of ions. For individual samples, ions were 
removed from the data set if they were not observed in at least two technical replicates. 
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Combined, these steps were taken to ensure that only the most consistently detected ions 
with high-quality technical replicates were included in the data set for further analysis. 
To extract a “final” ion intensity across each set of technical injection triplicates for a 
given sample, the median intensity of each ion was taken. The median intensity for each 
ion was then used to sum ions to peptide areas, and then sum peptides to protein areas – 
an approach which reliably estimates global protein intensities [300-302]. Group sizes 
(n=5-8) were too small to assess whether protein data were normally distributed, 
therefore no protein data were log2-transformed as would be performed for non-normally 
distributed data. Statistical analysis was carried out on protein level data. 
7.1.7 Statistical	Analysis	
All statistical analyses were performed using R [299] and RStudio [254]. Three 
separate Welch one-way tests were performed using the tableone package [303] to 
identify proteins differentially expressed between the groups (healthy control sheep vs 
sheep with ADHF; healthy control sheep vs recovered sheep; sheep with ADHF vs 
recovered sheep). Welch one-way tests are more reliable than a traditional ANOVA in 
samples with unequal sample distribution variance and/or unequal sample sizes [304] (as 
is the case in the current experiment). P values were adjusted using the Benjamini-
Hochberg method to decrease the false discovery rate, and fold-changes calculated.  
7.1.8 Identifying	enriched	and	activated/repressed	pathways	
The Core and Comparative gene set enrichment analysis workflow in Ingenuity 
Pathway Analysis software (IPA; Qiagen Inc., https://www.qiagenbioinformatics.com/ 
products/ingenuity-pathway-analysis) was used to test for enrichment of canonical 
pathways. Z-scores were used to determine the net effect of individual gene expression 
changes on a pathway – that is, whether the combined effect of independent gene 
expression alterations predicted activation or repression of a pathway. Z-scores > 2 
indicate pathway activation and Z-scores < -2 indicate pathway repression. A p-value of 




Potential circulating or urinary biomarkers were identified using (i) the IPA 
software ‘Biomarker Filter’ workflow, which annotates proteins that have been 
experimentally observed in the biofluids of choice based on current literature (primarily 
[305, 306]) and (ii) the Human Protein Atlas secretome (proteinatlas.org), which includes 
2,641 proteins with a signal peptide and no transmembrane-spanning region, annotated 
with plasma concentrations where available (bioinformatics approach). These potential 
circulating or urinary biomarkers were compiled into a list for comparison with proteins 
identified in the current experiment.  
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7.2 Method	 optimisation:	 Determining	 the	 optimal	 protein	
preparation	method	for	kidney	tissue	and	plasma	
To identify the optimal method for preparing proteins from sheep kidney tissue and 
plasma for SWATH-MS, three protein preparation methods (SDC, SPEED and S-Trap) 
were assessed. The number of peptides, proteins and post-translational modifications 
detected and the efficiency of trypsin digestion (i.e. missed cleavages) were compared. 
An overview of the proteomics optimisation study is given in Figure 31. For each 
method, tissue homogenisation, plasma preparation and protein quantification are 
described.  
7.2.1 Samples	utilised	
Paired kidney cortex and plasma samples from three sheep (2x healthy controls, 
1x pacing induced HF) were randomly selected from the pool of archived sheep samples 
from Ucn2, RNA-Seq and control studies (Figure 30). Three sample preparation methods 





Figure 31: Experimental workflow for determining the optimal protein preparation method for 




The SDC, SPEED (Sample Preparation by Easy Extraction and Digestion [290]) 
and S-Trap 96-well plate (Protifi, Farmingdale, NY) protein preparation methods are all 
‘bottom-up’ proteomics strategies in which proteins are enzymatically digested into 
peptides prior to analysis by MS, with several critical elements in common [307]. In all 
three of these protocols i) tissues or cells are lysed and proteins are extracted; ii) proteins 
are reduced to break disulphide bonds and allow the protein to unfold; iii) proteins are 
alkylated to covalently cap the reduced SH-groups and prevent novel disulphide bond 
formation; and iv) proteins are digested enzymatically to peptides.  
The key difference in methodology across these protein preparation methods 
occurs at the protein extraction phase (step i). SDC and S-Trap protocols both use 
detergents to lyse tissues and cells, whilst SPEED relies on a strong acid for lysis. To 
minimise variability between the protein extraction methods, I standardised the protocols 
across steps ii-iii (reduction to alkylation) and standardised the ratio of protein:trypsin 
utilised in step iv. 
For each method, all samples were processed in a single batch to eliminate batch 
effects. Prior to processing, frozen kidney tissue was ground using a mortar and pestle 
chilled with liquid nitrogen and plasma was thawed on ice and centrifuged for 5 minutes 
at 13,000 g at 10°C to remove particulate matter. 
First, the amount of protein was standardised across the three protocols. Based on 
previous work in our laboratory using the 5600+ TripleTOF mass spectrometer coupled 
to an ekspert nanoLC 415 system (eksigent, AB Sciex, Dublin, CA, USA), a starting 
amount of 150 µg of protein was selected [294]. This is equivalent to 2.5 µL plasma 
[308], and an equivalent amount of kidney tissue is determined in Sections 7.2.3.1, 
7.1.3.1 and 7.2.5.2, allowing sufficient material for repeat measures.  
Second, protein reduction and alkylation were kept consistent across the three 
protocols. Multiple studies have described simultaneous use of reducing agent Tris(2-
carboxyethyl)phosphine (TCEP) and alkylation agent 2-Chloroacetamide (CAA) [309-
312]. This reduction/alkylation strategy was compatible with all three methods [290, 294, 
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313]. Samples were reduced using TCEP at a final concentration of 10mM and 
simultaneously alkylated using CAA at a final concentration of 40mM, and incubated at 
95°C for 5 minutes [290]. 
Third, trypsin (Sequencing Grade Modified Trypsin, PRV5111, Promega, 
Fitchburg, WI) was used for the digestion of proteins into peptides, with a protein:trypsin 
ratio of 25:1. 
7.2.3 SDC	peptide	preparation	
7.2.3.1 Tissue	preparation	for	SDC	
Ground tissue (1 g) was added to a pre-chilled 7 mL Precellys tissue 
homogenisation tube (Hard Tissue Homogenizing CK28 7 mL, P000911-LYSK0-A, 
Bertin Instruments, Rockville, MD) containing 2.8 mm ceramic (zirconium oxide) beads. 
Tissue Denaturing and Homogenising Solution (composition listed in Table 51 Appendix 
Section 2.1) was added (5 mL) containing 0.1% sodium deoxycholate (SDC),  
333.3 mM ammonium hydrogen carbonate, PhosSTOP phosphatase inhibitor (Roche 
Diagnostics, Mannheim, Germany) and cOmplete Protease Inihibitor Cocktail (Roche 
Diagnostics, Mannheim, Germany) at the manufacturer’s recommended concentrations 
(one PhosSTOP tablet per 10 mL of extraction solution, one cOmplete tablet per 50 mL 
extraction solution). SDC was added at 0.1% to avoid over-foaming during the 
homogenisation step. Samples were homogenised on a Cryolys Evolution machine 
(Bertin Instruments, Rockville, MD) at the following conditions: 4 x 15 second cycles, 
30-second break between cycles, 8000 rpm, 4°C. Following homogenisation, the SDC 
concentration was increased from 0.1% to 1.67%, consistent with the method developed 
by Lassé et al. [294]. 
Protein concentration was measured using the Pierce bicinchoninic acid (BCA) 
assay (catalogue #23225, ThermoFisher Scientific, Rockford, USA) following the 
manufacturer’s instructions. In brief, 25 μL of sample was pipetted into a well of 96-well 
plate, and 200 μL of BCA assay Working Reagent was added. Plates were mixed 
thoroughly for 30 seconds on a plate mixer before being covered and incubated for  
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30 minutes at 37 °C. Absorbance (562 nm) was measured in triplicate on a Multiskan Go 
(ThermoFisher Scientific, Rockford, USA) using SkanIt Re 5.0 software (ThermoFisher 
Scientific, Rockford, USA). An aliquot of homogenised sample containing 150 µg of 
protein was diluted to a final volume of 62.5 μL with Denaturing Solution 1 containing 
1.67% sodium deoxycholate (SDC), 333.3 mM ammonium hydrogen carbonate, 
PhosSTOP phosphatase inhibitor and cOmplete Protease Inihibitor Cocktail at the 
manufacturer’s recommended concentrations (one PhosSTOP tablet per 10 mL of 
extraction solution, one cOmplete tablet per 50 mL extraction solution (refer to Table 51 
Appendix Section 2.1 - protocol of tissue trypsinisation). 
Samples were further denatured using 82 µL of Denaturing Solution 2 (see Table 
52 Appendix Section 2.1 for solution composition) containing ACN and calcium 
chloride. Samples were briefly vortexed and incubated for 5 minutes at room temperature 
before and after addition of Denaturing Solution 2. Next, simultaneous alkylation and 
reduction was performed using TCEP and CAA as described above in Section 7.2.2. The 
denatured and reduced/alkylated samples were digested using porcine trypsin 
(Sequencing Grade Modified Trypsin, PRV5111, Promega, Fitchburg, WI) at a 
protein:trypsin ratio of 25:1 (w/w), (i.e 150 μg protein: 6 μg trypsin). Initially, half  
(3 µg) of the trypsin was added and samples incubated for 3 hours at 42°C, before 
addition of the remaining trypsin (3 µg) (i.e. trypsin boost) and incubation at 37°C for  
16 hours. Digestion was terminated and SDC precipitated simultaneously by the addition 
of formic acid at a final concentration of 0.2%. The final supernatant was concentrated 
in a Speed-Vac (Concentrator 5301, Eppendorf, Hamburg, Germany) at 37 ºC to near-
dryness (~5 µL remaining). Samples were stored at -80 °C degrees until analysis. 
7.2.3.2 Plasma	preparation	for	SDC	
Plasma (2.5 μL, containing approximately 150 µg of protein) was mixed with 
Denaturing Solution 1 (60 μL), containing 1.67% sodium deoxycholate (SDC), 333.3 
mM ammonium hydrogen carbonate, PhosSTOP phosphatase inhibitor (catalogue 
#04906837001, Roche, Mannheim, Germany) and cOmplete Protease Inihibitor Cocktail 
(catalogue #11697498001, Roche, Mannheim, Germany) at the manufacturer’s 
recommended concentrations (one PhosSTOP tablet per 10 mL of extraction solution, 
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one cOmplete tablet per 50 mL extraction solution (refer to Table 52 Appendix Section 
2.1 – protocol of plasma trypsinisation). 
Samples were then denatured, alkylated and reduced, trypsinised, dried down and 
stored as described in Section 7.2.3.1. 
7.2.4 SPEED	peptide	preparation	
7.2.4.1 Tissue	preparation	for	SPEED	
Kidney tissue was prepared for SPEED as described above in Section 7.1.3.1. 
7.2.4.2 Plasma	preparation	for	SPEED	
Plasma (2.5 μL, containing approximately 150 μg of protein) was mixed with 
trifluoroacetic acid (TFA) at a 1:4 (v/v) ratio to denature proteins and incubated at room 
temperature for 10 minutes with occasional mixing by inversion. To neutralise the acid, 
2M TrisBase was added at 10x the volume of TFA. Next, simultaneous alkylation and 
reduction was performed using TCEP and CAA as described in Section 7.2.2. Sample 
volume was adjusted to a concentration of 0.75 μg/μL using Dilution Buffer (a 10:1 (v/v) 
mixture of 2M TrisBase and TFA) and diluted 1:5 using HPLC water before 
trypsinisation. Digestion was carried out for 20 hours at 37°C at 600 rpm on a 
Thermomixer, using a protein:enzyme ratio of 25:1 (Sequencing Grade Modified 
Trypsin, PRV5111, Promega, Fitchburg, WI). To cease digestion, TFA was added to a 
final concentration of 2%. 
7.2.5 S-Trap	peptide	preparation	
The ‘S-Trap midi protocol long 4.1’ (Protifi, Farmingdale, NY) was performed 




In contrast to SDC and SPEED (both ‘In-Solution’ protein extraction methods), 
S-Trap utilises a filter-based system made up of a 96-well plate, with each well 
containing a quartz spin column with submicron pores (to capture proteins). An essential 
step in the S-Trap protocol is the shearing or lysis of DNA in samples by sonication, to 
prevent DNA from clogging the filter membranes.  
To determine the optimal sonication procedure for sufficient fragmentation of 
DNA without unduly modifying or damaging proteins, 8 different sonication conditions 
were assessed for their effectiveness of DNA shearing in kidney tissue samples. A Sonic 
Ruptor 400 Ultrasonic Homogeniser (Omni International, GA, USA) was used to 
sonicate homogenised samples with a volume of 250 µL. All samples were sonicated on 
ice to counter heating induced by sonication. DNA fragmentation and protein integrity 
were examined using a Tapestation 2200 (model # G2964AA, Agilent Techologies Inc, 
Germany) with Genomic DNA ScreenTapes (catalogue #s 5067-5365 and 5067-5366, 
Agilent Technologies) and P200 ScreenTapes (catalogue #s 5067-5171 and 5067-5372, 
Agilent Technologies). A sonication step at 30% power, 50% pulse rate for 100 seconds 
was selected as the optimal condition (see Appendix Section 2.2). 
7.2.5.2 Tissue	lysis	for	S-Trap	
Ground, frozen kidney tissue (1 g) was added to a pre-chilled 7 mL Precellys 
tissue homogenisation tube (Hard Tissue Homogenizing CK28 2 mL, P000911-LYSK0-
A, Bertin Instruments, Rockville, MD) containing 2.8 mm ceramic (zirconium oxide) 
beads. Lysis buffer (5 mL) was added containing 0.1% sodium dodecyl sulphate (SDS), 
50 mM TEAB, and PhosSTOP phosphatase inhibitor and cOmplete Protease Inhibitor 
Cocktail according to manufacturer’s recommendations (one PhosSTOP tablet per  
10 mL of extraction solution, one cOmplete tablet per 50 mL extraction solution). SDS 
was added at 0.1% to avoid over-foaming during the homogenisation step. Samples were 
homogenised on a Cryolys Evolution machine (Bertin Instruments, Rockville, MD) at 
the following conditions: 4 x 15 second cycles, 30-second break between cycles,  
8000 rpm, 4°C. Subsequently, samples were sonicated on ice at 30% power, 50% pulse 
rate for 100 seconds. The SDS concentration was increased from 0.1% to 5%. 
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Protein concentration was quantified using a Pierce bicinchoninic acid (BCA) 
assay (catalogue #23225, ThermoFisher Scientific) as described above (Section 7.2.3.1). 
An aliquot of homogenised sample containing 150 μg of protein was made up to a volume 
of 50 μL with 1x lysis buffer for processing as described in Section 7.2.5.4 below. 
7.2.5.3 Plasma	lysis	for	S-Trap	
A minimum volume of 250 µL (sample in lysis buffer) was required for adequate 
sonication with the available microprobe (Omni International, GA, USA). 12.5 μL of 
plasma (containing approximately 1,875 μg of protein) was first diluted  to a final volume 
of 125 μL with lysis buffer (5% SDS, 50 mM triethylammonium bicarbonate) and then 
further diluted to 250 μL with 2x lysis buffer containing PhosSTOP phosphatase inhibitor 
(catalogue #04906837001, Roche, Mannheim, Germany) and cOmplete Protease 
Inhibitor Cocktail (catalogue #11697498001, Roche, Mannheim, Germany) according to 
manufacturer’s recommendations (one PhosSTOP tablet per 10 mL of extraction 
solution, one cOmplete tablet per 50 mL extraction solution). Samples were probe 
sonicated as described on ice at 30% power, 50% pulse rate for 100 seconds. Of the  
250 μL sonicated sample, a 50 μL aliquot containing 150 μg of protein was carried 
through the S-Trap protocol (Section 7.2.5.4). 
7.2.5.4 Tissue	and	plasma	digestion	for	S-Trap	
Aliquots (50 μL) containing 150 μg of protein from kidney tissue or plasma, were 
simultaneously reduced and alkylated using TCEP and CAA as described in Section 
7.2.2. Phosphoric acid was added to the SDS lysate to a final concentration of 1.2%.  
S-Trap binding buffer (90% aqueous methanol containing 100 mM Triethylammonium 
bicarbonate (TEAB; 350 μL) was added to the acidified lysate and loaded onto to an  
S-Trap column. The plate was centrifuged at 1,500g for 2 minutes until all solution had 
passed through the membranes. Bound proteins were washed three times, each time with 
200 μL of S-Trap binding buffer followed by centrifugation at 1,500g for 2 minutes. 
After the last washing step, S-Trap digestion buffer (50 mM TEAB) containing trypsin 
(Sequencing Grade Modified Trypsin, PRV5111, Promega, Fitchburg, WI) at a 
protein:enzyme ratio of 25:1 was added directly to the column and samples were 
incubated for 1 hour at 47ºC for on-column trypsinisation. Following incubation, 
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peptides were eluted in three stages. First, peptides were eluted in 80 μL digestion buffer, 
next in 80 μL of 0.2% aqueous formic acid, and finally in 80 μL of 50% ACN containing 
0.2% formic acid (to assist in recovery of hydrophobic peptides) with centrifugation at 
1,500 g for 2 minutes between each addition. All elutions were pooled, and peptides were 
concentrated in a Speed-Vac (Concentrator 5301, Eppendorf) at 37 ºC to near-dryness 
(~5 μL remaining).  
7.2.6 ProteoMiner	Protein	Depletion	of	a	Pooled	Plasma	Sample	
In mass spectrometry, the high-abundance proteins present in plasma, such as 
albumin and fibrinogen [314] make the detection of medium- and low-abundance 
proteins challenging [315]. To overcome this challenge, high abundance proteins can be 
depleted to allow a more comprehensive exploration of the entire proteome [314]. One 
approach is to create a depleted library to maximise the number of possible target proteins 
and run undepleted SWATH samples [316]. To create a pooled, depleted plasma library, 
plasma samples from the three sheep were combined in equal volumes to yield 1 mL of 
pooled plasma (~333.33 μL of plasma from each sheep) and depleted using a 
ProteoMiner Protein Enrichment Large-Capacity Kit (#263-3007, BioRad) following the 
manufacturer’s instructions. Briefly, ProteoMiner columns were washed twice with 600 
μL of wash buffer before loading with 1 mL of plasma sample. Loaded columns were 
rotated and incubated at room temperature for 1 hour before washing thrice with 600 μL 
of wash buffer. Samples were eluted in 200 μL of elution agent. This method uses a large, 
diverse bead-based library of combinatorial peptide ligands [317], in which a mixture of 
porous beads each carry a large number of copies of the same peptide bait. Each bead 
carries different peptides, and when a plasma sample is applied to the beads, high 
abundance proteins saturate the high affinity ligands and excess proteins are washed 
away. In contrast, medium- and low-abundance proteins are concentrated on their 
specific affinity ligands. This strategy reduces the dynamic range of protein 
concentrations, but maintains representation by all proteins present in the original sample 
[315]. It is therefore particularly useful for DDA library generation but due to altering 
the relative protein concentrations it should not be used for SWATH samples. 
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This depleted, pooled plasma sample was then prepared for MS using the S-Trap 
method for plasma, as outlined in Sections 7.2.5.3 - 7.2.5.4. 
7.2.7 Purifying	and	drying	down	peptides	
Peptide purification was performed using reverse phase Vydac C18 Silica 96-
well MACROSpin plates (SNS SS18V-L, The Nest Group Inc.). The dried peptides 
prepared using the SDC method and S-Trap method were first resuspended in 120 μL of 
2% ACN containing 0.2% formic acid. Peptides were loaded onto the C18 resin and salts 
and buffers washed thrice using 200 μL of 2% ACN containing 0.2% formic acid and 
centrifugation (50 g, 110 g, 200 g and 400 g for 1 minute each, followed by 750 g for 2 
minutes) [294]. Peptides were eluted using a high-organic mobile phase (0.2% formic 
acid in 75% ACN) [294] and centrifugation (50 g, 110 g, 200 g and 400 g for 1 minute 
each, followed by 750 g for 2 minutes). Peptides prepared using the SPEED method were 
purified as described in Section 7.1.4. All peptides were stored at 4ºC for 72 hours to 
achieve equilibrium of peptide degradation, before being concentrated in a Speed-Vac 
(Concentrator 5301, Eppendorf) at 37 ºC to near-dryness (~5 μL remaining). 
7.2.8 Mass	Spectrometry	
DDA and SWATH-MS were performed as described in Section 7.1.5.1. 
7.2.9 Data	Processing	
7.2.9.1 DDA	searches	
To identify the proteins present in a sample, the spectra generated in DDA-MS 
must be searched and matched against a reference proteome. AB Sciex *.wiff files were 
converted to *.mgf files using the AB Sciex MS Data Converter (Beat1.3, AB ScieX, 
Dublin, CA, USA) for compatibility with SearchGUI software [318]. The search was 
conducted using SearchGUI version 3.3.20 and peak lists obtained from MS/MS spectra 
were identified using the X!Tandem Vengeance search engine (2015.12.15.2) [319]. 
Protein identification was conducted against a concatenated target/decoy [320] version 
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of the Ovis aries (27638, 99.8%), Ovis aries musimon (46, 0.2%) and Ovis aries platyura 
(1, < 0.1%) sheep proteomes from UniProtKB [295] TrEMBL (27,685 target sequences, 
accessed 22 July 2020). Decoy sequences were created in SearchGUI by reversing target 
sequences. This is performed to determine the number of peptide spectra being falsely 
assigned to decoys (i.e. the number of incorrect peptide identifications) and thereby 
estimate a false discovery rate (FDR) for peptide spectra matching [320]. Precursor mass 
tolerance was set to 50 parts per million and the fragment ion tolerance to 0.2 Daltons. 
Trypsin was selected as the protein digestion enzyme and a maximum of 2 missed 
cleavages was allowed. Carbamidomethylation (+57.02 Da, Unimod #4) of cysteine was 
included as a fixed modification to account for the alkylation step in protein preparation, 
and the variable modifications included were oxidation of methionine (+15.99 Da, 
Unimod #35), acetylation of the protein N-terminal (+42.01 Da, Unimod #1) and 
carbamidomethylation of lysine (+57.02 Da, Unimod #4). Variable modifications 
included during the refinement procedure were pyrolidone from glutamic acid (-17.03 
Da, Unimod #27), pyrolidone from glutamine (+X Da, Unimod #28) and pyrolidone from 
carbamidomethylated cysteine (-17.03 Da, Unimod #385). 
PeptideShaker version 1.16.45 [321] was used to infer peptides and proteins from 
the spectrum identification results. Peptide spectrum matches (PSMs), peptides and 
proteins were validated at a 1.0% FDR using the decoy hit distribution. Post-translational 
modification (PTM) localisations were scored using the phosphoRS score [322] and the 
D-score [323] with a threshold of 95.0 as implemented in the compomics-utilities 
package [324].  
Default peptide reports, default protein reports and custom reports were exported 
from PeptideShaker to summarise detected proteins, detected peptides, validated unique 
peptides, missed cleavages, protein coverage and post-translation modifications for 
comparisons across the three protein preparation methods. 
7.2.9.2 Creating	Spectral	Libraries	for	SWATH	Using	DDA	Data	
Spectral libraries were created as described in Section 7.1.6.1. This process was 
run three times; once for all kidney tissue DDA files, once for all plasma DDA files, and 
once for a single DDA file of a pooled depleted plasma sample, resulting in generation 
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of three spectral libraries (comprehensive kidney tissue library, comprehensive plasma 
library and depleted plasma library). At an FDR of 1.0%, this yielded 1,186 proteins in 
the tissue library, 203 proteins in the plasma library and 231 proteins in the depleted 
plasma library. These spectral libraries were exported as *.group files. The 
SWATHXtend R package [325] was used to construct an extended spectral library which 
merged the three libraries generated above (tissue, plasma and depleted plasma) for use 
as the final spectral library when analysing plasma SWATH-MS data. This tissue spectral 
library and extended spectral library were used for all subsequent kidney tissue SWATH-
MS analyses. 
7.2.9.3 SWATH-MS	searches	
Searches were carried out as outlined in Section 7.1.6.2. Retention times for 27 
plasma SWATH-MS files (three biological samples, three sample preparation methods 
and three technical injection replicates each) were aligned using retention time standard 
peptides from Biognosys. Retention times for 27 kidney tissue SWATH-MS files (three 
biological samples, three sample preparation methods and three technical injection 
replicates each) were aligned using a combination of retention time standard peptides 
from Biognosys and low-density lipoprotein (LDL). In the kidney tissue samples, three 
of the eleven spike-in Biognosys retention time standard peptides did not produce 
consistent peaks across all of the samples and were excluded, resulting in incomplete 
coverage by retention time peptides across the entire time window of the experiment for 
alignment. Use of medium to high abundance spike-in peptides or endogenous peptides 
present in both the DDA ion library and SWATH samples is a common strategy for 
retention time alignment [326] - therefore, two peptides were selected from endogenous 
LDL due to their high abundance and consistent detection across all samples. 
7.2.9.4 SWATH	data	processing	
SWATH data generated using PeakView was further processed using R [299] and 




With respect to which sample preparation method would yield the best qualitative 
and quantitative performance, a number of MS relevant metrics were compared. For 
DDA data I summarised the percentage of missed tryptic cleavages and the total number 
of proteins and peptides detected by each method. Peptides and proteins detected by each 
method were compared. Median protein coverage, incidence of post-translational 
modifications and the identities of post-translational modifications were compared. Next, 
data collected using SWATH-MS was assessed by calculating the number of proteins 
and peptides detected by each method and comparing the identities of proteins and 
peptides. To determine whether any of the sample preparation methods was better suited 
to identifying proteins enriched in the kidney or plasma, the proteins identified in each 
method were compared against a list of kidney tissue enriched proteins and secreted 
proteins obtained from The Human Protein Atlas [327, 328]. Finally, the quality of 
technical and biological replicates was assessed by calculating coefficients of variation 
and comparing the median CV across methods. SPEED was determined to be the best 
method for subsequent SWATH-MS analysis of kidney tissue and was consequently used 





Results of Optimisation of 
Proteomics Sample Preparation 
8.1 Introduction	
This chapter aimed to assess the performance of three separate sample preparation 
methods for SWATH-MS, in both ovine kidney tissue and plasma. Several metrics of 
DDA and SWATH-MS data quality were assessed including the number of proteins and 
peptides detected, post-translational modifications, missed protein cleavages (from 
incomplete trypsinisation), protein coverage and consistency within technical replicates 
(Figure 32). Results from this experiment were used to design a proteomic study to 
discover new biomarkers for AKI in a pre-clinical (ovine) model of acute HF (Chapter 
Nine). 
Mass spectrometry (MS) is a key tool for the identification and quantification of 
proteins, capable of identifying thousands of proteins in a wide range of biological 
samples [329] (for an overview of MS methodology see Literature Review Section 2.7). 
In bottom-up proteomics, proteins are enzymatically proteolysed into peptides and 
analysed via tandem mass spectrometry (MS/MS) [330]. This process fragments peptides 
into ions, separates the ions based on the specific mass-to-charge ratios (m/z) and records 
the relative abundance of each type of ion (referred to as ion intensities). These peptide 
ion intensities can be used for protein quantification using bioinformatic algorithms 
which reconstruct peptide sequences [331]. The bioinformatics process involves scoring 
the reconstructed peptide sequences via database searching to match back to the proteins 
they originated from, and subsequently calculating protein intensities.  
In bottom-up proteomics, efficient sample extraction and proteolysis of proteins 
into their peptides is critical for the success of protein quantification [332]. Furthermore, 
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the depth of coverage of the proteome is also dependent on the selected sample 
preparation technique [329]. Various protein sample preparation methods for 
downstream MS differ greatly depending on the sample type, lysis conditions and 
proteolysis, with all methods possessing both advantages and disadvantages. 
Comparative studies have aimed to address these strengths and weaknesses [329, 333-
335], concluding that there is no universal sample preparation method which performs 
best for all types of tissues [333]. These findings emphasise that it is important to 
thoroughly consider and optimise the sample preparation method for any given sample 
type to be interrogated by MS. This chapter aimed to identify the optimal protein sample 
preparation method for subsequent SWATH-MS analysis for two different sample types: 
ovine kidney tissue and plasma. 
To investigate the best method of preparation for ovine kidney and plasma for the 
purpose of SWATH-MS, three different protein preparation methods were compared. 
The first protein preparation method was an in-solution proteolysis method, referred to 
throughout the chapter as the SDC method (named after the ionic detergent, sodium 
deoxycholate). This in-solution sample preparation method works by using the detergent, 
SDC, to solubilise proteins [336]. However, the removal of detergents, including SDC, 
is critical before MS analysis, due to its ability to dominate mass spectra and contaminate 
liquid chromatography systems [329]. The second method was Sample Preparation by 
Easy Extraction and Digestion (SPEED) [290]. This method employs pure trifluoroacetic 
acid for protein extraction rather than detergents or chaotropic agents such as urea, and 
consists of three steps: i) acidification, ii) neutralisation and iii) digestion. The third 
method trialled was a commercially available S-Trap (Protifi, Farmingdale, NY) kit. In 
this method, the detergent sodium dodecyl sulphate (SDS) is used for lysis and a fine 
protein particulate suspension is formed through the addition of buffer solution and 
phosphoric acid [313]. Samples are then loaded onto a quartz spin column containing 
submicron pores which capture proteins, and residual SDS is washed away. The captured 
proteins are digested in the filter before elution [313].  
The key difference in methodology across these protein preparation methods 
occurs at the lysis phase - SDC and S-Trap methods both use detergents to lyse tissues 
and cells, whilst SPEED employs a strong acid. It is critical to ensure the complete lysis 
of tissues and cells prior to protein proteolysis in order to represent the in vivo state of 
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the proteome (including membrane-bound proteins) [312]. To ensure valid comparisons 
between sample preparation methods, the amount of input protein, method of reduction 
and alkylation, and the amount of proteolysis enzyme (trypsin) were standardised across 
the three methods (refer to Section 7.2.2 for detail). MS data were collected and assessed 




Figure 32: Overview of the analysis process to compare the efficiency of three sample preparation 
methods – SDC, SPEED and S-Trap. Several metrics of data quality were assessed at both the DDA 




Kidney tissue from three sheep (2x healthy controls, 1x pacing induced HF) were 
randomly selected from the pool of archived sheep samples from Ucn2, RNA-Seq and 
control studies (described in Section 7.1.1 and 7.1.2). Three sample preparation methods 
were trialled, resulting in a total of 9 kidney tissue protein preparations. 
8.2.1 Assessment	of	sample	preparation	methods	for	DDA	MS	
To assess the efficacy of the three protein preparation methods on ovine kidney 
tissue, an assessment of data quality was performed using data collected in DDA mode.  
8.2.1.1 Number	of	proteins	and	peptides	detected	
To identify the sample preparation method allowing detection of the maximal number of 
proteins and peptides, the number of proteins and peptides detected with 100% 
confidence and the number of validated unique peptides were compared between the 
three methods (Figure 33). Peptides were classified as unique if they appeared in only 
one protein. These comparisons revealed that SPEED identified the greatest median 
number of proteins (552), peptides (2,333) and validated unique peptides (2,415), 
followed by S-Trap (proteins 369, peptides 1,115, validated unique peptides 1,583), and 
then SDC (proteins 311, peptides 928, validated unique peptides 1,527, Figure 3). There 
was substantial overlap in the proteins and peptides identified by each preparation 











Figure 33: Number of (A) proteins, (B) peptides and (C) validated unique peptides by sample 







Number of Validated Unique Peptides Detected






























Number of Proteins Detected with 100% Confidence























Number of Peptides Detected with 100% Confidence
























Figure 34: Venn diagram of the number of (A) 100% confidently identified proteins and (B) peptides 
detected with 100% confidence. Areas of overlap indicate where multiple methods identified the same 
protein or peptide. 
 
To assess the quality of peptide identifications, the percentage of confidently 
identified peptides was calculated for each method (Table 34). The percentage of 
confidently identified peptides was broadly similar across the three sample preparation 
methods, with SPEED possessing the highest percentage (62.7 %, Table 34). 
Table 34: The proportion of total peptides detected by each sample preparation method which were 
identified with 100% confidence. 
 SDC SPEED S-Trap 
All peptides detected 3349 7623 3917 
100% confidence peptides 
detected 
1688 4777 2011 
Proportion of confidently 
identified peptides 





The efficiency of enzymatic proteolysis was assessed by recording the peptides 
with missed cleavage sites as a percentage of the total number of peptides detected. The 
data for each of the three methods are illustrated in Figure 35. SPEED had the lowest 
proportion of missed cleavages (6.2% of peptides had at least one missed cleavage site), 









Figure 35: The (A) mean number and (B) mean percentage of total detected peptides with missed 
cleavages for proteins prepared using the SDC, SPEED and S-Trap methods. A lower proportion of 
missed cleavages indicated more efficient enzymatic proteolysis of proteins. Missed cleavage data 


















































Protein coverage refers to the percentage of the total protein sequence represented 
by peptides detected during MS [337]. A greater sequence coverage increases the 
probability of a correct protein identification and hence identification confidence [337]. 
Protein coverage was compared two ways: i) across all detected proteins, 
including proteins uniquely detected in each method data set (Figure 36A), and ii) across 
proteins in common to all three preparation methods (Figure 36B). When considering all 
proteins detected in DDA, SPEED had the greater protein coverage (median 16.3%, IQR 
15.1-16.6%), followed by SDC (median 13.2%, IQR 12.6-13.5%) and then S-Trap 
(12.4%, IQR 11.9-12.5%). This pattern was also reflected when considering the subset 
of proteins detected by all three methods (SPEED median 15.3%, IQR 14.8-17.3%; SDC 































Figure 36: Median protein coverage for (A) all proteins detected with 100% confidence by DDA for 




Post-translational modifications (PTMs) are changes in polypeptide chains as a 
result of removal or addition of distinct chemical groups, formation of covalent crosslinks 
between protein domains, or proteolytic processing of the protein termini [338]. The 
majority of PTMs can be detected by MS either as a specific mass increase or mass 
decrease relative to the unmodified protein [338]. Sample processing for bottom-up 
proteomics has been shown to introduce exogenous PTMs which are artefacts of sample 
processing [339]. In the current experiment, the analysis was limited to a set of 
commonly occurring PTMs including oxidation of methionine, acetylation of the protein 
N-terminal and carbamidomethylation of lysine to assess the unintended introduction of 
PTMs during sample preparation using the three methods (SDC, SPEED and S-Trap). 
Identification of the incidence of PTMs is important for subsequent SWATH, as only 
unmodified proteotypic peptides are used for quantification. 
To assess the extent of PTMs unintentionally introduced during sample 
preparation, the proportion of confidently identified peptides with PTMs was calculated 
as the total number of peptide modifications within all confidently identified peptides 
divided by the number of confidently identified peptides (Figure 37). The identities and 
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prepared using S-Trap had the lowest incidence of PTMs (4.4%), whilst SPEED and SDC 
had a higher incidence of PTMs at 8.0 and 8.7%, respectively. Of these, pyrolidone from 
glutamine (Q) was the most common across all three preparation methods (38.6% in 
SDC; 51.1% in SPEED; 61.4% in S-Trap). This PTM produces pyrolidone carboxylic 
acid from N-Terminal glutamic acid, either naturally by enzymatic synthesis under mild 









Figure 37: (A) Absolute number of PTMs and (B) proportion of modified peptides per sample 
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To assess whether the greater number of confidently detected peptides in SPEED 
was negated by the higher incidence of PTMs when compared to S-Trap (which had 
fewer confidently detected peptides but a lower incidence of PTMs) the total number of 
unmodified, confidently identified peptides was calculated (Table 35). Despite the higher 
incidence of PTMs, SPEED produced the highest number of unmodified, confidently 
identified peptides compared with S-Trap and SDC methods. 
Table 35: Number of total unmodified, confidently identified peptides across each sample preparation 
method. This number was calculated by multiplying the number of confidently identified peptides by 
the percentage of peptides which remained unmodified.  




0.913 x 1688 
= 1,541 
0.92 x 4,777 
= 4,395 
0.956 x 2011 
=1,923 
 
In summary, these results (Sections 8.2.1.2-8.2.1.4) suggest that SPEED is the 






Data collected in SWATH-MS mode was assessed to determine the efficacy of 
the three protein preparation methods on ovine kidney tissue for protein quantitation. 
Data in the following section was processed through a quality control pipeline (developed 
by Dr Moritz Lassé, described in Section 7.1.6.3), to allow accurate relative 
quantification of consistently detected ions. 
8.2.2.1 Comparing	protein	intensity	across	sample	preparation	methods	
The same kidney tissue samples were run on SWATH-MS and the signal intensity 











Figure 38: Volcano plots displaying false discovery rate adjusted p-values [341] and fold-changes 
in protein intensity between methods. Proteins displayed in red represent those with a fold-change 
with a p-value ≤ 0.05; grey dashed line represents p(adjusted)=0.05. A: Volcano plot of protein 
intensity in SDC method versus SPEED and S-Trap. B: Volcano plot of protein intensity in SPEED 
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This revealed modest but significant differences in protein intensities between 
methods, for a small proportion of proteins (represented by red data points in Figure 38). 
Because a similar proportion of proteins were differentially quantified for each method 
when compared to the other two methods (SDC 185 proteins, SPEED 182, S-Trap 173), 
these data suggest that overall, any of the three sample preparation methods would be 
equivalent for quantification of proteins from kidney tissue samples. 
8.2.2.2 Identifying	sources	of	variation	in	SWATH-MS	data	
Principal Component Analysis (PCA) of the protein intensity data produced three 
distinct clusters revealing that sample preparation method, rather than biological 
specimen (sheep), was the leading cause of variation between the samples (Figure 39). 
This suggests that while a different combination of proteins is quantified by each method, 
within each method the proteins identified and the magnitude of their intensities are 
relatively consistent between samples. 
 
Figure 39: Principal component analysis of protein intensity data. The colour of data points indicates 
the sample preparation method used, and the shape of data points indicates the identity of the sheep 
samples originated from. The distribution of samples across the three clusters by colour indicates 
that the first two principal components account for a significant proportion of the variability in 






















Comparing the number of proteins and peptides quantified using SWATH-MS 
(identified using the same DDA spectral library) across the three preparation methods 
revealed that SPEED generated the greatest median number of quantified proteins 
(1,031) and peptides (4,080) compared with SDC (996 proteins, 3,743 peptides) and S-
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When quality control measures (as described in Methods Section 7.1.6.3) were 
applied across all three samples within each sample preparation method, there was 
substantial overlap of proteins and peptides quantified across the three preparation 
methods (Figure 41). SPEED consistently displayed the greatest number of quantified 
proteins, whilst SDC consistently displayed the lowest number of quantified proteins. S-





Figure 41: Number of (A) proteins and (B) peptides quantified by each protein preparation method 




To determine whether any of the sample preparation methods were better at 
identifying candidate biomarkers of AKI in ADHF, the identities of quantified proteins 
were compared against a list of proteins enriched in kidney tissue [327] and a list of 
secreted proteins (for identification of potential circulating biomarkers) ([328] using IPA 
(Qiagen Inc., https://www.qiagenbioinformatics.com/products/ingenuity-pathway-
analysis) (Figure 42). The total number of kidney enriched and secreted proteins was 







Figure 42: Overlap between proteins quantified in SWATH-MS using the three sample preparation 
methods with (A) enriched kidney tissue proteins and (B) secreted proteins. 
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Table 36: Total numbers of kidney enriched and secreted proteins identified by each of the three 
sample preparation methods. 
 SDC SPEED S-Trap 
Number of kidney 
proteins (n = 413) 
detected  
67 71 68 
Number of secreted 
proteins (n = 956) 
detected 
237 249 232 
 
These analyses showed that a relatively low proportion of kidney enriched 
proteins (16-17%) and secreted proteins (24-26%) were detected and there was little 
difference between the sample preparation methods. 
8.2.2.5 Assessing	the	quality	of	SWATH-MS	data	
To assess the quality of the collected ion intensity SWATH-MS data for each 
sample preparation method, the number of outliers and the number of ions with 
coefficients of variation (CV) > 25% across technical replicates (n=3) were compared 
(Table 37). This revealed that of the sample preparation methods, SPEED produced the 
SWATH-MS data set with the greatest number of consistently detected ions with high-
quality technical replicates. The CVs of remaining technical replicates were then 








Table 37: Number of missing data points, outlier data points and number of ions with coefficient of 
variation (CV) >25% across technical replicates per sample preparation method. Outliers and ions 
with CVs >25% were removed from the data set, leaving a set of consistently detected ions remaining. 
Data from all three sample preparation methods was run through PeakView software in one session 
for peak picking, therefore the total number of ions reported by PeakView is the same for each method.  
 SDC SPEED S-Trap 
Total ions reported on from PeakView 31,716 31,716 31,716 
Percentage of missing ion level data points 13.5% 12.7% 13.2% 
Percentage of outlier ion level data points 1.96% 2.0% 1.88% 














Figure 43: Median CV (IQR) of ion intensities across technical replicates (n=3) by sample 
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All methods had relatively low ion intensity CVs across technical injection 
replicates, with the lowest median CV seen for S-Trap (6.51%) followed by SPEED 
(8.23%) and SDC (10.1%). This suggested that S-Trap was less likely to adversely 
influence the reproducibility of liquid chromatography and MS consistency across 
technical injection replicates than SPEED and SDC. 
Taken together, the results from Section 8.2.2 suggest that out of the three methods 
assessed, SPEED performed best for preparation of proteins from ovine kidney tissue for 
SWATH-MS mass spectrometry, as it demonstrated the largest number of protein 





Three sample preparation methods were trialled on plasma samples paired with the 
kidney tissue samples used in Section 8.2, resulting in a total of 9 plasma protein 
preparations. 
8.3.1 Assessment	of	DDA	data	
To assess the efficacy of the three protein preparation methods for protein 
quantification in ovine plasma, data collected in the DDA-MS mode was analysed as 
described for kidney tissue (Section 8.2.1). 
8.3.1.1 Number	of	proteins	and	peptides	detected	
Comparing the total number of detected proteins and peptides across the three 
preparation methods revealed that S-Trap detected the greatest median number of 
proteins (S-Trap 130, SDC 124, SPEED 111), but SDC detected the greatest median 
number of peptides (SDC 935, S-Trap 803, SPEED 612) and validated unique peptides 
(SDC 1,096, S-Trap 996, SPEED 816, Figure 44). This suggests that the proteins detected 
by S-Trap had less coverage, whilst the proteins identified by SDC, although fewer, had 
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Figure 44: Number of (A) proteins, (B) peptides and (C) validated unique peptides detected per 






























Number of Validated Unique Peptides Detected












































Number of Peptides Detected with 100% Confidence 
Per Sample Preparation Method
 
 227 






Figure 45: Number of (A) proteins, (B) peptides and (C) peptides detected with 100% confidence. 
Areas of overlap indicate where multiple methods identified the same protein or peptide. 
 
There was substantial overlap in the proteins and peptides identified across preparation 
methods. S-Trap identified the greatest number of unique proteins, whilst SDC identified 
the greatest number of peptides (both total peptides and unique validated peptides). 
Similarly, S-Trap and SDC had high percentages of confidently identified peptides 
(73.5% and 73.8%, respectively), whilst the percentage of confidently identified peptides 
using SPEED was approximately 10% less (64.2 %, Table 38). This is in direct contrast 
to the data obtained in kidney tissue samples, in which SPEED demonstrated the greatest 
proportion of confidently identified peptides (Table 34, Section 8.2.1.1). 
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Table 38: The proportion of confidently identified peptides per sample preparation method. 
 SDC SPEED S-Trap 
All peptides detected 1822 1849 1606 
100% confidence peptides 
detected 
1344 1187 1180 
Percentage of confidently 
identified peptides 
73.8% 64.2% 73.5% 
 
8.3.1.2 Missed	enzymatic	cleavages	
The percentage of missed cleavage sites present in peptides after trypsinisation 
of plasma samples was compared as a measure of protein proteolysis efficiency (Figure 
46). SPEED and S-Trap had similar proportions of missed cleavages (14.6% and 15.2%, 
respectively), whilst for SDC 37.8% of peptides had at least one missed cleavage site, 
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Figure 46: The (A) mean number and (B) mean percentage of total detected peptides with missed 
cleavages for proteins prepared using the SDC, SPEED and S-Trap methods. A lower proportion of 
missed cleavages indicated more efficient enzymatic proteolysis of proteins. Missed cleavage data 
was generated using PeptideShaker. 
8.3.1.3 Protein	coverage	
Protein coverage (percentage of protein sequence represented by peptides 
detected during MS) was similar across all three methods, with SDC resulting in the 
highest median coverage (median 16.3%, IQR 16.1-16.6%), followed by S-Trap (15.4%, 
IQR 14.1-16.3%) and SPEED (14.6%, IQR 13.6-15.5%) (Figure 47A). The greater 
protein coverage demonstrated by the SDC method reflects the greater number of 
peptides identified using SDC when compared to the other methods. These results are in 
contrast to the data obtained in kidney tissue samples, in which SPEED had the greatest 
median protein coverage. Examining only proteins detected across all three sample 
preparation methods also demonstrated similar median protein coverages between 
methods. S-Trap displayed the highest median protein coverage (median 17.5%, IQR 
16.6-17.8%), followed by SPEED (median 16.1%, IQR 15.0-16.2%) and SDC (median 


























































Figure 47: Median protein coverage for proteins detected (A) with 100% confidence by DDA for 
SDC, SPEED and S-Trap methods, and (B) proteins detected across all protein preparation methods. 
8.3.1.4 Post-translational	modifications	
The incidence and identity of PTMs between the three sample preparation methods were 
examined as described in Section 8.2.1.4 (Figure 46). Samples prepared using SPEED 
had the lowest incidence of PTMs (12.2%), whilst samples prepared using S-Trap had an 
intermediary incidence (13.3%) and samples prepared using the SDC method had the 
highest incidence (27.0%). Of these PTMs, pyrolidone from glutamine (Q) (23.2% in 
SDC, 37.9% in SPEED and 38.8% in S-Trap) and oxidation of methionine (M) (38.7% 
in SDC, 21.5% in SPEED and 33.4% in S-Trap) were the two most common across all 
three preparation methods. The total number of unmodified, confidently identified 
peptides was calculated for each sample preparation method (Table 38). Although the 
SDC method confidently identified the greatest number of peptides, once PTMs were 
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Both SPEED and S-Trap identified fewer peptides than SDC but had lower incidences 







Figure 48: (A) Absolute number of PTMs and (B) proportion of modified peptides per sample 
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Table 39: Number of total unmodified, confidently identified peptides across each sample preparation 
method. This number was calculated by multiplying the number of confidently identified peptides by 
the percentage of peptides which remained unmodified. 




0.730 x 1344 
= 981 
0.878 x 1187 
= 1,042 
0.867 x 1180 
= 1,023 
 
These results (Sections 8.3.1.2-8.3.1.4) do not clearly identify a superior sample 
preparation method for DDA mass spectrometry of ovine plasma. Additional 
considerations, such as the performance of the methods in the DIA/SWATH-MS mode 
(Section 8.3.2), time to complete the methods and cost should also be taken into account. 
8.3.2 Assessment	of	DIA/SWATH-MS	data	
To assess the efficacy of the three protein preparation methods for protein 
quantification in ovine plasma, data collected in the SWATH-MS mode was analysed. 
As described for kidney tissue (Section 8.2.2), data were processed through a quality 
control pipeline to ensure that only consistently detected ions with high-quality technical 
injection replicates (n=3 injections per sample) were used for peptide and protein 
quantitation. 
8.3.2.1 Comparing	protein	intensity	across	sample	preparation	methods	
Several proteins were detected at different intensities based on the sample 
preparation method (represented by red data points in Figure 49), with the SDC method 
displaying the greatest number of proteins detected at different intensities compared with 
the other two methods (n=6). However, all of the observed fold changes were of very 
small magnitude (from -1.1 to 1.09), indicating that any of the three preparation methods 
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Figure 49: Volcano plots displaying false discovery rate adjusted p-values [341] and fold-changes 
in protein intensity between methods. Proteins displayed in red represent those with a fold-change 
with a p-value ≤ 0.05; grey dashed line represents p=0.05. A: Volcano plot of protein intensity in 
SDC method versus SPEED and S-Trap. B: Volcano plot of protein intensity in SPEED method versus 
SDC and S-Trap. C: Volcano plot of protein intensity in S-Trap method versus SDC and SPEED. 
 
8.3.2.2 Identifying	sources	of	variation	in	SWATH-MS	data	
Principal Component Analysis (PCA) of the protein intensity data did not 
produce any distinct clusters of samples, indicating that variability in protein identity and 
intensity is not determined by the sample preparation method or the identity of the sheep 
(Figure 50). This is in keeping with the small differences observed in DDA performance 
between the three methods (Sections 8.3.1 and 8.3.2), suggesting that the tested sample 
preparation methods yield similar results in qualitative DDA and quantitative SWATH 






















Figure 50: Principal component analysis of protein intensity data. The colour of data points indicates 
the sample preparation method used, and the shape of data points indicates the identity of the sheep 
samples originated from. 
 
8.3.2.3 Number	of	proteins	and	peptides	detected	in	SWATH-MS	
Comparison of the number of quantified proteins and peptides across the three 
preparation methods revealed that SPEED quantified the greatest median number of 
























S-Trap quantified the greatest median number of proteins (341), followed by SPEED 





Figure 51: Number of (A) peptides and (B) proteins quantified per sample preparation method. Each 
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Figure 52: Number of (A) proteins and (B) peptides quantified by each protein preparation method 
using SWATH-MS. Areas of overlap indicate where multiple methods identified the same protein or 
peptide. 
After quality control measures were applied, there was a moderate amount of overlap in 
the identities of both the proteins and peptides quantified across the preparation methods 
(Figure 52). Nearly two-thirds (62%) of proteins quantified in at least two methods, and 
49% of peptides quantified in at least two methods. SPEED displayed the greatest 
number of unique identifications at the peptide level, whilst S-Trap consistently 
displayed the lowest number of unique identifications for proteins and peptides. 
8.3.2.4 Kidney	enriched	and	secreted	proteins	
The identities of quantified proteins were compared against a published list of 
proteins enriched in kidney tissue [327] and a list of secreted proteins ([328] and IPA). 
None of the kidney enriched proteins and only a small number of secreted proteins were 
detected in plasma (Figure 53). The total number of secreted proteins detected by each 




Figure 53: Overlap between proteins quantified in SWATH-MS using the three sample preparation 
methods with secreted proteins. 
 
Table 40: Total numbers of kidney enriched and secreted proteins identified by each of the three 
sample preparation methods 
 SDC SPEED S-Trap 
Number of kidney 
proteins (n = 413) 
detected  
0 0 0 
Number of secreted 
proteins (n = 956) 
detected 
34 40 35 
 
As previously demonstrated for kidney tissue, these analyses showed that a 
similar number of secreted proteins were quantified in SWATH by each of the sample 




The number of outliers and the number of ions with coefficients of variation (CV) 
> 25% across technical replicates (n=3) were compared to assess the quality of the 
collected SWATH-MS ion intensity data for each sample preparation method (Table 41). 
SPEED and S-Trap produced datasets with comparable numbers of consistently detected 
ions with high-quality replicates, whilst SDC produced slightly fewer. Following the 
removal of all low-quality data points (outliers and technical replicates with CVs > 25%), 
the CVs of remaining technical replicates were compared across preparation methods 
(Figure 54).  
A much higher proportion of reported ions were excluded because of poor CVs 
in plasma than in kidney tissue (Table 37 in Section 8.2.2.5), due to SWATH peak 
picking being performed against an extended spectral library created by merging plasma 
and tissue libraries (refer to methods Section 7.2.9.2). The original tissue library 
contained 1,186 proteins, the plasma library contained 203 proteins and the depleted 
plasma library contained 231 proteins before being joined. Therefore, PeakView reported 
on ions which originated from the tissue component of the spectral library which were 
sporadically or falsely detected – giving an inflated number of total ions and resulting in 
a high percentage of ions being excluded once quality control was applied. The number 
of ions reliably detected was sufficient to quantify ~100 proteins in each method, similar 
to the number of proteins quantified by Lassé et. al. using SWATH-MS and the same 








Table 41: Number of missing data points, outlier data points and number of ions with coefficient of 
variation (CV) >25% across technical replicates per sample preparation method. Outliers and ions 
with CVs >25% were removed from the data set, leaving a set of consistently detected ions remaining. 
Data from all three sample preparation methods was run through PeakView software in one session 
for peak picking, therefore the total number of ions reported by PeakView is the same for each method. 
 SDC SPEED S-Trap 
Total ions reported on from PeakView 16,102 16,102 16,102 
Percentage of missing ion level data points 15.8%  17.0% 16.5% 
Percentage of outlier ion level data points  0.52% 0.50% 0.47% 










Figure 54: Median CV (IQR) of ion intensities across technical replicates (n=3) by sample 














Median Coefficient of Variation of Ions
 for Technical Injection Replicates
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SPEED displayed the lowest median CV across replicates at the ion (8.89%) 
intensity level, closely followed by SDC (9.82%) and then S-Trap (10.0%). It should be 
noted that the amount of variation across all three sample preparation methods was 
similar for ion and protein intensities. 
The findings from the assessment of DIA/SWATH-MS data in ovine plasma 
(Section 8.3.2) suggest that out of the tested methods, SPEED slightly out-performed S-
Trap and SDC for SWATH-MS, as it quantified the greatest number of proteins and 
possessed the lowest CVs across technical replicates, indicating the greatest 
reproducibility. However, SPEED was not superior at the DDA level (Section 8.3.1). 
Furthermore, PCA analysis demonstrated that sample preparation method was not a 
leading source of variation in protein identity and intensity (Section 8.3.2.2), suggesting 
that all three methods quantified the majority of proteins similarly. Therefore, any of the 
three trialled methods were deemed appropriate for processing ovine plasma for 
subsequent SWATH-MS, although no subsequent SWATH plasma analysis was 





This experiment aimed to determine the sample preparation method that performed 
best for subsequent SWATH-MS analysis on both ovine kidney tissue and plasma 
samples. Of the three methods trialled in kidney tissue, SPEED demonstrated the best 
quantitative and qualitative performance, as assessed by several metrics of DDA and 
SWATH-MS data quality. For plasma, all three methods performed similarly. Efficient 
and reproducible protein extraction and trypsinisation is the basis of successful protein 
quantification [332]; therefore, the results of this optimisation were critical to inform the 
experimental procedure used for AKI marker identification in a pre-clinical model 
(Chapter Nine). 
In SWATH-MS, performance depends on the comprehensiveness of the spectral 
library generated using DDA-MS – therefore, the selected sample preparation method 
should facilitate identification of the maximal number of peptides and proteins possible 
at the DDA level [140]. This spectral library determines (and limits) the number of 
proteins which can be quantified in subsequent SWATH-MS scans [140], thus it is 
crucial to employ a strategy which effectively solubilises and digests proteins for DDA-
MS. In the current experiment, SPEED identified a 1.5-fold higher number of proteins 
and 2-fold higher number of validated unique peptides in DDA-MS in kidney tissue than 
the SDC and S-Trap methods, possibly attributable to differences at the cell lysis step. 
Lysis is required to break connective tissue, disrupt cell membranes and solubilise 
proteins for subsequent trypsinisation [332]. The lysis agent (i.e. TFA for SPEED, SDS 
for S-Trap or SDC for the SDC method) in combination with the sample tissue type (i.e. 
plasma or kidney tissue) may have proven a key interaction. Tissues, such as kidney, are 
difficult to lyse compared with plasma [290]. Detergent based methods such as S-Trap 
and SDC require additional mechanical disruption to facilitate adequate lysis such as 
grinding, heat [342] or ultra-sonication [290, 343]. On the other hand, the detergent-free 
SPEED method achieves tissue lysis through exposure to a strong acid (trifluoroacetic 
acid, pKa = 0.2) known to be an excellent solvent for proteins [344]. Trifluoracetic by 
itself achieves tissue and membrane disruption as well as protein extraction even in lysis-
resistant samples by using complete sample dissolution [290] – an effect observed when 
lysing tissue samples in the current experiment. This complete tissue dissolution and 
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resultant solubilisation of proteins may contribute to the greater number of peptides and 
proteins identified in DDA-MS for kidney tissue in SPEED than in the detergent-based 
methods. In plasma, lysis is not required, so that SDC and SDS methods may have 
solubilised proteins to a similar extent as the TFA in SPEED. This is likely the most 
important factor contributing to SPEED outperforming the detergent-based methods in 
kidney tissue, but performing similarly to the other two methods in plasma. 
Work by HaileMariam et al. [335] demonstrated that some proteins will not be 
captured by all sample preparation methods. For this study, it was important to assess 
whether any of the trialled preparation methods detected proteins enriched in the kidney 
or secreted into circulation, as these proteins will be most likely to yield biologically 
relevant, circulating biomarkers for AKI in ADHF. For plasma proteomics my analysis 
showed that all three methods would be equally appropriate for identifying candidate 
biomarkers of AKI in ADHF due to similar numbers of kidney specific and secreted 
proteins detected and quantified. The number of proteins quantified in plasma was 
approximately 10-fold less than the number quantified in kidney tissue, as plasma is a 
more challenging sample type to work with due to the lower protein concentration  and 
wide dynamic range of protein concentrations compared with tissues [315]. This dynamic 
range can result in high-abundance proteins impeding the detection of medium- and low-
abundance proteins [315]. Important candidate biomarkers may be missed if discovery 
studies are limited to SWATH-detectable plasma proteins, therefore kidney tissue (and 
its larger set of SWATH-detectable proteins) was selected for investigation of AKI 
markers in a pre-clinical model (Chapter Nine). 
Each preparation method possesses distinct advantages and disadvantages which 
must be considered in the context of specific experiments [329, 333-335]. Many 
detergents, including SDC and SDS, are incompatible with LC-MS due to their ability to 
dominate mass spectra and contaminate LC systems [329]. Therefore detergent-based 
preparation methods require the removal of interfering detergents prior to MS either by 
bead-based purification [345], filtration [346] or precipitation [313, 347]. These protein 
purification processes require additional sample handling steps, which are labour-
intensive, time-consuming and crucially are associated with diminished reproducibility, 
increased risk of contamination, biases and attendant losses [290]. Both the SDC and S-
Trap methods require a precipitation step for the removal of detergents prior to LC-MS, 
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whilst SPEED involves fewer processing steps, reducing the opportunity for introduction 
of error (Figure 55). 
 
Figure 55: Hands-on experimental time for each sample preparation method. Hands-on is 
defined as in-laboratory time excluding incubations of >1 hour. Times are for running single 
samples and assume that all reagents are pre-prepared and plasma samples thawed. The 
proteolysis step has been omitted from this graph as this is a hands-off step in which trypsin is 
added and samples are left to incubate. 
 
Time is a significant factor for consideration in large scale experiments in which 
many samples need to be processed [290]. In the absence of dedicated automation, the 
selection of sample preparation method could alter hands-on experimental time from 
days to weeks, depending on the scale of the study. The most time-consuming hands-on 
step across all three methods was peptide purification, which could be reduced using 
automation through use of a trap column or filter prior to the analytical column in a liquid 
chromatography setting or through trialling various commercially available purification 
devices [348]. Of the trialled sample preparation methods, SPEED was the most time-
effective. The detergent-based in-solution SDC method required the most hands-on time 
and identified the fewest number of proteins in kidney tissue, whilst S-Trap was 
intermediate for both the hands-on time and the total number of protein identifications in 
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tissue. In plasma, SPEED identified the greatest number of proteins at the SWATH-MS 
level, followed by SDC and then S-Trap.  
In conclusion, SPEED demonstrated the best overall performance in kidney 
tissue, with the largest number of proteins identified and comparable reproducibility to 
the other two methods. SPEED also demonstrated marginally better performance in 
plasma than S-Trap and SDC. In addition, the SPEED method requires relatively little 
hands-on experimental time and has few processing steps and required reagents. 
Therefore, SPEED provides the best balance of performance and time for processing 





Results of Proteomic AKI 
Biomarker Study 
9.1 Introduction	
In the search for diagnostic and prognostic markers of AKI, numerous biomarkers 
of renal cellular damage have been identified and extensively researched over the last 
two decades [20, 69, 70]. Such markers include neutrophil gelatinase-associated lipocalin 
(NGAL), interleukin-18 (IL-18), liver-type fatty acid-binding protein (L-FABP), tissue 
inhibitor of metalloproteinases type 2 (TIMP-2), insulin-like growth factor binding 
protein 7 (IGFBP7), kidney injury molecule-1 (KIM-1) and proenkephalin (PENK). 
Notably, a fluorescence immunoassay test measuring a combination of urinary TIMP-2 
and IGFBP7 (NephroCheck, Astute Medical Inc., USA) was approved by the FDA for 
identifying patients at risk of developing moderate-to-severe AKI within 12 hours of 
testing [73]. However, no other markers have entered clinical practice (with the exception 
of L-FABP, which has been used in Japan to detect AKI in patients with liver failure [69] 
and NGAL, which is available for use in some European jurisdictions as dictated by local 
policies [80]) and relatively few studies have explored these markers in ADHF.  
While it appears that TIMP-2, IGFBP7 and L-FABP may variably predict AKI 
within 1-7 days of ADHF onset [107-111], no biomarkers have proven definitively 
successful, with several studies presenting mixed and inconclusive results [106]. This is 
partly due to variations in methodologies, study populations, study setting and the lack 
of clear universal definitions of kidney impairment used in the experiments assessing the 
performance of biomarkers for AKI in ADHF [106]. Most importantly, all ADHF studies 
focusing on the interplay between heart and kidney dysfunction have been observational 
in nature [106-112, 114-116, 119, 120]. These studies have been limited by several 
confounders – the most significant being the modification of decongestive therapy 
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(which aims to remove large volumes of fluid safely and quickly [122]) in response to 
declining renal function [106]. Decongestive therapy may be withheld from ADHF 
patients with elevations in creatinine, influencing health outcomes [6]. However, these 
creatinine elevations do not always represent true kidney injury [123, 124] and emerging 
evidence indicates that the prognostic value of decongestion surpasses that of renal 
impairment during the treatment of ADHF [125-129]. A recent review from Manguba et. 
al. concluded that due to limited and inconclusive results, the current body of evidence 
for the prognostic and diagnostic utility of various protein biomarkers for kidney injury 
in ADHF does not support routine use of any of these biomarkers [106]. 
To address this, previous work by our Group investigated the physiological and 
transcriptomic response of the kidneys to development of, and recovery from ADHF 
using an established ovine model of ADHF (refer to Section 7.1.1) [289]. This research 
demonstrated an immediate and pronounced decline in renal function (as evidenced by a 
marked fall in creatinine clearance, decreased urine volume and reduced excretion of 
urea and sodium) in response to development of experimental ADHF, concurrent with 
neurohormonal activation and profound haemodynamic changes. Whilst most 
measurements returned to baseline levels after recovery from ADHF, the reductions in 
creatinine clearance persisted for at least 4 weeks, showing for the first time that ADHF 
may result in lasting kidney injury [289]. In addition, RNA sequencing of kidney biopsies 
was performed to characterise the changes in gene expression which occurred in response 
to development of, and recovery from ADHF. This identified 984 genes which differed 
between baseline and HF, 1,807 genes which differed between HF and recovery and 192 
genes which differed between baseline and recovery. From these, 32 genes which encode 
proteins detectable in the serum, plasma or urine were selected as candidate circulating 
or urinary markers of kidney injury in ADHF.  
This chapter builds on the Group’s mRNA research, aiming to identify additional 
protein candidate markers using a hypothesis-free approach, and determine whether 
changes in kidney gene expression are reflected at the protein level. I performed relative 
quantitative protein profiling in a subset of the same kidney biopsy samples, where tissue 
was still available, using SWATH-MS (n=5 healthy control sheep [Baseline group], n=8 
sheep with established ADHF [HF group], n=7 sheep after ~ 4 weeks recovery from 
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ADHF [Recovery group]). Proteins that differed in expression between time points were 
identified and proteins predicted to be detectable in plasma, serum or urine were selected 
as candidate urinary or circulating markers for AKI in ADHF. Finally, protein and gene 
expression data were compared [289]. This research has the potential to identify novel 
candidate protein biomarkers of kidney injury, recovery and long-term renal impairment 
in ADHF, as well as provide supporting evidence for candidate gene markers identified 





Of the 574 proteins that I quantified in sheep kidney tissue samples, 25 were 
differentially expressed between timepoints (fold-change ≥ 1.2, multiple-comparison 
adjusted p-value < 0.05, Figure 56). A total of 23 proteins differed between Baseline and 
Heart Failure (HF), one protein differed between HF and Recovery and one protein 
differed between Baseline and HF (Table 42). For a full list of all protein fold-changes 









































Figure 56: Volcano plots displaying -LOG10 of the Benjamini-Hochberg (BH) p-value against LOG2 of 
the protein fold-change. Red data points indicate a BH p-value <0.05, whilst blue data points indicate a 
BH p-value ≥ 0.05. Horizontal dashed line represents p=0.05. (A) Baseline vs Heart Failure. (B) Heart 
Failure vs Recovery and (C) Baseline vs Recovery. 
Table 42: Proteins differentially expressed between time-points with a fold change ≥ 1.2 and Benjamini-
Hochberg adjusted p-value <0.05. B = Baseline, BH = Benjamini-Hochberg, HF = Heart Failure, R = 
Recovery. 












 B-HF ­ 1.77 0.001 No 
Talin 1 TLN1 B-HF ­ 1.27 0.0052 No 
Apolipoprotein 
A4 
APOA4 B-HF ¯ 2.43 0.0069 Yes 
Filamin A FLNA B-HF ­ 1.36 0.020 No 







B-HF ¯ 2.65 0.023 No 
Uncharacterised 
protein W5P4A8 





FMO3 B-HF ¯ 1.72 0.039 No 
Solute carrier 
family 5 member 
12 
SLC5A12 B-HF ¯ 1.36 0.043 No 














Acyl-CoA synthetase medium chain family member 1
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 B-HF ­ 3.69 0.044 No 
Apolipoprotein 
E 
APOE B-HF ­ 1.41 0.044 Yes 
T-complex 
protein 1 subunit 
gamma 
CCT3 B-HF ­ 1.31 0.044 No 
Peroxiredoxin 
W5PAL7 





B-HF ­ 1.68 0.044 No 
T-complex 1 TCP1 B-HF ­ 1.25 0.044 No 
Vinculin VCL B-HF ­ 1.19 0.044 Yes 
Tripeptidyl 
peptidase 1 




CCT8 B-HF ­ 1.26 0.046 No 
Peroxiredoxin 
W5NUE3 
PRDX1 B-HF ¯ 1.25 0.046 Yes 
      
Apolipoprotein 
A4 
APOA4 HF-R ­ 2.20 0.0029 Yes 




family member 1 
ACSM1 B-R ­ 1.50 0.038 No 
 
For data exploration purposes, all proteins that differed by ≥ 1.2-fold between 
time-points were considered potentially differentially expressed and were included in 
subsequent analyses (n=189 proteins, p-value ranged from 0.003-0.81 after adjustment 
for multiple comparisons). 
Of the 189 proteins that differed by ≥ 1.2-fold between the time points, 154 
proteins were altered between Baseline and Heart Failure, 64 proteins were altered 
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between Heart Failure and Recovery, and 86 proteins were altered between Baseline and 
Recovery (Figure 57). There was considerable overlap of proteins which changed 
between each of the time-points – particularly between Baseline and Heart Failure and 
Baseline and Recovery (65 proteins had fold-changes ≥ 1.2 between both of these time-
points). This overlap indicates that the expression of a proportion of proteins may 
continue to be altered across development and recovery from ADHF, rather than only 
differing in expression between one pair of time-points. 
 
Figure 57: Proteins with fold-change of ≥ 1.2 between time-points. BL = Baseline, HF = Heart 
Failure, R = Recovery. 
9.3 Assessing	pathway	activation	and	inhibition	
To investigate the molecular pathways altered in the kidney in response to ADHF 
development and recovery, comparative pathway analysis was performed on the proteins 
above using IPA. Of the 189 proteins altered by ≥ 1.2-fold, 155 mapped to genes in the 
IPA database and could be included in the analysis. Proteins altered across these time 
points were enriched for two molecular pathways (absolute Z-score > 2 or < -2 and p< 
0.01 after adjustment for multiple comparisons, Figure 58). These were the Glycoprotein 
VI (GP6) signaling pathway and the acute phase response signaling pathway, both of 




Figure 58: Heat map of pathway enrichment and activation/inhibition. Red indicates a positive Z-score 
(activation of a pathway) and blue represents a negative Z-score (repression of a pathway). The intensity 
of colour represents the magnitude of the Z-score, with darker hues indicating greater scores. Starred 
time-points indicate an absolute Z-score >2 or <-2 and an adjusted p-value <0.01, representing enriched 
and activated/repressed pathways. 
9.4 Identifying	kidney	enriched	proteins	
To identify kidney-specific proteins, the identities of all quantified proteins were 
compared against a list of proteins (n=413) enriched in kidney tissue [327] as reported in 
the Human Protein Atlas (proteinatlas.org, accessed October 2020). Ultimately, 
candidate biomarkers would be measured in circulation – therefore, identifying kidney 
specific candidates (as opposed to ubiquitous proteins) ensures that quantified changes 
in expression in circulation can be confidently attributed to processes occurring in the 
kidney, rather than reflecting activity in other organs or tissues. A proportion of 
quantified proteins (11%) were reported to be highly-enriched or expressed only in the 
kidney [327]. A total of 24 proteins were kidney enriched and had a fold-change of ≥ 1.2 
between any two time-points (Table 43). This analysis was not used to exclude proteins 
from consideration as candidate markers, but was performed to gather additional 
information about the biology of proteins which could assist in prioritisation of protein 
candidates for future research. 
Table 43: Kidney enriched proteins with a fold-change of ≥ 1.2 between any two time-points (Baseline and 
Heart Failure, Heart Failure and Recovery, and Baseline and Recovery). Magnitudes and directions of 


























HF-R ­ 1.34 0.018 
Crystallin zeta CRYZ B-HF ¯ 1.22 0.020 No 
Solute carrier family 
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PDZK1IP1 B-HF ¯ 1.22 0.105 No 
Acyl-CoA 
dehydrogenase 

































































AMACR B-HF ¯ 1.27 0.314 No 
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Desirable candidate biomarkers should be detectable in the plasma, serum or urine 
for minimally invasive specimen procurement and measurement [351]. Putative secreted 
proteins were identified from the dataset including all quantified proteins with (i) the IPA 
software ‘Biomarker Filter’ workflow, which annotates proteins that have been 
experimentally observed in the biofluids of choice based on current literature (primarily 
[305, 306]) and (ii) the Human Protein Atlas secretome (proteinatlas.org), which includes 
2,641 proteins with a signal peptide and no transmembrane-spanning region, annotated 
with plasma concentrations where available (bioinformatics approach). A notable 
proportion of all quantified proteins in this experiment (43.7%) are proposed to be 
detectable in plasma, serum or urine. Of the 189 proteins with fold-changes ≥ 1.2 between 
any two time-points, 90 were predicted to be detectable in serum, plasma or urine. See 
Table 71 in Appendix Section Appendix Six for identities. 
9.6 Categorising	proteins	into	marker	types	
Proteins were categorised into three groups based on the pattern of expression 
across the time-points (Table 71 in Appendix Section Appendix Six): (i) proteins which 
differed from Baseline and HF but not HF to Recovery (‘kidney injury proteins’, 
potential markers of kidney injury); (ii) proteins which differed from Baseline to HF and 
from HF to Recovery, but not from Baseline to Recovery (‘kidney recovery’ proteins – 
potential markers of kidney recovery); and (iii) proteins which differed in expression 
between Baseline and Recovery (‘long-term renal impairment’ proteins, potential makers 
of long-term renal impairment). Refer to Figure 59 for examples. 
This resulted in identification of 28 kidney injury proteins, 16 kidney recovery 
proteins and 38 HF long-term renal impairment proteins with fold-changes ≥ 1.2 
predicted to be detectable in serum, plasma or urine (Table 71 in Appendix Section 
Appendix Six).  
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Of these, 11 had p-values ≤ 0.05 after adjustment for multiple comparisons, and 
were short-listed as potential markers for kidney injury, recovery or long-term renal 
impairment in ADHF (Table 44, Figure 59). Furthermore, 8 of these proteins had not 
been associated with AKI previously and represent truly novel candidates. 
 
Figure 59: Schematic illustrating protein biomarker discovery for renal impairment in ADHF. Venn 
diagram illustrates the number of proteins altered ≥ 1.2-fold between baseline (BL), heart failure (HF) 
and recovery (R) time-points. 
 
Table 44: Proteins with a fold-change ≥ 1.2 and Benjamini-Hochberg (BH) adjusted p-values<0.05 
detectable in the plasma, serum or urine. These 11 proteins were compared with 884 genes associated with 
AKI sourced from across two large databases: the IPA knowledgebase 
(https://qiagenbioinformatics.com/products/ingenuity-pathway-analysis) [352] and Harmonizome [353]. 












Kidney Injury Proteins 


















CCT3 B-HF ­ 1.31 0.044 No 
Talin 1 TLN1 
 
B-HF ­ 1.27 0.005 No 
Chaperonin 
containing 
TCP1 subunit 8 
CCT8 B-HF ­ 1.26 0.046 No 
T-complex 1 TCP1 B-HF ­ 1.25 0.044 No 
 
Crystallin zeta CRYZ B-HF ­ 1.22 0.020 No 
Peroxiredoxin PRDX1 B-HF ¯ 1.25 0.046 Yes 













Long-term Renal Impairment Proteins 
Apolipoprotein 
E 









CCT6A B-HF ­ 1.36 0.044 No 
 
Candidate markers were ranked based on the size of the fold-change observed, 
and direction of change, p-value and supporting gene evidence from Section 9.7 below 
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also considered. Therefore, based on the above data the top three protein candidates 
across each category were Filamin A (kidney injury), Apolipoprotein A4 (kidney 
recovery) and Apolipoprotein E (long-term renal impairment) 
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Figure 60: Box plots for differentially expressed proteins detectable in plasma, serum or urine with 
Benjamini-Hochberg p-values <0.05 and fold-changes ≥ 1.2. A) Proteins which change between baseline 
and heart failure but not between heart failure and recovery (termed ‘kidney injury’ proteins), B) proteins 
which are altered between baseline and heart failure, and heart failure and recovery (termed ‘kidney 
recovery’ proteins), C) proteins which differed in expression between Baseline and Recovery (termed 




























Protein expression was compared with gene expression data from the previous 
transcriptomic study [289], to identify whether results from the current study corroborate 
those of the transcriptomics.  
Fold-changes in expression between all quantified proteins and their corresponding 
genes (at the same time-point) demonstrated weak correlation overall (B-HF: Spearman 
correlation coefficient 0.218, p< 0.001; HF-R: Spearman correlation coefficient 0.167, 
p< 0.001; BL-R: Spearman correlation coefficient 0.125, p=0.007) (Figure 61). This 
means that overall, the changes observed in protein expression between particular time-
points were not generally reflected in the expression of corresponding genes. There are 
not always simple relationships between the concentration of a gene transcript and the 
concentration of the protein derived from a specific locus [354], which might explain this 
discordance, as discussed in Section 9.8. 
However, within the full data set a small number of proteins and their equivalent 
gene transcripts had fold-changes > 1.2 and appeared to be highly correlated based on 
their proximity to the line of perfect correlation in Figure 61. Between Baseline and HF 
these included CALB1, CCT6A, CTSC, CTSV, FGG, PRODH2, TAGLN and TINAG. 
Between HF and Recovery these included ANPEP, HAO1, HSP90AB1, LOC1-1114075 
and OXCT1, and between Baseline and Recovery these included AMBP, C9, COL6A3, 
SELENBP1 and TINAGL1. Of these proteins and genes, CCT6A, COL6A3, HSP90AB1 
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Figure 61: Scatterplots of fold-changes at the gene and protein level for all quantified proteins which 
map to a quantified gene. Dashed black lines represent the line of perfect correlation, dashed blue lines 
indicate the Log10 value equivalent to a 1.2-fold change. Values above the horizontal dashed blue line are 
gene fold-changes >1.2, and values to the right of the vertical dashed blue line are protein fold-changes 
>1.2. However, these fold-changes >1.2 did not necessarily meet statistical significance. A) Baseline and 
Heart Failure time-points, B) Heart Failure and Recovery time-points, C) Baseline and Recovery time-
points. 
 
Considering the subset of 189 proteins with a fold-change of ≥ 1.2 between time 
points, and comparing these with genes showing altered expression at any time-point 
(fold-change ≥ 1.2, p< 0.01 after correction for multiple comparisons) I identified 5 
proteins for which the gene encoding them was also altered (Table 45). Of these, four 
proteins/genes had similar fold-changes in expression (in terms of magnitude and 
direction) between the same time points (HSP90B1, CCT6A, TPM2 and CSRP2, Table 
45) and one had opposing changes between the same time-points (DES, Table 45). 
Table 45: Fold-changes for genes and the corresponding protein products between pairs of time-points. 
Magnitude and direction of fold-changes are presented. 









Baseline and Heart Failure 
HSP90B1 ­ 1.40 0.05 ­ 1.37 Yes 
CCT6A ­ 1.36 0.044 ­ 1.40 No 
     
Heart Failure and Recovery 
TPM2 ¯ 1.23 0.664 ¯ 2.05 No 
CSRP2 ¯ 1.24 0.462 ¯ 1.89 No 
     
Baseline and Recovery 




Proteins with a fold-change of ≥ 1.2 at any time-point for which the 
corresponding gene also had a fold-change of ≥ 1.2 and BH p-value ≤ 0.01 (selected to 
reduce the pool of gene candidates to a manageable level) at any time-point (not 
necessarily the same time-point as the protein fold-change of ≥ 1.2) were considered as 
potential biomarkers (n=14). Among these, 14 proteins were differentially expressed at 
both the gene and protein level and 11 proteins were predicted to be detectable in serum, 
plasma or urine. These were prioritised as potential markers for kidney injury, recovery 
or long-term renal impairment in ADHF (Table 46), alongside the list of 11 candidate 
protein markers identified in Table 44 in Section 9.6 above.
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Table 46: Proteins with a fold-change of ≥ 1.2 at any time-point for which the corresponding gene also 
had a fold-change of ≥ 1.2 and BH p-value ≤ 0.01 at any time-point, which are detectable in the serum, 
plasma or urine. Direction and magnitude of fold-changes are presented for both proteins and genes, along 





















­ 1.39 0.050 ­ 1.37 
¯ 1.42 
Yes 
Filamin B FLNB B-R 
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¯ 1.23 0.20  
¯ 1.28 
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Filamin A FLNA B-HF 
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­ 2.37 Yes 
Tropomyosin 
2 




Pathways that were enriched and activated/inhibited based on the protein data were 
compared with pathways enriched and activated/inhibited based on the genetic data. This 
revealed that based on transcriptomic evidence, the GP6 Signaling (Z-score -2.3, adjusted 
p-value 0.008 between HF and Recovery) and Acute Phase Response (APR) Signalling 
pathway (Z-score -2.17, adjusted p-value 0.002 between HF and Recovery) were also 
enriched and activated/inhibited, strengthening the evidence for the involvement of these 
pathways. 
9.7.2 Assessing	protein	targets	of	miR-454-3p	
In Chapter Six, I identified that lower plasma concentrations of miR-454-3p (~1.5-
fold lower, p=0.047) were associated with AKI and kidney dysfunction in ADHF patients 
and may add value beyond established risk factors in predicting AKI. One of the 
predicted targets of miR-454-3p is the mRNA encoded by the CCT6A gene and therefore 
miR-454-3p may alter the expression of the protein CCT6A (TargetScan database v7.1 
[355] and miRDB version 6.0 [356]) – one of the candidate markers of renal impairment 
identified in this Chapter. 
It would be expected that lower concentrations of miR-454-3p during kidney injury 
would result in increased concentrations of both the target CCT6A mRNA transcript and 
the encoded protein, CCT6A, due to reduced silencing and degradation of the target 
mRNA. Indeed, this effect was observed in the current study – between Baseline and HF 
(and therefore, between normal renal function and the induction of renal impairment), 
the concentration of CCT6A increased 1.40-fold and the concentration of CCT6A 
increased 1.36-fold. This indicates an expected association between the observed 
changes in expression between miRNA, mRNA and protein concentrations in renal 
impairment. This relationship could further be investigated in cultured kidney cells 
through the addition of oligonucleotides which mimic or inhibit the activity of miR-454-
3p [357]. Concentrations of CCT6A could then be quantified using Enzyme-Linked 
Immunosorbent Assays to determine whether there is a direct relationship between the 




This study aimed to identify candidate protein biomarkers of kidney injury, kidney 
recovery and long-term renal impairment in ADHF using an established ovine model of 
pacing-induced heart failure. SWATH-MS identified 11 protein markers which were 
differentially expressed in response to development of and/or recovery from ADHF, 8 of 
which had not been associated with AKI previously. This included seven kidney injury 
proteins which were differentially expressed between Baseline and Heart Failure, one 
kidney recovery protein which was differentially expressed between Baseline and Heart 
Failure and Heart Failure and Recovery, and 3 long-term renal impairment proteins 
which were differentially expressed between Baseline and Recovery. Protein expression 
data were compared to transcriptomic data previously acquired by our Group using the 
same ovine model [289], and 11 additional protein markers which corroborated the gene 
expression data were identified. SWATH-MS is a hypothesis-free method for protein 
quantification, which does not require prior knowledge of targets. Importantly, and 
advantageously, this enables the generation of data which is not limited by or 
“contaminated” by prior literature. Therefore, these data represent a novel contribution 
through identification of candidate proteins for targeted investigation as diagnostic and 
prognostic markers of AKI in patients with ADHF. 
Considering proteomic analyses alone, three top candidate markers identified were 
Filamin A (FLNA, translated from the FLNA gene), Apolipoprotein E (APOE, translated 
from the APOE gene) and Apolipoprotein A4 (APOA4, translated from the APOA4 
gene). Although FLNA has never previously been associated with AKI, both the APOE 
and APOA4 genes have been linked to AKI in large data sets numerous times [353]. 
APOE associates with lipid particles, and functions in lipoprotein-mediated transport of 
lipids between organs via the plasma and interstitial fluids [358]. Through this action, 
APOE plays a crucial role in tissue and plasma lipid homeostasis. In the current 
experiment, expression of APOE increased 1.41-fold between Baseline and HF, and 
concentrations of the protein remained elevated throughout the 4-week Recovery period, 
indicating APOE may serve as a biomarker of long-term renal impairment in ADHF. 
However, no differential expression was observed in the gene expression data, suggesting 
that changes in expression may only occur at the protein-level and not the mRNA level. 
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In the Harmonizome database, the APOE gene has been linked to renal disease in 354 
instances [353], and has been directly researched in regard to the development of AKI in 
response to cardiovascular surgery with conflicting results. Isbir et. al. tested the 
hypothesis that selected gene polymorphisms were associated with AKI following 
coronary bypass grafting surgery in 248 patients, and demonstrated that APOE gene 
polymorphisms contributed to development of AKI following surgery in this cohort 
[359]. However, subsequent investigation by Boehm et. al. concluded that APOE 
polymorphisms were not associated with development of renal injury following 
cardiopulmonary bypass in 1,415 patients [360]. Despite these conflicting findings, the 
numerous links between APOE and AKI in the Harmonizome database indicate an 
association between APOE and renal injury. Whether this association is robust enough 
to support the use of APOE as a biomarker of AKI is yet to be determined. 
APOA4 is a lipid-binding protein synthesised in the small intestine and secreted 
into the intestinal lymph during fat absorption [361]. In the circulation, it is present in a 
lipid-free form or can be present on high-density lipoproteins and chylomicron remnants. 
APOA4 is involved in numerous physiological processes including lipid absorption and 
metabolism, platelet aggregation and thrombosis, anti-atherosclerosis and glucose 
homeostasis [361]. In the current experiment, expression of APOA4 decreased 2.43-fold 
between Baseline and HF (p< 0.05), and increased 2.20-fold between Heart Failure and 
Recovery (p< 0.05), suggesting that APOA4 may serve as a kidney recovery biomarker 
which could be used to track the development of, and recovery from, kidney injury 
caused by ADHF. No evidence of differential gene expression for the corresponding 
gene, APOA4, was observed in the transcriptomics study. In the Harmonizome database, 
the APOA4 gene has been linked to renal disease in 242 instances [353] and APOA4 has 
been investigated directly in the context of renal injury, yielding strong evidence for an 
association. High plasma concentrations of APOA4 have been shown to be correlated 
with mild to moderate renal failure, thereby acting as a predictor for the progression of 
kidney disease [362, 363]. However, the specific role of APOA4 in renal injury remains 
unidentified and its efficacy as a marker of AKI subsequent to ADHF remains unknown. 
It would be beneficial to understand the molecular mechanisms by which APOA4 exerts 
its function [361], particularly if it were to be considered for other applications in the 
future such as a potential therapeutic target.  
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Two proteins, FLNA and Chaperonin containing TCP1 subunit 6A (CCT6A), were 
top candidates from both analysis of protein data alone and analysis of protein data in 
conjunction with transcriptomic data. FLNA is an actin-binding protein which crosslinks 
actin filaments and links them to membrane glycoproteins, and is involved in 
cytoskeleton remodelling to produce changes in cell shape and migration [364]. In the 
current experiment, expression of FLNA increased 1.36-fold between Baseline and HF, 
indicating it as a potential biomarker of kidney injury in response to development of 
ADHF, whilst in the transcriptomic experiment the mRNA for FLNA decreased 1.73-
fold between HF and Recovery (p< 0.01). FLNA has never previously been associated 
with AKI [353]. 
The protein CCT6A is a component of a molecular chaperone complex known as 
the chaperonin-containing T-complex (TRiC), which assists the folding of proteins 
including actin and tubulin [365]. In the current experiment, CCT6A was categorised as 
a long-term renal impairment protein as it increased 1.36-fold (p< 0.05) between Baseline 
and HF, and were also increased after recovery of sheep from pacing/ADHF (1.30-fold 
(p=0.066) between Baseline and Recovery). At the gene expression level, the mRNA for 
CCT6A increased 1.4-fold (p< 0.01) between Baseline and HF. These highly consistent 
changes in expression at both the gene and protein level between Baseline and HF 
indicate a strong relationship between gene and protein expression, and suggest that the 
protein product of CCT6A could be a potential biomarker of AKI in response to ADHF. 
This is the first time that CCT6A has been associated with AKI [353]. 
Whilst numerous candidate markers in the current experiment exhibited similar 
changes in expression at both the protein and gene level (in terms of both magnitude and 
direction), the majority of proteins/genes and a portion of candidate markers did not 
display consistent changes. One such example is that of the transcript for the gene DES 
and its protein product Desmin – concentrations of the transcript decreased 4.65-fold 
between Baseline and Recovery, whilst concentrations of the protein increased 1.23-fold. 
There are several reasons as to why this may have occurred, and why these seemingly 
contrary gene and protein expression data do not necessarily oppose or invalidate each 
other. It is widely acknowledged that there is not a simple contemporaneous relationship 
between the concentration of a gene transcript and the concentration of the protein 
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derived from a specific locus [354], and systematic studies have uncovered the 
importance of several processes beyond transcript concentration which influence the 
expression level of a protein [366]. As reviewed extensively by Liu et. al. [354], these 
processes include (i) the translation rate of mRNA to protein: this is significantly 
influenced by the sequence of the mRNA such as the codon composition, internal 
ribosome entry sites and upstream open reading frames [367]; (ii) translation rate 
modulation: the rate of translation can be modified by the binding of proteins to 
regulatory elements on transcripts, through binding of non-coding RNAs such as 
miRNAs [368], or through the relative availability of ribosomes and transcripts; (iii) 
modulation of protein half-life: autophagy or the ubiquitin-proteasome pathway may 
modify protein concentrations independent of the transcript concentrations [369]; (iv) 
delay in protein synthesis: the synthesis of proteins takes time, therefore changes in 
transcript concentration will affect protein concentrations only after a certain temporal 
delay [354]; and (v) protein transport: the export of proteins spatially disconnects the 
proteins from the transcripts from which they were synthesised [354]. In the current 
study, the windows of time represented by each kidney biopsy were quite broad, 
especially in terms of acute processes. For example, the kidney biopsy and measurements 
for the ‘Heart Failure’ time-point occurred at day 14 of ADHF, meaning that changes in 
transcript/protein expression that occurred early in this window (e.g. within the first 48 
hours) may not have persisted to day 14. Therefore, protein and mRNA abundances from 
the same location may not directly correlate, particularly during phases of cellular stress 
[354]. 
An important consideration in proteome profiling studies is the assessment of the 
biological relevance of alterations to protein expression. To address this, the molecular 
pathways altered in the kidney in response to ADHF development and recovery were 
investigated, revealing enrichment and alteration of pro-inflammatory pathways across 
the time-course of the study. AKI pathogenesis is characterised by endothelial injury and 
activation, which results in inflammation, tubular epithelial cell death and haemostasis 
[349, 370]. The GP6 signaling pathway, which was activated during ADHF development 
in the current study, is a pro-inflammatory pathway involved in early events in AKI 
[349]. The injury and subsequent activation of renal endothelial cells results in the 
binding of GP6 to platelet activating endothelial cell components, initiating platelet 
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activation and adhesion [349]. Consistent with activation of a pro-inflammatory pathway 
during the development of ADHF, another pro-inflammatory pathway was repressed 
during recovery from ADHF. The acute phase response (APR) signaling pathway is a 
pro-inflammatory pathway that is part of the immune response to tissue damage (such as 
that occurring in AKI) and infections [350]. Through production of pro-inflammatory 
mediators (such as chemokines, cytokines, free radical species and enzymes) with high 
cytotoxic potential, the APR pathway can amplify and extend cell death and damage, 
consolidating and worsening organ dysfunction following injury [350]. Changes in 
protein expression may mediate the switch from inflammation towards healing and repair 
- as evidenced by the repression of the pro-inflammatory APR pathway during the 
recovery period in the current study. These results demonstrate that the alterations in 
protein expression I observed reflect biologically relevant pathways concordant with the 
inflammatory pathogenesis of AKI.  
As reported by Manguba et. al., research into candidate protein biomarkers in the 
specific context of AKI subsequent to ADHF has produced mixed and inconclusive 
results thus far, in part due to the confounding factors implicit in observational patient 
cohorts [106]. A strength of the current study is the elimination of confounding factors 
such as age, gender, ethnicity, comorbidities and modification of decongestive therapy 
in response to declining renal function through the use of an established ovine model of 
ADHF. This animal model simplifies the identification of associations between disease 
state and candidate markers, although is not without limitations. There is no single animal 
model which can accurately reflect the entire complexity of ADHF observed in human 
patients, especially regarding the chronic nature of ADHF and the comorbidities which 
frequently affect elderly patients [371]. Furthermore, there is no consensus on whether 
animals should also receive standard ADHF medications which would better reflect the 
clinical setting [371]. Another limitation is that proteins were quantified from kidney 
tissue, rather than plasma. Whilst the IPA Biomarker Filter workflow and the Human 
Protein Atlas were used to select putative secreted proteins as candidate biomarkers, 
direct empirical evidence is still required to confirm whether the changes in expression 
observed in the kidney are also reflected and quantifiable in circulation. 
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In summary, this study identified a number of candidate protein markers of kidney 
injury in ADHF, including promising candidates supported by existing evidence and 
truly novel candidates never before implicated in AKI. Investigation of these proteins in 
a human cohort of patients with ADHF is needed to test the diagnostic and prognostic 






The research described in this thesis aimed to identify candidate miRNA and protein 
markers of AKI in ADHF, to improve early detection of AKI and facilitate targeted 
treatment and monitoring of ADHF patients. This research is based on three hypotheses: 
i) that in ADHF, AKI is triggered by haemodynamic derangement and is subsequently 
mediated by adverse and compensatory changes in kidney gene, miRNA and protein 
expression ii) that circulating concentrations of miRNAs would distinguish patients with 
ADHF who incurred AKI from those who did not incur AKI, and iii) that protein 
expression in the kidney would be altered in response to the development of and recovery 
from renal impairment as a result of ADHF and enable identification of candidate protein 
biomarkers of kidney injury, recovery and long-term renal impairment in ADHF. 
A miRNA screening study identified 26 miRNAs that were differentially expressed 
between patients with ADHF who experienced AKI, and those who did not. Of these, 10 
miRNAs were selected for validation in a larger, independent cohort (let-7g-5p, miR-
18a-5p, miR-26b-5p, miR-106a-5p, miR-140-5p, miR-146a-5p, miR-374b-5p, miR-382-
5p, miR-454-3p and miR-484). The validation study revealed that lower plasma 
concentrations of miR-454-3p were associated with AKI and kidney dysfunction in 
ADHF patients and may add value beyond established risk factors in predicting AKI. 
Next, a sample preparation method for processing ovine renal tissue for SWATH-MS 
was optimised and used to identify proteins that were differentially expressed in the 
kidney in response to development of and/or recovery from ADHF. This proteomics 
study corroborated existing gene expression data in the same ovine model of ADHF and 
prioritised a list of candidate protein markers for AKI in ADHF for further investigation. 
In combination, the current study has identified potential novel circulating biomarkers 
for further investigation for their utility to differentiate patients with ADHF who incur 
AKI from those who do not, both among candidate circulating miRNAs and among 
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Prior to the current research, only one study had investigated the utility of 
circulating miRNAs as markers of kidney function in ADHF patients. Bruno et al. found 
lower circulating concentrations of miR-423-3p, miR-199a-3p and miR-let-7i-5p in 
patients hospitalised for ADHF who had worsening renal function when compared to 
ADHF patients without worsening renal function [196]. While the sample size was small 
(98 patients), this research provided important proof-of-principle for the efficacy of 
circulating miRNAs as markers of renal injury in the specific setting of ADHF. The 
results from the current study support this concept. Moreover, one of the differentially 
expressed miRNAs identified by Bruno et al. (miR-let-7i-5p) and one of the top 
candidates from the miRNA screen in the current study, let-7g-5p, are both members of 
the let-7 miRNA family, indicating a shared seed sequence and thus a similar biological 
function [272]. However, let-7g-5p could not be validated in the current study, and none 
of the miRNAs implicated by Bruno et al. were found to be differentially expressed 
between ADHF patients who incurred AKI and ADHF patients who did not. The lack of 
similarity between the candidate miRNAs identified by Bruno et al. and those identified 
in the current study could be due to methodological differences, largely regarding sample 
timing and the definitions of renal impairment used. Bruno et al. measured circulating 
concentrations of miRNAs in samples obtained from patients on the first day of 
hospitalisation for ADHF [196], whilst in the current study, samples were assayed 
immediately prior to a creatinine peak indicative of AKI. In addition, different definitions 
for renal impairment were utilised between the two studies – Bruno et al. used worsening 
renal function (defined as an increase in serum creatinine by 0.3 mg per decilitre or more 
from admission to day 3), whilst the KDIGO definition of AKI was employed in the 
current study. Therefore, slightly different renal phentoypes were being assessed in each 
 
 277 
study, which may explain in part the lack of similarity between the candidate miRNAs 
identified, 
MiR-454-3p, the only candidate miRNA to show promise as a marker of AKI in 
an independent cohort of patients with ADHF, has not been associated with AKI 
previously, and represents a potential novel marker for AKI in ADHF. miR-454-3p has 
been strongly associated with HF. Wong et al. reported lower plasma concentrations of 
miR-454-3p in patients with HF compared to non-HF controls, and validated it as a 
diagnostic marker of HF in conjunction with seven additional miRNAs [171]. Data from 
the current study aligns with this finding - there were lower plasma concentrations of 
miR-454-3p in ADHF patients with AKI compared to ADHF patients without AKI - 
suggesting that miR-454-3p may be a marker of both HF severity and renal impairment. 
Based on these data, I predict that healthy controls would have the highest circulating 
concentrations of miR-454-3p, while patients with severe HF and strongly impaired 
kidney function would have the lowest concentrations, and those with less severe HF and 
mild renal impairment would have intermediate concentrations [278, 279].  
The miRNA portion of this thesis represents the first large scale screen and 
validation of miRNAs as candidate markers of AKI in ADHF, and posits miR-454-3p as 
a potential diagnostic tool for AKI diagnosis in ADHF. In contrast to the only previous 
study of miRNAs as markers of AKI in ADHF [196], the current investigation screened 
375 miRNAs expressed in human serum and plasma and then performed validation of 
promising candidates in a separate group of patients, providing the most extensive 
investigation of miRNAs as biomarkers of renal impairment in ADHF to date. In 
addition, this research was the first to assess the novel contribution of information 
provided by miRNAs compared to well-established markers of AKI and ADHF. Based 
on the added value miR-454-3p may provide in addition to established predictors of AKI 
and its implicated biological function in HF, miR-454-3p is a promising candidate 




In contrast to miRNAs, protein biomarkers of AKI in ADHF have been studied 
in considerable depth. The current study identified a number of candidate protein markers 
of AKI in ADHF, including promising candidates supported by existing evidence 
(APOA4, APOE, PRDX1) and novel candidates never before implicated in AKI (CCT3, 
CCT8, CCT6A, CRYZ, FLNA, TCP1, TLN1, TPP1). The gene transcripts for two of the 
top protein candidates identified, Apolipoprotein E (APOE gene) and Apolipoprotein A4 
(APOA4 gene), have both been linked to AKI in multiple large transcriptomics data sets 
[353] and have been directly implicated in AKI development [359, 362, 363]. APOE 
gene polymorphisms have been associated with the development of AKI following 
coronary bypass grafting surgery [359], whilst high plasma concentrations of APOA4 
have been correlated with mild to moderate renal failure and proposed as a predictor of 
kidney disease progression [362, 363]. In support of these findings, the current 
investigation identified APOE as a candidate biomarker of long-term renal impairment 
in ADHF (i.e. a marker which is altered during development of ADHF and remains 
altered after recovery from ADHF), whilst APOA4 was identified as a potential 
biomarker of kidney recovery in ADHF (i.e. a marker which is altered upon recovery 
from ADHF).  
Two top candidate protein markers of kidney injury in ADHF identified in this 
thesis, Filamin A (FLNA)and Chaperonin containing TCP1 subunit 6A (CCT6A), have 
never been associated with AKI and represent novel findings. FLNA is an actin-binding 
protein involved in cytoskeleton remodelling [364], whilst CCT6A is a component of a 
molecular chaperone complex which assists the folding of proteins including actin and 
tubulin [365]. Neither FLNA or CCT6A have described roles in the kidney. 
Beyond identification of specific candidate protein markers, the biological 
relevance of global alterations in protein expression was assessed and considered in the 
context of AKI pathogenesis. Pathway analysis showed that proteins altered over the 
time-course of the study were strongly enriched in two molecular pathways. The GP6 
signalling pathway, a pro-inflammatory pathway known to be involved in early events in 
AKI [349], was activated during ADHF development, whilst the acute phase response 
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pathway, a pro-inflammatory component of the immune response to tissue damage that 
is activated in AKI [350], was repressed during recovery from ADHF. These findings 
confirm previous gene expression analyses and for the first time indicates a central role 
for these pathways in AKI pathogenesis in ADHF. 
Whilst prior research has been conducted assessing the utility of protein markers 
of renal impairment in ADHF, this research has not been exhaustive and the current 
results indicate that there are more candidate protein markers in addition to those 
previously implicated which could hold promise. Furthermore, this research offers 
insight into concurrent gene and protein expression changes occurring in response to the 
development and recovery from ADHF, and its associated renal impairment.  
In summary, the findings from this thesis suggest that both miRNA and protein 
markers have the potential to improve the early detection of AKI, facilitating more 
targeted treatment and monitoring of ADHF patients. Fulfilling the important and 
currently unmet need for early markers of AKI in ADHF could ultimately improve 
patient outcomes by reducing mortality and morbidity. 
10.2 The	synergistic	power	of	combining	multiple	markers	
There is growing evidence that a panel of markers may be superior to the use of a 
single marker alone for prediction or detection of AKI in ADHF [70, 73, 171]. Currently, 
the only FDA approved marker which has entered clinical practice for the identifying 
patients at risk of moderate to severe AKI is a fluorescence immunoassay test measuring 
a combination of urinary TIMP-2 and IGFBP7 (NephroCheck, Astute Medical Inc., 
USA) [73]. The seminal research which discovered this combination of markers and led 
to the development of NephroCheck, concluded that combining measures of TIMP-2 and 
IGFBP7 was advantageous as each marker performed with varying degrees of efficacy 
in different clinical settings [70]. Kashani et al found that TIMP-2 was superior to 
IGFBP7 in sepsis-induced AKI, whilst IGFPB7 performed best in surgical patients. 
These differences in specific biomarker efficacy may underlie subtle mechanistic 
differences between different aetiologies of AKI and reflect that TIMP-2 and IGFBP7 
are involved in slightly different biological pathways [70]. This finding supports the 
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utilisation of both biomarkers in combination, which together provided the most 
consistent result across various cohorts of patients with AKI [70]. This principle was 
further supported when considering miRNAs as biomarkers in HF [171]. This evidence 
suggests that the small individual effects of single markers (be they miRNA or peptide) 
combine synergistically to improve diagnostic performance compared with any 
individual marker. On the basis of this concept, I hypothesise that a combination of the 
miRNA, miR-454-3p and some of the candidate proteins identified in the current study 
would provide superior diagnostic (or prognostic) accuracy than any of the markers 
alone.  
In the current thesis, conducting research across two species (human and sheep) 
prevented the opportunity to immediately assess miRNA data in conjunction with protein 
expression data. A feasible next step would involve quantifying the top ten candidate 
miRNAs in kidney tissue and archived plasma samples collected from the sheep in which 
protein profiling was carried out. Whilst sheep-specific commercial miRNA assays are 
not widely available [372], a species-agnostic approach such as RNA-sequencing could 
be applied to quantify evolutionarily-conserved candidate miRNAs in sheep samples. 
Similarly, candidate proteins identified in sheep kidney could also be tested in sheep and 
human plasma (discussed in Section 10.7 below). 
10.3 Utilisation	of	genomics	and	proteomics	
Approaching a research challenge from multiple perspectives provides greater 
insight than employing a single analytical strategy [373]. In this thesis, both genomics 
and proteomics approaches were used to identify markers of AKI in ADHF. There is an 
inherent relationship between miRNAs and proteins, as miRNAs can negatively regulate 
gene expression and consequently perform fine-scale alteration of protein output through 
mRNA degradation or protein translation inhibition [374]. MiRNAs can be considered 
master regulators which orchestrate biological processes, whilst proteins are the 
downstream effectors in these pathways [375]. Analysing miRNAs and proteins side by 
side may provide a more comprehensive understanding of the biological processes 
occurring in the disease of interest [376]. For example, Lei et al. recommended that the 
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investigation of miRNA biology should be performed in the context of protein interaction 
networks as opposed to isolated target genes, in order to better understand the function 
and roles of miRNAs in diseases [374]. MiR-454-3p is predicted to target the mRNA 
transcript from the CCT6A gene and therefore alter the expression of CCT6A 
(TargetScan database v7.1 [355] and miRDB version 6.0 [356]) – one of the candidate 
protein markers of renal impairment identified in the ovine model of ADHF. Further 
functional studies (discussed in Section 10.7 below) could be undertaken to further 
understand the role of miR-454-3p specifically in the kidney. 
When searching for early biomarkers of AKI, the timing of blood sampling is of 
critical importance. It is desirable to identify markers which are differentially expressed 
at the earliest time-point possible, to enable early intervention and changes in clinical 
management. In addition, profiling markers which change over a longer time window 
may help identify patients who are not responding as well to treatment or may be at risk 
of a poor prognosis. Consequently, different classes of molecules may be better markers 
at different times. It is widely acknowledged that there is not a simple relationship 
between the concentration of a gene transcript and the concentration of the protein 
derived from a specific locus [354]: multiple processes beyond transcript concentration 
influence protein abundance, including the rate of translation and degradation [366]. The 
rate of translation can be modified by the binding of proteins to regulatory elements on 
transcripts, and of particular relevance, through the binding of non-coding RNAs such as 
miRNAs to transcripts [368]. Assessing the expression of miRNAs and mRNAs in 
addition to proteins may capture extra information relating to this process, and may 
increase the likelihood of identifying an early marker [377] as alterations to expression 
of miRNAs (and therefore to the rate of protein translation or translation inhibition) may 
be occurring prior to the observed changes in protein expression or phenotype [377]. 
Furthermore, the protein profiling experiment carried out replicated and expanded upon 
existing work from the Group assessing the changes in gene expression in the same 
samples. Gathering data at both the gene- and protein-level helps provide a more 
complete picture of the processes occurring, therefore providing a better understanding 
of the molecular changes associated with AKI pathology (discussed above) [378, 379]. 
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10.4 Advantages	 and	 disadvantages	 of	 human	 cohorts	 and	
preclinical	models	
Conducting biomarker research in a human cohort versus a preclinical animal 
model presents advantages and disadvantages [380, 381]. The miRNA studies in this 
thesis were carried out in a cohort of patients admitted to hospital for ADHF. This confers 
the distinct advantage that results are directly applicable to patients in this specific 
clinical setting with no inter-species extrapolation, and that the conditions experienced 
by the cohort represent a real-world scenario similar to that in which a candidate 
biomarker would be utilised. However, in an all-comers case-control cohort such as that 
utilised in the miRNA study, confounding by uncontrollable variables poses a significant 
challenge [381]. Cohorts such as these include patients with a range of ages, ethnicities, 
co-morbidities and medications, and care must be taken to unravel the complex 
interactions between candidate markers and these potential confounders [162, 283]. This 
presents an analytical challenge and extra investigation should be undertaken to examine 
the relationships between candidate markers and potential confounders, as well as 
employment of multivariable statistical models which adjust for potential confounders 
[382]. Thus, the preliminary finding that miR-454-3p is a marker of AKI and kidney 
dysfunction in ADHF patients needs to be validated in large, independent cohorts and 
other ethnic groups before testing in a clinical trial. 
In contrast, a strength of preclinical animal models such as that used in the protein 
biomarker discovery study is the elimination of confounding factors such as age, gender, 
ethnicity, comorbidities and medications, and the ability to measure changes in protein 
expression directly within kidney tissue, both during development of, and recovery from 
ADHF. In particular, the ovine model of ADHF utilised in this research is a highly 
reproducible model which faithfully replicates the consequences of human ADHF – 
characterised by decline in cardiac output, widespread neurohormonal activation, 
development of pulmonary congestion and oedema, avid sodium and water retention, and 
a rise in systemic peripheral resistance and cardiac pre-load [287]. The large body size 
of sheep allows repeated blood and urine sampling, and comprehensive instrumentation, 
all of which are essential in determining combined effects of ADHF on the kidney. 
Furthermore, this model offers the unique ability to study the development and resolution 
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of ADHF in the same animal [287, 289]– a valuable asset for investigating markers of 
recovery. 
Although preclinical models simplify the identification of associations between 
disease state and candidate markers through their highly controlled nature, they are not 
without limitation [380]. Species-specific differences may exist, meaning that findings 
cannot be translated into humans [383]. Associations between candidate biomarkers and 
disease state identified in a homogeneous, highly controlled preclinical model may not 
extrapolate to a heterogeneous human population in a highly complex clinical scenario 
[383]. This creates a significant limitation in the current protein biomarker study – it is 
unknown (i) whether the candidate protein markers identified in the sheep kidney will be 
detectable in human plasma, and (ii) whether the changes in protein expression observed 
in response to development of ADHF in sheep also occur in humans. Although the 
Human Protein Atlas and Ingenuity Pathway Analysis Biomarker Filter analysis (IPA; 
Qiagen Inc.) indicate that the candidate protein biomarkers identified are detectable in 
plasma, serum or urine, this remains to be experimentally validated. Kidney tissue was 
utilised in the protein biomarker study to ensure that any changes in protein expression 
identified were kidney-specific. A method for quantifying proteins in sheep plasma was 
also established in this thesis to enable detection of high abundance candidate markers in 
circulation. However, as several of the candidates identified from the kidney were 
unlikely to be highly abundant in the circulation and other changes in protein expression 
observed in circulation may be related to non-renal factors associated with ADHF, 
analysis of sheep plasma using SWATH-MS was deprioritised and future studies will 
focus on investigating specific protein candidates in human plasma using highly sensitive 
and specific immunoassays (discussed in Section 1.8).  
Another disadvantage to the use of preclinical models for ADHF research is that 
there is no single animal model which can accurately reflect the entire complexity of 
ADHF observed in human patients – particularly regarding the chronic nature of ADHF 
and the comorbidities which frequently affect elderly patients [371]. Additionally, there 
is no consensus on whether animals should also receive standard ADHF medications 
which would better reflect the clinical setting [371]. Human cohorts and preclinical 
models both confer strengths and weaknesses which when utilised together, form 
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complementary approaches for investigating clinical challenges. The opportunity to 
study biofluids and tissues from humans and sheep provides a strategy for capitalising 
on the advantages and overcoming the disadvantages conferred by each method 
individually. 
10.5 Biomarkers	and	ethnicity	
In NZ Māori and Pasifika have higher rates of cardiovascular mortality and 
morbidity than non-Māori and non-Pasifika [284]. ADHF disproportionately affects 
Māori, who are > 1.8 times more likely to develop ADHF compared with non-Māori 
[242]. Further to this, Māori have an earlier age of onset that non-Māori [24], and have 
worse outcomes [242], experiencing > 3 times the health loss of non-Māori [384]. To 
avoid perpetuation of healthcare disparities, a candidate marker should perform equally 
across all ethnic groups [285, 286] - a factor which was considered in the miRNA cohort 
study. In this research, miR-454-3p was differentially expressed between European 
patients who remained kidney healthy and those who did not, whereas there was no 
evidence for this association in Māori or Pasifika patients. However, further exploration 
into each ethnic group separately revealed a consistent pattern of association between 
miR-454-3p expression and renal impairment across all ethnic groups (i.e. the study 
lacked sufficient statistical power to detect these effects in the smaller Māori and Pasifika 
sub-groups). This suggests that miR-454-3p may be an effective marker of AKI in ADHF 
for patients in all three major ethnic groups in NZ (NZ European, Māori and Pasifika), 
but further investigation must be undertaken in order to confirm this preliminary finding. 
In contrast to the miRNA studies, the protein data was collected in a preclinical ovine 
model, meaning that it is unknown whether any associations exist between ethnicity and 
the expression of candidate protein markers in humans. For this reason, it is of critical 
importance that any future human studies investigating miRNA or protein candidates be 
performed in a diverse cohort comprising a range of ethnicities - including a substantial 
number of Māori and Pasifika peoples to allow sufficiently powered and thorough 
exploration of potential associations between candidate markers and ethnicity.  
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Identifying effective markers for AKI in ADHF in Māori and Pasifika patients 
could help reduce health care disparities, as patients of these ethnicities are more likely 
to suffer adverse outcomes in ADHF [284]. Disparities in ADHF outcomes may, in part, 
be due to increased risk of kidney dysfunction among Māori patients. Previous studies 
have demonstrated that Māori have worse kidney disease related outcomes than non-
Māori in general [385-387], even when differences in socio-demographic and clinical 
characteristics are accounted for [388], and data from the IMPERATIVE-HF cohort 
(utilised for the miRNA portion of this thesis) indicate that the risk of incurring AKI in 
ADHF is greater among Māori than non-Māori. In addition to the increased risk of kidney 
dysfunction, Māori have less access to primary care and emergency departments 
throughout NZ [384]. The development of new biomarker assays for AKI in ADHF does 
not improve access to healthcare, but may eventually mitigate the impact of this inequity 
through the provision of a cost-effective and relatively non-invasive method for 
accurately assessing kidney function with a single blood test. Currently, assessing kidney 
function in patients with ADHF relies upon previous measures of creatinine taken before 
ADHF onset for comparison with creatinine concentrations upon hospital admission. 
Due to barriers to accessing healthcare, Māori patients are more likely to be among the 
proportion of patients who lack a creatinine measurement before hospitalisation. 
Therefore, new markers which could reliably detect AKI with a single measurement (and 
thereby do not rely upon prior access to healthcare) could disproportionately improve 
survival in Māori ADHF patients.  
10.6 Limitations	and	challenges	in	AKI	biomarker	research	
A significant limitation in the field of AKI biomarker research (and the current 
thesis) is the use of creatinine as a gold-standard with which to compare novel biomarkers 
and diagnose AKI. Creatinine is a breakdown product from muscle metabolism and its 
concentration in the circulation represents the balance between generation and excretion 
[31], therefore it is a marker of renal function but not kidney damage [17]. This means 
circulating concentrations of creatinine may only rise 24-72 hours after damage has 
occurred, making creatinine a delayed and insensitive biomarker of changes in kidney 
function [18]. Furthermore, circulating creatinine concentrations can be confounded by 
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many factors including muscle mass [16, 32] and medications [389]. Using an imperfect 
gold-standard such as creatinine, which is neither specific nor sensitive, carries inherent 
limitations [106] – even if a novel renal injury biomarker is 100% specific and 100% 
sensitive, it may appear inaccurate when using creatinine for comparison as the gold-
standard [121]. Additionally, novel biomarkers which have perfect correlation with 
creatinine will possess the same limiting characteristics as creatinine [121]. In order to 
mitigate this limitation, samples collected before, during and after AKI-indicating 
creatinine peaks were assayed in the miRNA screen, and proteins were quantified in 
kidney samples collected across the time course of ADHF development and recovery in 
the ovine model. This aimed to identify candidate markers not perfectly correlated with 
creatinine which would provide independent information.  
A further challenge in using creatinine to assess and diagnose AKI in biomarker 
studies is the reliance on previous measures of creatinine. KDIGO diagnostic criteria 
require a known historic baseline or pre-existing creatinine measurement(s) to diagnose 
a patient with AKI on presentation. Up to 50% of patients admitted to hospital do not 
have prior creatinine data [274-276], meaning that a patient presenting with a clear 
impairment of kidney function (as reflected by higher than normal creatinine) may not 
be diagnosed using the KDIGO criteria if they have missing baseline or historic 
creatinine data for comparison. For that reason, using KDIGO diagnostic criteria in 
biomarker research may not capture all patients with AKI and could blur the renal 
function phenotypes of case and control groups. To minimise this effect, clinical 
adjudication was employed in the miRNA screening study to ensure clear renal function 
phenotypes amongst the study groups. 
To complicate matters further, identifying control patients with ‘healthy’ kidneys 
in a cohort of ADHF patients is extremely challenging, as renal function is inherently 
impaired by HF [24]. In patients with HF, the renal system is adversely affected due to 
volume overload caused by congestion, and several medications administered in HF 
(including loop diuretics and vasodilators) are known to reduce renal perfusion and/or 
intra-glomerular filtration pressures, thereby promoting AKI in ADHF [24]. This makes 
it particularly difficult to define what healthy kidney function is in the context of ADHF 
and select a group of control patients for comparison. Furthermore, kidney dysfunction 
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manifests along a continuum of severity [10], making it difficult to dichotomise patients 
as being ‘kidney healthy’ or having AKI. Therefore, we included a third group in our 
validation study to reflect this continuum - patients with intermediate kidney dysfunction. 
As reflected by the scarcity of literature in this area, identifying appropriate control 
patients and fundamental issues with the utilisation of creatinine for classification of 
renal function makes the discovery of new biomarkers for AKI in ADHF challenging. 
Another challenge in AKI research is the variable timing of AKI onset, which 
coupled with the limited availability of research sample time-points, proved a limitation 
in the current study. In patients with ADHF, AKI onset typically occurs within the first 
few days after ADHF diagnosis [14, 15], but the exact timing from ADHF diagnosis to 
AKI onset varies considerably between patients. Ideally, to maximise the ability to 
identify rapid changes in creatinine and allow the assaying of potential biomarkers 
immediately preceding these creatinine changes, blood sampling would be done daily to 
provide a thorough time course of kidney function. Although samples from multiple 
time-points were available (baseline, pre-discharge, seven days, two-weeks, six weeks, 
twelve weeks), the cohort utilised in the current miRNA biomarker study 
(IMPERATIVE-HF) did not have such frequent sampling, as it was not specifically 
designed for monitoring creatinine and evolution of AKI. The timing of sample collection 
was also a limitation in the ovine protein biomarker study. Because it is not humane to 
perform multiple kidney biopsies in conscious sheep, the windows of time represented 
by each kidney biopsy were quite broad, particularly in terms of acute processes. For 
example, the kidney biopsy and measurements for the ‘Heart Failure’ time-point 
occurred at day 14 of ADHF, meaning that alterations in protein expression which 
occurred early in this time window (e.g. within the first 48 hours) may not have persisted 
to day 14 and therefore would not have been detected. This resulted in a lack of ability 
to detect very early markers of AKI, such as TIMP-2 and IGFBP7, which have been 
demonstrated to be altered in expression in patients with AKI within 24 hours of 
admission to an intensive care unit [78]. In order to gain the ability to detect such early 
markers, another preclinical ovine study would need to be performed in which there are 





Novel biomarkers derived from ‘omics’ technologies have the potential to deliver 
major advances in the timing and accuracy of AKI diagnosis in ADHF patients, improve 
the prediction of renal risk and outcome, and guide therapy [390, 391]. A better 
understanding of the complex pathophysiology of AKI and alterations to molecular 
pathways presents the possibility for the discovery of new therapeutic targets [390]. 
Future work arising from this thesis focuses on validating candidate miRNA and protein 
markers in patients and undertaking functional studies to understand their role in the 
evolution of AKI in ADHF. 
The first step would be to validate the associations between plasma concentrations 
of miR-454-3p and selected candidate proteins (from the ovine study) and AKI in patients 
with ADHF, in an independent replication cohort. An ideal cohort for this research would 
consist of a large number of patients recruited at admission for ADHF, including 
oversampling of Māori and Pasifika, in which multiple blood samples were collected 
over time to allow thorough monitoring of creatinine and ensure ample sample 
availability for biomarker assays at critical time-points. This would allow profiling of the 
expression of candidate markers over time to generate an understanding of the 
relationship between changes in concentrations of candidate markers and AKI and 
provide sufficiently powered exploration of biomarker efficacy across ethnic groups. 
Optimally, this sampling would begin upon hospital admission (0 hours) and occur 6-12 
hourly during the first 48 hours, then continue daily until discharge. Patient follow up 
and outcomes should be recorded for at least a year after study entry. The Indicators 
Detecting New Trends to Acute Kidney Injury and its Timing in acute Heart Failure 
(IDENTAKIT-HF) cohort, recently recruited by our Group, meets several of these 
criteria. This cohort consists of 85 patients with ADHF who have samples of both blood 
and urine collected on admission (0 hours), at 6, 12, 24, 48 hours and days 5-7. This 
cohort was not able to be utilised in the thesis due to slow recruitment to the study 
(IDENTAKIT-HF was an especially challenging protocol to recruit to), and performing 
investigation of candidate markers in the incomplete cohort would have been greatly 
underpowered. An additional cohort suitable for this research has also been recruited by 
collaborators in Singapore: the Nephropathy in Congestive Heart Failure and Biomarker 
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Evaluation-Exemplification (NICHE2) cohort. NICHE2 is a multicenter, longitudinal 
prospective cohort study led by Dr Shir Lynn Lim (National University Heart Centre 
Singapore) designed to assess emerging blood and urine biomarkers of evolving AKI in 
ADHF patients. This cohort consists of 125 patients with ADHF and has been recruited 
in parallel with IDENTAKIT-HF with an intentionally similar protocol. 
Results from the protein biomarker portion of this thesis are being used to support 
a Health Research Council of New Zealand project grant application to undertake such 
research in the pursuit of clinically useful biomarkers for AKI in ADHF. This work 
proposes to prioritise selected protein candidates identified in this thesis, alongside gene 
candidates identified in a previous gene expression study in the same ovine model of 
ADHF. This prioritisation will take into consideration the magnitude, direction of change 
(favouring those candidates which increase with AKI), temporal profile, concordance of 
gene and protein changes, consistency of change across animals and whether candidates 
may be detectable in human plasma or urine. Selected protein candidates will be 
quantified in human plasma (from IDENTAKIT-HF) using Enzyme-Linked 
Immunosorbent Assays or radioimmunoassays, and promising candidates will be 
validated in the NICHE2 cohort. Crucially, new markers will be compared against 
existing markers such as IGFBP7 and TIMP2.  
Functional studies could also be performed to elucidate the cellular function and 
role of miR-454-3p in AKI physiopathology. miRNAscopeTM could be performed on 
kidney tissue from the ovine ADHF model to visualise the expression and localisation of 
miR-454-3p in the kidney. miRNAscopeTM is an in situ hybridisation technology which 
allows the visualisation of miRNA target expression in cultured cells or intact tissues 
with single-cell resolution [392]. This preserves morphological and spatial context, and 
would allow examination of miR-454-3p status within the histopathological context of 
the ovine kidney specimens [393] – for example, miRNAscopeTM may reveal localisation 
of miR-454-3p expression in a particular cell type such as epithelial, glomerular or 
tubular cells. Subsequently, the phenotypic effects of miRNA-454-3p activity could be 
explored [357] by silencing or overexpressing miR-454-3p in cultured cells. For 
example, oligonucleotides which inhibit or mimic the activity of specific miRNAs [357] 
could be tested in cultured kidney cells and ultimately in intact animals [394], such as 
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Zebrafish, mice or potentially the ovine model of ADHF (using an appropriate delivery 
mechanism targeted to kidney cells). Similarly, to understand the cellular function and 
biological role of candidate proteins in AKI, the phenotypic effects could be investigated 
through overexpression, knockdown or knockout of the protein of interest. For example, 
knockdown technologies such as RNA interference could be tested in cultured kidney 
cells [395, 396] and eventually in intact animals [396] as described above. An alternative 
strategy for this research would involve CRISPR-Cas9 technology to generate a 
knockout mouse model [397, 398], in which one or more nucleotides in the gene for the 
protein of interest were mutated in such a way that the translated protein loses function 
[399, 400]. 
Further to these proposed functional studies, different technologies and techniques 
could be used to search for novel biomarkers of AKI in ADHF, including investigation 
of Extracellular Vesicle (EV) cargos as biomarkers. EV cargos have shown promise as 
diagnostic biomarkers in prostate cancer, as a combination of quantitative assays of 
multiple EV-derived proteins may improve diagnostic efficacy compared to the use of a 
single serum-derived protein biomarker such as Prostate Serum Antigen [401]. In 
addition to quantifying EV-derived proteins, RNA sequencing could be used to quantify 
miRNA cargos contained within EVs [402]. Investigating a combination of protein and 
miRNA markers within EV cargos in clinical studies could be a valuable strategy in 
discovering EVs as novel biomarkers for improved diagnosis of AKI in ADHF. 
This thesis highlighted the feasibility of using circulating miR-454-3p as a diagnostic 
marker of AKI in ADHF, and identified new candidate protein biomarkers through the 
characterisation of protein expression changes which occur in the kidney in response to 
renal impairment due to development of ADHF. Through these findings, new scientific 
questions have been generated which warrant further consideration. These include: 
• Does combining candidate protein markers with miR-454-3p in a panel of 
biomarkers increase the predictive power for detecting AKI above individual 
markers alone? Does this panel of markers augment the predictive power of 
clinical predictors including age, sex and creatinine? 
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• What cellular functions does the candidate biomarker miR-454-3p perform, and 
what is its role in the pathophysiology of AKI? 
• Will miR-454-3p validate as a biomarker of AKI in ADHF in Māori, Pasifika and 
international populations? 
• Are the candidate protein biomarkers identified in the preclinical ovine model of 
ADHF detectable in human circulation? 
• Do any of the candidate protein biomarkers identified in the preclinical ovine 
model translate into diagnostic markers of AKI in humans? 
10.8 Conclusions	
This thesis performed a combined investigatation of miRNAs and proteins as 
biomarkers for the detection of AKI subsequent to ADHF, using a large-scale miRNA 
screen and validation in ADHF patients, and a protein expression profiling study in a 
preclinical ovine model of ADHF. Results from this thesis provide new insights into the 
field of biomarkers of AKI in ADHF, through identification of novel candidate miRNAs 
and proteins for validation.   
The key findings of this research were: 
• In a screen of 375 circulating miRNAs, 26 miRNAs were differentially expressed 
between patients with ADHF who incurred AKI, and patients with ADHF who 
did not, and were identified as candidate biomarkers for AKI in ADHF. 
• The 26 differentially expressed candidate miRNAs clustered into groups of 
correlated miRNAs with similar expression profiles. The majority of miRNAs 
within each group had the same seed sequence, suggesting that miRNAs which 
carry out the same function have a similar expression pattern. 
• In a validation study of the top 10 candidate miRNA biomarkers from the screen, 
plasma concentrations of miR-454-3p were associated with kidney function in 
ADHF patients and may add prognostic value beyond established risk factors 
including age and NT-proBNP in predicting AKI in patients with ADHF. 
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• Although miR-454-3p was expressed in a consistent pattern across all three major 
ethnic groups in the validation (European, Māori and Pasifika), the study was not 
powered to detect associations with AKI in the smaller Māori or Pasifika sub-
groups. 
• A method for the preparation of ovine kidney tissue for subsequent SWATH-MS 
was optimised, and the SPEED experimental procedure demonstrated the best 
quantitative and qualitative performance. 
• Seven candidate protein markers of kidney injury (CCT3, CCT8, CRYZ, FLNA, 
PRDX1, TLN1, TCP1), one potential protein marker of kidney recovery 
(APOA4) and three potential protein markers of long-term renal impairment 
(APOE, TPP1, CCT6A) were identified from protein expression profiling data 
over the time-course of ADHF development and recovery a pre-clinical ovine 
model of ADHF. Of these candidates, eight had never previously been associated 
with AKI (CCT3, CCT8, CCT6A, CRYZ, FLNA, TCP1, TLN1, TPP1). 
• The pro-inflammatory GP6 signaling pathway was enriched and activated during 
ADHF development, and the pro-inflammatory acute phase response signaling 
pathway was enriched and was repressed during recovery from ADHF in a 
preclinical ovine model of ADHF. 
• Eleven candidate protein markers corroborating gene expression data previously 
gathered by our research Group in the same pre-clinical ADHF model were 
identified.  
Taken together, these findings suggest that miR-454-3p and proteins including 
Apolipoprotein A4, Apolipoprotein E, Chaperonin containing TCP1 subunit 6A and 
Filamin A have potential as novel biomarkers to improve detection of AKI and predict 
prognosis in ADHF. These findings could ultimately, through continued research and 
development, facilitate targeted treatment and monitoring of ADHF patients, reducing 
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1.1 Determining	 the	 optimal	 RNA	 input	 volume	 for	 cDNA	
synthesis	
 
Figure 62: Optimising the input volume of RNA for cDNA synthesis. To determine the optimal 
input volume of RNA for cDNA synthesis, three different input volumes – (2, 4 and 8 μL) were 
tested across seven probes including five synthetic spike-ins and two endogenous reference 
miRNAs. The mean Ct value generated in RTqPCR, which represents the amount of PCR product 
generated, is graphed on the y-axis, against the RNA input volume (x-axis). A lower Ct value 





Table 47: List of 80 most stably expressed miRNAs identified in the screen, to be tested as 
candidate reference miRNAs. 
miR-27b-3p miR-361-5p miR-342-3p miR-25-3p 
miR-629-5p miR-19b-3p miR-885-5p miR-142-3p 
miR-27a-3p miR-30e-5p miR-425-5p miR-197-3p 
miR-103a-3p miR-1 miR-379-5p miR-652-3p 
miR-374a-5p miR-142-5p miR-145-5p miR-30c-5p 
let-7d-5p miR-574-3p miR-16-5p miR-363-3p 
miR-181b-5p miR-148b-3p miR-126-3p miR-628-3p 
miR-21-5p miR-107 miR-15b-5p miR-199a-3p 
miR-24-3p miR-15a-5p miR-30d-5p miR-148a-3p 
miR-126-5p miR-150-5p miR-155-5p miR-423-3p 
mIR-23a-3p miR-222-3p miR-140-3p miR-376a-3p 
miR-144-3p miR-101-3p miR-195-5p mIR-421 
miR-340-5p miR-328-3p miR-29a-3p miR-98-5p 
miR-19a-3p miR-22-3p miR-134-5p miR-221-3p 
let-7c-5p miR-766-3p miR-186-5p miR-28-5p 
miR-143-3p miR-194-5p miR-409-3p let-7e-5p 
miR-30b-5p miR-432-5p miR-200c-3p miR-122-5p 
miR-505-3p miR-185-5p miR-29c-3p miR-30e-3p 
miR-223-3p miR-376c-3p miR-181a-5p miR-486-5p 
let-7a-5p miR-375 miR-151a-5p miR-151a-3p 
miR-92b-3p 





Table 48: Product numbers for Qiagen miRCURY LNA miRNA PCR Assays (Qiagen, Aarhus, 
Denmark) used in the validation study. 
Qiagen miRCURY LNA miRNA PCR 
Assay 
Catalogue Number 
hsa-let-7g-5p 339306, YP00204565 
hsa-miR-18a-5p 339306, YP00204207 
hsa-miR-26b-5p 339306, YP00204172 
hsa-miR-106a-5p 339306, YP00204563 
hsa-miR-140-5p 339306, YP00204540 
hsa-miR-146a-5p 339306, YP00204688 
hsa-miR-374b-5p 339306, YP00204608 
hsa-miR-382-5p 339306, YP00204169 
hsa-miR-454-3p 339306, YP00205663 
hsa-miR-484 339306, YP00205636 
 
1.4 Checking	for	outliers	in	miRNA	validation	data	
Table 49: Raw Ct data for endogenous reference miRNAs, before exclusion of outliers. Medians, 




Median IQR Minimum Maximum 
miR-576-5p 31.7 30.8-32.6 0 36.7 
miR-30b-5p 26.3 25.3-27.3 22 36.9 
miR-92b-3p 30 29.3-30.9 0 45 




Table 50: Raw Ct data for endogenous reference miRNAs, after excluding outliers. Medians, 
IQRs and rangers are presented. 
Reference 
miRNA 
Median IQR Minimum Maximum 
miR-576-5p 31.7 30.8-32.6 28.2 35.7 
miR-30b-5p 26.3 25.2-27.2 22 29.7 
miR-92b-3p 30.1 29.3-30.9 26.7 34.5 
miR-24-3p 22.6 21.7-23.6 19.3 26.5 
 
 
Figure 63: Raw Ct values for reference and spike-in miRNAs across all samples. The three 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 51: Protocol of tissue trypsinisation using the SDC method. 
Solution Composition µL 
Homogenised sheep kidney 
in Homogenising and 
Denaturing Solution with 
SDC concentration topped up 
to 1.67% 
150 µg protein  
10% SDC 8.85 
400 mM Ammonium 
hydrogen carbonate 
44.27 





25x stock solution cOmplete 
protease inhibitor cocktail* 
6.70 
Denaturing Solution 2 100% ACN 30.8 
100 mM CaCl2 2.0 
dH20 49.2 
dH20  48 
Trypsin (1) 0.5 µg/µL 6 
Trypsin (2) 0.5 µg/µL 6 
Formic acid 10% in dH20 40 




Table 52: Protocol of plasma trypsinisation using the SDC method 
Solution Composition µL 
Sheep plasma 60 µg/µL protein 2.5 
Denaturing Solution 1 10% SDC 8.55 
400 mM Ammonium 
hydrogen carbonate 
42.77 




25x stock solution cOmplete 
protease inhibitor cocktail* 
6.2 
Denaturing Solution 2 100% ACN 30.8 
CaCl2 2.0 
dH20 49.2 
dH20  48 
Trypsin (1) 0.5 µg/µL 6 
Trypsin (2) 0.5 µg/µL 6 
Formic acid 10% in dH20 40 
* made in 1.67% SDC, 333.33mM ammonium hydrogen carbonate 
2.2 Optimising	Sonication	for	S-Trap	
An essential step in the S-Trap protocol is the shearing or lysis of DNA in samples 
by sonication, to prevent DNA from clogging the filter membranes. To determine the 
optimal sonication procedure for sufficient fragmentation of DNA without unduly 
modifying or damaging proteins, 8 different sonication conditions were assessed for their 
effectiveness of DNA shearing in kidney tissue samples. A Sonic Ruptor 400 Ultrasonic 
Homogenizer (Omni International, GA, USA) was used to probe sonicate homogenised 
kidney tissue and plasma samples with a volume of 250 µL, and all samples were 
sonicated on ice to counter heating induced by sonication. Three power settings and two 
sonication durations were trialled using a microtip probe, as follows: 
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Condition 1: 10% power, 50% pulse rate, 30 seconds 
Condition 2: 10% power, 50% pulse rate, 100 seconds 
Condition 3: 20% power, 50% pulse rate, 30 seconds 
Condition 4: 20% power, 50% pulse rate, 100 seconds 
Condition 5: 30% power, 50% pulse rate, 30 seconds 
Condition 6: 30% power, 50% pulse rate, 100 seconds 
In addition, Condition 7 trialled an Elmasonic S 10 (1005507, Elma, Germany) for 30 
seconds on (sweep-function), 90 seconds off repeated for 6 cycles, at 4 degrees to test 
whether use of a method which facilitates processing multiple samples concurrently 
would sufficiently fragment DNA. Lastly, Condition 8 trialled the Omni Ruptor cup tip 
attachment (Omni International, GA, USA) on the Sonic Ruptor 400 Ultrasonic 
Homogenizer, in which samples were sonicated in ice cold water at 30% power, 50% 
pulse rate for 6 minutes, to test another method for processing multiple samples 
concurrently. 
Sonication efficiency was examined using a TapeStation 2200 system (Agilent 
Technologies) with Genomic DNA ScreenTapes (catalogue # 5067-5365 and 5067-5366, 
Agilent Technologies, Germany) to assess the size of DNA fragments and the overall 
DNA integrity (Figure 64). The effect of sonication on protein quality was also examined 
by running an Agilent P200 ScreenTape (P200 ScreenTape, 5067-5171; P200 Reagents, 




Figure 64: Results from running samples sonicated at various conditions on Genomic DNA 
ScreenTapes to assess DNA integrity. DIN = DNA Integrity Number, ranging from 1-10, with 10 
representing highly intact DNA and 1 representing highly degraded DNA.  Lane A1: genomic 
DNA ladder; Lane B1: sonication condition 1; Lane C1: sonication condition 2; Lane D1: 
sonication condition 3; Lane E1: sonication condition 4; Lane F1: sonication condition 5; Lane 
G1: sonication condition 6; Lane H1: sonication condition 7; Lane A2: sonication condition 8; 
Lane B2: unsonicated sample diluted 1:25; Lane C2: unsonicated sample diluted 1:50; Lane D2: 
unsonicated sample diluted 1:100. Yellow exclamation marks indicate that the sample 
concentration was outside the manufacturers recommended range, whilst red exclamation marks 
indicate sample concentration was outside the functional range for DIN. 
 
Based on the Genomic DNA ScreenTape pictured in Figure 64, all DNA samples 
appeared to be degraded and there were no obvious differences in DNA integrity 
(represented by the DNA Integrity Number, DIN) or the size of DNA fragments between 
conditions. However, the Genomic DNA ScreenTape system is designed for use on 
isolated DNA, rather than samples containing protein such as those trialled in Figure 64. 
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To confirm these findings DNA was isolated from whole blood using a KingFisher 
extraction system and the above sonication experiment repeated on the isolated DNA. 
Upon inspection of the P200 protein ScreenTape (Figure 65), protein integrity appeared 
consistent across the sonication conditions, with the exception of condition 2.  
 
Figure 65: Results from running samples sonicated at various conditions on P200 ScreenTapes 
to assess protein integrity. Lane A1: protein ladder; Lane B1: sonication condition 1; Lane C1: 
sonication condition 2; Lane D1: sonication condition 3; Lane E1: sonication condition 4; Lane 
F1: sonication condition 5; Lane G1: sonication condition 6; Lane H1: sonication condition 7; 
Lane A2: sonication condition 8; Lane B2: unsonicated sample diluted 1:25; Lane C2: 
unsonicated sample diluted 1:50; Lane D2: unsonicated sample diluted 1:100. Yellow 






DNA was extracted from 3 mL of whole blood from three individuals using MagMAX 
DNA Multi-Sample Ultra 2.0 Kit reagents (ThermoFisher Scientific) and a KingFisher 
Flex machine (ThermoFisher Scientific) according to manufacturer’s instructions. 
Briefly, samples were treated with proteinase K (PK) and PK-enhancer before addition 
of lysis/binding solution to simultaneously denature proteins, lyse cells and capture DNA 
on magnetic binding beads. Wash solution was then used to remove detergents, proteins 
and impurities from the bound nucleic acid and DNA was subsequently eluted from beads 
using a low-TE elution solution.  
Following extraction, isolated DNA (n=3) was separated into aliquots and sonicated 
using Conditions 1-6 and Condition 8 (Condition 7 was omitted due to its similarity to 
Condition 8 – both methods employ use of a water bath), before DNA integrity was 









Figure 66: (A), (B) and (C) Results from running isolated DNA samples sonicated at various 
conditions on Genomic DNA ScreenTapes to assess DNA integrity. DIN = DNA Integrity 
Number, ranging from 1-10, with 10 representing highly in-tact DNA and 1 representing highly 
degraded DNA. A, B and C represent DNA extracted from the whole blood of three different 
individuals. Lane A1: genomic DNA ladder; Lane B1: unsonicated DNA; Lane C1: sonication 
Condition 1; Lane D1: sonication Condition 2; Lane E1: sonication condition 3; Lane F1: 
sonication condition 4; Lane G1: sonication condition 5; Lane H1: sonication condition 6; Lane 
A2: sonication condition 8. Yellow exclamation marks indicate that the sample concentration 
was outside the manufacturers recommended range. 
 
Based on DINs and DNA fragment size, a clear distinction could be made between 
samples which had been sonicated using a microtip, samples which had been sonicated 
in the Omni cup tip attachment and samples which had not been sonicated. The Omni 
cup attachment did not shear DNA or largely decrease the integrity of DNA when 
compared to DNA which had not been sonicated. Across the sonication conditions 
employing a microtip, the DIN and DNA fragment size was largely reduced when 
compared to DNA which had not been sonicated.  
Based on the results of the P200 ScreenTape in Figure 65, the integrity of protein 
appeared consistent across the samples sonicated using a microtip (conditions 1-6), with 
the exception of Condition 2. Therefore, sonication conditions 1, 3, 4, 5 and 6 sufficiently 
sheared DNA whilst preserving the integrity of protein in samples. Condition 3 (20% 
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power, 50% pulse rate, 30 seconds) was selected for use in the following experiments as 
it was the gentlest sonication condition (power) which consistently produced DINs < 2.  
2.2.2 Biognosys	retention	time	standard	peptides	for	mass	spectrometry	















Median Cts for RNA spike-ins across batches appeared consistent, indicating no major 
RNA isolation batch effects (Figure 67).  
 
Figure 67: Median Ct of RNA spike-ins by RNA extraction batch. RNA extraction was performed 
in 7 batches, during which standardised amounts of three RNA spike-ins were added (UniSp2, 
UniSp4, UniSp5). The median Ct value of each spike-in is plotted per batch, with IQRs plotted 
as error bars. This demonstrates large overlap of the medians and IQRs across all batches and 




In the miRNA screen, levels of the RNA spike-ins were relatively uniform across RNA 
batches, suggesting there were no marked RNA extraction batch effects.  However, a 
difference in the means of 7.8 Cts (UniSp2 and UniSp4) and 6.2 Cts (UniSp4 and 
UniSp5) was observed between pairs of RNA spike-ins (Table 54, Figure 68). In contrast 
to UniSp4 and UniSp5, the difference in Cts between UniSp2 and UniSp4 varied slightly 
from the expected 6.6 Ct difference. This suggested the variation from the expected result 
may arise from UniSp2. This could be due to a better extraction efficiency of high 
abundance miRNAs than lower abundance miRNAs (as UniSp2 is the spike-in added at 
the highest concentration), or an error in the concentration of UniSp2 added at this step.  
In contrast, the difference in Ct values between UniSp4 and UniSp5 was very close to 
that expected for transcripts with a 100-fold difference in concentration (6.6 Ct cycles). 
However, the mean Ct difference for the UniSp4 and UniSp5 pair was more variable 
between samples. This may be because UniSp5 is added at a concentration near the limit 
of detection for RTqPCR and transcripts of low abundance result in more varied and less 
consistent Ct values [403].  
Table 54: Raw Ct data for RNA synthetic spike-ins. Medians, IQR and ranges are presented for 
the three synthetic RNA spike-ins added at the RNA extraction step. 
RNA Spike Median IQR Minimum Maximum 
UniSp2 22.0 20.8-26 18.8 28.3 
UniSp4 30.0 28.7-33.7 26.3 36.7 





Figure 68: Number of RTqPCR cycles between RNA spike-ins. At the RNA extraction step, each 
synthetic spike-in was added at a concentration 100-fold less than the previous spike-in, giving 
rise to a predicted 6.6 Ct difference between each pair of spike-ins.  A mean difference of 7.8 Cts 
(UniSp2 and UniSp4) and 6.2 Cts (UniSp4 and UniSp5) was observed between pairs of RNA 
spik- ins.  
 
Based on visual assessment, in samples with a lower concentration of one RNA spike-in 
there were also lower levels of the other two RNA spike-ins, and vice versa (Figure 69). 
In other words, within one sample, the variation in detected spike-in levels was relatively 
consistent across all three RNA spike-ins. This could be due to the presence of PCR 
inhibitors in specific samples (e.g. trace amounts of haemoglobin), which would affect 
all RNA spike-ins equally. Varying levels of inhibitor across plasma samples from the 
cohort could explain the variance observed in the concentrations of RNA spike ins, and 





Figure 69: Number of RTqPCR cycles for synthetic RNA spike-ins. For each sample assayed, the 
raw Ct value of each synthetic RNA spike-in is plotted. It would be expected that for each sample, 
there should be an approximate 6.6 Ct interval between each pair of synthetic spike-ins, and that 
the pattern of variation observed in one spike-in should be reflected in both other spike-ins. 
 
3.2 cDNA	spike-ins	for	screening	study	
Raw data for cDNA spike-ins is presented in Table 55. 
Table 55: Raw Ct data for cDNA synthetic spike-ins. Medians, IQR and ranges are presented for 
the three synthetic cDNA spike-ins added at the cDNA synthesis step. 
cDNA Spike Median IQR Minimum Maximum 
UniSp6 19.3 19-20.8 17.8 21.6 




In cDNA synthesis batch 1, the median Ct difference between spike-ins was 11.2 Cts 
(IQR 10.9-11.6), whilst in batch 2 the median Ct difference between spike-ins was 6.9 
Cts (IQR 6.9-7.1. 
Similar to the RNA spike-ins, visual assessment showed that within each batch, the 
relative abundance of cDNA spike-ins was consistent within samples (Figure 70). This 
could be due to the presence of inhibitors in samples, which would affect all cDNA spike-












Figure 70: Number of RTqPCR cycles for synthetic cDNA spike-ins in cDNA synthesis batch 1 
(A) and batch 2 (B).  For each sample assayed, the raw Ct value of each synthetic cDNA spike-
in is plotted. It would be expected that for each sample, there should be an approximate 6.6 Ct 
interval between UniSp6 and cel-miR-39-3p, and that the pattern of variation observed in one 
spike-in should be reflected in the other spike-in 
 
Comparing the median Ct and IQR for each spike-in between batches demonstrated an 
obvious batch effect during the cDNA synthesis step (Table 56 and Table 57). 
Interestingly, within batch 1 a handful of samples appeared to synthesise efficiently, 
whilst a few samples in batch 2 synthesised poorly (Figure 70). It is possible that we are 
observing a combination of effects resulting from differing enzyme efficiency due to 
environmental conditions, and the presence of inhibitors in specific samples.  
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Table 56: Raw Ct data for cDNA synthetic spike-ins by cDNA synthesis batch. Medians and IQRs 
are presented for the two synthetic cDNA spike-ins added at the cDNA synthesis step. 
cDNA Synthesis Batch UniSp6 Median Ct (IQR) Cel-miR-39-3p Median Ct 
(IQR) 
1 20.8 (20.4-21.1) 31.8 (31.5-32.5) 
2 19 (18.9-19.1) 26 (25.9-26.1) 
 
Table 57: Raw Ct data for endogenous reference miRNAs by cDNA synthesis batch. Medians and 
IQRs are presented for two validated endogenous reference miRNAs, miR-93 and miR-222. 
cDNA synthesis batch miR-93-5p Median Ct 
(IQR) 
miR-222-3p Median Ct 
(IQR) 
1 30.6 (29.9-31.7) 35.1 (34.2-36.1) 
2 25.8 (24.9-26.8) 28.9 (28.2-29.4) 
 
3.3 Endogenous	Reference	microRNAs	in	the	screening	study	
To explore the magnitude of the cDNA synthesis batch effect, the relationship between 
the synthetic spike ins, endogenous reference miRNAs (miR-93-3p and miR-222-3p, 
previously been validated for cardiometabolic phenotypes [248, 249]) and the global 
mean for each sample was assessed (Figure 71). A high global mean indicates more 
miRNA in a sample, whereas a high Ct value for a synthetic spike-in RNA or endogenous 
reference miRNA means a low concentration of that transcript in a sample. Therefore, 
the global mean should inversely reflect the pattern of spike-in and endogenous reference 
miRNAs. 
As visualised in Figure 71, synthetic spike-ins, endogenous reference miRNAs and 
global means behaved consistently within each tested sample. That is, in samples with 
Cts for synthetic spike-ins above the median, the Cts for the endogenous reference 
miRNAs were also above the median. In general, samples with a higher global mean 
(indicating higher mean miRNA content) also had lower Ct values (indicating higher 
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miRNA concentration) for synthetic spike-ins and endogenous reference miRNAs - this 
effect can particularly be seen when comparing cDNA synthesis batch one and batch two 
(Figure 71). This demonstrates consistency in RNA extraction efficiency and cDNA 
synthesis within each sample. Although there was variation in cDNA synthesis efficiency 
between batches, within each individual sample the relationship between the global 
mean, synthetic spike-ins and endogenous reference miRNAs appeared consistent, 
suggesting that in this data set, normalisation may be used to overcome technical 










Figure 71: (A) Cycle threshold values for synthetic spike-ins and endogenous reference miRNAs in cDNA synthesis batch one; (B) Cycle threshold values for 
synthetic spike-ins and endogenous reference miRNAs in cDNA synthesis batch two; (C) global means for samples in cDNA synthesis batch one; (D) global 
means for samples in cDNA synthesis batch two.  In all graphs, samples are ordered from highest to lowest based on the global mean. 
In general, samples in batch two had a higher global mean (higher mean miRNA content) and lower Ct values (higher miRNA concentration) for synthetic 
spike-ins and endogenous reference miRNAs, compared with batch one. UniSp6 (the cDNA spike-in added at the greatest abundance) appeared to amplify at 
approximately the same number of cycles across both batches, but all other spike-ins and reference miRNAs amplified later in cDNA synthesis batch 1, 
suggesting that less abundant miRNAs were less efficiently reverse transcribed. miRNAs of medium and low abundance (e.g. miR-93-3p and miR-222-3p, 





Figure 72: Median Ct and IQR of RNA spike-in UniSp2 by RNA synthesis batch. RNA extraction 
was performed in 20 batches, during which a standardised amount of UniSp2 was added. The 
median Ct value for UniSp2 is plotted per batch, with IQRs plotted as error bars. This 






Figure 73: Median Ct and IQR of cDNA spike-in by cDNA synthesis batch. cDNA synthesis was 
performed in four batches, during which a standardised amount of cel-miR-39-3p was added. 
The median Ct value for cel-miR-39-3p is plotted per batch, with IQRs plotted as error bars. This 







Figure 74 (A) The effect of normalisation on the relative expression of RNA synthetic spike-in 
UniSp2; (B) The effect of normalisation on the relative expression of cDNA synthetic spike-in 
cel-miR-39-3p. For Figures A and B the Log 2 of the miRNAs relative expression is plotted both 




4.1 Comparing	 expression	 levels	 of	 miRNAs	 between	 ADHF	
patients	with	and	without	AKI	in	the	screening	study	
Table 58 Associations between miRNA expression and patient group (ADHF patients with AKI 
versus those without AKI). F statistics and p values for all 135 consistently detected miRNAs are 
presented. 
miRNA F Sig. 
miR-26b-5p 17.155 0 
miR-106a-5p 11.535 0.002 
miR-17-5p 9.41 0.004 
miR-454-3p 8.831 0.005 
let-7g-5p 8.661 0.006 
miR-18a-5p 8.011 0.008 
miR-18b-5p 7.146 0.011 
miR-20a-5p 7.087 0.012 
miR-374b-5p 6.428 0.016 
miR-140-5p 5.732 0.022 
miR-484 5.557 0.024 
miR-382-5p 5.352 0.027 
let-7b-5p 4.897 0.034 
miR-10b-5p 4.171 0.049 
miR-93-5p 4.126 0.05 
miR-584-5p 3.917 0.056 
miR-146a-5p 3.793 0.06 
miR-152-3p 3.458 0.071 
miR-130b-3p 3.025 0.091 
miR-214-3p 2.928 0.096 
miR-125a-5p 2.887 0.098 
miR-320a 2.898 0.098 
miR-99b-5p 2.747 0.106 
 
 339 
miRNA F Sig. 
miR-106b-5p 2.652 0.112 
miR-665 2.661 0.112 
U6-snRNA 2.545 0.12 
miR-26a-5p 2.448 0.127 
let-7d-3p 2.19 0.148 
miR-23b-3p 2.095 0.157 
miR-410-3p 2.009 0.165 
miR-877-5p 1.89 0.178 
miR-92a-3p 1.853 0.182 
miR-30a-5p 1.706 0.2 
miR-378a-3p 1.603 0.214 
miR-125b-5p 1.535 0.224 
miR-215-5p 1.533 0.224 
miR-451a 1.462 0.235 
miR-146b-5p 1.417 0.242 
miR-132-3p 1.325 0.257 
miR-532-5p 1.32 0.258 
miR-193a-5p 1.267 0.268 
miR-192-5p 0.976 0.33 
mIR-590-5p 0.955 0.335 
miR-324-3p 0.914 0.346 
miR-598-3p 0.911 0.346 
miR-139-5p 0.874 0.356 
miR-32-5p 0.836 0.367 
miR-425-3p 0.834 0.367 
miR-7-5p 0.833 0.368 
miR-423-5p 0.829 0.369 
miR-191-5p 0.798 0.378 
let-7f-5p 0.771 0.386 
miR-130a-3p 0.705 0.407 
let-7i-5p 0.694 0.41 
miR-27b-3p 0.653 0.425 
miR-629-5p 0.653 0.425 
miR-27a-3p 0.647 0.427 
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miRNA F Sig. 
miR-103a-3p 0.595 0.446 
miR-374a-5p 0.553 0.462 
let-7d-5p 0.536 0.469 
miR-181b-5p 0.52 0.475 
miR-21-5p 0.517 0.477 
miR-24-3p 0.497 0.485 
miR-126-5p 0.481 0.493 
mIR-23a-3p 0.468 0.498 
miR-144-3p 0.468 0.499 
miR-340-5p 0.456 0.504 
miR-19a-3p 0.451 0.506 
let-7c-5p 0.435 0.514 
miR-143-3p 0.409 0.527 
miR-30b-5p 0.39 0.537 
miR-505-3p 0.367 0.548 
miR-223-3p 0.356 0.555 
let-7a-5p 0.338 0.565 
miR-361-5p 0.323 0.574 
miR-19b-3p 0.321 0.575 
miR-30e-5p 0.299 0.588 
miR-1 0.297 0.589 
miR-142-5p 0.296 0.59 
miR-574-3p 0.29 0.593 
miR-148b-3p 0.287 0.595 
miR-107 0.278 0.601 
miR-15a-5p 0.242 0.626 
miR-150-5p 0.227 0.637 
miR-222-3p 0.211 0.648 
miR-101-3p 0.207 0.652 
miR-328-3p 0.202 0.656 
miR-22-3p 0.179 0.675 
miR-766-3p 0.174 0.679 
miR-194-5p 0.173 0.68 
miR-432-5p 0.167 0.685 
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miRNA F Sig. 
miR-185-5p 0.16 0.692 
miR-376c-3p 0.16 0.692 
miR-375 0.158 0.693 
miR-342-3p 0.112 0.739 
miR-885-5p 0.113 0.739 
miR-425-5p 0.103 0.75 
miR-379-5p 0.098 0.756 
miR-145-5p 0.088 0.769 
miR-16-5p 0.085 0.772 
miR-126-3p 0.078 0.782 
miR-15b-5p 0.076 0.784 
miR-30d-5p 0.076 0.784 
miR-155-5p 0.07 0.793 
miR-140-3p 0.069 0.794 
miR-195-5p 0.067 0.797 
miR-29a-3p 0.059 0.809 
miR-134-5p 0.048 0.828 
miR-186-5p 0.047 0.83 
miR-409-3p 0.047 0.83 
miR-200c-3p 0.046 0.831 
miR-29c-3p 0.046 0.832 
miR-181a-5p 0.04 0.842 
miR-151a-5p 0.039 0.845 
miR-25-3p 0.038 0.847 
miR-142-3p 0.034 0.855 
miR-197-3p 0.033 0.857 
miR-652-3p 0.032 0.86 
miR-30c-5p 0.031 0.862 
miR-363-3p 0.029 0.866 
miR-628-3p 0.021 0.887 
miR-199a-3p 0.02 0.889 
miR-148a-3p 0.017 0.898 
miR-423-3p 0.015 0.904 
miR-376a-3p 0.013 0.909 
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miRNA F Sig. 
mIR-421 0.011 0.918 
miR-98-5p 0.01 0.92 
miR-221-3p 0.009 0.925 
miR-28-5p 0.006 0.936 
let-7e-5p 0.006 0.937 
miR-122-5p 0.005 0.946 
miR-30e-3p 0.004 0.948 
miR-486-5p 0.001 0.974 
miR-151a-3p 0.001 0.977 
miR-92b-3p 0 0.999 
 
4.2 Relative	 expression	 of	 selected	 candidate	 miRNAs	 in	 the	
screening	study	
Table 59: Associations between miRNAs and patient group at the before time point, adjusted for 
chemistry and cDNA synthesis batch. F statistics, effect sizes and p values are presented. 
miRNA F statistic Effect size p value 
let-7g-5p 5.959 0.79 0.002 
miR-18a-5p 7.417 0.88 0.001 
miR-26b-5p 10.366 1.05 <0.001 
miR-106a-5p 7.751 0.9 <0.001 
miR-140-5p 5.207 0.74 0.005 
miR-146a-5p 1.139 1.13 <0.001 
miR-374b-5p 11.337 1.09 <0.001 
miR-382-5p 2.096 0.47 0.119 
miR-454-3p 10.363 1.05 <0.001 






Details of the full model used to test for associations between miRNA expression, age, 
ethnicity and gender. 
Table 60: Details of the full model used to test for associations between the natural log of let-7g-
5p expression, age, ethnicity and gender. 
 Category Adjusted mean 
(95% CI) 
ß coefficient P-value 
Gender Male 0.590 (0.487 – 0.693)  0.928 
 Female 0.583 (0.427 – 0.738)   
Ethnicity NZ European 0.543 (0.423 – 0.664)  0.064 
 Māori 0.481 (0.286 – 0.675)   
 Pasifika 0.453 (0.286 – 0.620)   
 Other 0.868 (0.597 – 1.14)   
Age NA NA -3.23 0.001 
 
Table 61: Details of the full model used to test for associations between the natural log of miR-
18a-5p expression, age, ethnicity and gender. 
 Category Adjusted mean (95% CI) ß coefficient P-value 
Gender Male -0.184 (-0.276 - -0.091)  0.734 
 Female -0.209 (-0.350 - -0.069)   
Ethnicity NZ European -0.184 (-0.292 - -0.076)  0.787 
 Māori -0.269 (-0.444 - -0.094)   
 Pasifika -0.163 (-0.313 - -0.013)   
 Other -0.170 (-0.415 – 0.74)   




Table 62: Details of the full model used to test for associations between the natural log of miR-
26b-5p expression, age, ethnicity and gender. 
 Category Adjusted mean (95% CI) ß coefficient P-value 
Gender Male 0.203 (0.092 – 0.315)  0.773 
 Female 0.230 (0.061 – 0.399)   
Ethnicity NZ European 0.060 (-0.070 – 0.191)  0.010 
 Māori 0.227 (0.016 – 0.439)   
 Pasifika 0.034 (-0.147 – 0.215)   
 Other 0.545 (0.250 – 0.839)   
Age NA NA -0.018 0.001 
 
Table 63: Details of the full model used to test for associations between the natural log of miR-
106a-5p expression, age, ethnicity and gender. 
 Category Adjusted mean (95% CI) ß coefficient P-value 
Gender Male 0.125 (0.045 – 0.206)  0.301 
 Female 0.194 (0.072 – 0.315)   
Ethnicity NZ European 0.083 (-0.11 – 0.178)  0.070 
 Māori 0.115 (-0.037 – 0.267)   
 Pasifika 0.066 (-0.064 – 0.197)   
 Other 0.373 (0.160 – 0.585)   
Age NA NA -0.521 0.603 
 
Table 64: Details of the full model used to test for associations between the natural log of miR-
140-5p expression, age, ethnicity and gender. 
 Category Adjusted mean (95% CI) ß coefficient P-value 
Gender Male -0.932 (-1.16 - -0.709)  0.436 
 Female -1.07 (-1.41 - -0.737)   
Ethnicity NZ European -0.995 (-1.26 - -0.734)  0.765 
 Māori -1.18 (-1.60 - -0.755)   
 Pasifika -1.04 (-1.40 - -0.673)   
 Other -0.805 (-1.39 - -0.216)   
Age NA NA 0.010 0.992 
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Table 65: Details of the full model used to test for associations between the natural log of miR-
146a-5p expression, age, ethnicity and gender. 
 Category Adjusted mean (95% CI) ß coefficient P-value 
Gender Male -0.472 (-0.679 - -0.266)  0.676 
 Female -0.401 (-0.714 - -0.089)   
Ethnicity NZ European -0.492 (-0.734 - -0.251)  0.903 
 Māori -0.515 (-0.906 - -0.124)   
 Pasifika -0.356 (-0.691 - -0.021)   
 Other -0.385 (-0.930 – 0.161)   
Age NA NA -1.61 0.109 
 
Table 66: Details of the full model used to test for associations between the natural log of miR-
374b-5p expression, age, ethnicity and gender. 
 Category Adjusted mean (95% CI) ß coefficient P-value 
Gender Male -0.366 (-0.508 - -0.223)  0.516 
 Female -0.442 (-0.658 - -0.225)   
Ethnicity NZ European -0.485 (-0.652 - -0.318)  0.180 
 Māori -0.429 (0.699 - -0.158)   
 Pasifika -0.168 (-0.400 – 0.064)   
 Other -0.533 (-0.910 - -0.155)   
Age NA NA -1.15 0.250 
 
Table 67: Details of the full model used to test for associations between the natural log of miR-
382-5p expression, age, ethnicity and gender. 
 Category Adjusted mean (95% CI) ß coefficient P-value 
Gender Male 0.017 (-0.148 – 0.182)  0.525 
 Female 0.103 (-0.147 – 0.353)   
Ethnicity NZ European 0.243 (0.049 – 0.436)  0.025 
 Māori 0.081 (-0.232 – 0.394)   
 Pasifika -0.297 (-0.565 - -0.029)   
 Other 0.212 (-0.224 – 0.649)   
Age NA NA -0.717 0.474 
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Table 68: Details of the full model used to test for associations between the natural log of miR-
454-3p expression, age, ethnicity and gender. 
 Category Adjusted mean (95% CI) ß coefficient P-value 
Gender Male -0.132 (-0.265 – 0.002)  0.689 
 Female -0.176 (-0.378 – 0.027)   
Ethnicity NZ European -0.342 (-0.498 - -0.185)  0.028 
 Māori -0.151 (-0.404 – 0.102)   
 Pasifika -0.319 (-0.536 - -0.102)   
 Other 0.197 (-0.156 – 0.550)   
Age NA NA -2.28 0.024 
 
Table 69: Details of the full model used to test for associations between the natural log of miR-
484 expression, age, ethnicity and gender. 
 Category Adjusted mean (95% CI) ß coefficient P-value 
Gender Male 0.262 (0.140 – 0.383)  0.897 
 Female 0.275 (0.090 – 0.459)   
Ethnicity NZ European 0.191 (0.049 – 0.334)  0.384 
 Māori 0.141 (-0.089 – 0.372)   
 Pasifika 0.308 (0.111 – 0.506)   
 Other 0.431 (0.109 – 0.753)   





Table 70: Masterfile of protein data, including the protein name, Uniprot ID and Gene identifier. The median relative intensity for each protein at baseline is 
presented, along with adjusted and unadjusted p values for the change in protein expression between time-points. Adj = adjusted, B= baseline, FC = fold-
change, HF = heart failure, R = recovery. 



























Talin 1 W5PQK6 TLN1 1872686 1.27 Up 0.01 1.06 Down 0.68 1.20 Up 0.22 
Apolipoprotein A4 W5NWM2 APOA4 525843 2.43 Down 0.01 2.20 Up 0.00 1.11 Down 0.65 
NTR domain-containing 
protein W5NUX8 NA 396514 1.77 Up 0.01 1.51 Down 0.07 1.18 Up 0.57 
Filamin A W5P5A0 FLNA 3095750 1.36 Up 0.02 1.16 Down 0.60 1.17 Up 0.59 
Crystallin zeta W5PSF8 CRYZ 27631117 1.22 Down 0.02 1.09 Up 0.60 1.12 Down 0.36 
Aldo_ket_red domain-
containing protein W5PN69 
LOC101
109111 1118677 2.65 Down 0.02 1.03 Up 0.95 2.56 Down 0.07 
Uncharacterised protein W5P4A8 NA 478704 2.04 Up 0.03 1.23 Down 0.61 1.65 Up 0.27 
Dimethylaniline 
monooxygenase [N-oxide-
forming] W5PRR0 FMO3 2494432 1.72 Down 0.04 1.36 Up 0.17 1.27 Down 0.28 
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Uncharacterised protein W5NYA7 
LOC101
114319 40014888 1.37 Down 0.04 1.09 Up 0.73 1.27 Down 0.12 
Solute carrier family 5 
member 12 W5PYF4 
SLC5A1
2 1192670 1.36 Down 0.04 1.10 Up 0.68 1.24 Down 0.22 
Sulfurtransferase W5QCW9 TST 10138606 1.50 Down 0.04 1.13 Up 0.68 1.32 Down 0.22 
Solute carrier family 27 
member 2 W5QIK9 
SLC27A
2 3401376 1.33 Down 0.04 1.24 Up 0.15 1.07 Down 0.57 
T-complex 1 W5P375 TCP1 1586296 1.25 Up 0.04 1.07 Down 0.55 1.17 Up 0.17 
T-complex protein 1 subunit 
gamma W5P765 CCT3 2228153 1.31 Up 0.04 1.10 Down 0.51 1.19 Up 0.07 
Peroxiredoxin W5PAL7 PRDX5 9185835 1.12 Down 0.04 1.13 Up 0.31 1.01 Up 0.97 
Vinculin W5PFI7 VCL 4248304 1.19 Up 0.04 1.05 Down 0.74 1.13 Up 0.39 
Apolipoprotein E W5PI61 APOE 883895 1.41 Up 0.04 1.05 Down 0.87 1.34 Up 0.46 
Chaperonin containing TCP1 
subunit 6A W5PJX0 CCT6A 1421715 1.36 Up 0.04 1.01 Down 0.95 1.35 Up 0.07 
Uncharacterised protein W5PZU9 
LOC101
106720 2502285 1.68 Up 0.04 1.05 Down 0.85 1.59 Up 0.19 
SERPIN domain-containing 
protein W5Q124 NA 7583682 3.69 Up 0.04 1.54 Down 0.46 2.40 Up 0.12 
Peroxiredoxin W5NUE3 PRDX1 11476170 1.25 Down 0.05 1.10 Up 0.75 1.15 Down 0.58 
Chaperonin containing TCP1 
subunit 8 W5PYM5 CCT8 1883766 1.26 Up 0.05 1.07 Down 0.68 1.17 Up 0.28 
Tripeptidyl peptidase 1 W5Q689 TPP1 4556198 1.44 Up 0.05 1.01 Down 0.95 1.43 Up 0.27 
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containing 17 C5IWT7 
TXNDC
17 10176029 1.23 Up 0.05 1.05 Up 0.78 1.30 Up 0.12 
Filamin B W5PT68 FLNB 1145261 1.29 Up 0.05 1.19 Down 0.39 1.08 Up 0.60 
Heat shock protein 90 beta 
family member 1 W5Q4E1 
HSP90B
1 13362558 1.39 Up 0.05 1.18 Down 0.46 1.18 Up 0.26 
Integrin beta W5Q883 ITGB1 2741916 1.24 Up 0.05 1.11 Down 0.60 1.12 Up 0.47 
Dehydrogenase/reductase 1 W5QCV4 DHRS1 469827 1.25 Down 0.05 1.08 Down 0.73 1.35 Down 0.12 
T-complex protein 1 subunit 
delta W5QFZ3 NA 939180 1.20 Up 0.05 1.06 Down 0.61 1.13 Up 0.07 
3-hydroxybutyrate 
dehydrogenase 1 W5QGP1 BDH1 1789312 1.40 Down 0.05 1.07 Up 0.82 1.31 Down 0.26 
PDZ domain containing 1 W5QHA3 PDZK1 11932684 1.27 Down 0.05 1.15 Up 0.46 1.11 Down 0.54 
Polyadenylate-binding protein W5NPI6 PABPC1 2092972 1.24 Up 0.05 1.05 Down 0.75 1.18 Up 0.22 
Cytochrome c oxidase subunit W5P4E7 
COX6B
1 5759602 1.25 Down 0.06 1.03 Down 0.83 1.29 Down 0.17 
Stress induced 
phosphoprotein 1 W5P359 STIP1 2763827 1.28 Up 0.06 1.04 Down 0.83 1.24 Up 0.23 
Clusterin W5PZI1 
LOC101
113728 1062951 1.79 Up 0.06 1.15 Down 0.74 1.56 Up 0.28 
GM2 ganglioside activator W5PF33 GM2A 3864452 2.03 Up 0.06 1.13 Down 0.78 1.79 Up 0.07 
T-complex protein 1 subunit 
eta W5PQF0 CCT7 1116475 1.27 Up 0.07 1.11 Down 0.57 1.14 Up 0.27 
Vimentin (Fragment) A4ZYA6 NA 28226924 1.46 Up 0.07 1.05 Down 0.86 1.39 Up 0.27 
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Collagen type XII alpha 1 
chain W5P8W6 
COL12
A1 5333357 1.50 Up 0.07 1.06 Up 0.87 1.58 Up 0.28 
Proteasome subunit alpha 
type W5PC09 PSMA6 1212259 1.22 Up 0.07 1.15 Down 0.31 1.06 Up 0.54 
Triosephosphate isomerase W5P5W9 TPI1 15509831 1.11 Down 0.07 1.03 Up 0.78 1.08 Down 0.33 
Plastin 3 W5Q6H1 PLS3 475031 1.14 Down 0.08 1.02 Up 0.85 1.11 Down 0.28 
Complement C9 W5PID9 C9 3925351 1.85 Up 0.08 1.12 Down 0.84 1.65 Up 0.42 
Uncharacterised protein W5QDT8 NA 416834 1.16 Up 0.08 1.19 Down 0.13 1.02 Down 0.87 
Heat shock protein alpha A8DR93 HSPCA 8323580 1.37 Up 0.08 1.18 Down 0.46 1.17 Up 0.08 
Alpha-1-B glycoprotein W5P101 A1BG 545156 1.74 Up 0.08 1.49 Down 0.31 1.17 Up 0.57 
Heat shock protein 90 alpha 
family class B member 1 W5PHW0 
HSP90A
B1 1034893 1.37 Up 0.08 1.32 Down 0.15 1.04 Up 0.82 
EH domain containing 1 W5PL84 EHD1 910220 1.07 Up 0.08 1.04 Down 0.68 1.02 Up 0.81 
Uncharacterised protein W5PTE9 NA 3511364 1.41 Up 0.08 1.08 Up 0.85 1.53 Up 0.38 
Cytochrome c oxidase subunit 
5B W5PW27 COX5B 7145200 1.28 Down 0.08 1.07 Up 0.75 1.20 Down 0.36 
Hemopexin W5QAB1 HPX 1641650 2.14 Up 0.08 1.47 Down 0.51 1.45 Up 0.48 
Peptidyl-prolyl cis-trans 
isomerase K4P1S5 PPIA 48688223 1.10 Down 0.08 1.08 Up 0.51 1.02 Down 0.88 
Actin-related protein 2 W5QFG8 ACTR2 3623850 1.22 Up 0.08 1.08 Down 0.60 1.13 Up 0.28 
D-3-phosphoglycerate 
dehydrogenase W5QGS4 PHGDH 3550678 1.68 Down 0.08 1.60 Up 0.07 1.05 Down 0.87 
Solute carrier family 22 
member 8 W5NQX8 
SLC22A
8 316920 1.51 Down 0.08 1.46 Up 0.09 1.04 Down 0.91 
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ribonucleoprotein Sm D3 W5PX22 
SNRPD
3 2265274 1.23 Up 0.08 1.11 Down 0.53 1.11 Up 0.40 
SERPIN domain-containing 
protein W5PHP7 NA 2906461 2.69 Up 0.09 1.59 Down 0.46 1.69 Up 0.18 
Myosin heavy chain 9 W5QBQ9 MYH9 3656952 1.33 Up 0.09 1.13 Down 0.66 1.18 Up 0.39 
NIMA related kinase 9 W5NUK4 NEK9 356228 1.24 Up 0.09 1.13 Down 0.56 1.10 Up 0.63 
Microtubule-associated 
protein W5NXB5 MAP4 1050226 1.21 Up 0.09 1.10 Down 0.73 1.10 Up 0.75 
Acyl-CoA synthetase medium 
chain family member 3 W5PUH2 ACSM3 4203785 1.49 Down 0.09 1.52 Up 0.07 1.02 Up 0.92 
Uncharacterised protein W5P694 RPLP2 3116526 1.16 Up 0.10 1.00 Down 0.95 1.15 Up 0.18 
Lon protease homolog, 
mitochondrial W5P994 LONP1 1913035 1.07 Up 0.10 1.02 Up 0.83 1.10 Up 0.35 
Calbindin 1 W5PKW1 CALB1 25978895 1.46 Down 0.10 1.34 Up 0.34 1.09 Down 0.69 
Apolipoprotein A1 W5NX51 APOA1 9410954 1.50 Down 0.10 1.01 Down 0.95 1.52 Down 0.12 
Actinin alpha 4 W5P707 ACTN4 3204867 1.15 Up 0.10 1.18 Down 0.15 1.02 Down 0.85 
Heat shock protein family A 
(Hsp70) member 5 W5PTR5 HSPA5 7891889 1.29 Up 0.10 1.16 Down 0.46 1.11 Up 0.45 
Succinyl-CoA:3-ketoacid-
coenzyme A transferase W5PGM1 OXCT1 41684823 1.22 Down 0.10 1.22 Up 0.39 1.00 Down 0.99 
Triokinase and FMN cyclase W5PSZ8 TKFC 3127154 1.32 Down 0.10 1.12 Up 0.66 1.18 Down 0.23 
Myosin light chain 6 
(Fragment) B0FZM4 NA 15754666 1.16 Up 0.10 1.11 Down 0.68 1.04 Up 0.89 
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protein 1 W5NYU9 MPP1 674513 1.20 Up 0.10 1.01 Down 0.95 1.19 Up 0.26 
Heterogeneous nuclear 
ribonucleoprotein U W5P4I9 
HNRNP
U 2265994 1.21 Up 0.10 1.11 Down 0.51 1.10 Up 0.47 
60S ribosomal protein L6 W5P1D5 NA 3136659 1.21 Up 0.10 1.05 Down 0.81 1.16 Up 0.36 
Cytochrome b-c1 complex 
subunit 6 B9VH04 UQCRH 722062 1.42 Down 0.10 1.10 Up 0.72 1.29 Down 0.41 
Protein disulfide-isomerase C6JUQ0 PDIA3 6888674 1.18 Up 0.10 1.05 Down 0.79 1.13 Up 0.45 
40S ribosomal protein SA D5HKJ4 RPSA 5407122 1.18 Up 0.10 1.09 Down 0.65 1.08 Up 0.54 
PDZK1 interacting protein 1 W5NZR4 
PDZK1I
P1 1620887 1.22 Down 0.10 1.17 Up 0.46 1.05 Down 0.82 
Transgelin W5P214 TAGLN 7040685 1.36 Up 0.10 1.24 Down 0.60 1.10 Up 0.85 
Uncharacterised protein W5P7Z1 NA 2628221 1.24 Up 0.10 1.09 Down 0.66 1.14 Up 0.28 
2-oxoisovalerate 
dehydrogenase subunit alpha W5PBX9 
BCKDH
A 1599277 1.28 Down 0.10 1.09 Up 0.72 1.17 Down 0.38 
Caldesmon 1 W5PD77 CALD1 2630123 1.21 Up 0.10 1.11 Down 0.65 1.09 Up 0.69 
Collagen type VI alpha 2 
chain W5PTN6 
COL6A
2 334803 1.36 Up 0.10 1.09 Up 0.86 1.49 Up 0.50 
NADH dehydrogenase 
[ubiquinone] flavoprotein 1, 
mitochondrial W5PUX0 
NDUFV
1 703183 1.16 Down 0.10 1.04 Up 0.81 1.11 Down 0.52 
Chaperonin containing TCP1 
subunit 5 W5PXX7 CCT5 516521 1.26 Up 0.10 1.09 Down 0.71 1.15 Up 0.38 
Dopa decarboxylase W5PYB5 DDC 2800577 1.30 Down 0.10 1.05 Up 0.83 1.24 Down 0.36 
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H 4084743 1.60 Down 0.10 1.37 Up 0.58 1.16 Down 0.76 
Solute carrier family 3 
member 2 W5Q8K4 SLC3A2 6098102 1.21 Up 0.10 1.00 Down 0.99 1.21 Up 0.28 
Uncharacterised protein W5Q9M9 GK 1405693 1.36 Up 0.10 1.22 Down 0.51 1.12 Up 0.58 
Splicing factor proline and 
glutamine rich W5QDT2 SFPQ 1578757 1.20 Up 0.10 1.10 Down 0.66 1.09 Up 0.66 
Desmin W5QG29 DES 1512000 1.33 Up 0.10 1.08 Down 0.84 1.23 Up 0.59 
Sodium/potassium-
transporting ATPase subunit 
alpha W5QG59 ATP1A1 29519849 1.19 Down 0.10 1.13 Up 0.46 1.06 Down 0.51 
Moesin W5P4R1 MSN 2306079 1.14 Up 0.11 1.01 Down 0.95 1.13 Up 0.38 
Ribosomal protein L18 W5PQR5 RPL18 2343505 1.18 Up 0.11 1.05 Down 0.76 1.13 Up 0.28 
Malate dehydrogenase 2 W5PW05 MDH2 53842788 1.12 Down 0.11 1.10 Up 0.46 1.01 Down 0.92 
Ribosomal protein S2 W5Q675 RPS2 1711166 1.20 Up 0.11 1.12 Down 0.52 1.07 Up 0.64 
RAB14, member RAS 
oncogene family W5P645 RAB14 1118192 1.15 Up 0.11 1.06 Down 0.65 1.08 Up 0.44 
Uncharacterised protein W5QAY5 RAB10 1644785 1.21 Up 0.11 1.01 Down 0.94 1.20 Up 0.25 
Uncharacterised protein W5P6P4 
LOC101
110647 1857265 1.27 Up 0.11 1.08 Down 0.78 1.18 Up 0.36 
Clathrin heavy chain W5PUT6 CLTC 8608663 1.13 Up 0.11 1.02 Up 0.87 1.14 Up 0.25 
DEAD-box helicase 17 W5Q1M9 DDX17 1305202 1.26 Up 0.11 1.09 Down 0.66 1.16 Up 0.48 
Uncharacterised protein W5NPL9 NA 1911119 1.22 Up 0.11 1.06 Down 0.73 1.14 Up 0.35 
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Uncharacterised protein W5P5Q1 NA 1487902 1.20 Up 0.11 1.08 Down 0.72 1.11 Up 0.63 
Acyl-CoA dehydrogenase 
family member 11 W5PGK3 
ACAD1
1 6453025 1.24 Up 0.11 1.03 Up 0.87 1.28 Up 0.12 
Uncharacterised protein W5QB95 
LOC114
113944 428915 1.22 Up 0.11 1.09 Down 0.66 1.12 Up 0.38 
Pyr_redox_2 domain-
containing protein W5QIQ6 SQOR 888591 1.37 Up 0.11 1.12 Up 0.09 1.54 Up 0.12 
Annexin W5PSZ5 ANXA1 2318295 1.39 Up 0.11 1.07 Down 0.83 1.29 Up 0.36 
Uncharacterised protein W5QE14 PCBP1 5700087 1.14 Up 0.11 1.08 Down 0.51 1.06 Up 0.51 
Argininosuccinate synthase 1 W5PCU1 ASS1 29705038 1.25 Up 0.12 1.12 Down 0.63 1.11 Up 0.51 
Hydroxyacid oxidase 1 W5NPE4 HAO1 1688435 1.32 Down 0.12 1.22 Up 0.46 1.08 Down 0.81 
Hydroxysteroid 17-beta 
dehydrogenase 4 W5NRH5 
HSD17B
4 25575489 1.43 Down 0.12 1.12 Up 0.77 1.27 Down 0.36 
Annexin W5PEC3 ANXA6 1202277 1.17 Up 0.12 1.00 Down 0.99 1.17 Up 0.51 




3 1842435 1.56 Down 0.12 1.16 Up 0.72 1.34 Down 0.47 
Uridine phosphorylase W5PCQ3 UPP2 1728879 1.86 Down 0.12 2.31 Up 0.07 1.24 Up 0.57 
SERPIN domain-containing 
protein W5PHI7 NA 1397612 1.66 Up 0.12 1.56 Down 0.46 1.07 Up 0.92 
Aconitate hydratase, 
mitochondrial W5QAA9 ACO2 21664333 1.18 Down 0.12 1.16 Up 0.44 1.01 Down 0.97 
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Zinc binding alcohol 
dehydrogenase domain 
containing 2 W5P382 ZADH2 1021953 1.10 Down 0.12 1.07 Up 0.54 1.02 Down 0.84 
Uncharacterised protein W5PP95 GLYAT 12316656 1.23 Down 0.12 1.38 Up 0.09 1.12 Up 0.48 
Adducin 1 W5PZG0 ADD1 1080196 1.12 Down 0.12 1.06 Up 0.66 1.05 Down 0.35 
Malate dehydrogenase W5QFQ1 MDH1 49547892 1.12 Down 0.12 1.06 Up 0.65 1.06 Down 0.42 
Fermitin family member 2 W5QIT7 
FERMT
2 596356 1.14 Up 0.12 1.25 Down 0.07 1.09 Down 0.61 
Acetyl-Coenzyme A 
acyltransferase 2 G3CH53 ACAA2 20088641 1.17 Down 0.13 1.05 Up 0.73 1.11 Down 0.42 
Uncharacterised protein W5NVC9 RAC1 3458693 1.09 Up 0.13 1.10 Down 0.31 1.01 Down 0.91 
Erythrocyte membrane 
protein band 4.1 W5NX11 EPB41 170508 1.17 Down 0.13 1.12 Up 0.65 1.05 Down 0.81 
Uncharacterised protein W5PEQ9 NA 1124026 1.13 Up 0.13 1.04 Down 0.84 1.09 Up 0.59 
Ribosomal_L18_c domain-
containing protein W5PF97 NA 620782 1.18 Up 0.13 1.15 Down 0.51 1.03 Up 0.89 
Uncharacterised protein W5PGN1 
HNRNP
K 6102713 1.18 Up 0.13 1.17 Down 0.34 1.00 Up 0.98 
F-actin-capping protein 
subunit beta W5PJ98 CAPZB 648583 1.23 Up 0.13 1.01 Down 0.95 1.22 Up 0.28 
Aldo_ket_red domain-
containing protein W5PJU2 NA 8802960 1.27 Down 0.13 1.06 Down 0.84 1.35 Down 0.16 
Eukaryotic translation 
elongation factor 2 W5PN84 EEF2 4174517 1.17 Up 0.13 1.07 Down 0.71 1.10 Up 0.48 
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Carbonic anhydrase W5PTU7 CA2 43454931 1.15 Up 0.13 1.06 Down 0.78 1.09 Up 0.63 
ST13 Hsp70 interacting 
protein W5Q8I4 ST13 7309807 1.17 Up 0.13 1.07 Down 0.72 1.10 Up 0.44 
ATPase H+ transporting V1 
subunit A W5QDY5 
ATP6V1
A 538849 1.21 Up 0.13 1.01 Down 0.95 1.20 Up 0.25 
Heme binding protein 1 W5QI36 HEBP1 283457 1.43 Down 0.13 1.01 Up 0.95 1.41 Down 0.30 
Acetyl-coenzyme A 
synthetase W5P9I9 ACSS1 2208372 1.40 Down 0.13 1.16 Up 0.48 1.21 Down 0.51 
Ribosomal protein L8 W5PSW9 RPL8 861600 1.29 Up 0.13 1.10 Down 0.73 1.18 Up 0.28 
UBIQUITIN_CONJUGAT_2 
domain-containing protein W5Q2R9 NA 2255917 1.14 Up 0.13 1.00 Down 0.96 1.13 Up 0.43 
Tr-type G domain-containing 
protein W5PHA3 NA 9921191 1.22 Up 0.13 1.12 Down 0.60 1.09 Up 0.48 
14-3-3 protein zeta/delta W5QBD7 
YWHA
Z 4389240 1.15 Up 0.13 1.12 Down 0.65 1.03 Up 0.91 
Uncharacterised protein W5PW62 VDAC1 8052585 1.14 Down 0.13 1.04 Up 0.81 1.10 Down 0.48 
Collagen type VI alpha 3 
chain W5QCP9 
COL6A
3 2366493 1.43 Up 0.13 1.08 Up 0.87 1.54 Up 0.43 
Signal sequence receptor 
subunit 4 W5P940 SSR4 358672 1.38 Up 0.13 1.00 Down 1.00 1.38 Up 0.25 
Acyl-coenzyme A oxidase W5PFE6 ACOX1 990095 1.29 Down 0.13 1.44 Up 0.11 1.12 Up 0.59 
20beta-hydroxysteroid 
dehydrogenase type 2 
A0A088Q7
11 hsd20b2 1831540 1.48 Down 0.13 1.38 Up 0.46 1.07 Down 0.82 
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carboxykinase 1 W5Q7T9 PCK1 2384690 1.30 Down 0.13 1.04 Up 0.87 1.25 Down 0.33 
Tubulointerstitial nephritis 
antigen W5P9S4 TINAG 8317252 1.30 Down 0.14 1.06 Up 0.87 1.23 Down 0.36 
Cytochrome b-c1 complex 
subunit 7 W5P642 UQCRB 3340373 1.11 Down 0.14 1.11 Up 0.68 1.00 Down 0.99 
40S ribosomal protein S25 W5PL43 NA 3712591 1.22 Up 0.14 1.06 Down 0.82 1.15 Up 0.51 
WD repeat domain 1 W5PDL1 WDR1 3133962 1.11 Up 0.15 1.04 Down 0.72 1.06 Up 0.59 
GrpE protein homolog W5PPL5 GRPEL1 144499 1.23 Up 0.15 1.07 Down 0.79 1.15 Up 0.55 
Alpha-2-macroglobulin W5NSA6 A2M 1599274 1.35 Down 0.15 1.03 Down 0.91 1.40 Down 0.12 
40S ribosomal protein S7 W5P5T8 RPS7 1288598 1.18 Up 0.15 1.10 Down 0.60 1.07 Up 0.25 
S4 RNA-binding domain-
containing protein W5NXM4 NA 3328711 1.20 Up 0.15 1.05 Down 0.78 1.13 Up 0.46 
Immunoglobulin heavy 
constant mu W5NXW9 IGHM 2222807 1.71 Up 0.15 1.07 Up 0.87 1.83 Up 0.24 
Dolichyl-
diphosphooligosaccharide--
protein glycosyltransferase 48 
kDa subunit W5PGX0 DDOST 432054 1.15 Up 0.15 1.01 Down 0.93 1.14 Up 0.26 
Proteasome activator subunit 
2 W5QD41 PSME2 211341 1.24 Up 0.15 1.10 Down 0.78 1.12 Up 0.76 
Uncharacterised protein W5PKD3 GNAI2 3847381 1.15 Up 0.16 1.04 Down 0.82 1.10 Up 0.48 
Heat shock protein family A 
(Hsp70) member 8 W5NPN4 HSPA8 2534834 1.27 Up 0.16 1.12 Down 0.70 1.14 Up 0.43 
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Cytochrome c oxidase subunit 
2 E0A2H0 COX2 16660378 1.13 Down 0.16 1.03 Up 0.87 1.10 Down 0.51 
Heterogeneous nuclear 
ribonucleoprotein H3 W5P4I5 
HNRNP
H3 536619 1.15 Up 0.16 1.05 Down 0.78 1.10 Up 0.37 
Catalase W5QB36 CAT 49276376 1.27 Down 0.16 1.13 Up 0.62 1.13 Down 0.58 
AdoHcyase_NAD domain-
containing protein W5PHX1 AHCY 39008823 1.42 Up 0.16 1.10 Down 0.82 1.29 Up 0.38 
Uncharacterised protein W5QGG7 CCT2 2103634 1.17 Up 0.16 1.12 Down 0.46 1.04 Up 0.62 
Peroxiredoxin W5PQA8 PRDX6 31517902 1.10 Down 0.16 1.10 Up 0.51 1.00 Up 0.99 
Dipeptidyl peptidase 4 W5P906 DPP4 1881679 1.43 Up 0.17 1.26 Down 0.58 1.13 Up 0.58 
S-formylglutathione 
hydrolase W5PE27 ESD 1046292 1.13 Down 0.17 1.01 Up 0.95 1.12 Down 0.35 
Histone H2B W5QA51 
HIST1H
2BN 65247109 1.15 Up 0.17 1.03 Up 0.87 1.19 Up 0.38 
Transferrin W5PF65 TF 3285177 1.51 Up 0.17 1.43 Down 0.46 1.06 Up 0.82 
Epoxide hydrolase 2 W5PIU4 EPHX2 4091747 1.18 Down 0.17 1.05 Up 0.85 1.13 Down 0.43 
Cytochrome c oxidase subunit 
4I1 W5PPE8 COX4I1 21205018 1.15 Down 0.17 1.04 Up 0.83 1.11 Down 0.58 
Cathepsin V W5PEY2 CTSV 1774111 1.28 Up 0.17 1.03 Up 0.91 1.32 Up 0.06 
Pyruvate carboxylase W5PG75 PC 12385373 1.19 Down 0.17 1.04 Up 0.82 1.15 Down 0.39 
Hydroxyacyl-CoA 
dehydrogenase W5PEH2 HADH 18410579 1.10 Down 0.17 1.02 Up 0.87 1.08 Down 0.57 
40S ribosomal protein S6 W5PXV8 RPS6 2232088 1.15 Up 0.18 1.12 Down 0.46 1.02 Up 0.85 
Cathepsin C W5P1H0 CTSC 321446 1.40 Up 0.18 1.21 Down 0.68 1.16 Up 0.64 
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Serine dehydratase like W5PBH0 SDSL 5881061 1.25 Up 0.18 1.04 Up 0.87 1.29 Up 0.25 
Ribosomal protein S3 W5PPH6 RPS3 1811792 1.16 Up 0.19 1.10 Down 0.60 1.05 Up 0.73 
Polypyrimidine tract binding 
protein 1 W5PI44 PTBP1 669756 1.19 Up 0.19 1.06 Down 0.81 1.13 Up 0.40 
Pyruvate kinase W5P276 PKLR 3520288 1.16 Down 0.19 1.07 Up 0.46 1.08 Down 0.65 
Glyceraldehyde-3-phosphate 
dehydrogenase D7R7V6 GAPDH 96419208 1.09 Down 0.19 1.02 Up 0.85 1.07 Down 0.55 
Galectin Q6J275 NA 1042513 1.30 Up 0.19 1.17 Down 0.74 1.11 Up 0.84 
Ribosomal protein L32 W5Q000 RPL32 127412 1.33 Up 0.20 1.41 Down 0.52 1.06 Down 0.92 
Pyridoxal kinase W5PNY4 PDXK 1199816 1.13 Down 0.20 1.09 Down 0.60 1.23 Down 0.07 
Cathepsin D (Fragment) C9DFF9 CTSD 9309547 1.31 Up 0.20 1.19 Up 0.68 1.55 Up 0.28 
Calreticulin W5PJG7 CALR 1284905 1.15 Up 0.21 1.11 Down 0.66 1.03 Up 0.88 
Heterogeneous nuclear 
ribonucleoprotein M W5P1D7 
HNRNP
M 2259160 1.23 Up 0.21 1.07 Down 0.82 1.15 Up 0.57 
Stomatin W5P601 STOM 563517 1.14 Up 0.21 1.02 Up 0.93 1.16 Up 0.54 
SH3 domain-containing 
protein W5PJ75 NA 2351296 1.13 Down 0.21 1.02 Up 0.87 1.10 Down 0.26 
Interleukin enhancer binding 
factor 3 W5Q697 ILF3 400080 1.16 Up 0.21 1.05 Down 0.82 1.11 Up 0.28 
Protein kinase C substrate 
80K-H W5QAL0 
PRKCS
H 598116 1.15 Up 0.21 1.21 Down 0.31 1.05 Down 0.71 
Alpha-2-HS-glycoprotein W5QH56 AHSG 1564554 1.98 Up 0.21 1.70 Down 0.51 1.17 Up 0.47 
Adducin 3 W5PHR3 ADD3 603423 1.16 Down 0.21 1.09 Up 0.72 1.07 Down 0.71 
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dimethylaminohydrolase 1 W5PY34 DDAH1 409752 1.20 Down 0.21 1.05 Up 0.85 1.14 Down 0.57 
40S ribosomal protein S3a W5QG75 RPS3A 1083319 1.13 Up 0.21 1.10 Down 0.63 1.03 Up 0.88 
Acyl-CoA dehydrogenase 
short/branched chain W5PHF2 
ACADS
B 4081703 1.11 Down 0.22 1.02 Down 0.87 1.13 Down 0.35 
Succinate dehydrogenase 
[ubiquinone] flavoprotein 




3A 648424 1.11 Up 0.22 1.07 Up 0.82 1.19 Up 0.51 
Cadherin 16 W5NWL5 CDH16 16093335 1.21 Down 0.22 1.24 Up 0.31 1.03 Up 0.85 
Aquaporin-1 W5PD28 AQP1 858885 1.43 Down 0.22 1.11 Down 0.72 1.59 Down 0.28 
Hydroxyacyl-CoA 
dehydrogenase trifunctional 
multienzyme complex subunit 
beta W5QBF9 HADHB 14432432 1.16 Up 0.23 1.04 Up 0.85 1.21 Up 0.38 
Nidogen 1 W5P094 NID1 2461672 1.19 Up 0.23 1.17 Down 0.51 1.01 Up 0.94 
Electron transfer flavoprotein-
ubiquinone oxidoreductase W5P1M1 ETFDH 994344 1.08 Down 0.25 1.01 Down 0.95 1.09 Down 0.48 
Nidogen 2 W5QHQ8 NID2 1859590 1.17 Up 0.25 1.10 Up 0.72 1.29 Up 0.28 
Microtubule-associated 
protein W5PNU3 MAPT 923796 1.11 Down 0.25 1.27 Up 0.31 1.14 Up 0.54 
40S ribosomal protein S8 W5NSP2 RPS8 1395760 1.14 Up 0.25 1.04 Down 0.85 1.10 Up 0.48 
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containing protein W5NW47 NA 794239 1.18 Up 0.25 1.22 Down 0.51 1.03 Down 0.91 
Histone H4 W5QFN3 NA 148215819 1.13 Up 0.25 1.03 Down 0.85 1.10 Up 0.60 
DAB adaptor protein 2 W5PI56 DAB2 5312548 1.14 Up 0.26 1.04 Up 0.83 1.19 Up 0.28 
Uncharacterised protein W5PSQ7 NA 8126954 1.31 Up 0.26 1.22 Up 0.66 1.59 Up 0.25 
Uncharacterised protein W5PUH7 NA 3207989 1.18 Down 0.27 1.05 Up 0.87 1.13 Down 0.51 
Abhydrolase domain 
containing 14B W5P985 
ABHD1
4B 2382613 1.14 Down 0.27 1.02 Down 0.93 1.16 Down 0.28 
Peptidylprolyl isomerase W5PNZ5 FKBP4 1292518 1.11 Up 0.27 1.04 Down 0.82 1.07 Up 0.70 
Mitochondrial ribosomal 
protein S36 W5P6V5 MRPS36 515825 1.16 Down 0.27 1.05 Up 0.86 1.11 Down 0.63 
Prosaposin W5PAJ2 PSAP 27756765 1.33 Up 0.27 1.31 Down 0.54 1.01 Up 0.98 
2,4-dienoyl-CoA reductase 2 W5PQX6 DECR2 4616222 1.19 Down 0.27 1.07 Up 0.84 1.11 Down 0.60 




subunit 1 W5P1S6 NA 1369546 1.09 Up 0.28 1.03 Up 0.83 1.11 Up 0.18 
Uncharacterised protein W5PAT6 NA 327694 1.22 Down 0.28 1.08 Down 0.82 1.31 Down 0.38 
Aminopeptidase W5PFV5 NPEPPS 849441 1.15 Down 0.28 1.09 Up 0.62 1.05 Down 0.72 
Dihydropyrimidine 
dehydrogenase [NADP(+)] W5Q7Y9 DPYD 5117140 1.55 Up 0.28 1.06 Down 0.89 1.46 Up 0.26 
Crystallin lambda 1 W5PWX3 CRYL1 25961221 1.12 Down 0.29 1.17 Up 0.46 1.05 Up 0.80 
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Heat shock protein family D 




NME2 7792718 1.09 Up 0.29 1.02 Down 0.87 1.07 Up 0.57 
Ribosomal protein S18 W5PH51 RPS18 4477047 1.10 Up 0.29 1.07 Down 0.73 1.03 Up 0.89 
Epoxide hydrolase W5Q7Q6 EPHX1 2814027 1.18 Down 0.29 1.14 Up 0.68 1.03 Down 0.91 
CDGSH iron sulfur domain 1 W5PTS5 CISD1 9305272 1.07 Down 0.30 1.07 Up 0.51 1.00 Down 0.99 
Sulfotransferase W5NZJ5 
LOC101
114075 2038158 1.55 Up 0.30 1.28 Down 0.68 1.21 Up 0.45 
Voltage dependent anion 
channel 2 W5PG36 VDAC2 7160291 1.10 Down 0.30 1.01 Up 0.94 1.09 Down 0.51 
TPD52 like 2 W5PJ64 
TPD52L
2 675955 1.16 Up 0.30 1.03 Up 0.89 1.20 Up 0.38 
Methionine 
adenosyltransferase 2 subunit 
beta W5PXJ1 MAT2B 327784 1.11 Up 0.30 1.03 Down 0.87 1.08 Up 0.60 
Proteasome endopeptidase 
complex W5PZ65 PSMA7 1598332 1.10 Up 0.30 1.03 Down 0.83 1.07 Up 0.70 
Aconitase 1 W5PZ94 ACO1 6745925 1.09 Down 0.30 1.05 Up 0.68 1.05 Down 0.77 
D-amino acid oxidase W5Q7P0 DAO 6016076 1.33 Up 0.30 1.11 Down 0.83 1.21 Up 0.58 
Uncharacterised protein W5QB30 NA 678879 1.18 Down 0.30 1.02 Down 0.93 1.20 Down 0.35 
Uncharacterised protein W5P0I6 NA 2631911 1.12 Up 0.30 1.04 Down 0.85 1.08 Up 0.63 
Cysteine and glycine rich 
protein 2 W5PZX1 CSRP2 182611 1.17 Up 0.30 1.24 Down 0.46 1.06 Down 0.87 
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reductase core protein 1 W5Q5G6 
UQCRC
1 7617897 1.11 Down 0.31 1.06 Up 0.68 1.04 Down 0.82 
Aldehyde dehydrogenase W5Q9M1 
ALDH3
A2 1767787 1.17 Down 0.31 1.08 Down 0.68 1.26 Down 0.35 
Sorbitol dehydrogenase W5QIT0 SORD 18829956 1.10 Down 0.31 1.03 Up 0.87 1.08 Down 0.64 
Alpha-methylacyl-CoA 
racemase W5PQJ5 AMACR 1173929 1.27 Down 0.31 1.07 Up 0.81 1.18 Down 0.58 
Sulfurtransferase W5QCZ0 MPST 1473494 1.10 Up 0.31 1.02 Up 0.87 1.13 Up 0.46 
Heterogeneous nuclear 
ribonucleoprotein A2/B1 W5PK95 
HNRNP
A2B1 16467737 1.09 Up 0.32 1.02 Down 0.91 1.08 Up 0.66 
Methylcrotonoyl-CoA 
carboxylase 2 W5P5E2 MCCC2 755388 1.14 Down 0.32 1.13 Up 0.46 1.01 Down 0.97 
Electron transfer flavoprotein 
subunit beta W5PZB6 ETFB 11994523 1.07 Down 0.32 1.07 Up 0.60 1.01 Up 0.97 
Peptidase A1 domain-
containing protein W5P1A3 NA 15249091 1.26 Up 0.33 1.19 Up 0.72 1.50 Up 0.37 
Peptidase D W5P2V3 PEPD 3137668 1.18 Down 0.33 1.06 Up 0.60 1.11 Down 0.68 
Glutaryl-CoA dehydrogenase W5PKD2 GCDH 7947120 1.11 Down 0.33 1.03 Up 0.87 1.08 Down 0.69 
Glutamyl-prolyl-tRNA 
synthetase W5PQF8 EPRS 248946 1.12 Up 0.33 1.03 Down 0.89 1.09 Up 0.68 
Acyl-CoA synthetase medium 
chain family member 1 W5PTQ8 ACSM1 15815219 1.24 Up 0.33 1.20 Up 0.51 1.50 Up 0.04 
Legumain W5PUH5 LGMN 3066439 1.42 Up 0.33 1.34 Down 0.62 1.05 Up 0.89 
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oxidoreductase core subunit 
S1 W5QB34 
NDUFS
1 6025806 1.09 Up 0.33 1.01 Down 0.91 1.07 Up 0.60 




protein theta W5Q0Q1 
YWHA
Q 2575856 1.21 Up 0.33 1.43 Down 0.07 1.18 Down 0.63 
Hydroxysteroid 17-beta 
dehydrogenase 10 W5PF12 
HSD17B
10 6508538 1.13 Down 0.33 1.02 Down 0.90 1.15 Down 0.50 
Aspartyl aminopeptidase W5QG01 DNPEP 1568696 1.13 Up 0.33 1.08 Down 0.73 1.05 Up 0.85 
Serine 
hydroxymethyltransferase W5QB21 SHMT1 9669236 1.14 Up 0.34 1.04 Up 0.86 1.18 Up 0.50 
Ribosomal protein L15 W5P374 NA 109969 1.17 Up 0.35 1.23 Down 0.51 1.05 Down 0.85 
Carboxymethylenebutenolidas
e homolog W5PXJ8 CMBL 1227831 1.19 Down 0.35 1.02 Up 0.94 1.17 Down 0.28 




coenzyme A hydratase 
(Trifunctional protein) alpha 
subunit B6UV59 HADHA 6719433 1.11 Up 0.36 1.03 Up 0.89 1.14 Up 0.57 
Superoxide dismutase W5P340 NA 5472413 1.21 Up 0.36 1.07 Down 0.82 1.12 Up 0.72 
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containing protein W5Q9Z9 RPL4 1373135 1.13 Up 0.36 1.07 Down 0.78 1.06 Up 0.76 
Macrophage migration 
inhibitory factor (Fragment) Q30DR4 MIF 18206385 1.10 Up 0.37 1.13 Down 0.46 1.02 Down 0.91 
Alpha-mannosidase W5PS45 NA 676560 1.17 Down 0.37 1.32 Up 0.46 1.13 Up 0.71 
Acyl-CoA thioesterase 9 W5Q5F5 ACOT9 455421 1.23 Up 0.37 1.04 Down 0.90 1.18 Up 0.77 
Proteasome subunit alpha 
type W5QD30 PSMA5 441726 1.10 Up 0.37 1.05 Down 0.82 1.05 Up 0.70 
Na(+)/H(+) exchange 
regulatory cofactor NHE-RF W5PRP1 
SLC9A3
R1 27482248 1.09 Down 0.37 1.01 Up 0.93 1.07 Down 0.58 
Fructose-1,6-bisphosphatase 1 W5PFR8 FBP1 25156464 1.22 Down 0.39 1.11 Up 0.78 1.10 Down 0.69 
Ribosomal protein S13 W5P4C0 RPS13 2510233 1.08 Up 0.39 1.03 Down 0.83 1.05 Up 0.51 
Delta-aminolevulinic acid 
dehydratase W5P8G0 ALAD 679146 1.15 Down 0.39 1.04 Down 0.85 1.19 Down 0.43 
Uncharacterised protein W5QHQ7 NCL 614549 1.17 Up 0.39 1.11 Down 0.72 1.06 Up 0.75 
Fibrinogen alpha chain W5Q5H8 FGA 3307819 1.59 Up 0.40 1.31 Down 0.74 1.21 Up 0.60 
Aspartoacylase W5Q5Q7 ASPA 4436261 1.16 Down 0.40 1.11 Up 0.69 1.04 Down 0.82 
Heat shock protein family A 
(Hsp70) member 9 W5Q4W8 HSPA9 16933126 1.10 Up 0.40 1.02 Down 0.91 1.08 Up 0.39 




1 1538019 1.17 Up 0.40 1.10 Up 0.68 1.29 Up 0.26 
Histone H2A W5PY18 H2AFV 3168267 1.10 Up 0.40 1.07 Up 0.68 1.18 Up 0.28 
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Apoptosis inducing factor 
mitochondria associated 1 W5Q1F6 AIFM1 8503264 1.07 Up 0.40 1.02 Down 0.87 1.05 Up 0.51 
Mitochondrial fission 1 
protein W5PZP9 FIS1 1641499 1.07 Down 0.40 1.01 Up 0.95 1.07 Down 0.54 
Arp2/3 complex 34 kDa 
subunit W5QDZ3 NA 165781 1.16 Up 0.40 1.11 Down 0.65 1.05 Up 0.85 
Proline dehydrogenase W5P4U5 
PRODH
2 846812 1.27 Up 0.40 1.20 Down 0.68 1.05 Up 0.89 
Uncharacterised protein W5QBS0 NA 1444644 1.09 Down 0.40 1.07 Down 0.72 1.16 Down 0.28 
H1 histone family member 0 W5QGM7 H1F0 1263728 1.15 Down 0.40 1.11 Down 0.78 1.28 Down 0.25 
Uncharacterised protein W5QD93 
LOC101
119050 33782720 1.13 Down 0.40 1.06 Down 0.83 1.20 Down 0.36 
Aminotran_1_2 domain-
containing protein W5Q1I4 NA 1239515 1.36 Up 0.40 1.16 Down 0.83 1.18 Up 0.82 
NADH:ubiquinone 
oxidoreductase subunit B4 W5QF73 
NDUFB
4 3290986 1.08 Down 0.40 1.06 Up 0.51 1.02 Down 0.92 
Pyruvate dehydrogenase E1 
component subunit alpha W5PYS5 PDHA1 2725269 1.15 Down 0.40 1.09 Up 0.66 1.05 Down 0.85 
Phosphoenolpyruvate 
carboxykinase 2, 
mitochondrial W5QD66 PCK2 23198104 1.15 Down 0.40 1.04 Down 0.89 1.19 Down 0.25 
Heat shock protein family A 
(Hsp70) member 12A W5Q7Q4 
HSPA12
A 2875389 1.07 Up 0.41 1.07 Down 0.68 1.00 Up 1.00 
RAS like proto-oncogene A W5Q8A7 RALA 473143 1.09 Up 0.41 1.02 Up 0.87 1.11 Up 0.25 
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2 754213 1.20 Down 0.41 1.07 Up 0.82 1.11 Down 0.62 
Sorting nexin 2 W5QCB0 SNX2 1752871 1.06 Up 0.42 1.07 Up 0.71 1.14 Up 0.38 
Acetyl-CoA acetyltransferase 
1 W5PN85 ACAT1 8814660 1.12 Down 0.42 1.08 Down 0.72 1.21 Down 0.39 
Glyoxalase domain-
containing protein 4 
A0A5C2D1
47 GLOD4 2246692 1.12 Down 0.42 1.11 Up 0.66 1.01 Down 0.98 
VAMP associated protein B 
and C W5Q6Q7 VAPB 279234 1.10 Down 0.42 1.15 Up 0.46 1.05 Up 0.79 
Leucine aminopeptidase 3 W5NZQ2 LAP3 13115029 1.07 Down 0.43 1.12 Up 0.31 1.05 Up 0.63 
Aldehyde dehydrogenase 8 
family member A1 W5PZD2 
ALDH8
A1 3392589 1.23 Down 0.43 1.19 Up 0.68 1.04 Down 0.91 
4-hydroxyphenylpyruvate 
dioxygenase W5PSL9 HPD 14636032 1.10 Up 0.43 1.05 Down 0.83 1.04 Up 0.85 
Cell division cycle 37 W5Q3Q7 CDC37 352869 1.08 Up 0.44 1.07 Down 0.72 1.01 Up 0.91 
Glyoxylate and 
hydroxypyruvate reductase W5PPD5 GRHPR 1894333 1.15 Down 0.44 1.11 Up 0.75 1.04 Down 0.81 
Rab GDP dissociation 
inhibitor C5IJ88 NA 1181164 1.09 Up 0.44 1.01 Down 0.95 1.08 Up 0.74 
Propionyl-CoA carboxylase 
subunit beta W5PDK7 PCCB 3231042 1.11 Up 0.44 1.08 Up 0.74 1.20 Up 0.35 
Annexin W5QEU6 ANXA4 3304758 1.15 Up 0.44 1.14 Down 0.65 1.01 Up 0.97 
RNA helicase W5P7B0 DDX31 579581 1.09 Up 0.44 1.05 Down 0.83 1.04 Up 0.85 
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Chromosome 21 open reading 
frame 33 C5IWT4 
C21orf3
3 6445269 1.08 Down 0.44 1.14 Up 0.46 1.06 Up 0.78 
Uncharacterised protein W5PJY3 
LOC114
116858 510763 1.11 Up 0.44 1.17 Down 0.46 1.05 Down 0.81 
Lamin B1 W5Q9T3 LMNB1 1291824 1.10 Up 0.44 1.02 Down 0.91 1.08 Up 0.71 
Uncharacterised protein W5QEA9 ATP5PB 5392147 1.08 Down 0.45 1.01 Up 0.94 1.07 Down 0.70 
2-amino-3-carboxymuconate-
6-semialdehyde 
decarboxylase W5PNY8 ACMSD 1818299 1.33 Down 0.45 1.12 Up 0.85 1.18 Down 0.70 
Aldo_ket_red domain-
containing protein W5PJJ7 NA 7815614 1.16 Down 0.45 1.05 Down 0.87 1.22 Down 0.28 
GTP-binding nuclear protein 
Ran C5IJA0 RAN 1236778 1.13 Up 0.45 1.14 Down 0.60 1.00 Down 0.99 
Alpha-1-
microglobulin/bikunin 
precursor W5P812 AMBP 3902403 1.35 Up 0.45 1.36 Up 0.60 1.85 Up 0.22 
Isovaleryl-CoA 
dehydrogenase W5QG64 IVD 6076337 1.12 Down 0.45 1.07 Up 0.79 1.05 Down 0.90 
Fumarate hydratase C5IWV1 FH 8527263 1.05 Up 0.45 1.08 Up 0.68 1.12 Up 0.43 
Peroxiredoxin C8BKC5 PRDX2 8998310 1.07 Up 0.45 1.04 Down 0.82 1.03 Up 0.90 
Enolase 1 W5PIG7 ENO1 24654533 1.04 Up 0.46 1.05 Down 0.72 1.01 Down 0.92 
Aldedh domain-containing 
protein W5PLV2 ALDH2 4689336 1.17 Down 0.46 1.11 Down 0.75 1.30 Down 0.25 
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family member 8 W5PW04 ACAD8 586198 1.10 Down 0.46 1.07 Up 0.78 1.03 Down 0.88 
Ubiquinol-cytochrome c 
reductase core protein 2 W5Q0F9 
UQCRC
2 8616631 1.08 Down 0.46 1.08 Up 0.66 1.01 Down 0.97 
Aldo-keto reductase family 1 
member A1 W5NUN8 
AKR1A
1 34846036 1.08 Down 0.46 1.04 Up 0.72 1.03 Down 0.85 
Uncharacterised protein W5PC25 
LOC101
116273 4084971 1.11 Down 0.47 1.17 Up 0.51 1.05 Up 0.72 
ETHE1 persulfide 
dioxygenase W5PFR7 ETHE1 1764164 1.11 Down 0.47 1.01 Up 0.95 1.11 Down 0.50 
Stomatin like 2 W5PRD7 
STOML
2 543600 1.11 Up 0.47 1.03 Down 0.87 1.07 Up 0.58 
MICOS complex subunit 
MIC60 W5QHI0 IMMT 4361142 1.09 Up 0.47 1.04 Down 0.85 1.05 Up 0.72 
Fructose-bisphosphate 
aldolase W5PCA0 ALDOB 64895329 1.09 Down 0.47 1.03 Down 0.85 1.13 Down 0.36 
Quinoid dihydropteridine 
reductase W5PKX5 QDPR 10566822 1.06 Down 0.47 1.17 Up 0.46 1.11 Up 0.60 
Fibrinogen gamma chain W5Q5A6 FGG 1232445 1.50 Up 0.47 1.38 Down 0.72 1.09 Up 0.85 
Villin 1 W5QE76 VIL1 11687942 1.10 Down 0.47 1.01 Down 0.95 1.11 Down 0.56 
Tubulointerstitial nephritis 
antigen like 1 W5NTG6 
TINAG
L1 173324 1.29 Down 0.48 1.03 Down 0.95 1.33 Down 0.36 
Fructose-bisphosphate 
aldolase W5P1X9 ALDOA 4873534 1.07 Down 0.48 1.05 Up 0.83 1.02 Down 0.92 
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Aldehyde dehydrogenase 6 
family member A1 W5NS43 
ALDH6
A1 20041848 1.07 Up 0.48 1.02 Up 0.87 1.09 Up 0.51 
Aminomethyltransferase W5PWD5 AMT 749542 1.10 Down 0.48 1.11 Up 0.72 1.00 Up 0.99 
COX6C domain-containing 
protein W5PXG3 NA 1395182 1.11 Up 0.49 1.09 Down 0.62 1.02 Up 0.95 
Isochorismatase domain 
containing 1 W5Q691 ISOC1 1769369 1.05 Down 0.49 1.14 Up 0.46 1.08 Up 0.57 
Cell division cycle 42 W5PE11 CDC42 2097182 1.07 Up 0.49 1.07 Down 0.72 1.00 Up 0.99 
Uncharacterised protein W5PHR0 NA 15440987 1.07 Down 0.49 1.02 Up 0.90 1.05 Down 0.56 
Glutathione peroxidase W5PDJ6 GPX3 55140314 1.12 Down 0.49 1.02 Up 0.93 1.10 Down 0.75 
Ornithine aminotransferase W5PK12 OAT 1164709 1.15 Up 0.49 1.10 Up 0.83 1.26 Up 0.50 
Aspartate aminotransferase W5PS88 GOT1 3220934 1.06 Up 0.49 1.01 Down 0.93 1.05 Up 0.65 
Uncharacterised protein W5PG64 BSG 2363417 1.08 Up 0.49 1.06 Down 0.78 1.02 Up 0.91 
Transketolase W5Q5G8 TKT 10628391 1.11 Up 0.50 1.10 Down 0.68 1.01 Up 0.97 
Acyl-CoA dehydrogenase 
long chain W5QD03 ACADL 3085073 1.08 Down 0.50 1.12 Up 0.63 1.04 Up 0.82 
Acyl-coenzyme A oxidase W5PTR6 ACOX3 1612744 1.13 Down 0.51 1.01 Up 0.95 1.12 Down 0.57 
Uncharacterised protein W5NRA9 NA 262407 1.17 Up 0.51 1.07 Down 0.86 1.09 Up 0.82 
Methylmalonyl-CoA mutase W5PR64 MMUT 3905063 1.11 Down 0.51 1.32 Up 0.09 1.20 Up 0.07 
Vesicle amine transport 1 W5P363 VAT1 16919013 1.09 Up 0.52 1.02 Down 0.89 1.06 Up 0.60 
4-aminobutyrate 
aminotransferase W5P5B2 ABAT 1025409 1.10 Down 0.52 1.04 Up 0.85 1.05 Down 0.81 
RAS oncogene family-like 7A B2LYK6 RAB7A 1442501 1.03 Up 0.53 1.01 Down 0.89 1.02 Up 0.82 
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Cubilin W5PJU0 CUBN 3934496 1.06 Down 0.53 1.07 Up 0.73 1.01 Up 0.97 
3-hydroxy-3-methylglutaryl-
CoA lyase W5PAS5 HMGCL 435047 1.08 Up 0.53 1.02 Up 0.91 1.09 Up 0.63 
Methionine sulfoxide 
reductase A W5Q0D6 MSRA 1418751 1.11 Down 0.53 1.06 Up 0.78 1.05 Down 0.84 
Arginyl aminopeptidase W5NQ97 RNPEP 12580727 1.07 Down 0.53 1.04 Down 0.85 1.12 Down 0.53 
Fumarylacetoacetate 
hydrolase domain containing 
2A W5PXA6 
FAHD2
A 13006689 1.09 Down 0.53 1.10 Up 0.60 1.01 Up 0.97 
Heparan sulfate proteoglycan 
2 W5PEL7 HSPG2 11542868 1.09 Down 0.53 1.05 Up 0.87 1.04 Down 0.91 
Biliverdin reductase A W5Q633 BLVRA 1170654 1.12 Up 0.53 1.25 Down 0.46 1.12 Down 0.58 
Superoxide dismutase [Cu-
Zn] B9VGZ6 SOD1 7250865 1.11 Down 0.54 1.04 Up 0.87 1.07 Down 0.81 
G protein subunit alpha 11 W5PU75 GNA11 904515 1.06 Up 0.54 1.04 Down 0.83 1.03 Up 0.89 
40S ribosomal protein S4 W5Q8J9 RPS4X 2228379 1.09 Down 0.54 1.04 Up 0.72 1.05 Down 0.85 
EH domain containing 4 W5QGX7 EHD4 802829 1.07 Down 0.54 1.11 Up 0.44 1.04 Up 0.82 
Uncharacterised protein W5NRG0 PTGR2 2447207 1.09 Down 0.54 1.05 Down 0.87 1.15 Down 0.53 
Tropomyosin 2 W5PQL4 TPM2 3072577 1.15 Up 0.54 1.23 Down 0.66 1.07 Down 0.89 
Glutathione S-transferase W5QDF4 GSTM3 860227 1.24 Down 0.54 1.18 Up 0.72 1.05 Down 0.92 
Peroxiredoxin W5NUN0 PRDX3 16287595 1.11 Down 0.55 1.09 Up 0.78 1.01 Down 0.95 
Succinate dehydrogenase 
complex iron sulfur subunit B W5PNR7 SDHB 6882937 1.08 Up 0.55 1.03 Up 0.87 1.11 Up 0.51 
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Chromosome 11 open reading 
frame 54 W5NVR9 
C11orf5
4 8614736 1.09 Down 0.55 1.16 Down 0.46 1.27 Down 0.38 
Aldehyde dehydrogenase 1 
family member L1 W5P8S8 
ALDH1
L1 9530455 1.12 Down 0.55 1.13 Up 0.60 1.01 Up 0.95 
Glycoprotein nmb W5PT76 GPNMB 5834066 1.17 Up 0.55 1.22 Up 0.73 1.42 Up 0.57 
Cytochrome c1 W5Q0A9 CYC1 3552971 1.08 Down 0.55 1.06 Up 0.82 1.02 Down 0.92 
NADH:ubiquinone 
oxidoreductase subunit B7 W5P5V3 
NDUFB




A1 222754 1.22 Down 0.57 1.06 Up 0.87 1.15 Down 0.80 
SLC25A3 B7U168 
SLC25A
3 9625138 1.10 Down 0.58 1.01 Down 0.95 1.11 Down 0.66 
Calmodulin W5P5I7 CALM2 1329489 1.09 Up 0.58 1.01 Up 0.97 1.09 Up 0.78 
Myosin heavy chain 11 W5PGT0 MYH11 519231 1.13 Up 0.58 1.24 Down 0.62 1.10 Down 0.78 
SMB domain-containing 
protein W5Q9D5 NA 1942907 1.20 Up 0.58 1.12 Up 0.83 1.35 Up 0.48 
NADH dehydrogenase 
[ubiquinone] 1 alpha 
subcomplex subunit 2 W5QAH8 
NDUFA
2 2367904 1.05 Up 0.58 1.00 Down 0.99 1.05 Up 0.80 
Mitochondrial amidoxime 
reducing component 2 W5PUD8 Mar-02 7825087 1.08 Up 0.58 1.02 Down 0.94 1.06 Up 0.80 
ATP synthase subunit e, 
mitochondrial W5PF18 
LOC101
102454 4688775 1.05 Down 0.58 1.08 Up 0.66 1.03 Up 0.85 
 
 373 




























CoA reductase W5QDI9 PECR 5069577 1.07 Down 0.58 1.22 Up 0.21 1.14 Up 0.51 
Transgelin W5PE01 
TAGLN
2 4893506 1.06 Down 0.58 1.08 Up 0.82 1.02 Up 0.94 
Ribosomal protein S19 W5PEV6 RPS19 531414 1.06 Up 0.58 1.08 Down 0.68 1.03 Down 0.86 
Serum albumin W5PWE9 ALB 99276819 1.13 Down 0.58 1.06 Down 0.85 1.19 Down 0.44 
Oxoglutarate dehydrogenase W5PZR4 OGDH 6264148 1.06 Up 0.58 1.03 Up 0.83 1.10 Up 0.56 
11 beta-hydroxysteroid 
dehydrogenase type 2 O19059 
11 beta -
HSD2 2419926 1.07 Up 0.58 1.10 Up 0.75 1.18 Up 0.48 
Elongation factor Tu W5NWF7 TUFM 8336202 1.04 Up 0.58 1.02 Up 0.85 1.06 Up 0.54 
D-aspartate oxidase W5PK01 DDO 857162 1.20 Down 0.58 1.10 Up 0.86 1.09 Down 0.87 
Succinate--CoA ligase [GDP-
forming] subunit beta, 
mitochondrial W5PL67 
SUCLG
2 15419371 1.04 Down 0.59 1.04 Up 0.83 1.00 Down 0.99 
Hydroxysteroid 17-beta 
dehydrogenase 14 W5PRQ8 
HSD17B
14 2071937 1.10 Down 0.59 1.13 Up 0.68 1.03 Up 0.92 
Phosphoglycerate kinase B7TJ13 PGK1 8385796 1.05 Down 0.59 1.08 Up 0.65 1.02 Up 0.82 
Karyopherin subunit beta 1 W5PF71 KPNB1 520652 1.06 Up 0.59 1.05 Down 0.82 1.01 Up 0.97 
Acetyltransferase component 
of pyruvate dehydrogenase 
complex W5Q2C5 NA 2247715 1.06 Up 0.59 1.06 Up 0.78 1.12 Up 0.44 
Uncharacterised protein W5Q9Y3 
SLC25A
10 3176463 1.07 Down 0.59 1.07 Up 0.72 1.00 Down 0.98 
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dioxygenase W5QF94 HGD 2061370 1.08 Down 0.59 1.08 Down 0.72 1.17 Down 0.28 
NADH:ubiquinone 
oxidoreductase subunit S5 W5QFF9 
NDUFS
5 880620 1.08 Up 0.59 1.05 Up 0.85 1.13 Up 0.62 
14_3_3 domain-containing 
protein W5PRN8 NA 4050727 1.06 Up 0.60 1.08 Down 0.72 1.01 Down 0.92 
Aspartate dehydrogenase 





synthetase 1 W5QJ31 
MTHFD
1 3731196 1.05 Down 0.60 1.08 Up 0.71 1.03 Up 0.87 
Glutamate dehydrogenase W5NRK4 GLUD1 2765622 1.05 Up 0.61 1.06 Down 0.74 1.01 Down 0.97 
Guanine nucleotide-binding 
protein subunit gamma W5PP04 GNG12 1299673 1.08 Down 0.61 1.07 Down 0.78 1.15 Down 0.44 
Pyruvate kinase W5QC41 PKM 5005760 1.06 Up 0.61 1.01 Down 0.95 1.05 Up 0.84 
Carboxylic ester hydrolase W5NX87 CES2 1396272 1.11 Down 0.62 1.10 Down 0.78 1.23 Down 0.28 
Ubiquinol-cytochrome c 
reductase, complex III subunit 
X W5P6B2 
UQCR1
0 1437345 1.09 Down 0.62 1.07 Down 0.71 1.17 Down 0.56 
Glycine amidinotransferase W5QIR6 GATM 2849967 1.17 Down 0.62 1.00 Down 1.00 1.17 Down 0.85 
Uncharacterised protein W5PD03 NA 2216177 1.03 Up 0.62 1.01 Up 0.93 1.05 Up 0.71 
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Translocase of outer 
mitochondrial membrane 70 W5Q9E1 
TOMM7
0 1344556 1.03 Down 0.62 1.02 Down 0.82 1.05 Down 0.55 
Serine--pyruvate 
aminotransferase W5QAB6 AGXT 3590707 1.11 Up 0.62 1.08 Up 0.82 1.20 Up 0.51 
Proline and arginine rich end 
leucine rich repeat protein W5NUA0 PRELP 991369 1.09 Up 0.63 1.08 Up 0.84 1.18 Up 0.60 
Sterol carrier protein 2 W5P7N5 SCP2 12916629 1.12 Up 0.64 1.06 Down 0.85 1.06 Up 0.81 
Succinate--CoA ligase [ADP-
forming] subunit beta, 
mitochondrial W5PEA4 
SUCLA
2 1614320 1.08 Down 0.64 1.01 Up 0.97 1.08 Down 0.82 
Peptidase M20 domain-
containing protein 2 W5PTG8 PM20D2 835224 1.07 Down 0.64 1.06 Up 0.82 1.01 Down 0.97 
Ferritin W5PVJ0 NA 5202008 1.47 Down 0.64 2.46 Up 0.47 1.67 Up 0.63 
Isocitrate dehydrogenase 
[NADP] W5QCD6 IDH1 13682366 1.18 Up 0.64 1.06 Down 0.89 1.11 Up 0.81 
Peptidyl-prolyl cis-trans 




H 1536985 1.07 Up 0.66 1.03 Down 0.87 1.04 Up 0.89 
Pyrophosphatase (inorganic) 2 W5PL66 PPA2 1378149 1.06 Down 0.66 1.04 Up 0.84 1.02 Down 0.92 
S-(hydroxymethyl)glutathione 
dehydrogenase W5Q2F4 ADH5 827800 1.06 Down 0.67 1.02 Down 0.89 1.08 Down 0.46 
Chloride intracellular channel 
protein W5P8X9 CLIC4 4600253 1.04 Up 0.67 1.04 Down 0.75 1.00 Up 0.99 
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Secernin 2 W5PDD6 SCRN2 347864 1.06 Down 0.67 1.15 Up 0.68 1.09 Up 0.81 
ATP synthase subunit d, 
mitochondrial W5PP37 ATP5PD 11013067 1.04 Down 0.67 1.03 Up 0.83 1.01 Down 0.97 
Cystathionine gamma-lyase W5PQY4 CTH 2804806 1.08 Up 0.67 1.14 Down 0.60 1.05 Down 0.86 
Aspartate aminotransferase W5NUG0 GOT2 4541011 1.06 Down 0.68 1.05 Up 0.81 1.01 Down 0.97 
Amine oxidase W5NZA9 MAOB 16137040 1.06 Down 0.69 1.07 Up 0.78 1.02 Up 0.92 
Uncharacterised protein W5P1W7 NA 1691637 1.08 Up 0.69 1.07 Down 0.82 1.01 Up 0.97 
Parkinsonism associated 
deglycase W5PK66 PARK7 7296685 1.04 Down 0.69 1.03 Down 0.83 1.08 Down 0.54 
Uncharacterised protein W5Q1T4 NA 24963682 1.05 Up 0.69 1.00 Up 0.99 1.05 Up 0.85 
Cytochrome c oxidase subunit 
5A W5NXT8 COX5A 7629269 1.05 Down 0.70 1.01 Up 0.95 1.03 Down 0.84 
6-phosphogluconate 
dehydrogenase, 
decarboxylating W5P5M3 PGD 3188281 1.02 Up 0.70 1.07 Up 0.45 1.09 Up 0.27 
Uncharacterised protein W5NZM0 NA 1162555 1.09 Down 0.70 1.04 Down 0.85 1.14 Down 0.69 
Prohibitin W5P7Q3 PHB 8050437 1.02 Down 0.70 1.02 Up 0.86 1.00 Down 0.97 
Keratin 8 W5Q5N9 KRT8 4529509 1.09 Up 0.70 1.10 Up 0.77 1.19 Up 0.43 
B-cell receptor-associated 
protein W5PB89 BCAP31 1339962 1.06 Up 0.71 1.06 Down 0.78 1.00 Down 0.98 
Uncharacterised protein W5NRY1 NA 60111267 1.05 Up 0.71 1.00 Down 0.98 1.05 Up 0.78 
OCIA domain containing 2 W5Q9Q8 OCIAD2 1250435 1.07 Up 0.71 1.21 Down 0.46 1.13 Down 0.64 
GLOBIN domain-containing 
protein W5QCY8 NA 28246865 1.18 Up 0.71 2.00 Down 0.46 1.69 Down 0.28 
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Leucine zipper and EF-hand 
containing transmembrane 
protein 1 W5Q2P3 LETM1 305992 1.08 Up 0.71 1.11 Up 0.78 1.20 Up 0.54 
Acyl-CoA synthetase short 
chain family member 3 W5Q0R0 ACSS3 3303733 1.05 Down 0.72 1.11 Up 0.69 1.06 Up 0.80 
Rho GDP dissociation 
inhibitor alpha W5Q9B2 
ARHGD
IA 1633108 1.05 Up 0.72 1.05 Down 0.82 1.00 Down 0.98 




H 49825576 1.06 Down 0.72 1.15 Up 0.65 1.08 Up 0.63 
GTP:AMP 
phosphotransferase AK3, 
mitochondrial W5PVD4 AK3 9844075 1.05 Down 0.72 1.01 Down 0.95 1.07 Down 0.75 
Phospholysine 
phosphohistidine inorganic 
pyrophosphate phosphatase W5PKU1 LHPP 1042387 1.05 Down 0.72 1.07 Up 0.68 1.02 Up 0.92 
Xylulokinase W5NT64 XYLB 1289076 1.08 Down 0.73 1.08 Down 0.81 1.16 Down 0.58 
N-
ribosyldihydronicotinamide:q
uinone reductase 2 W5NUJ5 NQO2 4279219 1.06 Up 0.73 1.06 Down 0.85 1.00 Down 0.99 
Glucose-6-phosphate 
isomerase W5P323 GPI 5185361 1.05 Down 0.73 1.09 Up 0.66 1.04 Up 0.70 
MISP family member 3 W5P9M1 MISP3 1154257 1.07 Down 0.73 1.01 Up 0.95 1.05 Down 0.85 
Valosin containing protein W5PRJ4 VCP 4880968 1.04 Up 0.73 1.09 Up 0.68 1.14 Up 0.35 
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Solute carrier family 25 
member 1 W5Q718 
SLC25A
1 2472810 1.04 Down 0.73 1.03 Up 0.83 1.00 Down 0.98 
Tetratricopeptide repeat 
domain 38 W5QDU4 TTC38 6227551 1.08 Up 0.73 1.06 Up 0.85 1.14 Up 0.64 
Uncharacterised protein W5PW57 
LOC101
114408 2014025 1.10 Down 0.73 1.01 Up 0.97 1.10 Down 0.80 
Uncharacterised protein W5NV97 NA 2978797 1.02 Down 0.73 1.03 Up 0.82 1.00 Up 0.97 
Pipecolic acid and sarcosine 
oxidase W5P674 PIPOX 1381731 1.08 Up 0.73 1.03 Down 0.93 1.05 Up 0.82 
MICOS complex subunit W5P9X2 
CHCHD
3 1452206 1.05 Down 0.73 1.08 Up 0.75 1.04 Up 0.90 
Beta-2-microglobulin A4ZVY8 NA 2928610 1.06 Up 0.74 1.37 Up 0.07 1.45 Up 0.12 
Enoyl-CoA delta isomerase 2 W5NQ36 ECI2 1297677 1.10 Up 0.74 1.08 Up 0.83 1.19 Up 0.63 
Enoyl-CoA hydratase, short 
chain 1 W5NQC6 ECHS1 806545 1.07 Down 0.74 1.01 Down 0.95 1.08 Down 0.71 
Ubiquitin-like domain-
containing protein W5NX91 RPS27A 2508592 1.05 Up 0.74 1.02 Up 0.94 1.07 Up 0.75 
Calnexin W5NYZ5 CANX 1170715 1.07 Up 0.74 1.21 Down 0.60 1.13 Down 0.52 
Glutamate-cysteine ligase 
catalytic subunit W5PAX1 GCLC 503219 1.05 Down 0.74 1.01 Up 0.95 1.04 Down 0.91 
Phosphoglucomutase 2 W5PJD0 PGM2 639181 1.06 Up 0.74 1.03 Down 0.89 1.03 Up 0.89 
Isocitrate dehydrogenase 
[NADP] W5PR04 IDH2 44965126 1.02 Down 0.74 1.04 Up 0.73 1.02 Up 0.91 
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carrier W5PS50 MPC2 747146 1.04 Down 0.74 1.08 Up 0.61 1.04 Up 0.81 
Glutathione S-transferase 
kappa W5Q894 GSTK1 4614506 1.06 Down 0.74 1.05 Down 0.87 1.11 Down 0.71 
Lysophospholipase I W8R447 
LYPLA
1 14065114 1.03 Down 0.74 1.06 Up 0.66 1.03 Up 0.84 
L-lactate dehydrogenase W5QGD1 NA 44597767 1.04 Down 0.74 1.03 Up 0.85 1.01 Down 0.97 
N-myc downstream regulated 
1 W5P5W6 NDRG1 10606203 1.07 Up 0.74 1.18 Down 0.51 1.10 Down 0.67 
Cortactin W5NQM5 CTTN 2861751 1.03 Up 0.74 1.08 Down 0.82 1.04 Down 0.90 
Prostaglandin reductase 1 W5P9M2 PTGR1 6088952 1.08 Down 0.75 1.03 Down 0.93 1.12 Down 0.66 
Aldehyde dehydrogenase 7 
family member A1 W5QAE8 
ALDH7
A1 5002580 1.05 Down 0.75 1.06 Up 0.82 1.01 Up 0.97 
MHD domain-containing 
protein W5QHF2 AP2M1 627687 1.04 Up 0.75 1.10 Down 0.72 1.06 Down 0.80 
Spectrin beta chain W5NZX9 SPTBN1 5049862 1.02 Down 0.75 1.04 Up 0.72 1.02 Up 0.80 
Uncharacterised protein W5PLE9 ERP29 2329315 1.05 Up 0.76 1.05 Up 0.83 1.10 Up 0.60 
Aminopeptidase W5PQH2 ANPEP 3392993 1.13 Up 0.76 2.26 Down 0.31 2.00 Down 0.27 
Serine/threonine-protein 
phosphatase 2A activator W5PG83 PTPA 687235 1.05 Up 0.76 1.09 Up 0.68 1.14 Up 0.26 
NADH dehydrogenase 
[ubiquinone] 1 alpha 
subcomplex subunit 8 W5PYA5 
NDUFA
8 3812238 1.03 Up 0.77 1.04 Down 0.82 1.01 Down 0.97 
RHOA C5IJ99 RHOA 3769423 1.04 Down 0.77 1.11 Down 0.46 1.16 Down 0.50 
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Phosphoglucomutase 1 W5PJB6 PGM1 1153957 1.05 Up 0.77 1.09 Up 0.70 1.14 Up 0.44 
Alpha-galactosidase W5QBZ7 NAGA 501524 1.05 Down 0.77 1.13 Up 0.72 1.08 Up 0.80 
Acyl-CoA synthetase long 
chain family member 1 W5PCL4 ACSL1 3245244 1.07 Up 0.77 1.16 Down 0.73 1.08 Down 0.70 
Glycerol-3-phosphate 
dehydrogenase [NAD(+)] W5Q983 GPD1 21707800 1.03 Up 0.79 1.03 Up 0.85 1.06 Up 0.71 
Adenylyl cyclase-associated 
protein W5QG16 CAP1 1204518 1.03 Up 0.79 1.02 Down 0.89 1.01 Up 0.97 
Proteasome 26S subunit, non-
ATPase 5 W5P6M2 PSMD5 708168 1.03 Up 0.79 1.13 Up 0.41 1.17 Up 0.18 
Uncharacterised protein W5NRE6 NA 473369 1.03 Down 0.79 1.03 Down 0.85 1.07 Down 0.80 
Carnosine dipeptidase 2 W5P3I5 CNDP2 18462072 1.05 Up 0.79 1.01 Down 0.95 1.04 Up 0.88 
Propionyl-CoA carboxylase 
subunit alpha W5P2V1 PCCA 3937128 1.03 Up 0.80 1.06 Up 0.78 1.09 Up 0.70 
Catenin beta 1 W5NY24 
CTNNB
1 271129 1.03 Down 0.80 1.01 Down 0.95 1.04 Down 0.85 
NADH:ubiquinone 
oxidoreductase core subunit 
S3 W5PB27 
NDUFS
3 4580429 1.02 Up 0.80 1.03 Down 0.83 1.00 Down 0.99 
3-hydroxybutyrate 
dehydrogenase 2 W5PPP4 BDH2 4442417 1.04 Down 0.80 1.08 Up 0.82 1.04 Up 0.91 
Annexin W5PZM9 ANXA5 16018687 1.06 Down 0.80 1.07 Up 0.85 1.01 Up 0.97 
PKS_ER domain-containing 
protein W5Q2E8 NA 1134775 1.06 Down 0.80 1.08 Down 0.81 1.14 Down 0.68 
 
 381 



























Cathepsin Z W5Q3N1 CTSZ 1645323 1.06 Up 0.80 1.08 Up 0.85 1.14 Up 0.69 
ATP synthase subunit beta W5PEP7 
ATP5F1
B 94178038 1.02 Down 0.80 1.05 Up 0.73 1.03 Up 0.84 
Carnitine O-acetyltransferase W5PGA4 CRAT 3670087 1.03 Down 0.80 1.05 Up 0.82 1.02 Up 0.92 
LDL receptor related protein 
2 W5P0B2 LRP2 14069829 1.01 Up 0.81 1.03 Up 0.72 1.04 Up 0.63 
ATP synthase subunit alpha W5NY50 
ATP5F1
A 145220479 1.02 Up 0.81 1.07 Up 0.68 1.09 Up 0.50 
Heparin binding growth factor W5P8R3 HDGF 1564223 1.03 Up 0.81 1.00 Up 0.98 1.03 Up 0.88 
Hydroxysteroid 
dehydrogenase like 2 W5P973 HSDL2 1666953 1.03 Down 0.81 1.05 Up 0.86 1.01 Up 0.96 
Dihydrolipoyl dehydrogenase W5PB39 DLD 4820255 1.04 Down 0.81 1.09 Up 0.78 1.05 Up 0.88 
Adenylate kinase 4 W5PKF1 AK4 6794172 1.04 Down 0.81 1.15 Up 0.51 1.10 Up 0.54 
Multifunctional fusion protein W5PL79 
ALDH4
A1 13279478 1.04 Up 0.81 1.08 Up 0.78 1.13 Up 0.72 
USO1 vesicle transport factor W5Q2I7 USO1 232419 1.03 Up 0.81 1.06 Up 0.68 1.09 Up 0.51 
Adenylate kinase 2, 
mitochondrial W5QI77 AK2 7755539 1.03 Down 0.81 1.07 Up 0.78 1.04 Up 0.87 
Uncharacterised protein W5QB48 NA 13164720 1.02 Down 0.82 1.01 Down 0.95 1.03 Down 0.82 
Cytochrome b-c1 complex 
subunit Rieske, mitochondrial W5P2X9 
LOC101
113001 947050 1.02 Up 0.82 1.06 Up 0.68 1.08 Up 0.58 
Aldehyde dehydrogenase 
family 16 member A1 W5PU89 
ALDH1
6A1 1702284 1.03 Up 0.82 1.02 Up 0.86 1.05 Up 0.82 
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SEC22 homolog B, vesicle 
trafficking protein 
(gene/pseudogene) W5QGX9 SEC22B 223352 1.03 Up 0.82 1.10 Up 0.71 1.13 Up 0.35 
Sidoreflexin W5Q5A2 SFXN1 4979736 1.01 Down 0.82 1.05 Up 0.73 1.04 Up 0.78 
Eukaryotic translation 
initiation factor 5A W5PQK7 EIF5A 2780209 1.02 Down 0.84 1.02 Up 0.93 1.01 Down 0.97 




A6 NNT 10892404 1.02 Down 0.84 1.08 Up 0.72 1.06 Up 0.81 
Aldedh domain-containing 
protein W5PPG3 NA 18862426 1.02 Up 0.84 1.01 Up 0.87 1.03 Up 0.81 
Selenium binding protein 1 W5QIK8 
SELEN
BP1 21149409 1.08 Down 0.85 1.15 Down 0.83 1.24 Down 0.58 
Fumarylacetoacetase W5Q0Y4 FAH 7127178 1.02 Up 0.85 1.07 Down 0.78 1.05 Down 0.83 
Acyl-CoA dehydrogenase 
very long chain W5PLW6 
ACADV
L 5676793 1.02 Down 0.85 1.07 Down 0.75 1.10 Down 0.38 
Proteasome subunit beta W5QE19 PSMB2 1053252 1.02 Up 0.86 1.09 Down 0.60 1.07 Down 0.64 
NAD-dependent protein 
deacetylase W5PGB0 SIRT3 873466 1.02 Down 0.87 1.06 Down 0.79 1.08 Down 0.70 
Nicotinate-nucleotide 
pyrophosphorylase 
[carboxylating] W5P6S5 QPRT 1293311 1.03 Down 0.87 1.09 Up 0.85 1.06 Up 0.91 
Diazepam binding inhibitor, 
acyl-CoA binding protein W5PSF3 DBI 4423583 1.02 Down 0.88 1.05 Up 0.85 1.02 Up 0.92 
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Pyruvate dehydrogenase E1 
component subunit beta W5PRM8 NA 2077290 1.03 Down 0.89 1.13 Up 0.60 1.10 Up 0.58 
Lamin A/C W5P640 LMNA 2888582 1.02 Up 0.89 1.01 Up 0.97 1.02 Up 0.94 
ATPase ASNA1 W5PP30 ASNA1 1946855 1.01 Down 0.89 1.07 Up 0.60 1.05 Up 0.71 
Tubulin alpha chain C5ISA2 
TUBA4
A 11696039 1.02 Up 0.90 1.03 Down 0.82 1.02 Down 0.91 
Ferritin K4PF69 FTH1 1222274 1.14 Down 0.90 2.41 Up 0.46 2.11 Up 0.40 
Electron transfer flavoprotein 
subunit alpha W5NTP6 NA 11823547 1.01 Up 0.90 1.01 Down 0.95 1.01 Up 0.97 
Ankyrin 3 W5P2C2 ANK3 1771740 1.01 Up 0.90 1.07 Up 0.68 1.08 Up 0.30 
Uncharacterised protein W5P8I3 RIDA 32241978 1.02 Down 0.90 1.02 Down 0.92 1.04 Down 0.90 
H1 histone family member X W5PY64 H1FX 1761181 1.02 Up 0.90 1.03 Down 0.85 1.01 Down 0.95 
3-hydroxyisobutyryl-CoA 
hydrolase, mitochondrial W5Q437 HIBCH 2534485 1.02 Up 0.90 1.07 Up 0.75 1.09 Up 0.58 
Pyrroline-5-carboxylate 




subunit 2 W5Q8Q7 RPN2 390686 1.02 Up 0.90 1.04 Up 0.81 1.06 Up 0.62 
NADH:ubiquinone 
oxidoreductase subunit A9 W5PI58 
NDUFA
9 1707401 1.01 Up 0.90 1.00 Up 0.95 1.01 Up 0.91 
4-hydroxy-2-oxoglutarate 
aldolase 1 W5PMQ2 HOGA1 9594966 1.03 Down 0.90 1.04 Down 0.87 1.07 Down 0.87 
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Aldehyde oxidase 1 W5Q3F9 AOX1 711111 1.02 Up 0.91 1.04 Down 0.87 1.02 Down 0.94 
Heat shock protein family B 
(small) member 1 W5PWA8 HSPB1 24334194 1.02 Down 0.91 1.01 Down 0.94 1.03 Down 0.88 
Uncharacterised protein W5PTA0 ATP5PO 20228684 1.01 Up 0.91 1.05 Up 0.74 1.07 Up 0.60 
MICOS complex subunit W5Q5Z6 APOO 644052 1.02 Down 0.92 1.03 Up 0.90 1.01 Up 0.95 
Retinol-binding protein W5NZ47 RBP4 5882701 1.03 Down 0.93 1.18 Up 0.71 1.15 Up 0.54 
Aldose 1-epimerase W5PGC5 GALM 5781018 1.01 Down 0.94 1.04 Up 0.84 1.03 Up 0.85 
IlvB acetolactate synthase like W5P2A5 ILVBL 1301095 1.01 Up 0.94 1.02 Up 0.87 1.02 Up 0.89 
Uncharacterised protein W5P4X4 
LOC101
109899 1168565 1.01 Down 0.94 1.07 Down 0.73 1.08 Down 0.58 
Thioesterase superfamily 
member 4 W5QIU3 THEM4 1812115 1.02 Up 0.94 1.13 Up 0.68 1.15 Up 0.56 
Ribosomal protein S5 W5P114 RPS5 771494 1.01 Up 0.94 1.14 Down 0.46 1.13 Down 0.51 
Beta-ureidopropionase 1 W5PXC4 UPB1 8316245 1.02 Up 0.94 1.00 Up 1.00 1.02 Up 0.97 
NADH:ubiquinone 
oxidoreductase subunit B10 W5Q5Y9 
NDUFB
10 2037429 1.01 Down 0.94 1.02 Down 0.93 1.03 Down 0.91 
ATP binding cassette 
subfamily D member 3 W5Q740 ABCD3 1344733 1.01 Up 0.94 1.01 Down 0.95 1.00 Up 0.99 
Cytochrome b5 C9E8M7 CYB5 20867814 1.01 Down 0.94 1.06 Up 0.81 1.05 Up 0.85 
Dihydrolipoamide S-
succinyltransferase W5NTS6 DLST 10802802 1.01 Down 0.95 1.13 Up 0.51 1.12 Up 0.51 
Acetyl-CoA acyltransferase 1 W5NS74 ACAA1 1071299 1.01 Down 0.95 1.08 Up 0.74 1.07 Up 0.81 
Obg-like ATPase 1 W5NQL2 OLA1 1364257 1.01 Up 0.95 1.09 Down 0.65 1.07 Down 0.84 
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hydroxylase W5P6D9 PHYH 2665376 1.01 Up 0.95 1.09 Down 0.82 1.08 Down 0.81 
Mitochondrial carrier 2 W5PBQ7 MTCH2 4480560 1.01 Up 0.95 1.01 Up 0.93 1.02 Up 0.88 
Acyl-CoA dehydrogenase 
short chain W5PUC2 ACADS 6999512 1.01 Up 0.95 1.13 Down 0.69 1.12 Down 0.63 
LIM and SH3 protein 1 W5PK26 LASP1 3157476 1.01 Up 0.95 1.02 Down 0.90 1.02 Down 0.95 
Calcium regulated heat stable 
protein 1 W5P5P6 
CARHS
P1 2108758 1.01 Down 0.95 1.01 Up 0.95 1.00 Up 0.99 
Proteasome subunit beta W5QDM2 PSMB5 235255 1.01 Up 0.96 1.04 Down 0.87 1.03 Down 0.91 
Membrane 
metalloendopeptidase W5NZL3 MME 8335299 1.01 Down 0.96 1.02 Down 0.93 1.03 Down 0.89 
Heat shock protein family A 
(Hsp70) member 1A W5PG95 
HSPA1
A 3717301 1.01 Down 0.96 1.29 Down 0.46 1.31 Down 0.36 
Growth hormone inducible 
transmembrane protein W5PL52 GHITM 707205 1.01 Up 0.96 1.10 Up 0.60 1.11 Up 0.57 
Carnitine palmitoyltransferase 
2 W5P878 CPT2 1634889 1.01 Down 0.96 1.06 Up 0.72 1.05 Up 0.72 
Alanine--glyoxylate 
aminotransferase 2 W5PPB3 AGXT2 2940281 1.01 Down 0.96 1.02 Down 0.93 1.03 Down 0.92 
Dihydropyrimidinase W5Q252 DPYS 3968169 1.01 Up 0.96 1.06 Up 0.83 1.06 Up 0.82 
Citrate synthase W5PI34 CS 4643999 1.00 Up 0.97 1.07 Up 0.68 1.08 Up 0.48 
Ubiquitin like modifier 
activating enzyme 1 W5PVT6 UBA1 1887151 1.01 Up 0.97 1.03 Down 0.87 1.03 Down 0.88 
Anion exchange protein W5PS41 SLC4A4 3441971 1.00 Down 0.98 1.03 Up 0.87 1.02 Up 0.89 
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Prohibitin W5P4M1 PHB2 6367860 1.00 Up 0.98 1.01 Up 0.91 1.01 Up 0.91 
Aldo_ket_red domain-
containing protein W5PC00 
AKR1B
1 784151 1.00 Up 0.98 1.05 Down 0.86 1.05 Down 0.91 
DEK proto-oncogene W5PKS6 DEK 314074 1.00 Down 0.98 1.01 Up 0.93 1.01 Up 0.92 
Lamin B2 W5PW39 LMNB2 722390 1.00 Down 0.98 1.03 Down 0.78 1.04 Down 0.64 
Heterogeneous nuclear 
ribonucleoprotein A3 W5Q7M7 
HNRNP
A3 2206528 1.00 Down 0.98 1.02 Down 0.93 1.02 Down 0.93 
Dihydrolipoamide 
acetyltransferase component 
of pyruvate dehydrogenase 
complex W5Q9Q2 DBT 2406050 1.00 Down 0.98 1.01 Down 0.95 1.01 Down 0.97 
Calpain II 80 kDa subunit A8IF71 NA 535824 1.00 Up 0.99 1.08 Down 0.72 1.08 Down 0.71 
Aminopeptidase W5P0N0 ENPEP 5756100 1.00 Up 0.99 1.01 Down 0.95 1.01 Down 0.97 
Succinate--CoA ligase 
[ADP/GDP-forming] subunit 
alpha, mitochondrial W5QGQ8 
SUCLG
1 12292936 1.00 Up 0.99 1.02 Up 0.91 1.02 Up 0.92 
Collagen type I alpha 2 chain W5NTT7 
COL1A
2 456342 1.00 Down 1.00 1.28 Up 0.78 1.28 Up 0.81 
Uncharacterised protein W5PBY5 NA 1845338 1.00 Up 1.00 1.00 Up 0.98 1.00 Up 0.99 





Table 71 Proteins with a fold-change ≥ 1.2 between any two time-points which are detectable in the serum, plasma or urine. Proteins have been categorised 
based on the pattern of expression into types of markers – kidney recovery, long term-renal impairment and kidney injury. Protein name, Uniprot ID and Gene 
identifier are listed. along with adjusted p values for the changes in protein expression between time-points. Adj = adjusted, B= baseline, FC = fold-change, 

















































4 2.43 0.01 2.20 0.00     N Y Y N N 
Filamin A 
W5P5














1 APOE 1.41 0.04     1.34 0.46 N Y N Y N 
T-complex 1 
W5P3
















































































B1 1.39 0.05         N Y N N Y 
Filamin B 
W5PT



























































F0 CCT7 1.27 0.07         N Y N N Y 
Collagen 
type XII 















D9 C9 1.85 0.08     1.65 0.42 N Y N Y N 
Hemopexin 
W5QA











































































































































Z8 TKFC 1.32 0.10         N Y N N Y 
Lumican 
W5Q2












B5 DDC 1.30 0.10     1.24 0.36 Y Y N Y N 
Collagen 
type VI 




A2 1.36 0.10     1.49 0.50 N Y N Y N 
Desmin 
W5QG



















































































Q3 UPP2 1.86 0.12 2.31 0.07 1.24 0.57 Y Y N N N 
ATPase H+ 
transporting 





























































1 1.43 0.13     1.41 0.30 N Y N Y N 
Collagen 
type VI 




























































































06 DPP4 1.43 0.17 1.26 0.58     N Y Y N N 
Transferrin 
W5PF
65 TF 1.51 0.17 1.43 0.46     N Y Y N N 
Cathepsin C 
W5P1


























































56 AHSG 1.98 0.21 1.70 0.51     N Y Y N N 
Aquaporin-1 
W5PD
28 AQP1 1.43 0.22     1.59 0.28 Y Y N Y N 
Prosaposin 
W5PA













































































46 FGB 1.73 0.40 1.47 0.71     N Y Y N N 
Aldehyde 
dehydrogena





















































































































1         1.21 0.39 N Y N Y N 
Ferritin 
K4PF6























































NBP1         1.24 0.58 N Y N Y N 
Collagen 































































































Table 72: Proteins differentially expressed between time-points with BH adjusted p-values 































Filamin A FLNA B-HF ­ 1.36 0.020 ­ 1.19 0.35 
Crystallin zeta CRYZ B-HF ¯ 1.22 0.020 ¯ 1.07 0.77 




CCT3 B-HF ­ 1.31 0.044 ­ 1.14 0.15 
Uncharacterised 
protein 
CCT6A B-HF ­ 1.36 0.044 ­ 1.40 <0.001 
Apolipoprotein 
E 
APOE B-HF ­ 1.41 0.044 ­ 1.02 0.97 
Peroxiredoxin PRDX1 B-HF ¯ 1.25 0.046 ­ 1.07 0.73 
Chaperonin 
containing 
TCP1 subunit 8 
CCT8 B-HF ­ 1.26 0.046 ­ 1.13 0.13 
Tripeptidyl 
peptidase 1 
TPP1 B-HF ­ 1.44 0.046 ¯ 1.12 0.67 
 
